<SEC-DOCUMENT>0001104659-25-061397.txt : 20250623
<SEC-HEADER>0001104659-25-061397.hdr.sgml : 20250623
<ACCEPTANCE-DATETIME>20250623074143
ACCESSION NUMBER:		0001104659-25-061397
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250622
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250623
DATE AS OF CHANGE:		20250623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		251062974

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2518620d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:CARM="http://carismatx.com/20250622">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_CARM_carismatx.com_20250622 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20250622_20250622 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001485003 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000004" name="dei:EntityCentralIndexKey">0001485003</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="carm-20250622.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-22</xbrli:startDate>
        <xbrli:endDate>2025-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt"></p>

<p style="margin: 0pt">&#160;</p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_902_edei--DocumentType_c20250622__20250622_zkcD711EhkWi"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_900_edei--DocumentPeriodEndDate_c20250622__20250622_zyYKjlub8HT2"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">June 22, 2025</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20250622__20250622_zt8WrQVKfnf9"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000012" name="dei:EntityRegistrantName">Carisma Therapeutics Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in its
Charter)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20250622__20250622_zhtLqlS2KT92"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20250622__20250622_zykhS9uO3JM1"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000014" name="dei:EntityFileNumber">001-36296</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20250622__20250622_zdAYjZbdxGSi"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000015" name="dei:EntityTaxIdentificationNumber">26-2025616</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b>(State or other jurisdiction<br/> of incorporation)</b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(Commission<br/> File Number)</b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(IRS Employer<br/> Identification No.)</b></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20250622__20250622_zyPefiO81rF"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000016" name="dei:EntityAddressAddressLine1">3675 Market Street</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20250622__20250622_zfC4TcXCupR5"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite&#160;401</ix:nonNumeric></span><br/> <span id="xdx_90C_edei--EntityAddressCityOrTown_c20250622__20250622_zDQ4UrbIBxy2"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000018" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20250622__20250622_zo5c8b0uDtJb"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000019" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric> </span></b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20250622__20250622_zuiN8yYOve6j"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000020" name="dei:EntityAddressPostalZipCode">19104</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of Principal Executive Offices)</b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>( Zip Code)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_902_edei--CityAreaCode_c20250622__20250622_zzDdehnX3vAk"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000021" name="dei:CityAreaCode">267</ix:nonNumeric></span>) <span id="xdx_90B_edei--LocalPhoneNumber_c20250622__20250622_zrsfhQzzU2ud"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000022" name="dei:LocalPhoneNumber">491-6422</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed
Since Last Report)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction
A.2 below):<span style="font-family: Wingdings"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--WrittenCommunications_c20250622__20250622_zSXsxTbaaDii"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt:booleantrue" id="Fact000023" name="dei:WrittenCommunications">x</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--SolicitingMaterial_c20250622__20250622_zdMFEjElAh56"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20250622__20250622_zRD1rfpPQYV8"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20250622__20250622_zlbwQyrVyDx2"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 45%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 24%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 29%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading<br/> Symbol(s)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Name of exchange<br/> on which registered</b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--Security12bTitle_c20250622__20250622_z8rhN715mx54"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000027" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--TradingSymbol_c20250622__20250622_z9UZ1pAUJlea"><ix:nonNumeric contextRef="AsOf2025-06-22" id="Fact000028" name="dei:TradingSymbol">CARM</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--SecurityExchangeName_c20250622__20250622_zDQRCG3XGQIl"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Emerging growth company&#160;</span><span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20250622__20250622_z25sDpFPlsf5"><ix:nonNumeric contextRef="AsOf2025-06-22" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;1.01.</b></span></td>
    <td style="font-size: 10pt; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Merger Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&#160;22, 2025, Carisma Therapeutics Inc.,
a Delaware corporation (&#8220;Carisma&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), by
and among Carisma, Azalea Merger Sub,&#160;Inc., a Delaware corporation and a wholly owned subsidiary of Carisma (&#8220;Merger Sub&#8221;),
Ocugen,&#160;Inc. (&#8220;Ocugen), a Delaware corporation, and OrthoCellix,&#160;Inc. (&#8220;OrthoCellix&#8221;), a Delaware corporation
and wholly-owned subsidiary of Ocugen, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions
set forth in the Merger Agreement, Merger Sub will merge with and into OrthoCellix (the &#8220;Merger&#8221;), with OrthoCellix continuing
as a wholly owned subsidiary of Carisma and the surviving company of the Merger. The Merger is intended to qualify for federal income
tax purposes as a tax-free reorganization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions of the Merger
Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of common stock, par value $0.00001 per
share, of OrthoCellix (&#8220;OrthoCellix Common Stock&#8221;), issued and outstanding (other than shares of OrthoCellix Common Stock
(a)&#160;held as treasury stock, (b)&#160;owned, directly or indirectly, by Carisma or Merger Sub immediately prior to the Effective Time
or (c)&#160;as to which appraisal rights have been properly exercised in accordance with Delaware law) shall be converted into and become
exchangeable for the right to receive a number of shares of common stock, par value $0.001 per share, of Carisma (&#8220;Carisma Common
Stock&#8221;), based on a ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exchange Ratio formula in the
Merger Agreement, upon the closing of the Merger (the &#8220;Closing&#8221;), on a pro forma basis and based upon the number of
shares of Carisma Common Stock expected to be issued in the Merger, Ocugen (as the sole stockholder of OrthoCellix) and investors in
the Concurrent Investment (as defined below) will own approximately 90.0% of the combined company and pre-Merger Carisma
stockholders will own approximately 10.0% of the combined company, assuming a $25.0 million Concurrent Investment (as defined below)
(the &#8220;Concurrent Investment Amount&#8221;) in each case, on a fully-diluted basis. Under certain circumstances, as described
below, the ownership percentages may be adjusted upward or downward based on the level of Carisma&#8217;s net cash at the Closing
and the size of the anticipated Concurrent Investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Exchange Ratio assumes (a)&#160;a valuation
for OrthoCellix of $135.0 million (less the amount, if any, by which the actual amount of the Concurrent Investment is less than $25.0
million), and (b)&#160;a valuation for Carisma of $15.0 million, which is subject to adjustment based on the amount by which Carisma&#8217;s
net cash is greater than or less than $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, Carisma plans to
seek the approval of its stockholders (a)&#160;at a special meeting to amend its restated certificate of incorporation, as amended, to
effect a reverse stock split of then-outstanding shares of Carisma Common Stock (the &#8220;Reverse Stock Split&#8221;), at a reverse
stock split ratio to be mutually agreed to by Carisma and OrthoCellix, and (b)&#160;at a separate special meeting to, among other things,
(i)&#160;issue the shares of Carisma Common Stock issuable in connection with the Merger pursuant to the rules&#160;of The Nasdaq Stock
Market LLC (&#8220;Nasdaq&#8221;), (ii)&#160;amend its restated certificate of incorporation, as amended to (A)&#160;change the name of
Carisma to &#8220;OrthoCellix,&#160;Inc.&#8221; or such other name as determined by OrthoCellix, and (B)&#160;if needed, increase the
number of shares of Carisma capital stock that Carisma is authorized to issue to a number mutually agreed between Carisma and OrthoCellix,
and (iii)&#160;adopt new equity incentive plans (the &#8220;Equity Plan Proposals&#8221;) as described in the Merger Agreement (all such
voting proposals in this paragraph, the &#8220;Carisma Voting Proposals&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of Carisma and OrthoCellix has agreed to
customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (a)&#160;obtaining
the requisite approval of their respective stockholders, (b)&#160;non-solicitation of alternative acquisition proposals, (c)&#160;the
conduct of their respective businesses during the period between the date of signing the Merger Agreement and the Closing, (d)&#160;Carisma
maintaining the existing listing of the Carisma Common Stock on Nasdaq and causing the shares of Carisma Common Stock to be issued in
connection with the Merger to be approved for listing on Nasdaq prior to the Closing and (e)&#160;Carisma filing with the U.S. Securities
and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement on Form&#160;S-4 to register
the shares of Carisma Common Stock to be issued in connection with the Merger (the &#8220;Registration Statement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the Closing, Carisma will seek to enter
into a series of transactions with certain third parties to monetize certain legacy assets in accordance with the limitations and requirements
set forth in the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consummation of the Merger is subject to certain
closing conditions, including, among other things, (a)&#160;approval by Carisma&#8217;s stockholders of the Carisma Voting Proposals,
other than the Equity Plan Proposals, (b)&#160;approval by the requisite OrthoCellix stockholders of the adoption and approval of the
Merger Agreement, the Merger and the transactions contemplated thereby, (c)&#160;Nasdaq&#8217;s approval of the listing of the shares
of Carisma Common Stock to be issued in connection with the Merger, (d)&#160;the effectiveness of the Registration Statement, (e)&#160;Carisma&#8217;s
net cash at Closing being at least negative $1,000,000, (f)&#160;the Lock-Up Agreement (as defined below) continuing to be in full force
and effect as of immediately following the Effective Time and (g)&#160;the absence of any orders or injunctions by any governmental entity
that would prohibit consummation of the Merger. Each party&#8217;s obligation to consummate the Merger is also subject to other specified
customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to applicable
materiality standards, and the performance in all material respects by the other party of its obligations under the Merger Agreement required
to be performed on or prior to the date of the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement contains certain termination
rights of each of Carisma and OrthoCellix. Upon termination of the Merger Agreement under specified circumstances, Carisma may be required
to pay OrthoCellix a termination fee of $500,000. Upon termination of the Merger Agreement upon specified circumstances, including in
the event that OrthoCellix fails to secure the commitments equal to or in excess of the Concurrent Investment Amount by or before September&#160;15,
2025, OrthoCellix may be required to pay Carisma a termination fee of $750,000 and reimburse up to $500,000 of Carisma&#8217;s fees and
expenses incurred in connection with the transactions contemplated by the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, the board of directors
of the combined company is expected to consist of six members, five of whom will be designated by OrthoCellix and one of whom will be
designated by Carisma.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Contingent Value Rights Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At or prior to the Effective Time, Carisma will
enter into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with a rights agent (the &#8220;Rights Agent&#8221;)
pursuant to which pre-Merger Carisma common stockholders, subject to the terms and conditions set forth in the CVR Agreement will receive
one contingent value right (each, a &#8220;CVR&#8221;) for each outstanding share of Carisma Common Stock held by such stockholder on
such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each CVR will represent the contractual right
to receive a contingent cash payment equal to (i)&#160;the Net Proceeds (as defined in the CVR Agreement) received by Carisma to the extent
such payment related to the disposition of any legacy asset of Carisma during the period beginning on the execution date of the Merger
Agreement and ending on the second (2<sup>nd</sup>) anniversary of the Closing, if any, plus (ii)&#160;the Net Proceeds received by Carisma
to the extent such payment related to any royalties, milestones or other payments received by Carisma following the Closing under certain
of Carisma&#8217;s existing agreements, including its collaboration and license agreement with ModernaTX,&#160;Inc., in each case subject
to adjustment based on the terms and conditions set forth in the CVR Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contingent payments under the CVR Agreement,
if they become payable, will become payable to the Rights Agent for subsequent distribution to the holders of the CVRs. In the event that
no such proceeds are received, holders of the CVRs will not receive any payment pursuant to the CVR Agreement. There can be no assurance
that any holders of CVRs will receive any payments with respect thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right to the contingent payments contemplated
by the CVR Agreement is a contractual right only and will not be transferable, except in the limited circumstances specified in the CVR
Agreement. The CVRs will not be evidenced by a certificate or any other instrument and will not be registered with the SEC. The CVRs
will not have any voting or dividend rights and will not represent any equity or ownership interest in Carisma or any of its affiliates.
No interest will accrue on any amounts payable in respect of the CVRs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concurrent Investment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger Agreement, Carisma and
OrthoCellix have agreed to use commercially reasonable efforts to enter into subscription agreements with one or more investors designated
by OrthoCellix (the &#8220;Investors&#8221;), pursuant to which the Investors would agree to purchase shares of Carisma Common Stock for
aggregate gross proceeds (inclusive of the Guarantor Investment Amount (as defined below)) at least equal to the Concurrent Investment
Amount, which investment (the &#8220;Investor Investment&#8221;) is expected to be consummated at or immediately following the Closing.
On or before August&#160;1, 2025, Ocugen shall enter into a securities purchase agreement with Carisma, pursuant to which Ocugen will
commit to purchase (the &#8220;Guarantor Investment&#8221;, and together with the Investor Investment, the &#8220;Concurrent Investment&#8221;),
at or immediately following the Closing, shares of Carisma Common Stock for aggregate gross proceeds equal to not less than $5.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Support Agreements and Lock-Up Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently and in connection with the execution
of the Merger Agreement, (a)&#160;the sole stockholder of OrthoCellix (solely in its capacity as the stockholder of OrthoCellix) holding
100% of the outstanding shares of OrthoCellix capital stock entered into a support agreement with Carisma and OrthoCellix to vote all
of their shares of OrthoCellix capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated
thereby (the &#8220;OrthoCellix Support Agreement&#8221;) and (b)&#160;certain executive officers and directors of Carisma have entered
into support agreements with Carisma and OrthoCellix to vote all of their shares of Carisma Common Stock in favor of the Carisma Voting
Proposals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently and in connection with the execution
of the Merger Agreement, Ocugen, as the sole stockholder of OrthoCellix, has entered into a lock-up agreement (the &#8220;Lock-Up Agreement&#8221;)
pursuant to which, and subject to specified exceptions, they have agreed not to transfer their shares of Carisma Common Stock for the
180-day period following the Closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preceding summaries of the Merger Agreement, the CVR Agreement,
the Support Agreements and the Lock-Up Agreement do not purport to be complete and are qualified in their entirety by reference to the
Merger Agreement, the form of CVR Agreement, the form of Carisma Support Agreement, the form of OrthoCellix Support Agreement and the
form of Lock-Up Agreement, which are filed as Exhibits 2.1, 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K
and which are incorporated herein by reference. The Merger Agreement has been attached as an exhibit to this Current Report on Form 8-K
to provide investors and securityholders with information regarding its terms. It is not intended to provide any other factual information
about Carisma or OrthoCellix or to modify or supplement any factual disclosures about Carisma in Carisma&#8217;s public reports filed
with the SEC. The Merger Agreement includes representations, warranties and covenants of Carisma, OrthoCellix and Merger Sub made solely
for the purpose of the Merger Agreement and solely for the benefit of the parties thereto in connection with the negotiated terms of the
Merger Agreement. Investors should not rely on the representations, warranties and covenants in the Merger Agreement or any descriptions
thereof as characterizations of the actual state of facts or conditions of Carisma, OrthoCellix or any of their respective affiliates.
Moreover, certain of those representations and warranties may not be accurate or complete as of any specified date, may be modified in
important part by the underlying disclosure schedules which are not filed publicly, may be subject to a contractual standard of materiality
different from those generally applicable to SEC filings or may have been used for purposes of allocating risk among the parties to the
Merger Agreement, rather than establishing matters of fact.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 15%; font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;7.01.</b></span></td>
    <td style="font-size: 10pt; text-align: justify; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation FD Disclosure. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&#160;23, 2025, Carisma and OrthoCellix
issued a joint press release announcing the execution of the Merger Agreement. The press release is furnished as Exhibit&#160;99.1 to
this Current Report on Form&#160;8-K and incorporated herein by reference, except that the information contained on the websites referenced
in the press release is not incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 7.01, including
Exhibit&#160;99.1 and Exhibit&#160;99.2 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the
Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set
forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cautionary Note Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this communication, other
than purely historical information, may constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities
laws, including for purposes of the &#8220;safe harbor&#8221; provisions under the Private Securities Litigation Reform Act of 1995, concerning
Carisma, OrthoCellix, the proposed financing and the proposed Merger between Carisma and OrthoCellix (collectively, the &#8220;Proposed
Transactions&#8221;) and other matters. These forward-looking statements include, but are not limited to, express or implied statements
relating to Carisma&#8217;s and OrthoCellix&#8217;s management teams&#8217; expectations, hopes, beliefs, intentions or strategies regarding
the future including, without limitation, statements regarding: the structure, timing and completion of the proposed Merger between Carisma
and OrthoCellix; the Proposed Transactions and the expected effects, perceived benefits or opportunities of the Proposed Transactions;
the combined company&#8217;s listing on Nasdaq after the closing of the Proposed Transactions; expectations regarding the structure, timing
and completion of the Concurrent Investment, including investment amounts from investors, timing of closing of the Proposed Transactions,
expected proceeds, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing;
the expected executive officers and directors of the combined company; each company&#8217;s and the combined company&#8217;s expected
cash position at the closing and cash runway of the combined company following the proposed Merger and any Concurrent Investment; the
future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined
company; the development and commercial potential and potential benefits of any product candidates of the combined company, including
expectations around market exclusivity and intellectual property protection; anticipated clinical drug development activities and related
timelines, including the expected timing for announcement of data and other clinical results; expectations regarding or plans for discovery,
preclinical studies, clinical trials and research and development programs, in particular with respect to OrthoCellix&#8217;s NeoCart&#174;
technology, and any developments or results in connection therewith, including the target product profile of NeoCart&#174;; the anticipated
timing of the commencement of and results from those studies and trials; the sufficiency of post-transaction resources to support the
advancement of OrthoCellix&#8217;s pipeline through certain milestones and the time period over which OrthoCellix&#8217;s post-transaction
capital resources will be sufficient to fund its anticipated operations; the cash balance of the combined entity at closing; expectations
related to the anticipated timing of the closing of the Proposed Transactions; the expectations regarding the ownership structure of the
combined company; the expected trading of the combined company&#8217;s stock on Nasdaq under the ticker symbol &#8220;OCLX&#8221; after
the Closing; and other statements that are not historical fact. All statements other than statements of historical fact contained in this
communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations
of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;opportunity,&#8221;
&#8220;potential,&#8221; &#8220;milestones,&#8221; &#8220;pipeline,&#8221; &#8220;can,&#8221; &#8220;goal,&#8221; &#8220;strategy,&#8221;
&#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;achieve,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221;
&#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives
of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement
is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections,
as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance
that future developments affecting Carisma, OrthoCellix, or the Proposed Transactions will be those that have been anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements involve a number
of risks and uncertainties, some of which are beyond Carisma&#8217;s or OrthoCellix&#8217;s control, or other assumptions that may cause
actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks
and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transactions
are not satisfied, including the failure to timely obtain approval of (a)&#160;the proposed Reverse Stock Split from Carisma&#8217;s stockholders
and (b)&#160;the proposed Merger from both Carisma&#8217;s and OrthoCellix&#8217;s stockholders, if at all; the risk that the proposed
Concurrent Investment is not completed in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed
Transactions and the ability of each of Carisma and OrthoCellix to consummate the Proposed Transactions; risks related to Carisma&#8217;s
continued listing on Nasdaq until closing of the Proposed Transactions and the combined company&#8217;s ability to remain listed following
the Closing; risks related to Carisma&#8217;s and OrthoCellix&#8217;s ability to correctly estimate their respective operating expenses
and their respective expenses associated with the Proposed Transactions, as applicable, pending the Closing, as well as uncertainties
regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and
unanticipated spending and costs that could reduce the combined company&#8217;s cash resources; risks related to the failure or delay
in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions;
the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;
the effect of the announcement or pendency of the Merger on Carisma&#8217;s or OrthoCellix&#8217;s business relationships, operating results
and business generally; costs related to the Merger; the risk that as a result of adjustments to the exchange ratio, OrthoCellix stockholders
and Carisma stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price
of Carisma&#8217;s common stock relative to the value suggested by the exchange ratio; the uncertainties associated with OrthoCellix&#8217;s
NeoCart&#174; portfolio, as well as risks associated with the clinical development and regulatory approval of product candidates, including
potential delays in the completion of clinical trials; risks related to the inability of the combined company to obtain sufficient additional
capital to continue to advance these product candidates; uncertainties in obtaining successful clinical results for product candidates
and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates being developed
and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market;
the outcome of any legal proceedings that may be instituted against Carisma, OrthoCellix or any of their respective directors or officers
related to the Proposed Transactions; the ability of Carisma and OrthoCellix to obtain, maintain, and protect their respective intellectual
property rights; competitive responses to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges
or expenses resulting from the Proposed Transactions; potential adverse reactions or changes to business relationships, operating results,
and business generally, resulting from the announcement or completion of the Proposed Transactions; changes in regulatory requirements
and government incentives; risks associated with the possible failure to realize, or that it may take longer to realize than expected,
certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results, legislative,
regulatory, political and economic developments, and those uncertainties and factors; and the risk of involvement in litigation, including
securities class action litigation, that could divert the attention of the management of Carisma or the combined company, harm the combined
company&#8217;s business and may not be sufficient for insurance coverage to cover all costs and damages, among others. Actual results
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks
and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors
described in the section titled &#8220;Risk Factors&#8221; in Carisma&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31,
2024, which was originally filed with the SEC on March&#160;31, 2025, as amended by Amendment No.&#160;1 to the Annual Report on Form&#160;10-K/A,
which was filed with the SEC on April&#160;29, 2025, subsequent Quarterly Reports on Form&#160;10-Q filed with the SEC, and in other filings
that Carisma makes and will make with the SEC in connection with the Proposed Transactions, including the Form&#160;S-4 and Proxy Statement
described below under &#8220;Additional Information and Where to Find It&#8221;, as well as discussions of potential risks, uncertainties,
and other important factors included in other filings by Carisma from time to time, any risk factors related to Carisma or OrthoCellix
made available to you in connection with the Proposed Transactions, as well as risk factors associated with companies, such as OrthoCellix,
that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of Carisma&#8217;s
or OrthoCellix&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking
statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set
forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should
not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified
in their entirety by reference to the cautionary statements herein. Neither Carisma nor OrthoCellix undertakes or accepts any duty to
release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations
with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by
law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Carisma or
OrthoCellix.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Offer or Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication and the information contained
herein is not intended to and does not constitute a solicitation of a proxy, consent or approval with respect to any securities or in
respect of the Proposed Transactions or an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to
purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or
transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means
of a prospectus meeting the requirements of Section&#160;10 of the Securities Act, and otherwise in accordance with applicable law, or
an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the
public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the
laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission,
telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Important Additional Information about the
Proposed Transactions Will be Filed with the SEC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication relates to the proposed Merger
involving Carisma and OrthoCellix and may be deemed to be solicitation material in respect of the proposed Merger. In connection with
the Proposed Transactions, Carisma intends to file relevant materials with the SEC, including a registration statement on Form&#160;S-4
(the &#8220;Form&#160;S-4&#8221;) that will contain a proxy statement (the &#8220;Proxy Statement&#8221;) and prospectus. This communication
is not a substitute for the Form&#160;S-4, the Proxy Statement or for any other document that Carisma may file with the SEC and/or send
to Carisma&#8217;s stockholders in connection with the proposed Merger. CARISMA URGES, BEFORE MAKING ANY VOTING DECISION,&#160;INVESTORS
AND STOCKHOLDERS TO READ THE FORM&#160;S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY&#160;BE FILED WITH THE SEC,
AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CARISMA, ORTHOCELLIX, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors and stockholders will be able to obtain
free copies of the Form&#160;S-4, the Proxy Statement and other documents filed by Carisma with the SEC (when they become available) through
the website maintained by the SEC at <i>www.sec.gov</i>. Copies of the documents filed by Carisma with the SEC will also be available
free of charge on Carisma&#8217;s website at <i>www.carismatx.com</i>, or by contacting Carisma&#8217;s Investor Relations at investors@Carismatx.com.
In addition, investors and stockholders should note that Carisma communicates with investors and the public using its website at https://ir.Carismatx.com/.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Participants in the Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Carisma, OrthoCellix, and their respective directors
and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies
from Carisma&#8217;s stockholders in connection with the Proposed Transactions under the rules&#160;of the SEC. Information about Carisma&#8217;s
directors and executive officers, including a description of their interests in Carisma, is included in Carisma&#8217;s most recent Annual
Report on Form&#160;10-K for the year ended December&#160;31, 2024, which was filed with the SEC on March&#160;31, 2025, as amended by
Amendment No.&#160;1 to the Annual Report on Form&#160;10-K, which was filed with the SEC on April&#160;29, 2025. Additional information
regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers
of OrthoCellix, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in
the Form&#160;S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents
can be obtained free of charge from the sources indicated above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;9.01.</b></span></td>
    <td style="font-size: 10pt; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number</b></p></td>
    <td style="font-size: 10pt; width: 1%">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: justify; vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement and Plan of Merger, dated as of June&#160;22, 2025, by and among Carisma Therapeutics Inc., OrthoCellix,&#160;Inc., Azalea Merger Sub,&#160;Inc. and Ocugen,&#160;Inc.</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="font-size: 10pt"><a href="tm2518620d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Contingent Value Rights Agreement </span></a></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Carisma Support Agreement </span></a></td></tr>
  <tr>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of OrthoCellix Support Agreement </span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Lock-Up Agreement </span></a></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><a href="tm2518620d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Press Release, issued on June&#160;23, 2025</span></a></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5)&#160;of Regulation S-K. The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule&#160;24b-2 under the Exchange Act for any exhibits or schedules so furnished.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CARISMA THERAPEUTICS&#160;INC.</b></span></td></tr>
<tr>
<td style="vertical-align: top; width: 50%">&#160;</td>
<td style="vertical-align: top; width: 3%">&#160;</td>
<td style="vertical-align: bottom; width: 47%">&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
<td style="border-bottom: Black 1pt solid">/s/ Steven Kelly</td></tr>
<tr>
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 23, 2025</span></td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Kelly</span></td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: top">&#160;</td>
<td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LhpDBe2jRYtYRYqIr8FuJdhmyyb+HclbGlvEZWFZZr4ZIWKR08o0yHBalAUcsO0a7RFKrJHRnjE4svUmhXBLvBjnWVvfvz8wo8BgYKYjpXQQeuvdOKxSkMlYzscqATlLpwnstyL66hnZ2lRovdENaFvBnqljg17za0g46CdZal991RHZGbIpTEZykN+g5ETBju76QXx1UBSZiOJ+IpEz3brgWj492i8JywbbUOcG+r/RBwwoSpY= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>tm2518620d1_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution</I></B></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND
PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>by and among</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARISMA THERAPEUTICS INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AZALEA MERGER SUB,&nbsp;INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ORTHOCELLIX,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OCUGEN,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dated as of June&nbsp;22, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><U>Page</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;I DEFINITIONS&nbsp;&amp; INTERPRETATIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Definitions</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;II THE MERGER</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Formation of Merger Sub</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Time</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effects of the Merger</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Governance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surviving Company and Surviving Company Governance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;III EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT COMPANIES; EXCHANGE OF CERTIFICATES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion of Capital Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED.]</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange and Payment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding Rights</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenters Rights</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculation of Net Cash</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent Value Right</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization, Standing and Power</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict; Consents and Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Undisclosed Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Certain Changes or Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor and Employment Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.14</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties; Assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State Takeover Statutes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Rights Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Payments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Control Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.26</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Other Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;V REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization, Standing and Power</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Stock</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict; Consents and Approvals</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Reports; Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Undisclosed Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Certain Changes or Events</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor and Employment Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Payments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Control Laws</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Financial Advisor</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State Takeover Statutes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.26</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Other Representations or Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VI COVENANTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation of Parent&rsquo;s Business</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation of Company&rsquo;s Business</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access and Investigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Solicitation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notification of Certain Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent ESPP</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent 401(K)&nbsp;Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VII ADDITIONAL AGREEMENTS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement; Proxy Statement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Stockholder Approval</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stockholders&rsquo; Meeting</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts; Transaction Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification, Exculpation and Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;16 Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Officers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations of Merger Sub</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation Certificate</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent Investment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Equity Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent SEC Documents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Legacy Assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arrangements Between Company and Company Guarantor</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VIII CLOSING CONDITIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions Precedent of each Party</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions Precedent to Obligation of the Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions Precedent of Parent and Merger Sub</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IX TERMINATION</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">91</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses; Termination Fees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;X GENERAL PROVISIONS</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-survival of Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment or Supplement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees and Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.5</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Third Party Beneficiaries</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guaranty.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to Jurisdiction</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment; Successors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific Performance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver of Jury Trial</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile or .pdf Signature</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Presumption Against Drafting Party</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;A</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Form&nbsp;of Parent Support Agreement</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;B</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Form&nbsp;of Company Support Agreement</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;C</FONT> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Lock-Up Agreement</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;D</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Form&nbsp;of CVR Agreement</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 1.1(a)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Net Cash Schedule</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 2.6(c)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board of Directors</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INDEX OF DEFINED TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definition</U></FONT></TD>
    <TD STYLE="width: 50%"><U>Location</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014 Stock Incentive Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017 Stock Incentive Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 Equity Incentive Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 ESPP</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025 Plans</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>AAA &nbsp;</TD>
    <TD>Section&nbsp;3.6(e)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acceptable Confidentiality Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Firm</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(e)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition Inquiry</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition Proposal</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition Transaction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Action &nbsp;</TD>
    <TD>Section&nbsp;4.9</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Affiliate &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Valuation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(A)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Agreement &nbsp;</TD>
    <TD>Preamble</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation Certificate</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated Meeting Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Book-Entry Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Day</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Determination Time</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Merger</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Certificates &nbsp;</TD>
    <TD>Section&nbsp;3.3(b)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Closing &nbsp;</TD>
    <TD>Section&nbsp;2.3</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Code &nbsp;</TD>
    <TD>Recitals</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Company &nbsp;</TD>
    <TD>Preamble, Preamble</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Allocation Percentage</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(B)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Audited Financial Statements</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board Adverse Recommendation Change</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Board Recommendation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Bylaws</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Charter</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Common Stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Disclosure Letter</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article&nbsp;IV</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Employee</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Fundamental Representations</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Interim Financial Statements</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Merger Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(C)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Notice Period</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Outstanding Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(D)</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Owned IP</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Products</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Registered IP</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Service Providers</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.12(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Stockholder Approval</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Support Agreements</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Termination Fee</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Triggering Event</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Valuation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(E)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent Investment</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent Investment Amount</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent Investment Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(F)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contemplated Transactions</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Contract &nbsp;</TD>
    <TD>Section&nbsp;4.5(a)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>control &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Offering Period</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current Premium</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>CVR &nbsp;</TD>
    <TD>Section&nbsp;3.7(a)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVR Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D&amp;O Indemnified Parties</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data Processors</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19(h)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware Secretary of State</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>DGCL &nbsp;</TD>
    <TD>Recitals</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispute Notice</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dissenting Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective Time</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">End Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.1(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Law</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.14(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>ERISA &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Act</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.5(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Agent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Fund</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Ratio</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(a)(iii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>FDA &nbsp;</TD>
    <TD>Section&nbsp;4.11(c)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA Ethics Policy</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>FDCA &nbsp;</TD>
    <TD>Section&nbsp;4.11(a) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final Parent Net Cash</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>GAAP&nbsp;</TD>
    <TD> Section&nbsp;4.1(a) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guarantor Investment Amount</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guarantor Securities Purchase Agremeent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hazardous Substance</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.14(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Care Laws</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT Systems</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>knowledge &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Law &nbsp;</TD>
    <TD>Section&nbsp;4.5(a)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-Up Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.16(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measurement Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Merger &nbsp;</TD>
    <TD>Recitals </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Consideration</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(a)(i)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Merger Sub</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preamble</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiemployer Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Nasdaq &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Fees</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Issuance Proposal</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Listing Application</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Reverse Stock Split</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Cash</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Course</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Course Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.15(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Parent &nbsp;</TD>
    <TD>Preamble</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent 401(k)&nbsp;Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.9</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Allocation Percentage</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(G)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Board</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Board Adverse Recommendation Change</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Board Recommendation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Capital Stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Charter Amendment</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Common Stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Common Stock Issuance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Disclosure Letter</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article&nbsp;V</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Equity Plans</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent ESPP</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Fundamental Representations</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Intervening Event</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent IT Systems</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.19(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Legacy Assets</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Legacy Business</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1 (ii)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Legacy Transaction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Material Adverse Effect</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Material Contracts</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.16(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Net Cash Calculation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Net Cash Schedule</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Notice Period</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Options</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent OTM Options</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Outstanding Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(H)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Owned IP</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Plan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Preferred Stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Products</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.11(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Registered IP</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.19(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Restricted Stock Unit Awards</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent SEC Documents</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stockholder Approval</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stockholder Meeting</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Stockholder Proposals</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Support Agreements</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recitals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Termination Fee</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Triggering Event</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Valuation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(I)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Value Per Share</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(G)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parent Warrant</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Permits &nbsp;</TD>
    <TD>Section&nbsp;4.10 </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted Alternative Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.1(j)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted Liens</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.18(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Person &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Information</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19(h)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Closing Parent Shares</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1(i)(J)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Closing Distribution</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Closing Period</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy Laws</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.19(h)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Statement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Representative &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Response Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.6(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights Agent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.7(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety Notices</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.11(g)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sarbanes-Oxley Act</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>SEC &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Act</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.5(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent Transaction</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Subsidiary &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Superior Offer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surviving Company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Takeover laws</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Action</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.15(d)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Opinion</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.9(b)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Return</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Taxes &nbsp;</TD>
    <TD>Section&nbsp;1.1</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Approvals</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade Laws</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction Expenses</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction Litigation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4(c)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Tax Treatment</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.9(a)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding Agent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->x<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT AND PLAN OF MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND PLAN OF
MERGER (this &ldquo;<U>Agreement</U>&rdquo;), dated as of June&nbsp;22, 2025, by and among Carisma Therapeutics Inc., a Delaware corporation
(&ldquo;<U>Parent</U>&rdquo;), Azalea Merger Sub,&nbsp;Inc., a Delaware corporation (&ldquo;<U>Merger Sub</U>&rdquo;) and wholly owned
subsidiary of Parent, OrthoCellix,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;) and Ocugen,&nbsp;Inc., a Delaware
corporation (the &ldquo;<U>Guarantor</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent and the Company
intend to effect a merger of Merger Sub with and into the Company (the &ldquo;<U>Merger</U>&rdquo;) in accordance with this Agreement
and the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;). Upon consummation of the Merger, Merger Sub
will cease to exist and the Company will become a wholly owned subsidiary of Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Board of Directors
of the Company (the &ldquo;<U>Company Board</U>&rdquo;) <FONT STYLE="background-color: aqua"></FONT>has (i)&nbsp;determined that the Contemplated
Transactions (as defined below) are fair to, advisable and in the best interests of the Company and its sole stockholder, (ii)&nbsp;approved
and declared advisable this Agreement and the Contemplated Transactions and (iii)&nbsp;determined to recommend, upon the terms and subject
to the conditions set forth in this Agreement, that the sole stockholder of the Company vote to adopt this Agreement and thereby approve
the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company Board
has unanimously approved this Agreement and the Merger, with the Company continuing as the Surviving Company (as defined below), after
the Effective Time (as defined below), pursuant to which, among other things, each share of common stock, par value $0.00001 per share,
of the Company (the &ldquo;<U>Company Common Stock</U>&rdquo;) (other than any Excluded Shares or Dissenting Shares) shall be converted
into the right to receive a number of shares of common stock, par value $0.001 per share, of Parent (the &ldquo;<U>Parent Common Stock</U>&rdquo;)
equal to the Exchange Ratio;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Board of Directors
of Parent (the &ldquo;<U>Parent Board</U>&rdquo;) has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and
in the best interests of Parent and its stockholders, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions,
including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to this Agreement and the Parent
Support Agreements and the constructive issuance by the Company of the shares of Company Common Stock to stockholders of Parent (as reflected
in Rule&nbsp;145(a)&nbsp;of the Securities Act) (the &ldquo;<U>Constructive Issuance</U>&rdquo;), (iii)&nbsp;determined that the Reverse
Stock Split Proposal (as defined below), among other things, is advisable and in the best interests of Parent and its stockholders and
(iv)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of
Parent vote to authorize the issuance of the Parent Common Stock in accordance with Nasdaq Listing Rule&nbsp;5635 (the &ldquo;<U>Nasdaq
Issuance Proposal</U>&rdquo;), the Reverse Stock Split Proposal and the other Parent Stockholder Proposals;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Merger Sub is a newly
incorporated Delaware corporation that is wholly owned by Parent, and has been formed for the sole purpose of effecting the Merger;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, on June&nbsp;19,
2025, the Guarantor contributed the NeoCart Assets to the Company pursuant to an Asset Contribution Agreement, by and between the Guarantor
and the Company (the &ldquo;<U>Contribution Agreement</U>&rdquo;) in exchange for shares of Common Stock in the Company (such transactions,
the &ldquo;<U>Contribution</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREAS,
</FONT>the board of directors of Merger Sub has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in
the best interests of Merger Sub and its sole stockholder, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated
Transactions and (iii)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the
stockholder of Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, Merger Sub
and the Company each desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also
to prescribe certain conditions to the Merger as specified herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition and inducement to the Company&rsquo;s willingness to enter into this Agreement,
the officers, directors and stockholders of Parent listed on <U>Section&nbsp;A</U> of the Parent Disclosure Letter have entered into Parent
Support Agreements, dated as of the date of this Agreement, in the form attached hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;<U>Parent
Support Agreements</U>&rdquo;), pursuant to which such officers, directors and stockholders have, subject to the terms and conditions
set forth therein, agreed to vote all of their shares of Parent Common Stock in favor of the approval of this Agreement and thereby approve
the Contemplated Transactions, including, but not limited to the Parent Stockholder Proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition and inducement of Parent&rsquo;s willingness to enter into this Agreement,
the officers, directors and stockholders of the Company listed on <U>Section&nbsp;A</U> of the Company Disclosure Letter have entered
into Company Support Agreements, dated as of the date of this Agreement, in the form attached hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;<U>Company
Support Agreements</U>&rdquo;), pursuant to which such officers, directors and stockholders have, subject to the terms and conditions
set forth therein, agreed to vote all of their shares of Company Common Stock in favor of the adoption of this Agreement and thereby approve
the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition and inducement to Parent&rsquo;s willingness to enter into this Agreement,
certain members of the Company Board that are continuing in such role following the Merger, certain members of the Parent Board that are
continuing in such role following the Merger and stockholders of the Company listed on <U>Section&nbsp;B</U> of the Company Disclosure
Letter are executing lock-up agreements in the form attached hereto as <U>Exhibit&nbsp;C</U> (the &ldquo;<U>Lock-Up Agreement</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, for United States
federal income Tax purposes, it is intended that (i)&nbsp;the Merger shall qualify as a &ldquo;reorganization&rdquo; within the meaning
of Section&nbsp;368(a)&nbsp;of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), shall also qualify as a
non-taxable exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&nbsp;351(a)&nbsp;of
the Code and (ii)&nbsp;this Agreement shall constitute a &ldquo;plan of reorganization&rdquo; within the meaning of Treasury Regulations
Sections 1.368-2(g)&nbsp;and 1.368-3(a); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, it is expected that
within twenty-four (24) hours after the Registration Statement is declared effective under the Securities Act, the stockholders of the
Company will execute an action by written consent by all holders sufficient to authorize the Contemplated Transactions of outstanding
shares of Company Common Stock (the &ldquo;<U>Company Stockholder Approval</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as an inducement
by Guarantor for Parent to enter into this Agreement, Guarantor will execute a Securities Purchase Agreement (the &ldquo;<U>Guarantor
Securities Purchase Agreement</U>&rdquo;) committing to purchase not less than $5,000,000 of shares of Parent Common Stock, substantially
contemporaneously with the Closing (the &ldquo;<U>Guarantor Investment Amount</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises, and of the representations, warranties, covenants and agreements contained herein, and intending to be legally bound
hereby, Parent, Merger Sub and the Company hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;I</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
DEFINITIONS&nbsp;&amp; INTERPRETATIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Definitions</U>. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>2014
Stock Incentive Plan</U>&rdquo; means Parent&rsquo;s Amended and Restated 2014 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>2017
Stock Incentive Plan</U>&rdquo; means Parent&rsquo;s 2017 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>2025
Equity Incentive Plan</U>&rdquo; shall mean an equity incentive plan of Parent in form and substance as designated by the Company and
reasonably acceptable to Parent, reserving for issuance a number of shares of Parent Common Stock to designated by the Company and consented
to by Parent (such consent not to be unreasonably withheld, conditioned or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>2025
ESPP</U>&rdquo; shall mean an &ldquo;employee stock purchase plan&rdquo; of Parent in form and substance as designated by the Company
and reasonably acceptable to Parent, reserving for issuance a number of shares of Parent Common Stock to designated by the Company and
consented to by Parent (such consent not to be unreasonably withheld, conditioned or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>2025
Plans</U>&rdquo; shall mean both the 2025 Equity Incentive Plan and 2025 ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Acceptable
Confidentiality Agreement</U>&rdquo; means a confidentiality agreement containing terms not materially less restrictive in the aggregate
to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any
standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality
agreement with Parent or the Company, as applicable, relating to a potential Acquisition Proposal on terms that are not materially less
restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not
be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be
an Acceptable Confidentiality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Acquisition
Inquiry</U>&rdquo; means, with respect to a party, an inquiry, indication of interest or request for information (other than an inquiry,
indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to
the other party) that would reasonably be expected to lead to an Acquisition Proposal, other than the Concurrent Investment, or (subject
to <U>Section&nbsp;7.13</U>) a Parent Legacy Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Acquisition
Proposal</U>&rdquo; means, with respect to either party hereto, any proposal or offer (whether written or oral) from any Person (other
than the other party or any of its Representatives) contemplating or otherwise relating to an Acquisition Transaction (other than in connection
with the Concurrent Investment, or (subject to <U>Section&nbsp;7.13</U>) a Parent Legacy Transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Acquisition
Transaction</U>&rdquo; means any transaction or series of related transactions (other than the Concurrent Investment or any Parent Legacy
Transaction) involving:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization,
recapitalization, tender offer, exchange offer or other similar transaction: (i)&nbsp;in which a party is a constituent entity, (ii)&nbsp;in
which a Person or &ldquo;group&rdquo; (as defined in the Exchange Act and the rules&nbsp;promulgated thereunder) of Persons directly or
indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class
of voting securities of a party or any of its Subsidiaries or (iii)&nbsp;in which a party or any of its Subsidiaries issues securities
representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its Subsidiaries; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account
for 20% or more of the consolidated book value of the fair market value of the assets of a party and its Subsidiaries taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
of any Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such first Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Business
Day</U>&rdquo; means any day other than a Saturday, a Sunday or a day on which banks in New York, New York are authorized or required
by applicable Law to be closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Concurrent
Investment</U>&rdquo; means an aggregate commitment of not less than the Concurrent Investment Amount pursuant to which certain investors
will agree, subject to the terms and conditions of the applicable Securities Purchase Agreement, to subscribe for and purchase a number
of shares of Parent Common Stock substantially contemporaneously with the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Concurrent
Investment Amount</U>&rdquo; means $25,000,000. For the avoidance of doubt, the Concurrent Investment Amount shall be inclusive of the
Guarantor Investment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Fundamental Representations</U>&rdquo; means each of the representations and warranties of the Company set forth in <U>Section&nbsp;4.1</U>,
<U>Section&nbsp;4.2</U>, <U>Section&nbsp;4.4</U> and <U>Section&nbsp;4.25</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Owned IP</U>&rdquo; means all Intellectual Property owned by the Company in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Plan</U>&rdquo; means each Employee Plan that is sponsored, maintained, or contributed (or required to be contributed) to by the Company
or Guarantor for the benefit of current or former employees, officers, directors or other service providers of Guarantor or any of its
Subsidiaries providing services to the Company or with respect to which the Company has any liability, contingent or otherwise, other
than any plan, program, arrangement, agreement or policy mandated by applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Triggering Event</U>&rdquo; shall be deemed to have occurred if: (a)&nbsp;the Company Board shall have publicly approved, endorsed or
recommended any Acquisition Proposal, (b)&nbsp;the Company shall have entered into any letter of intent or similar document or any Contract
relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement) permitted pursuant to <U>Section&nbsp;6.4</U>
or (c)&nbsp;the Company shall have materially and willfully breached its obligations under <U>Section&nbsp;6.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Confidentiality
Agreement</U>&rdquo; means that certain Mutual Non-Disclosure Agreement, dated as of April&nbsp;7, 2025, between the Company and Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Contemplated
Transactions</U>&rdquo; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than
the Parent Legacy Transaction and Parent Charter Amendment) including the CVR Agreement, the Concurrent Investment and the Nasdaq Reverse
Stock Split (to the extent applicable and deemed necessary by Parent and the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>control</U>&rdquo;
(including the terms &ldquo;<U>controlled</U>,&rdquo; &ldquo;<U>controlled by</U>&rdquo; and &ldquo;<U>under common control with</U>&rdquo;)
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Employee
Plan</U>&rdquo; means each &ldquo;employee benefit plan&rdquo; (within the meaning of section&nbsp;3(3)&nbsp;of ERISA, whether or not
subject to ERISA), Multiemployer Plans, and all stock purchase, stock option, phantom stock or other equity-based plan, severance, employment,
change-in-control, fringe benefit, bonus, incentive, deferred compensation, compensation, supplemental retirement, health, life, or disability
insurance, dependent care, vacation and all other employee benefit and compensation plans, agreements, programs, policies or other arrangements,
whether or not subject to ERISA (including any funding mechanism therefor now in effect or required in the future as a result of the Contemplated
Transactions or otherwise), whether formal or informal, written or oral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>ERISA</U>&rdquo;
means the U.S. Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Intellectual
Property</U>&rdquo; means all intellectual property rights of any kind, including all of the following: (i)&nbsp;trademarks or service
marks (whether registered or unregistered), trade names, domain names, social media user names, social media addresses, logos, slogans,
and trade dress, including applications to register any of the foregoing, together with the goodwill symbolized by any of the foregoing;
(ii)&nbsp;patents, utility models and any similar or equivalent statutory rights with respect to the protection of inventions, and all
applications for any of the foregoing, together with all re-issuances, continuations, continuations-in-part, divisionals, revisions, extensions
and reexaminations thereof; (iii)&nbsp;copyrights (registered and unregistered) and applications for registration; (iv)&nbsp;trade secrets
and customer lists, in each case to the extent any of the foregoing derives economic value (actual or potential) from not being generally
known to other Persons who can obtain economic value from its disclosure or use, and other confidential information (&ldquo;<U>Trade Secrets</U>&rdquo;);
and (v)&nbsp;any other proprietary or intellectual property rights of any kind or nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>knowledge</U>&rdquo;
of any party means (i)&nbsp;the actual knowledge of any executive officer of such party or other officer having primary responsibility
for the relevant matter or any employee consultant or interim officer serving similar roles and (ii)&nbsp;any fact or matter which any
such Person would be expected to discover or otherwise become aware of in the course of conducting due inquiry, consistent with such Person&rsquo;s
title and responsibilities, concerning the existence of the relevant matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Manufacturing
and Supply Agreement</U>&rdquo; means a manufacturing and supply agreement to be negotiated (in a form and substance subject to Parent&rsquo;s
prior written consent, which shall not be unreasonably withheld, conditioned or delayed) pursuant to Section&nbsp;7.18, the material terms
of which will be substantially final on or prior to July&nbsp;11, 2025, and to be entered into between the Guarantor and the Company on
or prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Multiemployer
Plan</U>&rdquo; shall have the meaning set forth in Section&nbsp;3(37) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Nasdaq</U>&rdquo;
means The Nasdaq Stock Market LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Nasdaq
Fees</U>&rdquo; means all Nasdaq fees associated with any action contemplated by <U>Section&nbsp;7.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Nasdaq
Reverse Stock Split</U>&rdquo; means a reverse stock split of all outstanding shares of Parent Common Stock at a reverse stock split ratio
as mutually agreed to by Parent and the Company that is effectuated by Parent for the purpose of maintaining or achieving compliance with
Nasdaq listing standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>NeoCart
Assets</U>&rdquo; has the meaning set forth in the Contribution Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Net Cash</U>&rdquo; means, without duplication, (i)&nbsp;the sum of Parent&rsquo;s
unrestricted cash, cash equivalents and short-term marketable securities and the cash consideration attributable to the sale of
Legacy Assets, solely to the extent not received by Parent as of the Effective Time and solely to the extent Parent and the Company
mutually agree will be received within ninety (90) days following the Closing, <U>plus</U> (ii), solely to the extent Parent and the
Company mutually agree such funds will be available to and usable by Parent within ninety (90) days of the Closing Date, all prepaid
expenses and deposits, credits and refunds set forth on <U>Schedule 1.1(a)(ii)</U>, <U>minus</U> (iii)&nbsp;the sum of
Parent&rsquo;s short-term and long-term liabilities (including any outstanding liabilities with respect to Parent&rsquo;s
obligations with respect to the items set forth on <U>Schedule 1.1(a)(iii)</U>) (including all accounts payable and indebtedness),
including lease termination costs, all actual costs and expenses (and reasonably projected costs and expenses as mutually agreed
between Parent and the Company, acting in good faith) relating to the winding down of the Parent Legacy Business and any related
prepayment penalties and premiums and any unpaid Transaction Expenses (including any costs, fees or other liabilities, including
Taxes, related to the premiums, commissions and other fees payable in connection with obtaining Parent&rsquo;s D&amp;O tail policy
as set forth in <U>Section&nbsp;7.5(d)</U>), <U>minus</U> (iv)&nbsp;any and all change in control payments and severance payments,
in each case, payable to Parent&rsquo;s employees, and any employer-side payroll or similar Taxes owed in connection with the
foregoing or in connection with the exercise of Parent Options and vesting and settlement of Parent Restricted Stock Unit Awards, in
each case to the extent payable in connection with the consummation of the Contemplated Transactions, and <U>minus</U> (v)&nbsp;50%
of the mutually agreed estimated settlement amounts for any Transaction Litigation existing as of the Closing. Set forth on <U>Section&nbsp;1.1(a)</U>&nbsp;of
the Parent Disclosure Letter is an illustrative example of the calculation of Net Cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Ordinary
Course</U>&rdquo; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and
consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage
of development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Capital Stock</U>&rdquo; means the Parent Common Stock and the Parent Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Equity Plans</U>&rdquo; means each of Parent&rsquo;s 2014 Stock Incentive Plan, 2017 Stock Incentive Plan and Parent ESPP in each case,
as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
ESPP</U>&rdquo; means Parent&rsquo;s Amended and Restated 2014 Employee Stock Purchase Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Fundamental Representations</U>&rdquo; means each of the representations and warranties of Parent and Merger Sub set forth in <U>Section&nbsp;5.1</U>,
<U>Section&nbsp;5.2</U>, <U>Section&nbsp;5.3</U>, <U>Section&nbsp;5.4</U> and <U>Section&nbsp;5.25</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Legacy Assets</U>&rdquo; means all assets, technology and Intellectual Property of Parent, as they existed at any time prior to the date
of this Agreement, relating to the Company&rsquo;s research and development programs, as conducted and proposed to be conducted, including
its CT-0525, CT-0508, CT-1119 and its engineered macrophage, and <I>in vivo</I> mRNA/lipid nanopartical CAR-M programs and its partnership
with ModernaTX,&nbsp;Inc., including, for purposes of clarity, the tangible and intangible assets of Parent relating thereto (the &ldquo;<U>Parent
Legacy Business</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Options</U>&rdquo; means options to purchase shares of Parent Common Stock issued pursuant to a Parent Equity Plan, but excluding, for
the avoidance of doubt, the Parent ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
OTM Option</U>&rdquo; means Parent Options with an exercise price greater than $2.00 per share (before giving effect to the Nasdaq Reverse
Stock Split).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Owned IP</U>&rdquo; means all Intellectual Property owned by Parent in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Plan</U>&rdquo; means each Employee Plan that is sponsored, maintained, or contributed (or required to be contributed) to by Parent or
any of its Subsidiaries for the benefit of current or former employees, officers, directors or other service providers of Parent or any
of its Subsidiaries or with respect to which Parent or any of its Subsidiaries has any liability, contingent or otherwise, other than
any plan, program, arrangement, agreement or policy mandated by applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Preferred Stock</U>&rdquo; means the shares of Parent&rsquo;s capital stock designated as preferred stock, par value $0.001 per share
of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Restricted Stock Unit Awards</U>&rdquo; means each award of restricted stock unit awards with respect to shares of Parent Common Stock
issued pursuant to a Parent Equity Plan or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(rr)&#8239;&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent Warrant</U>&rdquo; means warrants to purchase shares of Parent
Capital Stock issued by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ss)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Triggering Event</U>&rdquo; shall be deemed to have occurred if: (i)&nbsp;Parent shall have failed to include in the Proxy Statement the
Parent Board Recommendation (as defined below), (ii)&nbsp;the Parent Board or any committee thereof shall have made a Parent Board Adverse
Recommendation Change or approved, endorsed or recommended any Acquisition Proposal, (iii)&nbsp;Parent shall have entered into any letter
of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement
permitted pursuant to <U>Section&nbsp;6.4</U>), (iv)&nbsp;a tender offer or exchange offer for outstanding shares of Parent Common Stock
is commenced, and the Parent Board (or any committee thereof) recommends that the stockholders of Parent tender their shares in such tender
or exchange offer or, within ten (10)&nbsp;Business Days after the commencement of such tender offer or exchange offer, the Parent Board
fails to recommend against acceptance of such offer, (v)&nbsp;Parent shall have failed to issue a press release confirming the Parent
Board Recommendation within ten (10)&nbsp;Business Days following the Company&rsquo;s written request to Parent to issue such press release
in response to any other publicly announced Acquisition Proposal with respect to Parent or (vi)&nbsp;Parent shall have materially and
willfully breached its obligations under <U>Section&nbsp;6.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including
any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Representative</U>&rdquo;
means a party&rsquo;s directors, officers, employees, investment bankers, financial advisors, attorneys, accountants or other advisors,
agents or representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>SEC</U>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ww)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Securities
Purchase Agreement</U>&rdquo; means each Contract, in form and substance as agreed to in writing between Parent and the Company, entered
into on or following the date hereof and prior to the Closing pursuant to which the signatory thereto has agreed to purchase for cash
shares of Parent Common Stock immediately following the Closing pursuant to <U>Section&nbsp;7.14</U> or as otherwise agreed in writing
between Parent and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Subsequent
Transaction</U>&rdquo; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being
treated as references to 50% for these purposes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(yy)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Subsidiary</U>&rdquo;
means, with respect to any Person, any other Person of which stock or other equity interests having ordinary voting power to elect more
than 50% of the board of directors or other governing body are owned, directly or indirectly, by such first Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(zz)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Superior
Offer</U>&rdquo; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition
Transaction being treated as references to 50% for these purposes) that: (i)&nbsp;was not obtained or made as a direct or indirect result
of a breach of (or in violation of) the Agreement, and (ii)&nbsp;is on terms and conditions that the Parent Board or the Company Board,
as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof
and the financing terms thereof), as well as any written offer by the other party to the Agreement to amend the terms of the Agreement,
and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of
view, to the Parent&rsquo;s stockholders or the Company&rsquo;s stockholders, as applicable, than the terms of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(aaa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Tax
Return</U>&rdquo; means any return, declaration, report, certificate, bill, election, claim for refund, information return, statement
or other written information and any other document filed or supplied or required to be filed or supplied to any Governmental Entity with
respect to Taxes, including any schedule, attachment or supplement thereto, and including any amendment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(bbb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Taxes</U>&rdquo;
means all U.S. federal, state and local and non-U.S. net income, gross income, gross receipts, sales, use, stock, ad valorem, transfer,
transaction, franchise, profits, gains, registration, license, wages, lease, service, service use, employee and other withholding, imputed
underpayment, social security, unemployment, welfare, disability, payroll, employment, excise, severance, stamp, occupation, workers&rsquo;
compensation, premium, real property, personal property, windfall profits, net worth, capital, value-added, alternative or add-on minimum,
customs duties, estimated and other taxes, fees, assessments, charges or levies in the nature of a tax (whether imposed, assessed, determined,
administered, enforced or collected directly or through withholding and including any amounts resulting from the failure to file any Tax
Return), whether disputed or not, together with any interest and any penalties, or additions to tax with respect thereto (or attributable
to the nonpayment thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ccc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Transaction
Expenses</U>&rdquo; means the aggregate amount (without duplication) of all costs, fees, Taxes and expenses incurred by Parent and Merger
Sub, or for which Parent or Merger Sub are or may become liable in connection with the Contemplated Transactions and the negotiation,
preparation and execution of this Agreement or any other agreement, document, instrument, filing, certificate, schedule, exhibit, letter
or other document prepared or executed in connection with the Contemplated Transactions, including (i)&nbsp;the amount of fees and expenses
payable to financial advisors, investment bankers, legal counsel, accountants, brokers, consultants, Tax advisors, transfer agents, proxy
solicitor and other advisors of Parent, including the employer portion of any payroll or similar Taxes incurred or to be incurred by Parent
or Merger Sub with respect to the payment of any item listed in this definition of Transaction Expenses; (ii)&nbsp;50% of the fees paid
to the SEC in connection with filing the Registration Statement, the Proxy Statement, and any amendments and supplements thereto, with
the SEC; (iii)&nbsp;50% of the fees and expenses incurred in connection with the printing, mailing and distribution of the Registration
Statement and any amendments and supplements thereto; (iv)&nbsp;50% of the fees and expenses incurred in connection with the Exchange
Agent; (v)&nbsp;50% of the Nasdaq Fees and (vi)&nbsp;100% of the fees of the Rights Agent under the CVR Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ddd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Transition
Services Agreement</U>&rdquo; means a transition services agreement to be negotiated in a form and substance subject to Parent&rsquo;s
prior written consent, which shall not be unreasonably withheld, conditioned or delayed) pursuant to Section&nbsp;7.18, the material terms
of which will be substantially final on or prior to July&nbsp;11, 2025, and to be entered into between the Guarantor and the Company on
or prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation</U>.
When a reference is made in this Agreement to a Section, Article, Exhibit&nbsp;or Schedule such reference shall be to a Section, Article,
Exhibit&nbsp;or Schedule of this Agreement unless otherwise indicated. The table of contents and headings contained in this Agreement
or in any Exhibit&nbsp;or Schedule are for convenience of reference purposes only and shall not affect in any way the meaning or interpretation
of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Any
capitalized terms used in any Exhibit&nbsp;or Schedule but not otherwise defined therein shall have the meaning as defined in this Agreement.
All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set
forth herein. The word &ldquo;including&rdquo; and words of similar import when used in this Agreement will mean &ldquo;including, without
limitation,&rdquo; unless otherwise specified. The words &ldquo;hereof,&rdquo; &ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words
of similar import when used in this Agreement shall refer to the Agreement as a whole and not to any particular provision in this Agreement.
The term &ldquo;or&rdquo; is not exclusive. The word &ldquo;will&rdquo; shall be construed to have the same meaning and effect as the
word &ldquo;shall.&rdquo; References to days mean calendar days unless otherwise specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;1.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Currency</U>.
All references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; or &ldquo;US$&rdquo; in this Agreement refer to United States dollars, which
is the currency used for all purposes in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;II</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
THE MERGER</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Formation
of Merger Sub</U>. Parent has caused Merger Sub to be organized under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>The
Merger</U>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with the DGCL, at the Effective
Time, Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger Sub shall cease, and the Company
shall continue as the surviving company of the Merger and a wholly owned subsidiary of Parent (the &ldquo;<U>Surviving Company</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing</U>.
Unless this Agreement is earlier terminated pursuant to the provisions of <U>Article&nbsp;IX</U>, and subject to the satisfaction or waiver
of the conditions set forth in <U>Article&nbsp;VIII</U>, the consummation of the Merger (the &ldquo;<U>Closing</U>&rdquo;) shall take
place remotely by the electronic exchange of documents, as promptly as practicable (but in no event later than the second Business Day
following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in <U>Article&nbsp;VIII</U>, other
than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such
conditions), unless another time, date and place is mutually agreed upon by Parent and the Company in writing. The date on which the Closing
actually takes place is referred to as the &ldquo;<U>Closing Date</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effective
Time</U>. Upon the terms and subject to the provisions of this Agreement, at the Closing, the parties shall cause the Merger to be consummated
by executing and filing a certificate of merger in a form to be mutually agreed by the parties hereto (the &ldquo;<U>Certificate of Merger</U>&rdquo;)
with the Secretary of State of the State of Delaware (the &ldquo;<U>Delaware Secretary of State</U>&rdquo; ), in such form as is required
by, and executed in accordance with the relevant provisions of the DGCL. The Merger shall become effective at the time of the filing of
such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate
of Merger (the time as of which the Merger becomes effective being the &ldquo;<U>Effective Time</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effects
of the Merger</U>. At and after the Effective Time, the Merger shall have the effects set forth in this Agreement and in the relevant
provisions of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all the property,
rights, privileges, powers and franchises of the Company and Merger Sub shall vest in the Surviving Company, and all debts, liabilities
and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Parent
Governance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Parent
Certificate of Incorporation</U>. At the Effective Time, or at such other time as Parent and the Company shall agree in writing, Parent
shall file an amendment to the certificate of incorporation to (i)&nbsp;change the name of Parent to &ldquo;OrthoCellix,&nbsp;Inc.&rdquo;
or such other name as determined by the Company, (ii)&nbsp;increase the number of shares of Parent Capital Stock that Parent is authorized
to issue to a number mutually agreed between Parent and the Company, such amount to be sufficient to allow for consummation of the Contemplated
Transactions and (iii)&nbsp;make such other changes as mutually agreeable to Parent and the Company (such amendment, the &ldquo;<U>Parent
Charter Amendment</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Parent
Bylaws</U>. At the Effective Time, the bylaws of Parent shall be identical to the bylaws of Parent immediately prior to the Effective
Time, until thereafter amended in accordance with their terms and as provided by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Board
of Directors</U>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation of any directors
on the Parent Board immediately prior to the Effective Time) so that, as of the Effective Time, the Board of Directors shall upon the
Effective Time initially include the Persons set forth on <U>Schedule 2.6(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Parent
Officers</U>. The parties shall take all action necessary (including, to the extent necessary, procuring the resignation or removal of
any officers of Parent immediately prior to the Effective Time) so that, as of the Effective Time, the Parent officers shall initially
consist of the Persons designated by the Company as of the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Surviving
Company and Surviving Company Governance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Effective Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Certificate of Incorporation of the Surviving Company shall, by virtue of the Merger and without any further action, be amended and restated
to read in its entirety as set forth on <U>Exhibit&nbsp;A</U> to the Certificate of Merger, and, as so amended and restated, shall be
the Certificate of Incorporation of the Surviving Company until thereafter amended in accordance with applicable Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The bylaws of the Surviving Company shall be amended and restated to read in
their entirety as the bylaws of Merger Sub as in effect immediately prior to the Effective Time (except that references to the name
of Merger Sub shall be replaced with references to the name of the Surviving Company), and, as so amended and restated, shall be the
bylaws of the Surviving Company until thereafter amended in accordance with applicable Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
directors of the Surviving Company shall be such persons as are designated by the Company prior to the Effective Time, each to hold office
in accordance with the certificate of incorporation and bylaws of the Surviving Company until the earlier of their resignation or removal
or until their respective successors are duly elected and qualified; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
officers of the Surviving Company shall be such persons as are designated by the Company prior to the Effective Time, each to hold office
in accordance with the certificate of incorporation and bylaws of the Surviving Company until the earlier of their resignation or removal
or until their respective successors are duly elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;III</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT COMPANIES; EXCHANGE OF CERTIFICATES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conversion
of Capital Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or the holders of any
shares of capital stock of the Parent, Merger Sub or the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to <U>Section&nbsp;3.3(f)</U>, each share of Company Common Stock issued and outstanding immediately prior to the Effective Time (other
than any Excluded Shares or Dissenting Shares) shall be converted into and become exchangeable for the right to receive, a number of shares
of Parent Common Stock equal to the Exchange Ratio (the &ldquo;<U>Merger Consideration</U>&rdquo; ). As of the Effective Time, all such
shares of Company Common Stock shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and shall
thereafter only represent the right to receive the Merger Consideration. For purposes of this Agreement, the &ldquo;<U>Exchange Ratio</U>&rdquo;
shall mean the ratio (rounded to four decimal places) equal to (A)&nbsp;the Company Merger Shares divided by (B)&nbsp;the Company Outstanding
Shares, in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Aggregate
Valuation</U>&rdquo; means the <U>sum</U> of (i)&nbsp;the Company Valuation and (ii)&nbsp;the Parent Valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Allocation Percentage</U>&rdquo; means the quotient (rounded to two decimal places) determined by dividing (i)&nbsp;the Company Valuation
by (ii)&nbsp;the Aggregate Valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(C)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Merger Shares</U>&rdquo; means (i)&nbsp;the product determined by multiplying (x)&nbsp;the Post-Closing Parent Shares by (y)&nbsp;the
Company Allocation Percentage minus (ii)&nbsp;the Concurrent Investment Shares<U>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(D)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Outstanding Shares</U>&rdquo; means the total number of shares of Company Common Stock outstanding immediately prior to the Effective
Time, expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the rights
or commitments to receive shares of Company Common Stock (or securities convertible or exercisable into shares of Company Common Stock),
whether conditional or unconditional, that are outstanding as of immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(E)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Company
Valuation</U>&rdquo; means (i)&nbsp;$135,000,000 <U>minus</U> (ii)&nbsp;the amount, if any, by which the Concurrent Investment Amount
is less than $25,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(F)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Concurrent
Investment Shares</U>&rdquo; means the number of shares of Parent Common Stock issued to investors in respect of the first $25,000,000
of Parent Common Stock purchased pursuant to the Concurrent Investment (or, if the aggregate amount of the Concurrent Investment is less
than $25,000,000, such number of shares of Parent Common Stock issued to investors pursuant to the Concurrent Investment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(G)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Allocation Percentage</U>&rdquo; means the quotient (rounded to two decimal places) determined by dividing (i)&nbsp;the Parent Valuation
by (ii)&nbsp;the Aggregate Valuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(H)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Outstanding Shares</U>&rdquo; means (i)&nbsp;the total number of shares of Parent Capital Stock outstanding immediately prior to the Effective
Time (after giving effect to the Nasdaq Reverse Stock Split), assuming the exercise, conversion or exchange of all options, warrants,
conversion rights, exchange rights or any other rights to receive shares of Parent Capital Stock which exist immediately prior to the
Effective Time, (ii)&nbsp;without duplication of any amounts set forth in the foregoing <U>clause (i)</U>, the exercise of Parent Options
outstanding as of immediately prior to the Effective Time and (iii)&nbsp;without duplication of any amounts set forth in the foregoing
<U>clauses (i)</U>&nbsp;and <U>(ii)</U>, the settlement in shares of Parent Common Stock of Parent Restricted Stock Unit Awards outstanding
as of immediately prior to the Effective Time. For the avoidance of doubt, Parent OTM Options and Parent Warrants, shall not be included
in the total number of shares of Parent Capital Stock for purposes of determining the Parent Outstanding Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(I)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Valuation</U>&rdquo; means (i)&nbsp;$15,000,000, minus (ii)&nbsp;the amount by which Net Cash is less than $0 (if any) and plus (iii)&nbsp;the
amount by which Net Cash is more than $0 (if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(J)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Parent
Value Per Share</U>&rdquo; equals the Parent Valuation divided by the number of Parent Outstanding Shares (rounded to four decimal places).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(K)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Post-Closing
Parent Shares</U>&rdquo; means the quotient determined by dividing (i)&nbsp;the Parent Outstanding Shares by (ii)&nbsp;the Parent Allocation
Percentage. For the avoidance of doubt, the Post-Closing Parent Shares shall include the Concurrent Investment Shares but shall exclude
any shares issued pursuant to the Concurrent Investment in excess of the Concurrent Investment Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubt and
for illustrative purposes only, sample &ldquo;Exchange Ratio&rdquo;, &ldquo;Company Valuation&rdquo; and &ldquo;Parent Valuation&rdquo;
calculations are set forth on <U>Section&nbsp;3.1(a)(i)(F)</U>&nbsp;of the Parent Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
the Effective Time, each share of Parent Capital Stock issued and outstanding immediately prior to the Effective Time shall remain outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
share of Company Common Stock held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately
prior to the Effective Time (collectively, &ldquo;<U>Excluded Shares</U>&rdquo;) shall automatically be cancelled and shall cease to exist,
and no consideration shall be delivered in exchange therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
share of common stock, par value $0.001 per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall
be converted into and become one validly issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the
Surviving Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
between the date of this Agreement and the Effective Time, the outstanding Company Common Stock or Parent Capital Stock shall have been
changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification,
recapitalization (including the Nasdaq Reverse Stock Split to the extent such split has not previously been taken into account in calculating
the Exchange Ratio), split, combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary,
be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Common Stock, and Parent Capital
Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization,
split, combination or exchange of shares or other like change; provided, however, that nothing herein will be construed to permit the
Company or Parent to take any action with respect to Company Common Stock or Parent Capital Stock, respectively, that is prohibited or
not expressly permitted by the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>[RESERVED.]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exchange
and Payment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
shall issue and deposit (or cause to be deposited) with a bank or trust company mutually agreed upon by the Company and Parent (the &ldquo;<U>Exchange
Agent</U>&rdquo;), in trust for the benefit of holders of shares of Company Common Stock immediately prior to the Effective Time (other
than holders to the extent they hold Excluded Shares or Dissenting Shares), book-entry shares (or certificates if requested) representing
the shares of Parent Capital Stock issuable pursuant to <U>Section&nbsp;3.1(a)(i)</U>. In addition, Parent shall make available by depositing
with the Exchange Agent, as necessary from time to time after the Effective Time any dividends or other distributions payable pursuant
to <U>Section&nbsp;3.3(d)</U>. All certificates representing shares of Parent Capital Stock, and any dividends, distributions and cash
deposited with the Exchange Agent are hereinafter referred to as the &ldquo;<U>Exchange Fund</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
soon as reasonably practicable after the Effective Time and in any event not later than the third (3<SUP>rd</SUP>) Business Day following
the Closing Date, the parties shall cause the Exchange Agent to mail to each holder of record of a certificate that immediately prior
to the Effective Time represented outstanding shares of Company Common Stock (collectively, the &ldquo;<U>Certificates</U>&rdquo;) and
to each holder of record of uncertificated shares of Company Common Stock represented by book entry (&ldquo;<U>Book-Entry Shares</U>&rdquo;)
that were converted into the right to receive the Merger Consideration (together with any dividends or other distributions payable pursuant
to <U>Section&nbsp;3.3(d)</U>), (i)&nbsp;a form of letter of transmittal (which shall specify that delivery shall be effected, and risk
of loss and title to any Certificates held by such Person shall pass, only upon proper delivery of such Certificates, if any, and identification
of the Book-Entry Shares, if any, to the Exchange Agent, and which letter shall be in customary form and contain such other provisions
as Parent or the Exchange Agent may reasonably specify) and (ii)&nbsp;instructions for use in effecting the surrender of any such Certificates
and identifying such Book-Entry Shares in exchange for the Merger Consideration (together with any dividends or other distributions payable
pursuant to <U>Section&nbsp;3.3(d)</U>). Upon surrender of a Certificate and identification of the Book-Entry Shares, as applicable, to
the Exchange Agent, together with such letter of transmittal, duly completed and validly executed in accordance with the instructions
thereto, and such other documents as the Exchange Agent may reasonably require, the holder of such Certificate or Book-Entry Share shall
be entitled to receive in exchange for the shares of Company Common Stock formerly represented by such Certificate or Book-Entry Share
(other than Excluded Shares or Dissenting Shares) (A)&nbsp;that number of whole shares of Parent Capital Stock (after taking into account
all shares of Company Common Stock then held by such holder under all Certificates so surrendered and Book-Entry Shares so identified)
to which such holder of Company Common Stock shall have become entitled pursuant to <U>Section&nbsp;3.1(a)(i)</U>&nbsp;(which shall be
in uncertificated book-entry form unless a physical certificate is requested), and (B)&nbsp;any dividends or other distributions payable
pursuant to <U>Section&nbsp;3.3(d)</U>, and any Certificate so surrendered, together with any Book-Entry Shares, shall forthwith be cancelled.
No interest will be paid or accrued on any unpaid dividends and distributions, if any, payable to holders of Certificates or Book-Entry
Shares. Until surrendered as contemplated by this <U>Section&nbsp;3.3</U>, each Certificate or Book-Entry Share shall be deemed after
the Effective Time to represent only the right to receive the Merger Consideration payable in respect thereof (together with any dividends
or other distributions payable pursuant to <U>Section&nbsp;3.3(d)</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
payment of the Merger Consideration is to be made to a Person other than the Person in whose name the surrendered Certificate or Book-Entry
Share is registered, it shall be a condition of payment that such Certificate so surrendered shall be properly endorsed or shall be otherwise
in proper form for transfer or such Book-Entry Share shall be properly transferred and that the Person requesting such payment shall have
paid any transfer and other Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered
holder of such Certificate or Book-Entry Share or shall have established to the satisfaction of Parent that such Tax is not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
dividends or other distributions with respect to Parent Capital Stock with a record date after the Effective Time shall be paid to the
holder of any unsurrendered Certificate with respect to the shares of Parent Capital Stock that the holder thereof has the right to receive
upon the surrender thereof until the holder thereof shall surrender such Certificate in accordance with this <U>Article&nbsp;III</U>.
Following the surrender of a Certificate in accordance with this <U>Article&nbsp;III</U>, there shall be paid to the record holder thereof,
without interest, (A)&nbsp;promptly after such surrender, the amount of any dividends or other distributions with a record date after
the Effective Time theretofore paid with respect to such whole shares of Parent Capital Stock, and (B)&nbsp;at the appropriate payment
date, the amount of dividends or other distributions with a record date after the Effective Time but prior to such surrender and a payment
date subsequent to such surrender payable with respect to such whole shares of Parent Capital Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Holders
of Book-Entry Shares who are entitled to receive shares of Parent Capital Stock under this <U>Article&nbsp;III</U> shall be paid (A)&nbsp;at
the time of payment of such Parent Capital Stock by the Exchange Agent under <U>Section&nbsp;3.3</U>, the amount of dividends or other
distributions with a record date after the Effective Time theretofore paid with respect to such whole shares of Parent Capital Stock,
and (B)&nbsp;at the appropriate payment date, the amount of dividends or other distributions with a record date after the Effective Time
but prior to the time of such payment by the Exchange Agent under <U>Section&nbsp;3.3</U> and a payment date subsequent to the time of
such payment by the Exchange Agent under <U>Section&nbsp;3.3</U> payable with respect to such whole shares of Parent Capital Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Merger Consideration (together with any dividends or other distributions payable pursuant to <U>Section&nbsp;3.3(d)</U>) shall be deemed
to have been issued and paid in full satisfaction of all rights pertaining to the shares of Company Common Stock formerly represented
by such Certificates or Book-Entry Shares. At the Effective Time, the stock transfer books of the Company shall be closed and there shall
be no further registration of transfers of the shares of Company Common Stock that were outstanding immediately prior to the Effective
Time. If, after the Effective Time, Certificates are presented to the Surviving Company or the Exchange Agent for transfer or transfer
is sought for Book-Entry Shares, such Certificates or Book-Entry Shares shall be cancelled and exchanged as provided in this <U>Article&nbsp;III</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional
shares shall be issued. For purposes of calculating the Merger Consideration issuable to each holder of Company Common Stock, the number
of shares of Company Common Stock to be issued shall be rounded down to the nearest whole number (without any consideration payable for
such fractional shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
portion of the Exchange Fund that remains undistributed to the holders of Certificates or Book-Entry Shares six months after the Effective
Time shall be delivered to the Surviving Company, upon demand, and any remaining holders of Certificates or Book-Entry Shares (except
to the extent representing Excluded Shares or Dissenting Shares) shall thereafter look only to the Surviving Company, as general creditors
thereof, for payment of the Merger Consideration (together with any dividends or other distributions payable pursuant to <U>Section&nbsp;3.3(d)</U>)
(subject to abandoned property, escheat or other similar laws), without interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>None
of Parent, the Surviving Company, the Exchange Agent or any other Person shall be liable to any Person in respect of shares of Parent
Capital Stock, dividends or other distributions with respect thereto properly delivered to a public official pursuant to any applicable
abandoned property, escheat or similar Law. If any Certificates or Book-Entry Shares shall not have been exchanged prior to two years
after the Effective Time (or immediately prior to such earlier date on which the related Merger Consideration (and all dividends or other
distributions with respect to shares of Parent Capital Stock) would otherwise escheat to or become the property of any Governmental Entity),
any such Merger Consideration (and such dividends, distributions and cash) in respect thereof shall, to the extent permitted by applicable
Law, become the property of the Surviving Company, free and clear of all claims or interest of any Person previously entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit, in form and substance reasonably acceptable
to Parent, of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by Parent or the Exchange
Agent, the posting by such Person of a bond in such amount as Parent or the Exchange Agent may determine is reasonably necessary as indemnity
against any claim that may be made against it or the Surviving Company with respect to such Certificate, then the Exchange Agent will
deliver in exchange for such lost, stolen or destroyed Certificate the Merger Consideration payable in respect thereof (together with
any dividends or other distributions payable pursuant to <U>Section&nbsp;3.3(d)</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withholding
Rights</U>. Parent, the Surviving Company and the Exchange Agent (each, a &ldquo;<U>Withholding Agent</U>&rdquo;) shall each be entitled
to deduct and withhold, or cause to be deducted and withheld, from the consideration otherwise payable pursuant to this Agreement such
amounts as any Withholding Agent is required to deduct and withhold under applicable Law. To the extent that amounts are so deducted and
withheld by a Withholding Agent and remitted to the appropriate Governmental Entity, such amounts shall be treated for all purposes of
this Agreement as having been paid to the Person in respect of whom such deduction and withholding was made. The Withholding Agent shall
use commercially reasonable efforts to (i)&nbsp;notify each holder of Company Common Stock at least five (5)&nbsp;Business Days prior
to deducting or withholding any amounts of its intent to deduct and withhold and (ii)&nbsp;cooperate with such holder to minimize any
such deductions and withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dissenters
Rights</U>. Notwithstanding anything in this Agreement to the contrary, each share of the Company Common Stock (other than Excluded Shares)
outstanding immediately prior to the Effective Time and held by a holder who is entitled to demand and has properly demanded appraisal
for such shares of the Company Common Stock in accordance with Section&nbsp;262 of the DGCL and, as of the Effective Time, have neither
effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL (&ldquo;<U>Dissenting Shares</U>&rdquo;), shall
not be converted into or be exchangeable for the right to receive a portion of the Merger Consideration but shall be entitled only to
such rights as are granted by Section&nbsp;262 of the DGCL, unless and until such holder fails to perfect or withdraws or otherwise loses
such holder&rsquo;s right to appraisal and payment under the DGCL. If, after the Effective Time, any such holder fails to perfect or withdraws
or loses such holder&rsquo;s right to appraisal, such Dissenting Shares shall thereupon be treated as if they had been converted as of
the Effective Time into the right to receive the portion of the Merger Consideration, if any, to which such holder is entitled pursuant
to <U>Section&nbsp;3.1(a)(i)</U>, without interest. The Company shall give Parent (a)&nbsp;prompt notice of any demands received by the
Company for appraisal of any shares of the Company Common Stock issued and outstanding immediately prior to the Effective Time, attempted
written withdrawals of such demands, and any other instruments served pursuant to the DGCL and received by the Company relating to stockholders&rsquo;
rights to appraisal with respect to the Merger and (b)&nbsp;the opportunity to participate in all negotiations and proceedings with respect
to any exercise of such appraisal rights under the DGCL. The Company shall not, except with the prior written consent of Parent, which
shall not be unreasonably withheld, conditioned or delayed, voluntarily make any payment with respect to any demands for payment of fair
value for capital stock of the Company, offer to settle or settle any such demands or approve any withdrawal of any such demands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Calculation
of Net Cash</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Not
less than five (5)&nbsp;Business Days prior to the anticipated date for the Parent Stockholder Meeting as mutually agreed in good faith
by Parent and the Company (the &ldquo;<U>Anticipated Meeting Date</U>&rdquo;), Parent will deliver to the Company a certificate signed
by an officer of Parent in the form reasonably acceptable to the Company setting forth a schedule (the &ldquo;<U>Parent Net Cash Schedule</U>&rdquo;
, and the date of delivery of the Parent Net Cash Schedule, the &ldquo;<U>Delivery Date</U>&rdquo;) setting forth, in reasonable detail,
Parent&rsquo;s good faith, estimated calculation of Net Cash (the &ldquo;<U>Parent Net Cash Calculation</U>&rdquo;) as of the close of
business on the Closing Date (the &ldquo;<U>Cash Determination Time</U>&rdquo;) prepared and certified by Parent&rsquo;s chief financial
officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall
make available to the Company (electronically to the greatest extent possible), as reasonably requested by the Company, the work papers
and back-up materials (including all relevant invoices and similar evidence of outstanding obligations) used or useful in preparing the
Parent Net Cash Schedule and, if reasonably requested by the Company, Parent&rsquo;s internal finance personnel, accountants and counsel
at reasonable times and upon reasonable notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Within
three (3)&nbsp;Business Days after the Delivery Date (the last day of such period, the &ldquo;<U>Response Date</U>&rdquo;), the Company
shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a
 &ldquo;<U>Dispute Notice</U>&rdquo;). Any Dispute Notice shall identify in reasonable detail and, to the extent known, the nature and
amounts of any proposed revisions to the Parent Net Cash Calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation
or, if prior to 11:59 p.m.&nbsp;(Eastern time) on the Response Date, the Company fails to deliver a Dispute Notice as provided in <U>Section&nbsp;3.6(b)</U>,
then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule shall be deemed to have been finally determined for
purposes of this Agreement and to represent the Net Cash at the Cash Determination Time (the &ldquo;<U>Final Parent Net Cash</U>&rdquo;)
for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the Company delivers a Dispute Notice on or prior to 11:59 p.m.&nbsp;(Eastern time) on the Response Date, then Representatives of Parent
and the Company shall promptly, and in no event later than one calendar day after the Response Date, communicate and attempt in good faith
to resolve the disputed item(s)&nbsp;and negotiate an agreed-upon determination of Net Cash, which agreed upon Net Cash amount (if so
resolved) shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Parent Net Cash for
purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
Representatives of Parent and the Company are unable to resolve the disputed items pursuant to <U>Section&nbsp;3.6(d)</U>&nbsp;within
three calendar days after delivery of the Dispute Notice (or such other period as Parent and the Company may mutually agree upon), then
any remaining disagreements as to the calculation of Net Cash shall be referred to an independent auditor of recognized national standing
jointly selected by Parent and the Company (provided that if the parties are unable to select an independent auditor within five (5)&nbsp;days,
then either Parent or the Company may thereafter request that the Philadelphia, Pennsylvania Office of the American Arbitration Association
(&ldquo;<U>AAA</U>&rdquo;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor
selected by the AAA, the &ldquo;<U>Accounting Firm</U>&rdquo;)). Parent shall promptly deliver to the Accounting Firm all work papers
and back-up materials used in preparing the Parent Net Cash Schedule, and Parent and the Company shall use commercially reasonable efforts
to cause the Accounting Firm to make its determination within five calendar days of accepting its selection. Parent and the Company shall
be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues
with the Accounting Firm; provided, however, that no such presentation or discussion shall occur without the presence of a Representative
of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting
Firm. The determination of the amount of Net Cash made by the Accounting Firm shall be made in writing delivered to each of Parent and
the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined
for purposes of this Agreement and to represent the Final Parent Net Cash for purposes of this Agreement. The parties shall delay the
Closing until the resolution of the matters described in this <U>Section&nbsp;3.6(e)</U>. The fees and expenses of the Accounting Firm
shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Net Cash that was unsuccessfully
disputed amount by such party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Net Cash amount
and such portion of the costs and expenses of the Accounting Firm borne by the Company and any other fees, costs or expenses incurred
by the Company following the Anticipated Meeting Date in connection with the procedures set forth in this <U>Section&nbsp;3.6(e)</U>&nbsp;shall
be deducted from the final determination of the amount of Net Cash, to the extent of available amounts. If this <U>Section&nbsp;3.6(e)</U>&nbsp;applies
as to the determination of the Final Parent Net Cash described in <U>Section&nbsp;3.6(a)</U>, upon resolution of the matter in accordance
with this <U>Section&nbsp;3.6(e)</U>, the parties shall not be required to determine the Net Cash again even though the Closing Date may
occur later than the Anticipated Meeting Date. Notwithstanding anything else in this Agreement, Parent shall redetermine the Final Parent
Net Cash if the Closing Date is more than ten calendar days after the Anticipated Meeting Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contingent
Value Right</U>. Prior to the Effective Time, Parent shall declare a distribution (the &ldquo;<U>Pre-Closing Distribution</U>&rdquo;)
to holders of Parent Common Stock of record the right to receive one contingent value right (each, a &ldquo;<U>CVR</U>&rdquo;) for each
outstanding share of Parent Common Stock held by such stockholder as of such date, each representing the right to receive contingent payments
upon the occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent
Value Rights Agreement in the form attached hereto as <U>Exhibit&nbsp;D</U>, to be entered into between Parent and Computershare (or such
other nationally recognized rights agent agreed to between Parent and the Company) (the &ldquo;<U>Rights Agent</U>&rdquo;), with such
revisions thereto requested by the Rights Agent that are not, individually or in the aggregate, materially detrimental to the holders
of CVRs and reasonably acceptable to Parent and the Company (the &ldquo;<U>CVR Agreement</U>&rdquo;). The record date for the Pre-Closing
Distribution shall be the close of business on the last Business Day prior to the day on which the Effective Time occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;IV</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in the
corresponding section or subsection of the disclosure letter delivered by the Company to Parent (the &ldquo;<U>Company Disclosure Letter</U>&rdquo;)
(it being agreed that the disclosure of any information in a particular section or subsection of the Company Disclosure Letter shall be
deemed disclosure of such information with respect to any other section or subsection of this Agreement to which the relevance of such
information is readily apparent on its face), each of the Company and Guarantor represents and warrants to Parent and Merger Sub as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization,
Standing and Power</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company (i)&nbsp;is an entity duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation,
(ii)&nbsp;has all requisite corporate or similar power and authority to own, lease and operate its properties and to carry on its business
as now being conducted and as currently contemplated to be conducted and (iii)&nbsp;is duly qualified or licensed to do business and is
in good standing in each jurisdiction in which the nature of its business or the ownership, leasing or operation of its properties makes
such qualification or licensing necessary, except in the case of clause&nbsp;(iii), where the failure to be so qualified or licensed or
in good standing, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect.
For purposes of this Agreement, &ldquo;<U>Material Adverse Effect</U>&rdquo; means any event, change, circumstance, occurrence, effect
or state of facts that (A)&nbsp;is or would reasonably be expected to be materially adverse to the business, assets, liabilities, financial
condition, or results of operations of the Company, taken as a whole, or (B)&nbsp;materially impairs the ability of the Company to consummate
the Merger or any of the other Contemplated Transactions; <U>provided</U>, <U>however</U>, that in the case of clause&nbsp;(A)&nbsp;only,
Material Adverse Effect shall not include any event, change, circumstance, occurrence, effect or state of facts to the extent resulting
from (1)&nbsp;changes or conditions generally affecting the industries in which the Company operates, or the economy or the financial,
debt, banking, capital, credit or securities markets, in the United States, including effects on such industries, economy or markets resulting
from any regulatory and political conditions or developments in general, (2)&nbsp;the outbreak or escalation of war or acts of terrorism
or any natural disasters, acts of God or comparable events, epidemic, pandemic or disease outbreak or any worsening of the foregoing,
or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity
in response thereto, (3)&nbsp;changes in Law or generally accepted accounting principles in the United States (&ldquo;<U>GAAP</U>&rdquo;),
or the interpretation or enforcement thereof or (4)&nbsp;the public announcement or pendency of this Agreement; <U>provided</U>, that,
with respect to clauses&nbsp;(1), (2)&nbsp;and (3), the impact of such event, change, circumstance, occurrence, effect or state of facts
is not disproportionately adverse to the Company as compared to other participants in the industries in which the Company operates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has previously made available to Parent true and complete copies of the Company&rsquo;s Certificate of Incorporation (the &ldquo;<U>Company
Charter</U>&rdquo;) and bylaws (the &ldquo;<U>Company Bylaws</U>&rdquo;), in each case as amended to the date of this Agreement, and each
as so delivered is in full force and effect. The Company is not in violation of any provision of its Certificate of Incorporation or bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capital
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
authorized capital stock of the Company consists of 1,000 shares of Company Common Stock. (i)&nbsp;1,000 shares of Company Common Stock
(excluding treasury shares) are issued and outstanding, all of which are owned by Guarantor, and (ii)&nbsp;no shares of Company Common
Stock are held by the Company in its treasury. All outstanding shares of capital stock of the Company are duly authorized, validly issued,
fully paid and nonassessable and not subject to any preemptive rights. The Company does not have any outstanding bonds, debentures, notes
or other obligations having the right to vote (or convertible into, or exchangeable or exercisable for, securities having the right to
vote) with the stockholders of the Company on any matter. Except as set forth above in this <U>Section&nbsp;4.2(a)</U>, the Company does
not have any outstanding (A)&nbsp;shares of capital stock or other voting securities or equity interests of the Company, (B)&nbsp;securities
of the Company convertible into or exchangeable or exercisable for shares of capital stock of the Company or other voting securities or
equity interests of the Company, (C)&nbsp;stock appreciation rights, &ldquo;phantom&rdquo; stock rights, performance units, interests
in or rights to the ownership or earnings of the Company or other equity equivalent or equity-based awards or rights, (D)&nbsp;subscriptions,
options, warrants, calls, commitments, Contracts or other rights to acquire from the Company, or obligations of the Company to issue,
any shares of capital stock of the Company, voting securities, equity interests or securities convertible into or exchangeable or exercisable
for capital stock or other voting securities or equity interests of the Company or rights or interests described in the preceding clause&nbsp;(C),
or (E)&nbsp;obligations of the Company to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell,
or cause to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements
or understandings to which the Company or Guarantor is a party or of which the Company or Guarantor has knowledge with respect to the
holding, voting, registration, redemption, repurchase or disposition of, or that restricts the transfer of, any capital stock or other
voting securities or equity interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the date hereof, there are no outstanding options or other similar rights to purchase or receive shares of Company Common Stock or
similar rights with respect to any Company Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsidiaries</U>.
 &lrm; The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership
or profit sharing interest of any nature in, or controls directly or indirectly, any other entity. The Company is not and has never otherwise
been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company
has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment
in or capital contribution to any other entity. The Company has not, at any time, been a general partner of, or has otherwise been liable
for any of the debts or other obligations of, any general partnership, limited partnership or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authority</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has all necessary corporate power and authority to execute, deliver and perform its obligations under this Agreement and to consummate
the Contemplated Transactions. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company
of the Contemplated Transactions have been duly authorized by all necessary corporate action on the part of the Company and no other corporate
proceedings on the part of the Company are necessary to approve this Agreement or to consummate the Merger and the other Contemplated
Transactions, subject, in the case of the consummation of the Merger, to receipt of the Company Stockholder Approval. This Agreement has
been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by Parent and Merger Sub,
constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (except to the
extent that enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the
enforcement of creditors&rsquo; rights generally or by general principles of equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company Board has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company
and its sole stockholder, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions, (iii)&nbsp;determined
to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole stockholder of the Company vote
to adopt this Agreement and thereby approve the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company Stockholder Approval is the only vote of the holders of any class or series of the Company Common Stock or other securities required
in connection with the consummation of the Merger. Other than the Company Stockholder Approval (and except with respect to the Concurrent
Investment), no vote of the holders of any class or series of the Company&rsquo;s capital stock or other securities is required in connection
with the consummation of any of the Contemplated Transactions to be consummated by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflict; Consents and Approvals</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in <U>Section&nbsp;4.5(a)</U>&nbsp;of the Company Disclosure Letter, the execution, delivery and performance of this Agreement
by the Company does not, and the consummation of the Merger and the other Contemplated Transactions (including the Contribution) and compliance
by the Company with the provisions hereof will not, conflict with, or result in any violation or breach of, or default (with or without
notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancellation, modification or acceleration
of any obligation or to the loss of a benefit under, or result in the creation of any pledge, claim, lien, charge, option, right of first
refusal, encumbrance or security interest of any kind or nature whatsoever (including any limitation on voting, sale, transfer or other
disposition or exercise of any other attribute of ownership) (collectively, &ldquo;<U>Liens</U>&rdquo;) in or upon any of the properties,
assets or rights of the Company under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under,
or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&nbsp;the Company Charter or Company Bylaws,
(ii)&nbsp;any material bond, debenture, note, mortgage, indenture, guarantee, license, lease, purchase or sale order or other contract,
commitment, agreement, instrument, obligation, arrangement, understanding, undertaking, permit, concession or franchise, whether oral
or written (each, including all amendments thereto, a &ldquo;<U>Contract</U>&rdquo;) to which the Company is a party or by which the Company
or any of its properties or assets may be bound or (iii)&nbsp;subject to the governmental filings and other matters referred to in <U>Section&nbsp;4.5(b)</U>,
any federal, state, local or foreign law (including common law), statute, ordinance, rule, code, regulation, order, judgment, injunction,
decree or other legally enforceable requirement (&ldquo;<U>Law</U>&rdquo;) applicable to the Company or by which the Company or any of
its properties or assets may be bound, except as, in the case of clause&nbsp;(iii), as individually or in the aggregate, has not had and
would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any federal, state, local or foreign
government or subdivision thereof or any other governmental, administrative, judicial, arbitral, legislative, executive, regulatory or
self-regulatory authority, instrumentality, agency, commission or body (each, a &ldquo;<U>Governmental Entity</U>&rdquo;) is required
by or with respect to the Company in connection with the execution, delivery and performance of this Agreement by the Company or the consummation
by the Company of the Merger and the other Contemplated Transactions or compliance with the provisions hereof, except for (i)&nbsp;the
filing with the SEC of such reports under Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934, as amended (the
 &ldquo;<U>Exchange Act</U>&rdquo;), as may be required in connection with this Agreement and the Contemplated Transactions, (ii)&nbsp;such
other filings and reports as may be required pursuant to the applicable requirements of the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;), the Exchange Act and any other applicable state or federal securities, takeover and &ldquo;blue sky&rdquo; laws, (iii)&nbsp;the
filing of the Certificate of Merger with the Delaware Secretary of State as required by the DGCL, and (iv)&nbsp;such other consents, approvals,
orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually or in
the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Financial
Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the Closing, the Company will have made available to the Parent true and correct copies of the Company Audited Financial Statements
and the Company Interim Financial Statements. Each of the Company Audited Financial Statements and the Company Interim Financial Statements
(i)&nbsp;will be, as of the Closing, correct and complete in all material respects and have been prepared in accordance with the books
and records of the Company; (ii)&nbsp;will have been prepared in accordance with GAAP applied on a consistent basis throughout the periods
indicated (except as may be indicated in the notes thereto); and (iii)&nbsp;will fairly present, in all material respects, the financial
position, results of operations and cash flows of the Company as at the respective dates thereof and for the respective periods indicated
therein, except as otherwise noted therein and subject, in the case of the Company Interim Financial Statements, to normal and recurring
year-end adjustments that will not, individually or in the aggregate, be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as and to the extent adequately accrued or reserved against in the balance sheet set forth in the Company Audited Financial Statements,
the Company does not have any liability or obligation of any nature, whether accrued, absolute, contingent or otherwise, whether known
or unknown and whether or not required by GAAP to be reflected in a balance sheet of the Company or disclosed in the notes thereto, except
for liabilities and obligations, incurred in the ordinary course of business consistent with past practice since the date of the Company
Audited Financial Statements, that are not, individually or in the aggregate, material to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Undisclosed Liabilities</U>. The Company does not have any liabilities or obligations of any nature, whether accrued, absolute, contingent
or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected on a balance sheet
under GAAP, except for liabilities and obligations incurred in the ordinary course of business consistent with past practice (none of
which is a liability for a breach or default under any contract, breach of warranty, tort, infringement, misappropriation or violation
of law) that are not individually or in the aggregate material to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Certain Changes or Events</U>. Except as set forth in <U>Section&nbsp;4.8</U> of the Company Disclosure Letter, since June&nbsp;19,
2025: (i)&nbsp;except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, the Company
has conducted their business only in the ordinary course consistent with past practice and consistent with the business of the Company
as currently contemplated to be conducted; (ii)&nbsp;there has not been any change, event or development or prospective change, event
or development that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect; and
(iii)&nbsp;the Company has not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;declared,
set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital
stock or other equity interests, (ii)&nbsp;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests
of the Company or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&nbsp;split, combined,
reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the issuance
of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>amended
or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar
organizational documents);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>issued,
granted, promised or otherwise committed to issue, any Company Common Stock or other securities of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sold,
leased, licensed or otherwise disposed of any of its assets or properties, or grant any Lien with respect to such assets or properties,
including with respect to any Company Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>adopted
or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>changed
its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable
Law, or revalued any of its material assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Litigation</U>.
There is no action, suit, claim, arbitration, investigation, inquiry, grievance or other proceeding (each, an &ldquo;<U>Action</U>&rdquo;)
(or basis therefor) pending or, to the knowledge of the Company, threatened against or affecting the Company, its properties or assets,
or any present or former officer, director or employee of the Company in such individual&rsquo;s capacity as such, other than any Action
that (a)&nbsp;does not involve an amount in controversy in excess of $100,000 and (b)&nbsp;does not seek injunctive or other non-monetary
relief. The Company&rsquo;s properties and assets are not subject to any outstanding judgment, order, injunction, rule&nbsp;or decree
of any Governmental Entity. There is no Action pending or, to the knowledge of the Company, threatened seeking to prevent, hinder, modify,
delay or challenge the Merger or any of the other Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Laws</U>. The Company has been in compliance in all material respects with all Laws applicable to their businesses, operations, properties
or assets. Neither Guarantor nor the Company has received, since January&nbsp;1, 2022 a notice or other written communication alleging
or relating to a possible material violation of any Law applicable to their businesses, operations, properties, assets or Company Products
(as defined below). The Company has in effect all material permits, licenses, variances, exemptions, applications, approvals, clearances,
authorizations, registrations, formulary listings, consents, operating certificates, franchises, orders and approvals (collectively, &ldquo;<U>Permits</U>&rdquo;)
of all Governmental Entities necessary or advisable for them to own, lease or operate its properties and assets and to carry on its businesses
and operations as now conducted and as currently contemplated to be conducted, and there has occurred no violation of, default (with or
without notice or lapse of time or both) under or event giving to others any right of revocation, non-renewal, adverse modification or
cancellation of, with or without notice or lapse of time or both, any such Permit, nor would any such revocation, non-renewal, adverse
modification or cancellation result from the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Health
Care Regulatory Matters</U>. Except as set forth in <U>Section&nbsp;4.11</U> of the Company Disclosure Letter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company and Guarantor, and to the knowledge of the Company, each of its directors, officers, management employees, agents (while acting
in such capacity), contract manufacturers, suppliers, and distributors are, and since January&nbsp;1, 2022 has been, in material compliance
with all health care laws to the extent applicable to the Company or any of its products or activities, including, but not limited to
the following: the Federal Food, Drug&nbsp;&amp; Cosmetic Act (&ldquo;<U>FDCA</U>&rdquo;); the Public Health Service Act (42 U.S.C. &sect;
201 et seq.), including the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. &sect; 263a); the Federal Trade Commission Act
(15 U.S.C. &sect; 41 et seq.); the Controlled Substances Act (21 U.S.C. &sect; 801 et seq.); the federal Anti-Kickback Statute (42 U.S.C.
 &sect; 1320a-7b(b)); the civil monetary penalties law (42 U.S.C. &sect; 1320a-7a); the civil False Claims Act (31 U.S.C. &sect; 3729 et
seq.); the administrative False Claims Law (42 U.S.C. &sect;&nbsp;1320a-7b(a)); the Stark law (42 U.S.C. &sect; 1395nn); the Criminal
Health Care Fraud Statute (18 U.S.C. &sect; 1347); the exclusion laws (42 U.S.C. &sect; 1320a-7); Medicare (Title XVIII of the Social
Security Act); Medicaid (Title XIX of the Social Security Act); any regulations promulgated pursuant to such laws; and any other state,
federal or ex-U.S. laws or regulations governing the manufacturing, development, testing, labeling, advertising, marketing or distribution
of drug, biologic and medical device products, kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements,
medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government
health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care, clinical
laboratory or diagnostic products or services, to the extent applicable to the Company (&ldquo;<U>Health Care Laws</U>&rdquo;). To the
knowledge of the Company, there are no facts or circumstances that reasonably would be expected to give rise to any material liability
under any Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company is not party to any material corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar
agreements with or imposed by any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived
therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the U.S. Food and Drug Administration
(&ldquo;<U>FDA</U>&rdquo;) or other Governmental Entity relating to products that are regulated as drugs, medical devices, or other healthcare
products under Health Care Laws, including drugs or medical devices, compounds or products being researched, tested, stored, developed,
labeled, manufactured, packed, imported, exported and/or distributed by the Company (&ldquo;<U>Company Products</U>&rdquo;), including,
without limitation, investigational new drug applications and investigational device exemptions, when submitted to the FDA or other Governmental
Entity were true, complete and correct in all material respects as of the date of submission and any necessary or required updates, changes,
corrections or modification to such applications, submissions, information and data have been submitted to the FDA or other Governmental
Entity. The Company does not have knowledge of any facts or circumstances that would be reasonably likely to lead to the revocation, suspension,
limitation, or cancellation of a Permit required under Health Care Laws or of any application for marketing approval currently pending
before the FA or such other Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
preclinical studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of the Company have been, and if still
pending are being, conducted in compliance with research protocols and all applicable Health Care Laws, including, but not limited to,
the FDCA and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314, 320 and 812. No clinical trial conducted
by or on behalf of the Company has been conducted using any clinical investigators who have been disqualified. No clinical trial conducted
by or on behalf of the Company has been terminated or suspended prior to completion, and no clinical investigator that has participated
or is participating in, or institutional review board that has or has had jurisdiction over, a clinical trial conducted by or on behalf
of the Company has placed a clinical hold order on, or otherwise terminated, delayed or suspended, such a Company clinical trial at a
clinical research site based on an actual or alleged lack of safety or efficacy of any Company Product or a failure to conduct such clinical
trial in compliance with applicable Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
manufacturing operations conducted by or, to the knowledge of the Company, for the benefit of the Company have been and are being conducted
in material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&rsquo;s current good manufacturing
practice (cGMP) regulations for drug products at 21 C.F.R. Parts 210 and 211, the Quality System (QS) regulations at 21 C.F.R. Part&nbsp;820
and all comparable foreign regulatory requirements of any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not received any written communication that relates to an alleged violation or non-compliance with any Health Care Laws, including
any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention
or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning
Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <U>Section&nbsp;4.11(f)</U>&nbsp;of
the Company Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Company
Products required or requested by a Governmental Entity, or other notice of action relating to an alleged lack of safety, efficacy, or
regulatory compliance of the Company Products, or any adverse experiences relating to the Company Products that have been reported to
FDA or other Governmental Entity (&ldquo;<U>Safety Notices</U>&rdquo;). All Safety Notices listed in <U>Section&nbsp;4.11(g)</U>&nbsp;of
the Company Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in <U>Section&nbsp;4.11(h)</U>&nbsp;of the Company Disclosure Letter, there are no unresolved Safety Notices, and to the
knowledge the Company, there are no facts or circumstances that would be reasonably likely to result in a Safety Notice with respect to
the Company Products or a termination or suspension of developing and testing of any of the Company Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
the Company, nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has made an untrue statement
of a material fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed
to a Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide
a basis for the FDA to invoke its policy respecting &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo;
Final Policy set forth in 56 Fed. Reg. 46191 (September&nbsp;10, 1991) and any amendments thereto (the &ldquo;<U>FDA Ethics Policy</U>&rdquo;).
None of the aforementioned is or has been under investigation resulting from any allegedly untrue, fraudulent, misleading, or false statement
or omission, including data fraud, or had any action pending or threatened relating to the FDA Ethics Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by
the Company have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims,
Permits or notices have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected
in or supplemented by a subsequent filing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
the Company nor, to the knowledge of the Company, any officer, employee, agent, or distributor of the Company has been convicted of any
crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including,
without limitation, 21 U.S.C. &sect; 335a, or exclusion under 42 U.S.C. &sect; 1320a-7, or any other statutory provision or similar law
applicable in other jurisdictions in which the Company Products are sold or intended to be sold. Neither the Company nor, to the knowledge
of the Company, any officer, employee, agent or distributor of the Company, has been excluded from participation in any federal health
care program or convicted of any crime or engaged in any conduct for which such Person could be excluded from participating in any federal
health care program under Section&nbsp;1128 of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Benefit
Plans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the date hereof, the Company does not have any Employee Plans or employees, independent contractors, consultants, temporary employees,
leased employees or other agents employed or used by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.12(a)&nbsp;</U>of
the Company Disclosure Letter contains a true, correct, and complete list of each material Company Plan, specifying thereon the Company
Plans that cover employees of and individual independent contractors (including those who work through substantially owned entities) that
provide services to the Company or that will be or are reasonably likely to be assigned to the Company (together, &ldquo;<U>Company Service
Providers</U>). Neither Guarantor, its Subsidiaries or any member of their Controlled Group has ever sponsored, maintained, contributed
to, or been required to contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&nbsp;a Multiemployer Plan,
(ii)&nbsp;an &ldquo;employee pension benefit plan&rdquo; (within the meaning of Section&nbsp;3(2)&nbsp;of ERISA) that is subject to Title
IV of ERISA or Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, (iii)&nbsp;any &ldquo;multiple employer plan&rdquo; as defined
in Section&nbsp;413 of the Code or Section&nbsp;210 of ERISA, (iv)&nbsp;a &ldquo;funded welfare benefit plan&rdquo; within the meaning
of Section&nbsp;419 of the Code or (v)&nbsp;any &ldquo;multiple employer welfare arrangement&rdquo; (as such term is defined in Section&nbsp;3(40)
of ERISA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>With
respect to the Company Plans:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Company Plan is and has been established, operated and administered in all material respects with its terms and materially complies in
form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
Company Plan is, or within the past six years has been, the subject of an application or filing under a government sponsored amnesty,
voluntary compliance, or similar program, or been the subject of any self-correction under any such program;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Company Plan intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code has received a favorable determination, advisory and/or
opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of Guarantor or the Company
since the date of such letter that would reasonably be expected to cause the loss of the sponsor&rsquo;s ability to rely upon such letter,
and nothing has occurred to the knowledge of Guarantor or the Company that would reasonably be expected to result in the loss of the qualified
status of such Company Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>there
is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the
IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Guarantor or the Company,
threatened, relating to the Company Plans, any fiduciaries thereof with respect to their duties to Company Plans or the assets of any
of the trusts under any of the Company Plans (other than routine claims for benefits);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>none
of the Company Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits
to any person for any reason, except as may be required by COBRA, and neither Company nor any members of its Controlled Group has any
liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee
or former employee of Guarantor or the Company (either individually or to such employees as a group) or any other person that such employee(s)&nbsp;or
other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except with
respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
payments and/or contributions required to have been timely made with respect to all Company Plans either have been made or have been accrued
in accordance with the terms of the applicable Company Plan and applicable law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Company Plan that includes Company Service Providers is subject exclusively to United States Law; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
execution and delivery of this Agreement, the Company Stockholder Approval, and the consummation of the Merger will not, either alone
or in combination with any other event, (A)&nbsp;entitle any Company Service Providers to severance pay, unemployment compensation or
any other similar termination payment, or (B)&nbsp;accelerate the time of payment or vesting, or increase the amount of or otherwise enhance
any benefit due any such Company Service Providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
is no agreement, plan or other arrangement to which Guarantor, the Company, or any of their Subsidiaries is a party or by which Guarantor,
the Company, or any of their Subsidiaries is otherwise bound to compensate any Company Service Providers in respect of Taxes or other
liabilities incurred with respect to Section&nbsp;409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Company Plan that relates to Company Service Providers is a &ldquo;nonqualified deferred compensation plan&rdquo; within the meaning of
Section&nbsp;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) complies in both form and operation
in all material respects with the requirements of Section&nbsp;409A of the Code (or any comparable or similar provision of state, local,
or foreign Law) and all applicable IRS guidance issued with respect thereto (and has so complied for the entire period during which Section&nbsp;409A
of the Code has applied to such Company Plan) so that no amount paid or payable pursuant to any such Company Plan is subject to any additional
Tax or interest under Section&nbsp;409A of the Code (or any comparable or similar provision of state, local, or foreign Law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
Company Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Labor
and Employment Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Solely
with respect to Company Service Providers, Guarantor and each of its Subsidiaries are and, since January&nbsp;1, 2022, have been, in compliance
in all material respects with all applicable Laws relating to labor or employment matters, including those relating to employment practices,
terms and conditions of employment, collective bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination
in employment, workers&rsquo; compensation, the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment
compensation, equal employment opportunity, discrimination, harassment, employee and contractor classification, restrictive covenants,
pay equity, information privacy and security, and continuation coverage with respect to group health plans, in each case to the extent
applicable to Company Service Providers. Since January&nbsp;1, 2022, there has not been, and as of the date of this Agreement there is
not pending or, to the knowledge of Guarantor or the Company, threatened, any labor dispute, work stoppage, labor strike or lockout with
respect to the Company and involving any employee of Guarantor or its Subsidiaries that provides services primarily or exclusively to
the Company or who will be or is reasonably likely to be assigned to the Company (a &ldquo;<U>Company Employee</U>&rdquo; ).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>None
of Guarantor nor its Subsidiaries is, or since January&nbsp;1, 2022 has been, party to, or bound by, a collective bargaining agreement
or similar labor agreement with respect to the Company Employees, and no such agreement is being negotiated. To the knowledge of Guarantor
or the Company, there has not been any activity on behalf of any labor union, labor organization or similar employee group to organize
any Company Employees. Solely with respect to Company Employees, there are no, and since January&nbsp;1, 2022, there has not been any:
(i)&nbsp;unfair labor practice charges or complaints against Guarantor, the Company, or any of their Subsidiaries pending before the National
Labor Relations Board or any other labor relations tribunal or authority in respect of any Company Employees, and to the knowledge of
Guarantor and the Company no such charges or complaints are threatened, or (ii)&nbsp;&nbsp;grievances or pending arbitration proceedings
against Guarantor or any of its Subsidiaries in respect of any Company Employees that arose out of or under any collective bargaining
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
January&nbsp;1, 2022, solely with respect to Company Employees, (i)&nbsp;neither Guarantor nor any of its Subsidiaries has effectuated
a &ldquo;plant closing&rdquo; (as defined in the WARN Act) affecting any site of employment or one or more facilities or operating units
within any site of employment or facility, and, in each case, impacting Company Employees, and (ii)&nbsp;there has not occurred a &ldquo;mass
layoff&rdquo; (as defined in the WARN Act) with respect to Guarantor or any of its Subsidiaries affecting any site of employment or one
or more facilities or operating units within any site of employment or facility and, in each case, impacting Company Employees. Except
as would not result in liability to the Company, Guarantor and its Subsidiaries properly classify and for the two (2)&nbsp;years immediately
preceding the date hereof have properly classified, solely with respect to Company Service Providers, its and their (i)&nbsp;Company Employees
as exempt or non-exempt in accordance with applicable overtime laws, and (ii)&nbsp;Company Service Providers employees or non-employees
(e.g., consultants, independent contractors), in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Section&nbsp;4.13(d)</U>&nbsp;of the Company Disclosure Letter, with respect to any Company Service Provider, there
are no Actions against Guarantor or any of its Subsidiaries pending, or to the knowledge of Guarantor or the Company, threatened to be
brought or filed, in connection with the employment or engagement of any current or former Company Service Provider, including, without
limitation, any claim relating to employment discrimination, harassment, retaliation, equal pay, employment classification, contractor
classification, wages, hours, and benefits or any other employment related matter arising under applicable Laws, except where such action
would not, individually or in the aggregate, result in the Company incurring a material liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
January&nbsp;1, 2022, (i)&nbsp;no allegations of harassment or unlawful discrimination (with respect to any category protected by applicable
law, including, without limitation, sexual harassment), retaliation on the basis of protected activity (including as a whistleblower)
or protected class status in accordance with applicable law, or other material misconduct relating to the workplace, have been made, initiated,
filed or, to the knowledge of Guarantor or the Company, threatened against or involving any current or former directors, officers or senior
level Company Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
Company Service Provider is subject to any service relationship with the Guarantor or its applicable Subsidiaries that either (i)&nbsp;with
respect to employees, is not &ldquo;at-will&rdquo;, or (ii)&nbsp;cannot be terminated on thirty (30) days&rsquo; or less notice without
penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Environmental
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&nbsp;the
Company has conducted its businesses in compliance with all, and have not violated any, applicable Environmental Laws; (ii)&nbsp;the Company
has obtained all Permits of all Governmental Entities and any other Person that are required under any Environmental Law; (iii)&nbsp;there
has been no release of any Hazardous Substance by the Company or any other Person in any manner that has given or would reasonably be
expected to give rise to any remedial or investigative obligation, corrective action requirement or liability of the Company under applicable
Environmental Laws; (iv)&nbsp;the Company has not received any claims, notices, demand letters or requests for information (except for
such claims, notices, demand letters or requests for information the subject matter of which has been resolved prior to the date of this
Agreement) from any federal, state, local, foreign or provincial Governmental Entity or any other Person asserting that the Company is
in violation of, or liable under, any Environmental Law; (v)&nbsp;no Hazardous Substance has been disposed of, arranged to be disposed
of, released or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably
be expected to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties
or facilities owned or operated by the Company or as a result of any operations or activities of the Company at any location and, to the
knowledge of the Company, Hazardous Substances are not otherwise present at or about any such properties or facilities in amount or condition
that has resulted in or would reasonably be expected to result in liability to the Company under any Environmental Law; and (vi)&nbsp;neither
the Company nor any of its properties or facilities are subject to, or are threatened to become subject to, any liabilities relating to
any suit, settlement, court order, administrative order, regulatory requirement, judgment or claim asserted or arising under any Environmental
Law or any agreement relating to environmental liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
used herein, &ldquo;<U>Environmental Law</U>&rdquo; means any Law relating to (i)&nbsp;the protection, preservation or restoration of
the environment (including air, surface water, groundwater, drinking water supply, surface and subsurface soils and strata, wetlands,
plant and animal life or any other natural resource) or (ii)&nbsp;the exposure to, or the use, storage, recycling, treatment, generation,
transportation, processing, handling, labeling, production, release or disposal of Hazardous Substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
used herein, &ldquo;<U>Hazardous Substance</U>&rdquo; means any substance listed, defined, designated, classified or regulated as a waste,
pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental
Law, including but not limited to petroleum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has (i)&nbsp;filed all income and other material Tax Returns required to be filed by or on behalf of it (taking into account any
applicable extensions) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&nbsp;timely paid in
full (or caused to be timely paid in full) all material Taxes that are required to be paid by or with respect to it, whether or not such
Taxes were shown as due on such Tax Returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not incurred, any liability for Taxes outside the ordinary course of business consistent with past practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not executed any waiver of any statute of limitations on, or extended the period for the assessment or collection of, any
amount of Tax, in each case that has not since expired (other than in connection with automatic extensions to file Tax Returns obtained
in the ordinary course of business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
material audits or other investigations, proceedings, claims, assessments or examinations by any Governmental Entity (each, a &ldquo;<U>Tax
Action</U>&rdquo;) with respect to Taxes or any Tax Return of the Company are presently in progress or have been asserted, threatened
or proposed in writing and to the knowledge of the Company, no such Tax Action is being contemplated. No deficiencies or claims for a
material amount of Taxes have been claimed, proposed, assessed or asserted in writing against the Company by a Governmental Entity, other
than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled or withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to exceptions as would not be material, the Company has timely withheld all Taxes required to have been withheld from payments made (or
deemed made) to its employees, independent contractors, creditors, shareholders and other third parties and, to the extent required, such
Taxes have been timely paid to the relevant Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not engaged in a &ldquo;listed transaction&rdquo; as set forth in Treasury Regulations &sect;&nbsp;1.6011-4(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company (i)&nbsp;is not a party to or bound by, and has no liability pursuant to, any Tax sharing, allocation, indemnification or similar
agreement or obligation, other than any such agreement or obligation which is a customary commercial agreement obligation entered into
in the ordinary course of business with vendors, lessors, lenders or the like the primary purpose of which is unrelated to Taxes (each,
an &ldquo;<U>Ordinary Course Agreement</U>&rdquo;); (ii)&nbsp;is not and has not been a member of a group (other than a group the common
parent of which is Guarantor.) filing a consolidated, combined, affiliated, unitary or similar income Tax Return; (iii)&nbsp;does not
have any liability for the Taxes of any Person (other than the Guarantor or the Company) pursuant to Treasury Regulations &sect;&nbsp;1.1502-6
(or any similar provision of state, local or non-United States Law), as a transferee or successor, by Contract or otherwise by operation
of Law; and (iv)&nbsp;is not and has not been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of having
a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
private letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested, entered into or issued
by any Governmental Entity with respect to the Company which rulings remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period
(or portion thereof) ending after the Closing Date as a result of (i)&nbsp;a change in, or use of improper, method of accounting requested
or initiated on or prior to the Closing Date, (ii)&nbsp;a &ldquo;closing agreement&rdquo; as described in Section&nbsp;7121 of the Code
(or any similar provision of Law) executed on or prior to the Closing Date, (iii)&nbsp;an installment sale or open transaction disposition
made on or prior to the Closing Date, (iv)&nbsp;any prepaid amount received or deferred revenue accrued on or prior to the Closing Date,
other than in respect of such amounts received in the ordinary course of business or (v)&nbsp;to the knowledge of the Company, an intercompany
transaction or excess loss amount described in Treasury Regulations under Section&nbsp;1502 of the Code (or any corresponding or similar
provision of state, local or foreign income Tax Law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no liens for Taxes upon any of the assets of the Company other than Liens described in clause (i)&nbsp;of the definition of Permitted
Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not distributed stock of another Person nor had its stock distributed by another Person, in a transaction (or series of transactions)
that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not been a United States real property holding corporation, as defined in Section&nbsp;897(c)(2)&nbsp;of the Code during the
applicable period specified in Section&nbsp;897(c)(1)(A)(ii)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
material claim has been made in writing by any Governmental Entity in a jurisdiction where the Company does not currently file a Tax Return
of a certain type or pay Taxes of a certain type that the Company is or may be subject to taxation of such type by such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no outstanding shares of Company stock issued in connection with the performance of services (within the meaning of Section&nbsp;83
of the Code) that immediately prior to the Effective Time are subject to a substantial risk of forfeiture (as such terms are defined in
Section&nbsp;83 of the Code) for which a valid election under Section&nbsp;83(b)&nbsp;of the Code has not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the knowledge of the Company, the Company has not been, is not, and immediately prior to the Effective Time will not be, treated as an
 &ldquo;investment company&rdquo; within the meaning of Section&nbsp;368(a)(2)(F)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has not taken any action, has not omitted to take any action, and has no knowledge of any fact or circumstance, the taking, omission,
or existence of which, as the case may be, would reasonably be expected to prevent (i)&nbsp;the Merger from constituting a reorganization
within the meaning of Section&nbsp;368(a)&nbsp;of the Code, or (ii)&nbsp;the Merger, from qualifying as a non-taxable exchange of shares
of Company Common Stock for shares of Parent Common Stock within the meaning of Section&nbsp;351(a)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contracts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.16(a)</U>&nbsp;of
the Company Disclosure Letter sets forth each contract that, as of the date of this Agreement, that would constitute a &ldquo;material
contract&rdquo; (as such term is defined in Item 601(b)(10)&nbsp;of Regulation&nbsp;S-K under the Securities Act), with respect to the
Company (assuming the Company were subject to the requirements of the Exchange Act) (all such contracts, in addition to those set forth
in <U>Section&nbsp;4.16(b)</U>&nbsp;of the Company Disclosure Letter, &ldquo;<U>Material Contracts</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.16(b)</U>&nbsp;of
the Company Disclosure Letter lists the following contracts, in effect as of the date of this Agreement, which for the purposes of this
Agreement shall be considered Material Contracts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract relating to any agreement for indemnification or guaranty not entered into in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract containing (A)&nbsp;any covenant prohibiting the Company or the Surviving Company from engaging in any line of business or competing
with any Person, or limiting the development, manufacture or distribution of the Surviving Company&rsquo;s products or services, (B)&nbsp;any
most-favored pricing arrangement, (C)&nbsp;any exclusivity provision in favor of a third party, or (D)&nbsp;any non-solicitation provision
applicable to the Company, in the case of the foregoing clause (D), which are material to the Company, taken as a whole;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each Contract relating to capital expenditures and requiring payments
in excess of $250,000 after the date of this Agreement pursuant to its express terms and not cancelable without penalty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract pursuant to which Guarantor has retained any right or interest that is used in or otherwise required for the operation of the
Company&rsquo;s business, as currently contemplated to be conducted by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each contract
to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of
or payment by, or annual payments to, the Company in excess of $100,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract relating to the disposition or acquisition of assets or any ownership interest in any Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
employment or independent contractor Contract or retention, severance, change in control, or deal-based bonus Employee Plan, arrangement,
or Contract that covers any Company Service Provider;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments
relating to the borrowing of money or extension of credit or creating any material Liens with respect to any assets of the Company or
any loans or debt obligations with officers or directors of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each
Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms
relating to: (A) any Contract involving supply or distribution (identifying any that contain exclusivity provisions), (B) any Contract
involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any
Contract involving a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other Contract currently
in force under which the Company has continuing obligations to develop or market any product, technology or service, or any Contract
pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in
part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright
registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to
sell, distribute or commercialize any products or service of the Company, in each case, except for Contracts entered into in the ordinary
course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services
to the Company in connection with the Contemplated Transactions; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract relating to leases of real properties with respect to which the Company directly or indirectly holds a valid leasehold interest
as well as any other real estate that is in the possession of or leased by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Each
Material Contract is valid and binding on the Company, and to the knowledge of the Company, each other party thereto, and is in full force
and effect and enforceable in accordance with its terms; and (ii)&nbsp;as of the date of this Agreement,&nbsp;the Company has not receive
any written notice of any material default under any Material Contract by the Company or of any event or condition that has occurred that
constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part of the Company. The Company has
made available to Parent true and complete copies of all Material Contracts, including all amendments thereto. Except as set forth in
<U>Section&nbsp;4.16(c)</U>&nbsp;of the Company Disclosure Letter, there are no Material Contracts that are not in written form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.
The Company is covered by valid and currently effective insurance policies issued in favor of the Company that are customary and adequate
for companies of similar size in the industries and locations in which the Company operates. <U>Section&nbsp;4.17</U> of the Company Disclosure
Letter sets forth, as of the date hereof, a true and complete list of all material insurance policies issued in favor of the Company,
or pursuant to which the Company is a named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still
in force. With respect to each such insurance policy, (a)&nbsp;such policy is in full force and effect and all premiums due thereon have
been paid, (b)&nbsp;the Company is not in breach or default, and has not taken any action or failed to take any action which (with or
without notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any
such policy and (c)&nbsp;to the knowledge of the Company, no insurer issuing any such policy has been declared insolvent or placed in
receivership, conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy,
nor will any such cancellation or termination result from the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Properties;
Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has, and will have after giving effect to the Contemplated Transactions (including the Contribution), good and valid title to,
or in the case of leased property and leased tangible assets, a valid leasehold interest in, all of its real properties and tangible and
other assets that are necessary for the Company to conduct the business and operate as operated by Guarantor and as currently contemplated
to be conducted by the Company, after taking into account the services to be provided by the Transition Services Agreement and the Manufacturing
and Supply Agreement, free and clear of all Liens other than (i)&nbsp;Liens for Taxes and assessments not yet due and payable or the amount
or validity of which is being contested in good faith by appropriate proceedings, (ii)&nbsp;mechanics&rsquo;, workmen&rsquo;s, repairmen&rsquo;s,
warehousemen&rsquo;s and carriers&rsquo; Liens arising in the ordinary course of business of the Company consistent with past practice
and (iii)&nbsp;any such matters of record, Liens and other imperfections of title that do not, individually or in the aggregate, materially
impair the continued ownership, use and operation of the assets to which they relate in the business of the Company as currently conducted
(&ldquo;<U>Permitted Liens</U>&rdquo;). Except as has not had and would not reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect, the tangible personal property currently used in the operation of the business of the Company is in good working
order (reasonable wear and tear excepted).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has complied with the terms of all leases to which it is a party, and all such leases are in full force and effect, except for
any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not had and would not reasonably
be expected to have a Material Adverse Effect. The Company enjoys peaceful and undisturbed possession under all such leases, except for
any such failure to do so that, individually or in the aggregate, has not had and would not reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.18(c)</U>&nbsp;of
the Company Disclosure Letter sets forth a true and complete list of (i)&nbsp;all real property owned by the Company and (ii)&nbsp;all
real property leased for the benefit of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; ">Section&nbsp;4.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.19(a)</U>&nbsp;of
the Company Disclosure Letter sets forth a true and complete list of all (i)&nbsp;patents and patent applications; (ii)&nbsp;trademark
registrations and applications; and (iii)&nbsp;material copyright registrations and applications, in each case owned or licensed by the
Company (collectively, &ldquo;<U>Company Registered IP</U>&rdquo;) and a true and complete list of all domain names owned or exclusively
licensed by the Company. Except as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material
Adverse Effect (A)&nbsp;all of the Company Registered IP is subsisting and, solely in the case of any Company Registered IP that is registered
or issued, to the knowledge of the Company, valid and enforceable, (B)&nbsp;no Company Registered IP is involved in any interference,
reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge of the Company, no such action
is threatened with respect to any of the Company Registered IP and (C)&nbsp;the Company owns exclusively, free and clear of any and all
Liens (other than Permitted Liens), all Company Owned IP, including all Intellectual Property created on behalf of the Company by employees
or independent contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.19(b)</U>&nbsp;of
the Company Disclosure Letter accurately identifies (i)&nbsp;all contracts pursuant to which any Intellectual Property is licensed to
the Company (other than (A)&nbsp;any non-customized software that (1)&nbsp;is so licensed solely in executable or object code form pursuant
to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&nbsp;is not incorporated
into, or material to the development, manufacturing, or distribution of, any of the products and services of the Company, (B)&nbsp;any
Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials, (C)&nbsp;any
confidential information provided under confidentiality agreements and (D)&nbsp;agreements between the Company and its employees in the
Company&rsquo;s standard form thereof), (ii)&nbsp;whether such contract involves the Company Registered IP licensed to the Company and
(iii)&nbsp;whether the license or licenses granted to the Company are exclusive or nonexclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;4.19(c)</U>&nbsp;of
the Company Disclosure Letter accurately identifies each of the Company&rsquo;s contracts pursuant to which any Person has been granted
any license or covenant not sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest
in, any Company Registered IP (other than (i)&nbsp;any confidential information provided under confidentiality agreements and (ii)&nbsp;any
Company Registered IP nonexclusively licensed to academic collaborators, suppliers, manufacturers or service providers for the sole purpose
of enabling such academic collaborator, supplier, manufacturer or service provider to provide services for the Company&rsquo;s benefit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company Registered IP constitutes all Intellectual Property owned by the Guarantor prior to the Contribution and necessary for the Company
to conduct its business as currently proposed to be conducted (after giving effect to the Contribution).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has taken commercially reasonable measures to maintain the confidentiality of all information that constitutes or constituted
a material Trade Secret of the Company, including requiring all Persons having access thereto to execute written non-disclosure agreements
or other binding obligations to maintain confidentiality of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&nbsp;to
the knowledge of the Company, the conduct of the businesses of the Company, including the manufacture, marketing, offering for sale, sale,
importation, use or intended use or other disposal of any product as currently sold or under development by Company or currently contemplated
to be sold or developed by the Company, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute,
any Intellectual Property of any Person, (ii)&nbsp;the Company has not received any written notice or claim asserting or suggesting that
any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&nbsp;to the knowledge
of the Company, no Person is infringing, misappropriating, or diluting in any material respect any Company Registered IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Material Adverse Effect, (i)&nbsp;the
Company has taken commercially reasonable steps to protect the confidentiality and security of the computer and information technology
systems used by the Company (the &ldquo;<U>IT Systems</U>&rdquo;) and the information and transactions stored or contained therein or
transmitted thereby, (ii)&nbsp;to the knowledge of the Company, since January&nbsp;1, 2022, there has been no unauthorized or improper
use, loss, access, transmittal, modification or corruption of any such information or data and (iii)&nbsp;since January&nbsp;1, 2022,
there have been no material failures, crashes, viruses, security breaches (including any unauthorized access to any personally identifiable
information), affecting the IT Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has at all times complied in all material respects with all: (i)&nbsp;applicable Laws, published privacy policies and contractual
obligations relating to privacy, data protection, and the collection, retention, protection, and use of information that alone or in combination
with other information can be used to identify an individual, household or device (&ldquo;<U>Personal Information</U>&rdquo;) collected,
used, or held for use by the Company (collectively, &ldquo;<U>Privacy Laws</U>&rdquo;), (ii)&nbsp;since January&nbsp;1, 2022, no claims
have been asserted or, to the knowledge of the Company, threatened in writing against the Company alleging a violation of any Person&rsquo;s
privacy or Personal Information, (iii)&nbsp;neither this Agreement nor the consummation of the Contemplated Transactions will breach or
otherwise violate any Privacy Laws and (iv)&nbsp;the Company has taken commercially reasonable steps to protect the Personal Information
collected, used or held for use by the Company against loss and unauthorized access, use, modification or disclosure, or other misuse.
The Company has contractually obligated all vendors, processors, service providers and other Persons collecting, using or otherwise processing
Personal Information by or for the Company (&ldquo;<U>Data Processors</U>&rdquo;) to comply with applicable Privacy Laws and to take reasonable
measures to protect Personal Information from unauthorized, access, use or disclosure. To the knowledge of the Company, no Data Processors
have failed to comply with Privacy Laws with respect to the Personal Information processed on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>To
the knowledge of the Company, no government funding, facilities or resources of a university, college, other educational institution or
research center or funding from third parties was used in the development of Company Owned IP or any Intellectual Property exclusively
licensed to the Company, and no Governmental Entity, university, college, other educational institution or research center has, to the
knowledge of the Company, any claim or right in or to such Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>Except
as set forth on <U>Section&nbsp;4.19(j)</U>&nbsp;of the Company Disclosure Letter, the execution, delivery and performance by the Company
of this Agreement, and the consummation of the Contemplated Transactions, will not result in the loss of, or give rise to any right of
any third party to terminate or modify any of the rights or obligations of the Company under any agreement under which the Company grants
to any Person, or any Person grants to the Company, a license or right under or with respect to any Intellectual Property that is material
to any of the businesses of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.20&#8239;&#8239;&#8239;</FONT><U>State
Takeover Statutes</U>. As of the date hereof and at all times on or prior to the Effective Time, the Company Board has taken all actions
so that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are, and will be, inapplicable
to the execution, delivery and performance of this Agreement and the timely consummation of the Merger and the other Contemplated Transactions
and will not restrict, impair or delay the ability of Parent or Merger Sub, after the Effective Time, to vote or otherwise exercise all
rights as a stockholder of the Company. No other &ldquo;moratorium,&rdquo; &ldquo;fair price,&rdquo; &ldquo;business combination,&rdquo;
 &ldquo;control share acquisition&rdquo; or similar provision of any state anti-takeover Law (collectively, &ldquo;<U>Takeover Laws</U>&rdquo;)
or any similar anti-takeover provision in the Company Charter or Company Bylaws is, or at the Effective Time will be, applicable to this
Agreement, the Merger or any of the other Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.21&#8239;&#8239;</FONT><U>No
Rights Plan</U>. There is no stockholder rights plan, &ldquo;poison pill&rdquo; anti-takeover plan or other similar device in effect
to which the Company is a party or is otherwise bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.22&#8239;&#8239;</FONT><U>Related
Party Transactions</U>. Except as set forth on <U>Section&nbsp;4.22</U> of the Company Disclosure Letter, there have been no transactions,
agreements, arrangements or understandings between the Company, on the one hand, and the Affiliates of the Company (including Guarantor),
on the other hand that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act (assuming the Company
was subject to the requirements of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.23&#8239;&#8239;</FONT><U>Certain
Payments</U>. Since January&nbsp;1, 2022, the Company has not, nor, to the knowledge of the Company, any of their respective directors,
executives, representatives, agents or employees (a)&nbsp;has used or is using any corporate funds for any illegal contributions, gifts,
entertainment or other unlawful expenses relating to political activity, (b)&nbsp;has used or is using any corporate funds for any direct
or indirect unlawful payments to any foreign or domestic governmental officials or employees, (c)&nbsp;has violated or is violating any
provision of the Foreign Corrupt Practices Act of 1977, as amended, (d)&nbsp;has established or maintained, or is maintaining, any unlawful
fund of corporate monies or other properties, or (e)&nbsp;has made any bribe, unlawful rebate, payoff, influence payment, kickback or
other unlawful payment of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.24&#8239;&#8239;</FONT><U>Trade
Control Laws</U>. Since January&nbsp;1, 2022, the Company has been in material compliance with all applicable import, export control,
and economic and trade sanctions laws, regulations, statutes, and orders, including the Export Administration Regulations, the International
Traffic in Arms Regulations, and the regulations administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(the &ldquo;<U>Trade Laws</U>&rdquo;) and have obtained, or are otherwise qualified to rely upon, all material import and export licenses,
consents, notices, waivers, approvals, orders, authorizations, registrations, declarations or other authorizations from, and made any
filings with, any governmental authority required for (i)&nbsp;the import, export, and reexport of products, services, software and technologies
and (ii)&nbsp;releases of technologies and software to foreign nationals (the &ldquo;<U>Trade Approvals</U>&rdquo;). There are no pending
or threatened claims against the Company, nor any actions, conditions, facts, or circumstances that would reasonably be expected to give
rise to any material future claims with respect to the Trade Laws or Trade Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.25&#8239;&#8239;</FONT><U>Brokers</U>.
No broker, investment banker, financial advisor or other Person, other than as set forth on <U>Section&nbsp;4.25</U> of the Company Disclosure
Letter, the fees and expenses of which will be paid by the Company, or following the Effective Time, Parent is entitled to any broker&rsquo;s,
finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission in connection with the Contemplated Transactions based upon
arrangements made by or on behalf of the Company or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;4.26&#8239;&#8239;</FONT><U>No
Other Representations and Warranties</U>. Except for the representations and warranties contained in <U>Article&nbsp;V</U>, the Company
acknowledges and agrees that none of Parent, Merger Sub or any other Person on behalf of Parent or Merger Sub makes any other express
or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of
Parent, its Subsidiaries or any other Person on behalf of Parent or Merger Sub makes any representation or warranty with respect to any
projections or forecasts delivered or made available to the Company or any of its Representatives of future revenues, results of operations
(or any component thereof), cash flows or financial condition (or any component thereof) of Parent (including any such projections or
forecasts made available to the Company and Representatives in certain &ldquo;data rooms&rdquo; or management presentations in expectation
of the Contemplated Transactions), and the Company has not relied on any such information or any representation or warranty not set forth
in <U>Article&nbsp;V</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;V</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except (a)&nbsp;as disclosed
in the Parent SEC Documents at least three (3)&nbsp;Business Days prior to the date of this Agreement and that is reasonably apparent
on the face of such disclosure to be applicable to the representation and warranty set forth herein (other than any disclosures contained
or referenced therein under the captions &ldquo;Risk Factors,&rdquo; &ldquo;Forward-Looking Statements,&rdquo; &ldquo;Quantitative and
Qualitative Disclosures About Market Risk,&rdquo; and any other disclosures contained or referenced therein of information, factors,
or risks that are predictive, cautionary, or forward-looking in nature); or (b)&nbsp;as set forth in the corresponding section or subsection
of the disclosure letter delivered by Parent to the Company (the &ldquo;<U>Parent Disclosure Letter</U>&rdquo;) (it being agreed that
the disclosure of any information in a particular section or subsection of the Parent Disclosure Letter shall be deemed disclosure of
such information with respect to any other section or subsection of this Agreement to which the relevance of such information is readily
apparent on its face), each of Parent and Merger Sub represent and warrant to the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.1&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization,
Standing and Power</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
of Parent and Merger Sub is a corporation duly organized or other entity duly formed, validly existing and in good standing under the
Laws of the jurisdiction of its incorporation. Each of Parent and Merger Sub (x)&nbsp;has all requisite corporate or similar power and
authority to own, lease and operate its properties and to carry on its business as now being conducted and (y)&nbsp;is duly qualified
or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing
or operation of its properties makes such qualification or licensing necessary, except in the case of clause (y), where the failure to
be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected to
have a Parent Material Adverse Effect. For purposes of this Agreement, &ldquo;<U>Parent Material Adverse Effect</U>&rdquo; means any
event, change, circumstance, occurrence, effect or state of facts that (A)&nbsp;is or would reasonably be expected to be materially adverse
to the business, assets, liabilities, financial condition, or results of operations of Parent and its Subsidiaries, taken as a whole,
or (B)&nbsp;materially impairs the ability of Parent or Merger Sub to consummate the Merger or any of the other Contemplated Transactions;
<U>provided</U>, <U>however</U>, that in the case of clause&nbsp;(A)&nbsp;only, Parent Material Adverse Effect shall not include any
event, change, circumstance, occurrence, effect or state of facts to the extent resulting from (1)&nbsp;changes or conditions generally
affecting the industries in which Parent and its Subsidiaries operate, or the economy or the financial, debt, banking, capital, credit
or securities markets, in the United States, including effects on such industries, economy or markets resulting from any regulatory and
political conditions or developments in general, (2)&nbsp;the outbreak or escalation of war or acts of terrorism or any natural disasters,
acts of God or comparable events, epidemic, pandemic or disease outbreak (including the COVID-19 virus) or any worsening of the foregoing,
or any declaration of martial law, quarantine or similar directive, policy or guidance or Law or other action by any Governmental Entity
in response thereto, (3)&nbsp;changes in Law or GAAP, or the interpretation or enforcement thereof, (4)&nbsp;the public announcement
or pendency of this Agreement, or (5)&nbsp;any specific action taken (or omitted to be taken) by Parent at or with the express written
consent of the Company; <U>provided</U>, that, with respect to clauses&nbsp;(1), (2)&nbsp;and (3), the impact of such event, change,
circumstance, occurrence, effect or state of facts is not disproportionately adverse to Parent and its Subsidiaries, as compared to other
participants in the industries in which Parent and its Subsidiaries operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
has previously made available to the Company true and complete copies of the Certificate of Incorporation and bylaws of each of Parent,
each of its Subsidiaries, and Merger Sub, in each case, as amended to the date of this Agreement, and each as so delivered is in full
force and effect. None of Parent, its Subsidiaries, or Merger Sub is in violation of any provision of their respective Certificate of
Incorporation or bylaws or equivalent governing documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.2&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Capital
Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
authorized capital stock of Parent consists of 350,000,000 shares of Parent Common Stock and 5,000,000 shares of Parent Preferred Stock.
As of the close of business on June&nbsp;20, 2025 (the &ldquo;<U>Measurement Date</U>&rdquo;), (i)&nbsp;41,788,096 shares of Parent Common
Stock (excluding treasury shares) were issued and outstanding, all of which were validly issued, fully paid and nonassessable (which
term means that no further sums are required to be paid by the holders thereof in connection with the issue of such shares) and were
free of preemptive rights, (ii)&nbsp;zero (0) shares of Parent Common Stock were held in treasury, (iii)&nbsp;an aggregate of 6,424,376
shares of Parent Common Stock were subject to the exercise of outstanding Parent Options, (iv)&nbsp;zero (0) shares of Parent Common
Stock were subject to outstanding Parent Restricted Stock Unit Awards in accordance with their respective terms, as in effect as of the
date hereof, (v)&nbsp;zero (0) shares of Parent Common Stock were subject to the exercise of outstanding Parent Warrants and (vi)&nbsp;no
shares of Parent Preferred Stock were issued and outstanding or held in treasury. Except as set forth above in this <U>Section&nbsp;5.2(a)</U>,
Parent does not have any outstanding bonds, debentures, notes or other obligations having the right to vote (or convertible into, or
exchangeable or exercisable for, securities having the right to vote) with the stockholders of Parent or any of its Subsidiaries on any
matter. Except as set forth above in this <U>Section&nbsp;5.2(a)</U>&nbsp;and except for changes since the close of business on the Measurement
Date resulting from the exercise of any options or vesting and settlement of outstanding Parent Restricted Stock Unit Awards as described
above, as of the Measurement Date, there are no outstanding (A)&nbsp;shares of capital stock or other voting securities or equity interests
of Parent or any of its Subsidiaries, (B)&nbsp;securities of Parent or any of its Subsidiaries convertible into or exchangeable or exercisable
for shares of capital stock of Parent or any of its Subsidiaries or other voting securities or equity interests of Parent or any of its
Subsidiaries, (C)&nbsp;stock appreciation rights, &ldquo;phantom&rdquo; stock rights, performance units, interests in or rights to the
ownership or earnings of Parent or any of its Subsidiaries or other equity equivalent or equity-based awards or rights, (D)&nbsp;subscriptions,
options, warrants, calls, commitments, Contracts or other rights to acquire from Parent or any of its Subsidiaries, or obligations of
Parent or any of its Subsidiaries to issue, any shares of capital stock of Parent or any of its Subsidiaries, voting securities, equity
interests or securities convertible into or exchangeable or exercisable for capital stock or other voting securities or equity interests
of Parent or any of its Subsidiaries or rights or interests described in the preceding clause&nbsp;(C), or (E)&nbsp;obligations of Parent
or any of its Subsidiaries to repurchase, redeem or otherwise acquire any such securities or to issue, grant, deliver or sell, or cause
to be issued, granted, delivered or sold, any such securities. There are no stockholder agreements, voting trusts or other agreements
or understandings to which Parent or any of its Subsidiaries is a party or of which Parent has knowledge with respect to the holding,
voting, registration, redemption, repurchase or disposition of, or that restricts the transfer of, any capital stock or other voting
securities or equity interests of Parent or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
authorized capital stock of Merger Sub consists of 1,000 shares of common stock, par value $0.001 per share, of which 1,000 shares are
issued and outstanding, all of which shares are beneficially owned by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
shares of Parent Common Stock to be issued pursuant to the Merger will be duly authorized, validly issued, fully paid and nonassessable
and not subject to any preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.3&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsidiaries</U>.
<U>Section&nbsp;5.3</U> of the Parent Disclosure Letter sets forth a true and complete list of each Subsidiary of Parent, including its
jurisdiction of incorporation or formation. Each of Parent&rsquo;s Subsidiaries (i)&nbsp;is an entity duly organized, validly existing
and in good standing under the Laws of the jurisdiction of its organization, (ii)&nbsp;has all requisite corporate or similar power and
authority to own, lease and operate its properties and to carry on its business as now being conducted and (iii)&nbsp;is duly qualified
or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership, leasing
or operations of its properties makes such qualification or licensing necessary, except in the case of clause (iii), where the failure
to be so qualified or licensed or in good standing, individually or in the aggregate, has not had and would not reasonably be expected
to have a Parent Material Adverse Effect. All outstanding shares of capital stock and other voting securities or equity interests of
each such Subsidiary are owned directly by Parent, free and clear of all Liens. Except for the capital stock of, or other equity or voting
interests in, its Subsidiaries, Parent does not own, directly or indirectly, any equity, membership interest, partnership interest, joint
venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of the
foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital
contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person. Merger Sub
was formed solely for the purpose of engaging in the Merger and the other Contemplated Transactions and has engaged in no business other
than in connection with the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.4&#8239;&#8239;&#8239;&#8239;</FONT><U>Authority</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
of Parent and Merger Sub has all necessary corporate power and authority to execute, deliver and perform its obligations under this Agreement
and to consummate the Merger and the other Contemplated Transactions, including the issuance of the shares of Parent Common Stock to
the holders of Company Common Stock as Merger Consideration (the &ldquo;<U>Parent Common Stock Issuance</U>&rdquo;). The execution, delivery
and performance of this Agreement by Parent and Merger Sub and the consummation by Parent and Merger Sub of the Merger and the other
Contemplated Transactions have been duly authorized by all necessary corporate action on the part of Parent and Merger Sub and no other
corporate proceedings on the part of Parent or Merger Sub are necessary to approve this Agreement or to consummate the Merger and the
other Contemplated Transactions, subject to (i)&nbsp;assuming the Parent Common Stock is listed on Nasdaq immediately before the amendment
to the Parent certificate of incorporation to effect the Reverse Stock Split is effective (the &ldquo;<U>Reverse Stock Split Proposal</U>&rdquo;),
obtaining the approval of the Nasdaq Issuance Proposal and the Reverse Stock Split Proposal by the holders of a majority of the votes
cast for such proposal (the &ldquo;<U>Parent Stockholder Approval</U>&rdquo;) and (ii)&nbsp;the approval of this Agreement by Parent
as the sole stockholder of Merger Sub. This Agreement has been duly executed and delivered by Parent and Merger Sub and, assuming the
due authorization, execution and delivery by the Company, constitutes a valid and binding obligation of each of Parent and Merger Sub,
enforceable against each of Parent and Merger Sub in accordance with its terms (except to the extent that enforceability may be limited
by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&rsquo; rights
generally or by general principles of equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Parent Board, at a meeting duly called and held at which all directors of Parent were present, unanimously adopted resolutions (i)&nbsp;determining
that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&nbsp;approving
and declaring advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to
the stockholders of the Company pursuant to this Agreement and the Parent Support Agreements and the Constructive Issuance, (iii)&nbsp;determining
that the Reverse Stock Split Proposal, among other things, is advisable and in the best interests of Parent and its stockholders, and
(iv)&nbsp;determining to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of
Parent vote to authorize the Nasdaq Issuance Proposal, the Reverse Stock Split Proposal and the other Parent Stockholder Proposals. The
board of directors of Merger Sub (by unanimous written consent) has: (x)&nbsp;determined that the Contemplated Transactions are fair
to, advisable, and in the best interests of Merger Sub and its sole stockholder, (y)&nbsp;approved and deemed advisable this Agreement
and the Contemplated Transactions and (z)&nbsp;determined to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the stockholder of Merger Sub vote to adopt this Agreement and thereby the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Parent Stockholder Approval is the only vote of the holders of any class or series of the Parent Common Stock or other securities required
in connection with the consummation of the Merger and the other Contemplated Transactions, including the Parent Common Stock Issuance.
Other than the Parent Stockholder Approval, no vote of the holders of any class or series of the Parent Common Stock or other securities
is required in connection with the consummation of any of the Contemplated Transactions to be consummated by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.5&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflict; Consents and Approvals</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in <U>Section&nbsp;5.5(a)</U>&nbsp;of the Parent Disclosure Letter, the execution, delivery and performance of this Agreement
by each of Parent and Merger Sub does not, and the consummation of the Merger and the other Contemplated Transactions (including the
Contribution) and compliance by each of Parent and Merger Sub with the provisions hereof will not, conflict with, or result in any violation
or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination,
cancellation, modification or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Lien
in or upon any of the properties, assets or rights of Parent or Merger Sub under, or give rise to any increased, additional, accelerated
or guaranteed rights or entitlements under, or require any consent, waiver or approval of any Person pursuant to, any provision of (i)&nbsp;the
Certificate of Incorporation or bylaws of Parent or Merger Sub, (ii)&nbsp;any Parent Material Contract to which Parent or Merger Sub
is a party by which Parent, Merger Sub or any of their respective properties or assets may be bound, or (iii)&nbsp;subject to the governmental
filings and other matters referred to in <U>Section&nbsp;5.5(b)</U>, any material Law or any rule&nbsp;or regulation of Nasdaq applicable
to Parent or Merger Sub or by which Parent, Merger Sub or any of their respective properties or assets may be bound, except as, in the
case of clauses&nbsp;(ii)&nbsp;and (iii), as individually or in the aggregate, has not had and would not reasonably be expected to have
a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
consent, approval, order or authorization of, or registration, declaration, filing with or notice to, any Governmental Entity is required
by or with respect to Parent or Merger Sub in connection with the execution, delivery and performance of this Agreement by Parent or
Merger Sub or the consummation by Parent or Merger Sub of the Merger and the other Contemplated Transactions or compliance with the provisions
hereof, except for (i)&nbsp;the filing with the SEC of such reports under Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act,
as may be required in connection with this Agreement and the Contemplated Transactions, (ii)&nbsp;such other filings and reports as may
be required pursuant to the applicable requirements of the Securities Act, the Exchange Act and any other applicable state or federal
securities, takeover and &ldquo;blue sky&rdquo; laws, (iii)&nbsp;the filing of the Certificate of Merger with the Delaware Secretary
of State as required by the DGCL, (iv)&nbsp;any filings required under the rules&nbsp;and regulations of Nasdaq and (v)&nbsp;such consents,
approvals, orders, authorizations, registrations, declarations, filings or notices the failure of which to be obtained or made, individually
or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.6&#8239;&#8239;&#8239;&#8239;</FONT><U>SEC
Reports; Financial Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
has filed with or furnished to the SEC on a timely basis true and complete copies of all forms, reports, schedules, statements and other
documents required to be filed with or furnished to the SEC by Parent since January&nbsp;1, 2022 (all such documents, together with all
exhibits and schedules to the foregoing materials and all information incorporated therein by reference, the &ldquo;<U>Parent SEC Documents</U>&rdquo;).
As of their respective filing dates (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of
such filing), the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act, the
Exchange Act and the Sarbanes-Oxley Act of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;), as the case may be, including, in each
case, the rules&nbsp;and regulations promulgated thereunder, and none of the Parent SEC Documents contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
financial statements (including the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents
(i)&nbsp;have been prepared in a manner consistent with the books and records of Parent, (ii)&nbsp;have been prepared in accordance with
GAAP (except, in the case of unaudited statements, as permitted by Form&nbsp;10-Q of the SEC) applied on a consistent basis during the
periods involved (except as may be indicated in the notes thereto), (iii)&nbsp;comply as to form in all material respects with applicable
accounting requirements and the published rules&nbsp;and regulations of the SEC with respect thereto and (iv)&nbsp;fairly present in
all material respects the consolidated financial position of Parent as of the dates thereof and their respective consolidated results
of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal and recurring year-end
audit adjustments that were not, or are not expected to be, material in amount), all in accordance with GAAP and the applicable rules&nbsp;and
regulations promulgated by the SEC. Since January&nbsp;1, 2022, Parent has not made any change in the accounting practices or policies
applied in the preparation of its financial statements, except as required by GAAP, SEC rule&nbsp;or policy or applicable Law. The books
and records of Parent have been, and are being, maintained in all material respects in accordance with GAAP (to the extent applicable)
and any other applicable legal and accounting requirements and reflect only actual transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
has established and maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the
Exchange Act). Such disclosure controls and procedures are designed to ensure that information relating to Parent required to be disclosed
in Parent&rsquo;s periodic and current reports under the Exchange Act, is made known to Parent&rsquo;s principal executive officer and
principal financial officer by others within those entities to allow timely decisions regarding required disclosures as required under
the Exchange Act. The chief executive officer and chief financial officer of Parent have evaluated the effectiveness of Parent&rsquo;s
disclosure controls and procedures and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that
is a report on Form&nbsp;10-K or Form&nbsp;10-Q, or any amendment thereto, its conclusions about the effectiveness of the disclosure
controls and procedures as of the end of the period covered by such report or amendment based on such evaluation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
has established and maintains a system of internal control over financial reporting (as defined in Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)&nbsp;under
the Exchange Act) which is effective in providing reasonable assurance regarding the reliability of Parent&rsquo;s financial reporting
and the preparation of Parent&rsquo;s financial statements for external purposes in accordance with GAAP. Parent has disclosed, based
on its most recent evaluation of Parent&rsquo;s internal control over financial reporting prior to the date hereof, to Parent&rsquo;s
auditors and audit committee (i)&nbsp;any significant deficiencies and material weaknesses in the design or operation of Parent&rsquo;s
internal control over financial reporting which are reasonably likely to adversely affect Parent&rsquo;s ability to record, process,
summarize and report financial information and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees
who have a significant role in Parent&rsquo;s internal control over financial reporting. A true, correct and complete summary of any
such disclosures made by management to Parent&rsquo;s auditors and audit committee is set forth as <U>Section&nbsp;5.6(d)</U>&nbsp;of
Parent Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
January&nbsp;1, 2022, (i)&nbsp;neither Parent nor, to the knowledge of Parent, any of its directors, officers, employees, auditors, accountants
or representatives has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether
written or oral, regarding the accounting or auditing practices, procedures, methodologies or methods of Parent or its internal accounting
controls, including any material complaint, allegation, assertion or claim that Parent has engaged in questionable accounting or auditing
practices and (ii)&nbsp;no attorney representing Parent, whether or not employed by Parent, has reported evidence of a material violation
of securities Laws, breach of fiduciary duty or similar violation by Parent or any of its officers, directors, employees or agents to
the Parent Board or any committee thereof or to any director or officer of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
of the date of this Agreement, there are no outstanding or unresolved comments in the comment letters received from the SEC staff with
respect to the Parent SEC Documents. To the knowledge of Parent, none of the Parent SEC Documents is subject to ongoing review or outstanding
SEC comment or investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
is not a party to, or has any commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract
(including any Contract or arrangement relating to any transaction or relationship between or among Parent, on the one hand, and any
unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or Person, on the other hand, or
any &ldquo;off balance sheet arrangements&rdquo; (as defined in Item 303(a)&nbsp;of Regulation S K under the Exchange Act)), where the
result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities
of, Parent in Parent&rsquo;s published financial statements or other Parent SEC Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
is in compliance in all material respects with the provisions of the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.7&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Undisclosed Liabilities</U>. Neither Parent nor any of its Subsidiaries has any liabilities or obligations of any nature, whether accrued,
absolute, contingent or otherwise, known or unknown, whether due or to become due and whether or not required to be recorded or reflected
on a balance sheet under GAAP, except (a)&nbsp;to the extent specifically and adequately accrued or reserved against in the audited balance
sheet of Parent as at December&nbsp;31, 2024 included in the Annual Report on Form&nbsp;10-K filed by Parent with the SEC on March&nbsp;31,
2025 (without giving effect to any amendment thereto filed on or after the date hereof) and (b)&nbsp;for liabilities and obligations
incurred in the ordinary course of business consistent with past practice (none of which is a liability for a breach or default under
any contract, breach of warranty, tort, infringement, misappropriation or violation of law) since December&nbsp;31, 2024 that are not
individually or in the aggregate material to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.8&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Certain Changes or Events</U>. Except as set forth in <U>Section&nbsp;5.8</U> of the Parent Disclosure Letter, since December&nbsp;31,
2024, (i)&nbsp;except in connection with the execution of this Agreement and the consummation of the Contemplated Transactions, Parent
and its Subsidiaries have conducted their business only in the ordinary course consistent with past practice; (ii)&nbsp;there has not
been any change, event or development or prospective change, event or development that, individually or in the aggregate, has had or
would reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;neither Parent nor any of its Subsidiaries has:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;declared,
set aside or paid any dividends on, or made any other distributions (whether in cash, stock or property) in respect of, any of its capital
stock or other equity interests, (ii)&nbsp;purchased, redeemed or otherwise acquired shares of capital stock or other equity interests
of Parent or any of its Subsidiaries or any options, warrants, or rights to acquire any such shares or other equity interests, or (iii)&nbsp;split,
combined, reclassified or otherwise amended the terms of any of its capital stock or other equity interests or issued or authorized the
issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other equity interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>amended
or otherwise changed, or authorized or proposed to amend or otherwise change, its certificate of incorporation or by-laws (or similar
organizational documents);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>adopted
or entered into a plan of complete or partial liquidation, dissolution, restructuring, recapitalization or reorganization; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>changed
its financial or Tax accounting methods, principles or practices, except insofar as may have been required by a change in GAAP or applicable
Law, or revalued any of its material assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.9&#8239;&#8239;&#8239;&#8239;</FONT><U>Litigation</U>.
There is no Action (or basis therefor) pending or, to the knowledge
of Parent, threatened against or affecting Parent or any of its Subsidiaries, any of its properties or assets, or any present or former
officer, director or employee of Parent or any of its Subsidiaries in such individual&rsquo;s capacity as such, other than any Action
that (a) does not involve an amount in controversy in excess of $100,000 and (b) does not seek injunctive or other non-monetary relief.
Neither Parent nor any of its Subsidiaries nor any of their respective properties or assets is subject to any outstanding judgment, order,
injunction, rule or decree of any Governmental Entity. There is no Action pending or, to the knowledge of Parent, threatened seeking to
prevent, hinder, modify, delay or challenge the Merger or any of the other Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.10&#8239;&#8239;</FONT><U>Compliance
with Law</U>. Parent and each of its Subsidiaries are and have been in compliance in all material respects with all Laws applicable to
its businesses, operations, properties or assets. Neither Parent nor any of its Subsidiaries has received, since January&nbsp;1, 2022,
a notice or other written communication alleging or relating to a possible material violation of any Law applicable to its business,
operations, properties, assets or Parent Products (as defined below). Parent and each of its Subsidiaries have in effect all material
Permits of all Governmental Entities necessary or advisable for it to own, lease or operate its properties and assets and to carry on
its business and operations as now conducted, and there has occurred no violation of, default (with or without notice or lapse of time
or both) under or event giving to others any right of revocation, non-renewal, adverse modification or cancellation of, with or without
notice or lapse of time or both, any such Permit, nor would any such revocation, non-renewal, adverse modification or cancellation result
from the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.11&#8239;&#8239;</FONT><U>Health
Care Regulatory Matters</U>. Except as set forth in <U>Section&nbsp;5.11</U> of the Parent Disclosure Letter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent,
and to the knowledge of Parent, each of its directors, officers, management employees, agents (while acting in such capacity), contract
manufacturers, suppliers, and distributors are, and at all times prior hereto were, in material compliance with all health care laws
to the extent applicable to Parent or any of its products or activities, including, but not limited to the Health Care Laws, to the extent
applicable to Parent. To the knowledge of Parent, there are no facts or circumstances that reasonably would be expected to give rise
to any material liability under any Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries is not party to any material corporate integrity agreements, monitoring agreements, consent decrees,
settlement orders, or similar agreements with or imposed by any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
applications, notifications, submissions, information, claims, reports and statistical analyses, and other data and conclusions derived
therefrom, utilized as the basis for or submitted in connection with any and all requests for a Permit from the FDA or other Governmental
Entity relating to products that are regulated as biologics under Health Care Laws, including biological candidates, compounds or products
being researched, tested, stored, developed, labeled, manufactured, packed, imported, exported and/or distributed by Parent or any of
its Subsidiaries (&ldquo;<U>Parent Products</U>&rdquo;), including, without limitation, investigational new drug applications, when submitted
to the FDA or other Governmental Entity were true, complete and correct in all material respects as of the date of submission and any
necessary or required updates, changes, corrections or modification to such applications, submissions, information and data have been
submitted to the FDA or other Governmental Entity. Parent does not have knowledge of any facts or circumstances that would be reasonably
likely to lead the revocation, suspension, limitation, or cancellation of a Permit required under Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
preclinical studies and clinical trials conducted by or, to the knowledge of Parent, on behalf of Parent in respect of a Parent Product
for submission to the FDA or other Governmental Entity have been since January&nbsp;1, 2022, and if still pending are being, conducted
in compliance with research protocols and all applicable Health Care Laws, including, but not limited to, the FDCA and its applicable
implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58, 312, 314 and 812. No clinical trial conducted by or on behalf of Parent has
been conducted using any clinical investigators who have been disqualified. Except as set forth on <U>Section&nbsp;5.11(d)</U>&nbsp;of
the Parent Disclosure Letter, no clinical trial conducted by or on behalf of the Company has been terminated or suspended prior to completion,
and no clinical investigator that has participated or is participating in, or institutional review board that has or has had jurisdiction
over, a clinical trial conducted by or on behalf of Parent has placed a clinical hold order on, or otherwise terminated, delayed or suspended,
such a clinical trial at a clinical research site based on an actual or alleged lack of safety or efficacy of any Parent Product or a
failure to conduct such clinical trial in compliance with applicable Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
manufacturing operations conducted by or, to the knowledge of Parent, for the benefit of Parent have been and are being conducted in
material compliance with all Permits under applicable Health Care Laws, all applicable provisions of the FDA&rsquo;s current good manufacturing
practice (cGMP) regulations at 21 C.F.R. Parts 210-211 and Parts 600 and 610 and FDA&rsquo;s Quality System (QS) regulations at 21 C.F.R.
Part&nbsp;820, and all comparable foreign regulatory requirements of any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
has not received any written communication that relates to an alleged violation or non-compliance with any Health Care Laws, including
any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration, import detention
or refusal, FDA Warning Letter or Untitled Letter, or any action by a Governmental Entity relating to any Health Care Laws. All Warning
Letters, Form-483 observations, or comparable findings from other Governmental Entities listed in <U>Section&nbsp;5.11(f)</U>&nbsp;of
the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
have been no seizures, withdrawals, recalls, detentions, or suspensions of manufacturing, testing, or distribution relating to the Parent
Products required or requested by a Governmental Entity, or other Safety Notices. All Safety Notices listed in <U>Section&nbsp;5.11(g)</U>&nbsp;of
the Parent Disclosure Letter have been resolved to the satisfaction of the applicable Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in <U>Section&nbsp;5.11(h)</U>&nbsp;of the Parent Disclosure Letter, there are no unresolved Safety Notices, and to the
knowledge Parent, there are no facts or circumstances that would be reasonably likely to result in a Safety Notice with respect to the
Parent Products or a termination or suspension of developing and testing of any of the Parent Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent, nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has made an untrue statement of a material
fact or fraudulent or misleading statement to a Governmental Entity, failed to disclose a material fact required to be disclosed to a
Governmental Entity, or committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide
a basis for the FDA to invoke its FDA Ethics Policy. None of the aforementioned is or has been under investigation resulting from any
allegedly untrue, fraudulent, misleading, or false statement or omission, including data fraud, or had any action pending or threatened
relating to the FDA Ethics Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
reports, documents, claims, Permits and notices required to be filed, maintained or furnished to the FDA or any Governmental Entity by
Parent have been so filed, maintained or furnished, except where failure to file, maintain or furnish such reports, documents, claims,
Permits or notices have not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.
All such reports, documents, claims, Permits and notices were true and complete in all material respects on the date filed (or were corrected
in or supplemented by a subsequent filing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has committed any act, made any statement
or failed to make any statement that violates the Federal Anti-Kickback Statute, 28 U.S.C. &sect; 1320a-7b, the Federal False Claims
Act, 31 U.S.C. &sect; 3729, other Health Care Laws, or any other similar federal, state, or ex-U.S. law applicable in the jurisdictions
in which the Parent Products are sold or intended to be sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor, to the knowledge of Parent, any officer, employee, agent, or distributor of Parent has been convicted of any crime or engaged
in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law, including, without limitation,
21 U.S.C. &sect; 335a, or exclusion under 42 U.S.C. &sect; 1320a-7, or any other statutory provision or similar law applicable in other
jurisdictions in which the Parent Products are sold or intended to be sold. Neither Parent nor, to the knowledge of Parent, any officer,
employee, agent or distributor of Parent, has been excluded from participation in any federal health care program or convicted of any
crime or engaged in any conduct for which such Person could be excluded from participating in any federal health care program under Section&nbsp;1128
of the Social Security Act of 1935, as amended, or any similar Health Care Law or program.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.12&#8239;&#8239;&nbsp;</FONT><U>Benefit
Plans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;5.12(a)</U>&nbsp;of
the Parent Disclosure Letter contains a true, correct, and complete list of each material Parent Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
has provided or made available to the Company a current, accurate and complete copy of each material Parent Plan, or if such Parent Plan
is not in written form, a written summary of all of the material terms of such Parent Plan. With respect to each Parent Plan, Parent
has furnished or made available to the Company a current, accurate and complete copy of, to the extent applicable: (i)&nbsp;all documents
embodying or governing such Parent Plan and any related trust agreement or other funding instrument, (ii)&nbsp;the most recent determination
letter of the IRS, (iii)&nbsp;any summary plan description, summary of material modifications, and other similar material written communications
(or a written description of any material oral communications) to the employees of Parent or any of its Subsidiaries concerning the extent
of the benefits provided under a Parent Plan, (iv)&nbsp;all non-routine correspondence to and from any governmental agency, and (v)&nbsp;for
the three most recent years and as applicable (A)&nbsp;the Form&nbsp;5500 and attached schedules, (B)&nbsp;audited financial statements,
(C)&nbsp;nondiscrimination testing results and (D)&nbsp;actuarial valuation reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent, its Subsidiaries or any member of their Controlled Group has ever sponsored, maintained, contributed to, or been required to
contribute to or incurred any liability (contingent or otherwise) with respect to: (i)&nbsp;a Multiemployer Plan, (ii)&nbsp;an &ldquo;employee
pension benefit plan&rdquo; (within the meaning of Section&nbsp;3(2)&nbsp;of ERISA) that is subject to Title IV of ERISA or Section&nbsp;412
of the Code or Section&nbsp;302 of ERISA, (iii)&nbsp;any &ldquo;multiple employer plan&rdquo; as defined in Section&nbsp;413 of the Code
or Section&nbsp;210 of ERISA, (iv)&nbsp;a &ldquo;funded welfare benefit plan&rdquo; within the meaning of Section&nbsp;419 of the Code
or (v)&nbsp;any &ldquo;multiple employer welfare arrangement&rdquo; (as such term is defined in Section&nbsp;3(40) of ERISA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>With
respect to the Parent Plans:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Parent Plan is and has been established, operated and administered in all material respects with its terms and materially complies in
form and in operation with the applicable provisions of ERISA and the Code and all other applicable legal requirements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>no
Parent Plan is, or within the past six years has been, the subject of an application or filing under a government sponsored amnesty,
voluntary compliance, or similar program, or been the subject of any self-correction under any such program;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Parent Plan intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code has received a favorable determination, advisory and/or
opinion letter, as applicable, from the IRS that it is so qualified and nothing has occurred to the knowledge of Parent since the date
of such letter that would reasonably be expected to cause the loss of the sponsor&rsquo;s ability to rely upon such letter, and nothing
has occurred to the knowledge of Parent that would reasonably be expected to result in the loss of the qualified status of such Parent
Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>there
is no material Action (including any investigation, audit or other administrative proceeding) by the Department of Labor, the PBGC, the
IRS or any other Governmental Entity or by any plan participant or beneficiary pending, or to the knowledge of Parent, threatened, relating
to the Parent Plans, any fiduciaries thereof with respect to their duties to Parent Plans or the assets of any of the trusts under any
of the Parent Plans (other than routine claims for benefits);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>none
of the Parent Plans currently provides, or reflects or represents any liability to provide post-termination or retiree welfare benefits
to any person for any reason, except as may be required by COBRA, and neither Parent nor any members of its Controlled Group has any
liability to provide post-termination or retiree welfare benefits to any person or ever represented, promised or contracted to any employee
or former employee of Parent (either individually or to Parent employees as a group) or any other person that such employee(s)&nbsp;or
other person would be provided with post-termination or retiree welfare benefits, except to the extent required by statute or except
with respect to a contractual obligation to reimburse any premiums such person may pay in order to obtain health coverage under COBRA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>all
payments and/or contributions required to have been timely made with respect to all Parent Plans either have been made or have been accrued
in accordance with the terms of the applicable Parent Plan and applicable law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Parent Plan is subject exclusively to United States Law; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
execution and delivery of this Agreement, the Parent Stockholder Approval, and the consummation of the Merger will not, either alone
or in combination with any other event, (A)&nbsp;entitle any current or former employee, officer, director or consultant of Parent or
any of its Subsidiaries to severance pay, unemployment compensation or any other similar termination payment, or (B)&nbsp;accelerate
the time of payment or vesting, or increase the amount of or otherwise enhance any benefit due any such employee, officer, director or
consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries is a party to any agreement, contract, arrangement or plan (including any Parent Plan) that may reasonably
be expected to result, separately or in the aggregate, in connection with the Contemplated Transactions (either alone or in combination
with any other events), in the payment of any &ldquo;parachute payments&rdquo; within the meaning of Section&nbsp;280G of the Code. There
is no agreement, plan or other arrangement to which Parent or any of its Subsidiaries is a party or by which Parent or any of its Subsidiaries
is otherwise bound to compensate any person in respect of Taxes or other liabilities incurred with respect to Section&nbsp;409A or 4999
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Parent Plan that is a &ldquo;nonqualified deferred compensation plan&rdquo; within the meaning of Section&nbsp;409A of the Code (or any
comparable or similar provision of state, local, or foreign Law) complies in both form and operation in all material respects with the
requirements of Section&nbsp;409A of the Code (or any comparable or similar provision of state, local, or foreign Law) and all applicable
IRS guidance issued with respect thereto (and has so complied for the entire period during which Section&nbsp;409A of the Code has applied
to such Parent Plan) so that no amount paid or payable pursuant to any such Parent Plan is subject to any additional Tax or interest
under Section&nbsp;409A of the Code (or any comparable or similar provision of state, local, or foreign Law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
Parent Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.13&#8239;&#8239;&nbsp;</FONT><U>Labor
and Employment Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
and each of its Subsidiaries are and, since January&nbsp;1, 2022, have been in compliance in all material respects with all applicable
Laws relating to labor or employment matters, including those relating to employment practices, terms and conditions of employment, collective
bargaining, disability, immigration, health and safety, wages, hours and benefits, non-discrimination in employment, workers&rsquo; compensation,
the collection and payment of withholding and/or payroll Taxes and similar Taxes, unemployment compensation, equal employment opportunity,
discrimination, harassment, employee and contractor classification, restrictive covenants, pay equity, information privacy and security,
and continuation coverage with respect to group health plans. Since January&nbsp;1, 2022, there has not been, and as of the date of this
Agreement there is not pending or, to the knowledge of Parent, threatened, any labor dispute, work stoppage, labor strike or lockout
against Parent or any of its Subsidiaries by employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
employee of Parent or any of its Subsidiaries is, or since January&nbsp;1, 2022 has been, covered by an effective or pending collective
bargaining agreement or similar labor agreement. To the knowledge of Parent, there has not been any activity on behalf of any labor union,
labor organization or similar employee group to organize any employees of Parent or any of its Subsidiaries. There are no and since January&nbsp;1,
2022 there has not been any: (i)&nbsp;unfair labor practice charges or complaints against Parent or any of its Subsidiaries pending before
the National Labor Relations Board or any other labor relations tribunal or authority and to the knowledge of Parent no such representations,
claims or petitions are threatened, (ii)&nbsp;representations, claims or petitions pending before the National Labor Relations Board
or any other labor relations tribunal or authority or (iii)&nbsp;grievances or pending arbitration proceedings against Parent or any
of its Subsidiaries that arose out of or under any collective bargaining agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
January&nbsp;1, 2022, (i)&nbsp;neither Parent nor any of its Subsidiaries has not effectuated a &ldquo;plant closing&rdquo; (as defined
in the WARN Act) affecting any site of employment or one or more facilities or operating units within any site of employment or facility,
(ii)&nbsp;there has not occurred a &ldquo;mass layoff&rdquo; (as defined in the WARN Act) in connection with Parent or any of its Subsidiaries
affecting any site of employment or one or more facilities or operating units within any site of employment or facility and (iii)&nbsp;neither
Parent nor any of its Subsidiaries has not engaged in layoffs or employment terminations sufficient in number to trigger application
of any similar state, local or foreign law. Parent and its Subsidiaries properly classify and for the two (2)&nbsp;years immediately
preceding the date hereof have properly classified its and their (i)&nbsp;employees as exempt or non-exempt in accordance with applicable
overtime laws, (ii)&nbsp;contingent workers in accordance with applicable law and (iii)&nbsp;workers as employees or non-employees (e.g.,
consultants, independent contractors), in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Section&nbsp;5.13(d)</U>&nbsp;of the Parent Disclosure Letter, with respect to any current or former employee, officer,
consultant or other service provider of Parent, there are no Actions against Parent or any of its Subsidiaries pending, or to the knowledge
of Parent, threatened to be brought or filed, in connection with the employment or engagement of any current or former employee, officer,
consultant or other service provider of Parent, including, without limitation, any claim relating to employment discrimination, harassment,
retaliation, equal pay, employment classification, contractor classification, wages, hours, and benefits or any other employment related
matter arising under applicable Laws, except where such action would not, individually or in the aggregate, result in Parent incurring
a material liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth on <U>Section&nbsp;5.13(e)</U>&nbsp;of the Parent Disclosure Letter or with respect to any Parent Plan (which subject is
addressed in <U>Section&nbsp;5.12</U> above), the execution of this Agreement and the consummation of the transactions set forth in or
contemplated by this Agreement will not result in any breach or violation of, or cause any payment to be made under, any applicable Laws
respecting labor and employment or any collective bargaining agreement to which Parent or any of its Subsidiaries is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Since
January&nbsp;1, 2022, no allegations of harassment or unlawful discrimination (with respect to any category protected by applicable law,
including, without limitation, sexual harassment), retaliation on the basis of protected activity (including as a whistleblower) or protected
class status in accordance with applicable law, or other material misconduct relating to the workplace have been made, initiated, filed
or, to the knowledge of Parent, threatened against or involving Parent or any of its Subsidiaries or any of their respective current
or former directors, officers or senior level management employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
employee or other worker of Parent is subject to any service relationship that is not &ldquo;at-will&rdquo; or that is terminable on
more than 30 days&rsquo; notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.14&#8239;&#8239;&nbsp;</FONT><U>Environmental
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;Parent
and its Subsidiaries have conducted its businesses in compliance with all, and have not violated any, applicable Environmental Laws;
(ii)&nbsp;Parent and its Subsidiaries have obtained all Permits of all Governmental Entities and any other Person that are required under
any Environmental Law; (iii)&nbsp;there has been no release of any Hazardous Substance by Parent or any of its Subsidiaries or any other
Person in any manner that has given or would reasonably be expected to give rise to any remedial or investigative obligation, corrective
action requirement or liability of Parent or any of its Subsidiaries under applicable Environmental Laws; (iv)&nbsp;Parent and its Subsidiaries
have not received any claims, notices, demand letters or requests for information (except for such claims, notices, demand letters or
requests for information the subject matter of which has been resolved prior to the date of this Agreement) from any federal, state,
local, foreign or provincial Governmental Entity or any other Person asserting that Parent or any of its Subsidiaries is in violation
of, or liable under, any Environmental Law; (v)&nbsp;no Hazardous Substance has been disposed of, arranged to be disposed of, released
or transported in violation of any applicable Environmental Law, or in a manner that has given rise to, or that would reasonably be expected
to give rise to, any liability under any Environmental Law, in each case, on, at, under or from any current or former properties or facilities
owned or operated by Parent or any of its Subsidiaries or as a result of any operations or activities of Parent or any of its Subsidiaries
at any location and, to the knowledge of Parent, Hazardous Substances are not otherwise present at or about any such properties or facilities
in amount or condition that has resulted in or would reasonably be expected to result in liability to Parent or any of its Subsidiaries
under any Environmental Law; and (vi)&nbsp;neither Parent or any of its Subsidiaries nor any of their properties or facilities are subject
to, or are threatened to become subject to, any liabilities relating to any suit, settlement, court order, administrative order, regulatory
requirement, judgment or claim asserted or arising under any Environmental Law or any agreement relating to environmental liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.15&#8239;&#8239;&#8239;</FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
and its Subsidiaries have (i)&nbsp;filed all income and other material Tax Returns required to be filed by or on behalf of them (taking
into account any applicable extensions) and all such Tax Returns are true, accurate and complete in all material respects; and (ii)&nbsp;timely
paid in full (or caused to be timely paid in full) all material Taxes that are required to be paid by or with respect to them, whether
or not such Taxes were shown as due on such Tax Returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
material Taxes not yet due and payable by Parent as of the date of the balance sheet included in the financial statements (including
the related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents have been, in all respects,
properly accrued in accordance with GAAP on the financial statements (including the related notes and schedules thereto) included (or
incorporated by reference) in the Parent SEC Documents, and such financial statements (including the related notes and schedules thereto)
included (or incorporated by reference) in the Parent SEC Documents reflect an adequate reserve (in accordance with GAAP) for all material
Taxes accrued but unpaid by Parent through the date of such financial statements. Since the date of financial statements (including the
related notes and schedules thereto) included (or incorporated by reference) in the Parent SEC Documents, neither Parent nor any of its
Subsidiaries has incurred, individually or in the aggregate, any liability for Taxes outside the ordinary course of business consistent
with past practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries has executed any waiver of any statute of limitations on, or extended the period for the assessment
or collection of, any amount of Tax, in each case that has not since expired (other than in connection with automatic extensions to file
Tax Returns obtained in the ordinary course of business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
material Tax Action with respect to Taxes or any Tax Return of Parent or any of its Subsidiaries are presently in progress or have been
asserted, threatened or proposed in writing and to the knowledge of Parent, no such Tax Action is being contemplated. No deficiencies
or claims for a material amount of Taxes have been claimed, proposed, assessed or asserted in writing against Parent or any of its Subsidiaries
by a Governmental Entity, other than any such claim, proposal, assessment or assertion that has been satisfied by payment in full, settled
or withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to exceptions as would not be material, Parent and its Subsidiaries have timely withheld all Taxes required to have been withheld from
payments made (or deemed made) to its employees, independent contractors, creditors, shareholders and other third parties and, to the
extent required, such Taxes have been timely paid to the relevant Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>Neither
Parent nor any of its Subsidiaries has engaged in a &ldquo;listed transaction&rdquo; as set forth in Treasury Regulations &sect; 1.6011-4(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries (i)&nbsp;is a party to or bound by, or has any liability pursuant to, any Tax sharing, allocation,
indemnification or similar agreement or obligation other than any Ordinary Course Agreement; (ii)&nbsp;is or has been a member of a group
(other than a group the common parent of which is Parent) filing a consolidated, combined, affiliated, unitary or similar income Tax
Return; (iii)&nbsp;has liability for the Taxes of any Person (other than Parent or its Subsidiaries) pursuant to Treasury Regulations
 &sect; 1.1502-6 (or any similar provision of state, local or non-United States Law) as a transferee or successor, by Contract, or otherwise
by operation of Law; or (iv)&nbsp;is or has been treated as a resident for any income Tax purpose, or as subject to Tax by virtue of
having a permanent establishment, an office or fixed place of business, in any country other than the country in which it was or is organized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
private letter rulings, technical advice memoranda, or similar material agreements or rulings have been requested, entered into or issued
by any Governmental Entity with respect to Parent or any of its Subsidiaries which rulings remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>Neither
Parent nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable
income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i)&nbsp;a change in, or use of improper,
method of accounting requested or initiated on or prior to the Closing Date, (ii)&nbsp;a &ldquo;closing agreement&rdquo; as described
in Section&nbsp;7121 of the Code (or any similar provision of Law) executed on or prior to the Closing Date, (iii)&nbsp;an installment
sale or open transaction disposition made on or prior to the Closing Date, (iv)&nbsp;any prepaid amount received or deferred revenue
accrued on or prior to the Closing Date, other than in respect of such amounts received in the ordinary course of business, or (v)&nbsp;to
the knowledge of Parent, an intercompany transaction or excess loss amount described in Treasury Regulations under Section&nbsp;1502
of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>There
are no liens for Taxes upon any of the assets of Parent or any of its Subsidiaries other than Liens described in clause (i)&nbsp;of the
definition of Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries has distributed stock of another Person or has had its stock distributed by another Person, in a transaction
(or series of transactions) that was purported or intended to be governed in whole or in part by Sections 355 or 361 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section&nbsp;897(c)(2)&nbsp;of
the Code during the applicable period specified in Section&nbsp;897(c)(1)(A)(ii)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
material claim has been made in writing by any Governmental Entity in a jurisdiction where Parent or any of its Subsidiaries does not
currently file a Tax Return of a certain type or pay Taxes of a certain type that Parent is or may be subject to taxation of such type
by such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>There
are no outstanding shares of Parent stock issued in connection with the performance of services (within the meaning of Section&nbsp;83
of the Code) that immediately prior to the Effective Time are subject to a substantial risk of forfeiture (as such terms are defined
in Section&nbsp;83 of the Code) for which a valid election under Section&nbsp;83(b)&nbsp;of the Code has not been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the knowledge of Parent, neither Parent nor any of its Subsidiaries has been, is, or immediately prior to the Effective Time will be,
treated as an &ldquo;investment company&rdquo; within the meaning of Section&nbsp;368(a)(2)(F)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
Parent nor any of its Subsidiaries has taken any action, has omitted to take any action, or has knowledge of any fact or circumstance,
the taking, omission, or existence of which, as the case may be, would reasonably be expected to prevent (i)&nbsp;the Merger from constituting
a reorganization within the meaning of Section&nbsp;368(a)&nbsp;of the Code, or (ii)&nbsp;the Merger, from qualifying as a non-taxable
exchange of shares of Company Common Stock for shares of Parent Common Stock within the meaning of Section&nbsp;351(a)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.16&#8239;&#8239;&nbsp;</FONT><U>Contracts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
for any Parent Plans (which are the subject of <U>Section&nbsp;5.12</U>), except as set forth in the Parent SEC Documents publicly available
prior to the date of this Agreement, and except for any agreement or contract, the expenses and obligations under which are included
in the calculation of Net Cash, Parent is not a party to or bound by any &ldquo;material contract&rdquo; (as such term is defined in
Item 601(b)(10)&nbsp;of Regulation S-K under the Securities Act) (all such contracts including those set forth in <U>Section&nbsp;5.16(b)</U>&nbsp;of
the Parent Disclosure Letter, &ldquo;<U>Parent Material Contracts</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;5.16(b)</U>&nbsp;of
the Parent Disclosure Letter lists the following contracts, which for the purposes of this Agreement shall be considered Parent Material
Contracts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>each
Contract relating to any agreement of indemnification or guaranty not entered into in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>each
Contract containing any covenant prohibiting Parent, its Subsidiaries or the Surviving Company from engaging in any line of business
or competing with any Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each Contract relating to capital expenditures and requiring payments
after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract relating to the disposition or acquisition of material assets or any ownership interest in any Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each Contract relating to any mortgages, indentures, loans, notes or
credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in
excess of $100,000 or creating any material Liens with respect to any assets of the Parent or any of its Subsidiaries or any loans or
debt obligations with officers or directors of the Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services
to the Parent in connection with the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each Contract to which the Parent is a party or by which any of its
assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Parent in excess
of $250,000 or pursuant to which the Company has outstanding unpaid obligations in excess of $250,000; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>each
Contract relating to leases of real properties with respect to which the Parent directly or indirectly holds a valid leasehold interest
as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 1.25in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Parent Material Contract is valid and binding on Parent, and to the knowledge of Parent, each other party thereto, and is in full force
and effect and enforceable in accordance with its terms; (ii)&nbsp;Parent, and, to the knowledge of Parent, each other party thereto,
has performed all material obligations required to be performed by it under each Parent Material Contract; and (iii)&nbsp;there is no
material default under any Parent Material Contract by Parent or, to the knowledge of Parent, any other party thereto, and no event or
condition has occurred that constitutes, or, after notice or lapse of time or both, would constitute, a material default on the part
of Parent or, to the knowledge of Parent, any other party thereto under any such Parent Material Contract, nor has Parent received any
notice of any such material default, event or condition. Parent has made available to the Company true and complete copies of all Parent
Material Contracts, including all amendments thereto. Except as set forth in <U>Section&nbsp;5.16(c)</U>&nbsp;of the Parent Disclosure
Letter, there are no Parent Material Contracts that are not in written form. No Person is renegotiating, or has a right pursuant to the
terms of any Parent Material Contract to change, any material amount paid or payable to the Parent under any Parent Material Contract
or any other material term or provision of any Parent Material Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.17&#8239;&#8239;&nbsp;</FONT><U>Insurance</U>.
Each of Parent and its Subsidiaries is covered by valid and currently effective insurance policies issued in favor of Parent or its Subsidiaries
that are customary and adequate for companies of similar size in the industries and locations in which Parent and its Subsidiaries operate.
<U>Section&nbsp;5.17</U> of the Parent Disclosure Letter sets forth, as of the date hereof, a true and complete list of all material
insurance policies issued in favor of Parent or any of its Subsidiaries, or pursuant to which Parent or any of its Subsidiaries is a
named insured or otherwise a beneficiary, as well as any historic incurrence-based policies still in force. With respect to each such
insurance policy, (a)&nbsp;such policy is in full force and effect and all premiums due thereon have been paid, (b)&nbsp;neither Parent
nor any of its Subsidiaries is in breach or default, and has not taken any action or failed to take any action which (with or without
notice or lapse of time, or both) would constitute such a breach or default, or would permit termination or modification of, any such
policy and (c)&nbsp;to the knowledge of Parent, no insurer issuing any such policy has been declared insolvent or placed in receivership,
conservatorship or liquidation. No notice of cancellation or termination has been received with respect to any such policy, nor will
any such cancellation or termination result from the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.18&#8239;&#8239;&#8239;</FONT><U>Properties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
and its Subsidiaries has good and valid title to, or in the case of leased property and leased tangible assets, a valid leasehold interest
in, all of its real properties and tangible assets that are necessary for Parent and its Subsidiaries to conduct its businesses as currently
conducted, free and clear of all Liens other than Permitted Liens. Except as has not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect, the tangible personal property currently used in the operation of
the business of Parent and its Subsidiaries is in good working order (reasonable wear and tear excepted).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
of Parent and its Subsidiaries has complied with the terms of all leases to which it is a party, and all such leases are in full force
and effect, except for any such noncompliance or failure to be in full force and effect that, individually or in the aggregate, has not
had and would not reasonably be expected to have a Parent Material Adverse Effect. Each of Parent and its Subsidiaries enjoys peaceful
and undisturbed possession under all such leases, except for any such failure to do so that, individually or in the aggregate, has not
had and would not reasonably be expected to have a Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;5.18(c)</U>&nbsp;of
the Parent Disclosure Letter sets forth a true and complete list of (i)&nbsp;all real property owned by Parent or any of its Subsidiaries
and (ii)&nbsp;all real property leased for the benefit of Parent or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.19&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Section&nbsp;5.19(a)</U>&nbsp;of
the Parent Disclosure Letter sets forth a true and complete list of all (i)&nbsp;patents and patent applications; (ii)&nbsp;trademark
registrations and applications; and (iii)&nbsp;material copyright registrations and applications, in each case owned or licensed by Parent
and its Subsidiaries (collectively, &ldquo;<U>Parent Registered IP</U>&rdquo;) and a true and complete list of all domain names owned
or exclusively licensed by Parent and its Subsidiaries. Except as, individually or in the aggregate, has not had and would not reasonably
be expected to have a Parent Material Adverse Effect (i)&nbsp;all of the Parent Registered IP is subsisting and, solely in the case of
any Parent Registered IP that is registered or issued and to the knowledge of Parent, valid and enforceable, (ii)&nbsp;no Parent Registered
IP, is involved in any interference, reissue, derivation, reexamination, opposition, cancellation or similar proceeding and, to the knowledge
of Parent, no such action is threatened with respect to any of the Parent Registered IP and (iii)&nbsp;Parent and its Subsidiaries own
exclusively, free and clear of any and all Liens (other than Permitted Liens), all Parent Owned IP, including all Intellectual Property
created on behalf of Parent or its Subsidiaries by employees or independent contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
and its Subsidiaries have taken commercially reasonable measures to maintain the confidentiality of all information that constitutes
or constituted a material Trade Secret of Parent and its Subsidiaries, including requiring all Persons having access thereto to execute
written non-disclosure agreements or other binding obligations to maintain confidentiality of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;to
the knowledge of Parent, the conduct of the businesses of Parent and its Subsidiaries, including the manufacture, marketing, offering
for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent or
any of its Subsidiaries, has not infringed, misappropriated or diluted, and does not infringe, misappropriate or dilute, any Intellectual
Property of any Person, (ii)&nbsp;neither Parent nor any of its Subsidiaries have received any written notice or claim asserting or suggesting
that any such infringement, misappropriation, or dilution is or may be occurring or has or may have occurred and (iii)&nbsp;to the knowledge
of Parent, no Person is infringing, misappropriating, or diluting in any material respect any Parent Registered IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;Parent
and its Subsidiaries have taken commercially reasonable steps to protect the confidentiality and security of the computer and information
technology systems used by Parent or any of its Subsidiaries (the &ldquo;<U>Parent IT Systems</U>&rdquo;) and the information and transactions
stored or contained therein or transmitted thereby, (ii)&nbsp;to the knowledge of Parent, during the past two (2)&nbsp;years, there has
been no unauthorized or improper use, loss, access, transmittal, modification or corruption of any such information or data, and (iii)&nbsp;during
the past two (2)&nbsp;years, there have been no material failures, crashes, viruses, security breaches (including any unauthorized access
to any personally identifiable information), affecting the Parent IT Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect, (i)&nbsp;to
the knowledge of Parent, Parent and its Subsidiaries have at all times complied in all material respects with all applicable Privacy
Laws, (ii)&nbsp;during the past two (2)&nbsp;years since the Effective Time, no claims have been asserted or, to the knowledge of Parent,
threatened in writing against Parent or any of its Subsidiaries alleging a violation of any Person&rsquo;s privacy or Personal Information,
(iii)&nbsp;neither this Agreement nor the consummation of the Contemplated Transactions will breach or otherwise violate any Privacy
Laws and (iv)&nbsp;Parent and its Subsidiaries have taken commercially reasonable steps to protect the Personal Information collected,
used or held for use by Parent or any of its Subsidiaries against loss and unauthorized access, use, modification or disclosure, or other
misuse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&nbsp;</FONT>To
the knowledge of Parent, no government funding, facilities or resources of a university, college, other educational institution or research
center or funding from third parties was used in the development of the Parent Owned IP or any Intellectual Property exclusively licensed
to Parent or any of its Subsidiaries, and no Governmental Entity, university, college, other educational institution or research center
has, to the knowledge of Parent, any claim or right in or to such Intellectual Property. Except as set forth on <U>Section&nbsp;5.19(f)</U>&nbsp;of
the Parent Disclosure Letter, the execution, delivery and performance by Parent of this Agreement, and the consummation of the Contemplated
Transactions, will not result in the loss of, or give rise to any right of any third party to terminate or modify any of the rights or
obligations of Parent or any of its Subsidiaries under any agreement under which Parent or any of its Subsidiaries grants to any Person,
or any Person grants to Parent or any of its Subsidiaries, a license or right under or with respect to any Intellectual Property that
is material to any of the businesses of Parent or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.20&#8239;&#8239;</FONT><U>Related
Party Transactions</U>. Since January&nbsp;1, 2022 through the date of this Agreement, there have been no transactions, agreements, arrangements
or understandings between Parent or any of its Subsidiaries, on the one hand, and the Affiliates of Parent or any of its Subsidiaries,
on the other hand that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act and that have not
been so disclosed in the Parent SEC Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.21&#8239;&#8239;</FONT><U>Certain
Payments</U>. For the five (5)&nbsp;years immediately preceding the date hereof, neither Parent nor any of its Subsidiaries nor, to the
knowledge of Parent, any of their directors, executives, representatives, agents or employees (a)&nbsp;has used or is using any corporate
funds for any illegal contributions, gifts, entertainment or other unlawful expenses relating to political activity, (b)&nbsp;has used
or is using any corporate funds for any direct or indirect unlawful payments to any foreign or domestic governmental officials or employees,
(c)&nbsp;has violated or is violating any provision of the Foreign Corrupt Practices Act of 1977, as amended, (d)&nbsp;has established
or maintained, or is maintaining, any unlawful fund of corporate monies or other properties, or (e)&nbsp;has made any bribe, unlawful
rebate, payoff, influence payment, kickback or other unlawful payment of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.22&#8239;&#8239;</FONT><U>Trade
Control Laws</U>. Since January&nbsp;1, 2022, Parent and its Subsidiaries have been in material compliance with all applicable Trade
Laws and have obtained, or are otherwise qualified to rely upon, all material Trade Approvals. There are no pending or threatened claims
against the Parent or its Subsidiaries, nor any actions, conditions, facts or circumstances that would reasonably be expected to give
rise to any material future claims with respect to the Trade Laws or Trade Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.23&#8239;&#8239;&nbsp;</FONT><U>Brokers</U>.
No broker, investment banker, financial advisor or other Person, other than Lucid Capital Markets, LLC, the fees and expenses of which
will be paid by Parent or any of its Subsidiaries, is entitled to any broker&rsquo;s, finder&rsquo;s, financial advisor&rsquo;s or other
similar fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent, any
of its Subsidiaries or any of its Affiliates. Parent has furnished to Company a true and complete copy of any Contract between Parent
and Lucid Capital Markets, LLC pursuant to which Lucid Capital Markets, LLC, could be entitled to any payment from Parent relating to
the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.24&#8239;&#8239;&nbsp;</FONT><U>Opinion
of Financial Advisor</U>. Parent Board has received the opinion of Lucid Capital Markets, LLC, dated the date of this Agreement, to the
effect that, as of such date and based upon and subject to the qualifications, limitations, assumptions and other matters set forth therein,
the Exchange Ratio is fair, from a financial point of view, to the stockholders of Parent, a signed true and complete copy of which opinion
has been or will promptly be provided on a non-reliance basis to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.25&#8239;&#8239;&nbsp;</FONT><U>State
Takeover Statutes</U>. No Takeover Laws or any similar anti-takeover provision in the Certificate of Incorporation or bylaws of Parent
applicable to Parent is, or at the Effective Time will be, applicable to this Agreement, the Merger, the Parent Common Stock Issuance,
or any of the other Contemplated Transactions. The Parent Board and the Merger Sub board have taken and will take all actions necessary
to ensure that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are, and will be, inapplicable
to the execution, delivery and performance of this Agreement, and to the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;5.26&#8239;&#8239;&nbsp;</FONT><U>No
Other Representations or Warranties</U>. Except for the representations and warranties contained in <U>Article&nbsp;IV</U>, each of Parent
and Merger Sub acknowledges and agrees that none of the Company or any other Person on behalf of the Company makes any other express
or implied representation or warranty whatsoever, and specifically (but without limiting the generality of the foregoing) that none of
the Company, or any other Person on behalf of the Company makes any representation or warranty with respect to any projections or forecasts
delivered or made available to Parent, Merger Sub or any of their respective Representatives of future revenues, results of operations
(or any component thereof), cash flows or financial condition (or any component thereof) of the Company (including any such projections
or forecasts made available to Parent, Merger Sub or any of their respective Representatives in certain &ldquo;data rooms&rdquo; or management
presentations in expectation of the Contemplated Transactions), and none of Parent or Merger Sub has relied on any such information or
any representation or warranty not set forth in <U>Article&nbsp;IV</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VI</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
COVENANTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.1&#8239;&#8239;&#8239;&#8239;</FONT><U>Operation
of Parent&rsquo;s Business</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
(i)&nbsp;as expressly contemplated or permitted by this Agreement, (ii)&nbsp;as expressly required by applicable Law, (iii)&nbsp;in connection
with the winding down of Parent&rsquo;s prior research and development activities (including the termination of employees, independent
contractors, service providers, and ongoing contractual obligations related to Parent&rsquo;s current products or product candidates,
as well as any Parent Legacy Transaction) (but in all cases of this clause (iii), in consultation with the Company and subject to the
Company&rsquo;s prior written consent, not to be unreasonably withheld, conditioned or delayed) or (iv)&nbsp;unless the Company shall
otherwise consent in writing (email being sufficient), during the period commencing on the date of this Agreement and continuing until
the earlier to occur of the termination of this Agreement pursuant to <U>Article&nbsp;IX</U> and the Effective Time (the &ldquo;<U>Pre-Closing
Period</U>&rdquo;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x)&nbsp;conduct its business
and operations in material compliance with the applicable Law and the requirements of all Contracts that constitute Parent Material Contracts
and (y)&nbsp;continue to pay material outstanding accounts payable and other material current liabilities (including payroll) when due
and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
(i)&nbsp;as expressly contemplated or permitted by this Agreement or the Securities Purchase Agreement, a Permitted Stock Purchase Agreement
or any Parent Legacy Transaction, (ii)&nbsp;as set forth in <U>Section&nbsp;6.1(b)</U>&nbsp;of the Parent Disclosure Letter, (iii)&nbsp;as
required by applicable Law, (iv)&nbsp;in connection the winding down of Parent&rsquo;s prior research and development activities (including
the termination of employees, independent contractors, service providers, and ongoing contractual obligations related to Parent&rsquo;s
current products or product candidates) (but in all cases of this clause (iv), in consultation with the Company and subject to the Company&rsquo;s
prior written consent, not to be unreasonably withheld, conditioned or delayed) or (v)&nbsp;with the prior written consent of the Company
(which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall
not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>declare,
accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem
or otherwise reacquire any shares of its capital stock or other securities (except for any CVR, or shares of Parent Common Stock from
terminated employees, directors or consultants of Parent in accordance with agreements in effect on the date of this Agreement providing
for the repurchase of shares at no more than the purchase price thereof in connection with any termination of services to Parent or any
of its Subsidiaries);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sell,
issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A)&nbsp;any capital stock or other security (except
for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options, Parent Warrants or Parent Restricted
Stock Unit Awards, as applicable), (B)&nbsp;any option, warrant or right to acquire any capital stock or any other security or (C)&nbsp;any
instrument convertible into or exchangeable for any capital stock or other security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>except
as required to give effect to anything in contemplation of the Closing, amend any of its organizational documents, or effect or be a
party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split,
reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>form
any Subsidiary (other than Merger Sub) or acquire any equity interest or other interest in any other entity or enter into a joint venture
with any other entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;lend
money to any Person, (B)&nbsp;incur or guarantee any indebtedness for borrowed money, (C)&nbsp;guarantee any debt securities or others
or (D)&nbsp;other than the incurrence or payment of Transaction Expenses, make any capital expenditure or commitment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;other
than as expressly required by applicable Law or the terms of any Parent Plan in effect as of the date of this Agreement: (A)&nbsp;adopt,
establish or enter into any Parent Plan, including, for the avoidance of doubt, any equity award plans, (B)&nbsp;cause or permit any
Parent Plan to be amended other than as required by Law or in order to make amendments for the purposes of Section&nbsp;409A of the Code,
(C)&nbsp;pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this
Agreement pursuant to any Parent Plan), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation
or remuneration payable to, any of its employees, directors or consultants, (D)&nbsp;increase the severance or change of control benefits
offered to any current or new employees, directors or consultants, or (E)&nbsp;hire or terminate (other than for cause, or absent such
a definition of cause, for conduct that the Parent or such Subsidiary determines in good faith constitutes material misconduct) any officer,
employee or consultant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>enter
into any transaction outside the Ordinary Course;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>acquire
any material asset or sell, lease, license or otherwise irrevocably dispose of any of its material assets or properties, or grant any
Lien with respect to such assets or properties (other than the disposition of Parent Legacy Assets, subject to and in accordance with
<U>Section&nbsp;7.17</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>make,
change or revoke any material Tax election; file any amended income or other material Tax Return; settle or compromise any material Tax
claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material Taxes
may be issued (other than any extension pursuant to an extension to file any Tax Return); enter into any &ldquo;closing agreement&rdquo;
as described in Section&nbsp;7121 of the Code (or any similar Law) with any Governmental Entity; surrender any material claim for refund;
or adopt or change any material accounting method in respect of Taxes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>waive,
settle or compromise any pending or threatened Action against Parent or any of its Subsidiaries, other than waivers, settlements or agreements
(A)&nbsp;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals
thereof) and (B)&nbsp;that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken
as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>delay
or fail to repay when due, any obligation, including accounts payable and accrued expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>forgive
any loans to any Person, including its employees, officers, directors or Affiliate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xiii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sell,
assign, transfer, license, sublicense or otherwise dispose of any Intellectual Property of the Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xiv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>terminate
or modify in any respect, or fail to exercise renewal rights with respect to, any material insurance policy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>enter
into, amend, terminate, or waive any option or right under, any Parent Material Contract or Contract that would be deemed to be a Parent
Material Contract if entered into on or prior to the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xvi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
than the incurrence or payment of any Transaction Expenses, make any expenditures, incur any liabilities or discharge or satisfy any
obligations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xvii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>enter
into any agreement to purchase or sell any interest in real property, grant any security interest in any real property, enter into any
lease, sublease, license or other occupancy agreement with respect to any real property or alter, amend, modify, exercise any extension
or expansion right under or violate or terminate any of the terms of any real property leases of Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xviii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
than as expressly required by Law or GAAP, take any action to change accounting policies or procedures;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;change
pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B)&nbsp;agree
to change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of
its Subsidiaries; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>agree,
resolve or commit to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing contained in this Agreement shall give
the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the Effective Time. Prior to the
Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision
over its business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
any provision herein to the contrary (including the foregoing provisions of this <U>Section&nbsp;6.1</U>), Parent may engage in the sale,
license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding down of, and/or
the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition
of any Parent Legacy Assets (each, an &ldquo;<U>Parent Legacy Transaction</U>&rdquo;); provided, however, that to the extent any Parent
Legacy Transaction results in any monetary or other material obligations of Parent or otherwise or which could cause Parent to incur
any material liability that could extend beyond Closing or contemplates that any consideration paid in respect thereof is in anything
other than immediately available cash, or otherwise interferes with or delays in any manner the ability of Parent to perform its obligations
under this Agreement or timely consummate the transactions contemplated hereby, Parent shall procure prior written consent of the Company
prior to entering into any Parent Legacy Transaction. Notwithstanding anything to the contrary herein, Parent (i)&nbsp;shall permit the
Company and its counsel to review and comment on the transaction documents related to the Parent Legacy Transaction; (ii)&nbsp;shall
consider any such comments in good faith and shall accept all reasonable additions, deletions or changes suggested by the Company and
its counsel in connection therewith; and (iii)&nbsp;shall not sign any agreements, contracts or other definitive documents (not including
term sheets or letters of intent) related to Parent Legacy Transaction without first providing the Company and its counsel the opportunity
to exercise their rights under clauses (i)&nbsp;and (ii)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.2&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Operation
of Company&rsquo;s Business</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
(i)&nbsp;as expressly contemplated or permitted by this Agreement, (ii)&nbsp;as set forth in Section&nbsp;6.2(a)&nbsp;of the Company
Disclosure Letter, (iii)&nbsp;as expressly required by applicable Law or (iv)&nbsp;unless Parent shall otherwise consent in writing (which
consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period, the Company shall, and shall cause
its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course and in material
compliance with the applicable Law and the requirements of all Contracts that constitute Material Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
(i)&nbsp;as set forth in <U>Section&nbsp;6.2(b)</U>&nbsp;of the Company Disclosure Letter, (ii)&nbsp;as expressly required by applicable
Law or (iii)&nbsp;with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned),
at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>declare,
accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem
or otherwise reacquire any shares of its capital stock or other securities (except for shares of Company Common Stock from terminated
employees, directors or consultants of the Company);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sell,
issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any of the foregoing actions: (A)&nbsp;any capital
stock or other security, (B)&nbsp;any option, warrant or right to acquire any capital stock or any other security or (C)&nbsp;any instrument
convertible into or exchangeable for any capital stock or other security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>amend
any of its organizational documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization,
reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated
Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>form
any Subsidiary or acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;lend
money to any Person, (B)&nbsp;incur or guarantee any indebtedness for borrowed money, or (C)&nbsp;guarantee any debt securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sell,
lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Lien with respect to such assets or
properties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;waive,
settle or compromise any pending or threatened Action against the Company or any of its Subsidiaries, other than waivers, settlements
or agreements (A)&nbsp;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies
or renewals thereof) and (B)&nbsp;that do not impose any material restrictions on the operations or businesses of the Company or its
Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by the Company or any of its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(viii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>delay
or fail to repay when due any material obligation, including accounts payable and accrued expenses, other than in the Ordinary Course;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ix)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>make,
change or revoke any material Tax election; file any amended income or other material Tax Return; settle or compromise any material Tax
claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material Taxes
may be issued (other than any extension pursuant to an extension to file any Tax Return); enter into any &ldquo;closing agreement&rdquo;
as described in Section&nbsp;7121 of the Code (or any similar Law) with any Governmental Entity; surrender any material claim for refund;
or adopt or change any material accounting method in respect of Taxes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>sell,
assign, transfer, license, sublicense or otherwise dispose of any Intellectual Property of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(xi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>agree,
resolve or commit to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nothing contained in this Agreement shall give Parent, directly or
indirectly, the right to control or direct the operations of the Company prior to the Effective Time. Prior to the Effective Time, the
Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over
its business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.3&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Access
and Investigation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the terms of the Confidentiality Agreement, which the parties agree will continue in full force following the date of this Agreement,
during the Pre-Closing Period, upon reasonable advance written notice and during normal business hours, Parent, on the one hand, and
the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such party&rsquo;s Representatives to: (a)&nbsp;provide
the other party and such other party&rsquo;s Representatives with reasonable access during normal business hours to such party&rsquo;s
Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and
information relating to such party and its Subsidiaries, (b)&nbsp;provide the other party and such other party&rsquo;s Representatives
with such copies of the existing books, records, Tax Returns, work papers, product data and other documents and information relating
to such party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such party
and its Subsidiaries as the other party may reasonably request, (c)&nbsp;permit the other party&rsquo;s officers and other employees
to meet with the chief financial officer and other officers and managers of such party responsible for such party&rsquo;s financial statements
and the internal controls of such party to discuss such matters as the other party may deem necessary and (d)&nbsp;make available to
the other party copies of any material notice, report or other document filed with or sent to or received from any Governmental Entity
in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this <U>Section&nbsp;6.3(a)</U>&nbsp;shall
be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything herein to the contrary in this <U>Section&nbsp;6.3(b)</U>, no access or examination contemplated by this <U>Section&nbsp;6.3(b)</U>&nbsp;shall
be permitted to the extent that it would require any party or its Subsidiaries (i)&nbsp;to waive the attorney-client privilege or attorney
work product privilege, (ii)&nbsp;violate any applicable Law or (iii)&nbsp;breach such party&rsquo;s confidentiality obligations to a
third party; provided, that such party or its Subsidiary (A)&nbsp;shall be entitled to withhold only such information that may not be
provided without causing such violation or waiver, (B)&nbsp;shall provide to the other party all related information that may be provided
without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information), (C)&nbsp;shall
enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by
the other party in order that all such information may be provide to the other party without causing such violation or waiver, and (D)&nbsp;in
the case of subsection (iii)&nbsp;above, upon the other party&rsquo;s reasonable request, such party shall use its reasonable efforts
to obtain such third party&rsquo;s consent to permit such other party access to such information, subject to appropriate confidentiality
protections. In addition, no access or examination contemplated by this <U>Section&nbsp;6.3</U> shall be permitted to the extent that
it would require any party or its Subsidiaries, except as otherwise expressly required by this Agreement, to provide (A)&nbsp;information
to the other party that relates to the negotiation of this Agreement, (B)&nbsp;information to the other party that relates to any process
a party has conducted with any financial advisor or other communications with any Persons in connection therewith, or (C)&nbsp;minutes
of the meetings of the board of directors of a party or any committee thereof discussing the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.4&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>No
Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
of Parent (except as it relates to the Concurrent Investment and any Parent Legacy Transaction) and the Company agrees that, during the
Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize any of its Representatives
to, directly or indirectly: (i)&nbsp;solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission
or announcement of any Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an
Acquisition Proposal or Acquisition Inquiry, (ii)&nbsp;furnish any nonpublic information regarding such party to any Person in connection
with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii)&nbsp;engage in discussions or negotiations with any Person
with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&nbsp;approve, endorse or recommend any Acquisition Proposal (subject
to <U>Section&nbsp;7.2</U> and <U>Section&nbsp;7.3</U>), (v)&nbsp;execute or enter into any letter of intent or any Contract contemplating
or otherwise relating to any Acquisition Transaction, (vi)&nbsp;take any action that would reasonably be expected to lead to an Acquisition
Proposal or Acquisition Inquiry or (vii)&nbsp;publicly propose to do any of the following; provided, however, that, notwithstanding anything
contained in this <U>Section&nbsp;6.4</U> and subject to compliance with this <U>Section&nbsp;6.4</U>, prior to obtaining the Parent
Stockholder Approval, Parent may furnish nonpublic information regarding Parent and its Subsidiaries to, and enter into discussions or
negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which the Parent Board determines
in good faith, after consultation with its financial advisors and outside legal counsel, constitutes, or is reasonably likely to result
in, a Superior Offer (and is not withdrawn) if: (A)&nbsp;such Acquisition Proposal was not obtained or made as a direct or indirect result
of any breach of this Agreement, (B)&nbsp;the Parent Board concludes in good faith, after consulting with outside counsel, that the failure
to take such action would reasonably be expected to be inconsistent with the Parent Board&rsquo;s fiduciary duties under applicable Law,
(C)&nbsp;at least two (2)&nbsp;Business Days prior to initially furnishing any such nonpublic information to, or enter into discussions
with, such Person, Parent provides the Company written notice of the identity of such Person and of Parent&rsquo;s intention to furnish
nonpublic information to, or enter into discussions with, such Person, (D)&nbsp;Parent receives from such Person an executed Acceptable
Confidentiality Agreement and (E)&nbsp;at least two (2)&nbsp;Business Days prior to furnishing any such nonpublic information to such
Person, Parent furnishes such nonpublic information to the Company (to the extent such information has not been previously furnished
by Parent to the Company). Without limiting the generality of the foregoing, each party acknowledges and agrees that, in the event any
Representative of such party takes any action that, if taken by such party, would constitute a breach of this <U>Section&nbsp;6.4</U>
by such party, the taking of such action by such Representative shall be deemed to constitute a breach of this <U>Section&nbsp;6.4</U>
by such party for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any party or any Representative of such party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing
Period, then such party shall promptly (and in no event later than one (1)&nbsp;Business Day after such party becomes aware of such Acquisition
Proposal or Acquisition Inquiry) advise the other party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including
the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such party
shall keep the other party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry
and any material modification or material proposed modification thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that
relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any
nonpublic information provided to such Person as soon as reasonably practicable after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.5&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Notification
of Certain Matters</U>. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly
notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a)&nbsp;any notice or other communication is
received from any Person alleging that the consent of such Person is or may be required in connection with any of the Contemplated Transactions,
(b)&nbsp;any Action against or involving or otherwise affecting such party or its Subsidiaries is commenced, or, to the knowledge of
such party, threatened against such party or, to the knowledge of such party, any director, officer or employee of such party, (c)&nbsp;such
party becomes aware of any inaccuracy in any representation or warranty made by such party in this Agreement or (d)&nbsp;the failure
of such party to comply with any covenant or obligation of such party; in each case that could reasonably be expected to make the timely
satisfaction of any of the conditions set forth in <U>Article&nbsp;VII</U> or <U>Article&nbsp;VIII</U>, as applicable, impossible or
materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure
Letter for the purpose of (x)&nbsp;determining the accuracy of any of the representations and warranties made by the Company or Parent
in this Agreement or (y)&nbsp;determining whether any condition set forth in Article&nbsp;VII or <U>Article&nbsp;VIII</U> has been satisfied.
Any failure by either party to provide notice pursuant to this <U>Section&nbsp;6.5</U> shall not be deemed to be a breach for purposes
of <U>Section&nbsp;8.2(b)</U>&nbsp;and <U>Section&nbsp;8.3(b)</U>, as applicable, unless such failure to provide such notice was knowing
and intentional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.6&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>[RESERVED]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.7&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>[RESERVED]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.8&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Parent
ESPP</U>. As soon as reasonably practicable following the date of this Agreement, the Parent Board shall adopt appropriate resolutions
to provide that (a)&nbsp;no offering periods or purchase periods shall be commenced following or in addition to the offering period underway
as of the date hereof under the Parent ESPP (the &ldquo;<U>Current Offering Period</U>&rdquo;), (b)&nbsp;no payroll deductions or other
contributions shall be made or effected after the Current Offering Period with respect to the Parent ESPP after the date of such resolutions,
and (c)&nbsp;the Current Offering Period shall be terminated and each Parent ESPP participant&rsquo;s accumulated contributions under
the Parent ESPP shall be returned to the participant in accordance with the terms of the Parent ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;6.9&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Parent
401(K)&nbsp;Plan</U>. If requested by the Company in writing at least ten (10)&nbsp;Business Days prior to the Closing Date, the Parent
Board or an authorized committee thereof shall take (or cause to be taken) all actions to adopt such resolutions as may be necessary
or appropriate to terminate, effective no later than the day prior to the Closing Date but subject to the Closing, any Parent Plan that
contains a cash or deferred arrangement intended to qualify under Section&nbsp;401(k)&nbsp;of the Code (a &ldquo;<U>Parent 401(k)&nbsp;Plan</U>&rdquo;).
If Parent is required to terminate any Parent 401(k)&nbsp;Plan, then Parent shall provide to the Company prior to the Closing Date written
evidence of the adoption by the Parent Board or an authorized committee thereof of resolutions authorizing the termination of such Parent
401(k)&nbsp;Plan (the form and substance of which shall be subject to the reasonable prior review and approval of the Company, not to
be unreasonably withheld, conditioned or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VII</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
ADDITIONAL AGREEMENTS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.1&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Registration
Statement; Proxy Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
promptly as practicable (but in any event, no later than July&nbsp;18, 2025), (i)&nbsp;Parent shall prepare, and file with the SEC a
proxy statement relating to the Parent Stockholders Meeting to be held in connection with the Merger (together with any amendments thereof
or supplements thereto, the &ldquo;<U>Proxy Statement</U>&rdquo;) and (ii)&nbsp;Parent, in cooperation with the Company, shall prepare
and file with the SEC a registration statement on Form&nbsp;S-4 (the &ldquo;<U>Form&nbsp;S-4</U>&rdquo;), in which the Proxy Statement
shall be included as a part (the Proxy Statement and the Form&nbsp;S-4, collectively, the &ldquo;<U>Registration Statement</U>&rdquo;),
in connection with the registration under the Securities Act of the shares of Parent Common Stock to be issued by virtue of the Contemplated
Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form&nbsp;S-4 pursuant to applicable
Law. Parent shall use its reasonable best efforts to (i)&nbsp;cause the Registration Statement to comply with the applicable rules&nbsp;and
regulations promulgated by the SEC, (ii)&nbsp;cause the Registration Statement to become effective as promptly as practicable, and (iii)&nbsp;respond
promptly to any comments or requests (written or oral) of the SEC or its staff relating to the Registration Statement. Parent shall promptly
notify the Company upon the receipt of any comments or requests (written or oral) from the SEC or its staff or any request from the SEC
or its staff for amendments or supplements to the Registration Statement. Parent shall take all or any action required under any applicable
federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated
Transactions. Each of the parties shall reasonably cooperate with the other party and furnish all information concerning itself and their
Affiliates, as applicable, to the other parties that is required by law to be included in the Registration Statement as the other parties
may reasonably request in connection with such actions and the preparation of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith)
will (i)&nbsp;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL,
and (ii)&nbsp;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
The Company covenants and agrees that the information supplied by or on behalf of the Company, concerning itself, to Parent for inclusion
in the Registration Statement will not contain any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading.
Notwithstanding the foregoing, neither party makes any covenant, representation or warranty with respect to statements made in the Registration
Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided
by the other party or any of their Representatives regarding such other party or its Affiliates for inclusion therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&rsquo;s stockholders as promptly as practicable
(but in any event no later than two (2)&nbsp;Business Days) after the Registration Statement is declared effective under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
at any time before the Effective Time (i)&nbsp;any party (A)&nbsp;becomes aware of any event or information that, pursuant to the Securities
Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement, (B)&nbsp;receives notice of
any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C)&nbsp;receives
SEC comments on the Registration Statement, or (ii)&nbsp;the information provided in the Registration Statement has become &ldquo;stale&rdquo;
and new information should be disclosed in an amendment or supplement to the Registration Statement; then, in each case such party, as
the case may be, shall promptly inform the other parties thereof and shall cooperate with such other parties in filing such amendment
or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing
such SEC request or comments and each party shall use their commercially reasonable efforts to cause any such amendment to become effective,
if required. Parent shall promptly notify the Company if it becomes aware (1)&nbsp;that the Registration Statement has become effective,
(2)&nbsp;of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuance in
connection with the Contemplated Transactions for offering or sale in any jurisdiction, or (3)&nbsp;any order of the SEC related to the
Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives,
on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the
SEC relating to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives,
with all true, correct and complete information regarding the Company that is required by law to be included in the Registration Statement
or reasonably requested by Parent to be included in the Registration Statement. Without limiting the Company&rsquo;s obligations in <U>Section&nbsp;7.1(a)</U>,
the Company will use commercially reasonable efforts to cause to be delivered to Parent a letter of the Company&rsquo;s independent accounting
firm, dated no more than two (2)&nbsp;Business Days before the date on which the Registration Statement becomes effective (and reasonably
satisfactory in form and substance to Parent), that is customary in scope and substance for letters delivered by independent public accountants
in connection with registration statements similar to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all
amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration
Statement, prior to the filing thereof with the SEC. No filing of, or amendment or supplement to, the Registration Statement will be
made by Parent, and no filing of, or amendment or supplement to, the Registration Statement will be made by Parent, in each case, without
the prior consent of the Company, which shall not be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
promptly as reasonably practicable (and in no event by July&nbsp;9, 2025), the Company shall furnish to Parent (i)&nbsp;audited financial
statements for each of its fiscal years required to be included in the Registration Statement (the &ldquo;<U>Company Audited Financial
Statements</U>&rdquo;) and (ii)&nbsp;unaudited interim financial statements for each interim period completed prior to Closing that would
be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject
to the periodic reporting requirements under the Securities Act or the Exchange Act (the &ldquo;<U>Company Interim Financial Statements</U>&rdquo;).
Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be prepared in accordance with GAAP
as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto and except, in the
case of any unaudited financial statements, to normal year-end audit adjustments) and on that basis will present fairly, in all material
respects, the financial position and the results of operations, changes in stockholders&rsquo; equity, and cash flows of the Company
as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.2&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Company
Stockholder Approval</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Promptly
after the Registration Statement has been declared effective under the Securities Act, and in any event no later than one (1)&nbsp;Business
Day thereafter, the Company shall solicit for approval the Company Stockholder Approval. Under no circumstances shall the Company assert
that any other approval or consent (including with respect to any approval by Guarantor) is necessary to approve this Agreement and the
Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company agrees that subject to <U>Section&nbsp;7.2(c)</U>: (i)&nbsp;the Company Board shall recommend that the Company&rsquo;s sole stockholders
vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such
approval within the time set forth in <U>Section&nbsp;7.2(a)</U>&nbsp;(the recommendation of the Company Board that the Company&rsquo;s
sole stockholder vote to adopt and approve this Agreement being referred to as the &ldquo;<U>Company Board Recommendation</U>&rdquo;)
and (ii)&nbsp;the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to
withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee
thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly
propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing
clause (ii), collectively, a &ldquo;<U>Company Board Adverse Recommendation Change</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything to the contrary contained in <U>Section&nbsp;7.2(b)</U>, and subject to compliance with <U>Section&nbsp;6.4</U> and <U>Section&nbsp;7.2</U>,
if at any time prior to approval and adoption of this Agreement by the Company Stockholder Approval, the Company receives a bona fide
written Superior Offer, the Company Board may make a Company Board Adverse Recommendation Change if, but only if, in the case of a Superior
Offer, following the receipt of and on account of such Superior Offer, (1)&nbsp;the Company Board determines in good faith, after consulting
with outside legal counsel, that the failure to withhold, amend, withdraw or modify such recommendation would reasonably be expected
to be inconsistent with its fiduciary duties under applicable Law, (2)&nbsp;the Company has, and has caused its financial advisors and
outside legal counsel to, during the Company Notice Period, negotiate with Parent in good faith to make such adjustments to the terms
and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer (to the extent Parent desires
to negotiate) and (3)&nbsp;if after Parent shall have delivered to the Company an irrevocable written offer to alter the terms or conditions
of this Agreement during the Company Notice Period, the Company Board shall have determined in good faith, based on the advice of its
outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected
to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions
of this Agreement); provided that (x)&nbsp;Parent receives written notice from the Company confirming that the Company Board has determined
to change its recommendation at least four (4)&nbsp;Business Days in advance of the Company Board Adverse Recommendation Change (the
 &ldquo;<U>Company Notice Period</U>&rdquo;), which notice shall include a description in reasonable detail of the reasons for such Company
Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential
Superior Offer, (y)&nbsp;during any Company Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals
to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent
Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition
Proposal ceases to constitute a Superior Offer and (z)&nbsp;in the event of any material amendment to any Superior Offer (including any
revision in the amount, form or mix of consideration or percentage of the combined company that the Company&rsquo;s stockholders would
receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment
and the Company Notice Period shall be extended, if applicable, to ensure that at least two (2)&nbsp;Business Days remain in the Company
Notice Period following such notification during which the parties shall comply again with the requirements of this <U>Section&nbsp;7.2(c)</U>&nbsp;and
the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Company Notice Period as so extended
(it being understood that there may be multiple extensions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.3&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Parent
Stockholders&rsquo; Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock
(the &ldquo;<U>Parent Stockholder Meeting</U>&rdquo;) to consider and obtain the Parent Stockholder Approval and thereby approve the
Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent, any Parent Legacy Transaction (the &ldquo;<U>Parent
Stockholder Proposals</U>&rdquo;). The Parent Stockholder Meeting shall be held as promptly as practicable after the Registration Statement
is declared effective under the Securities Act, and in any event no later than forty-five (45) days after the effective date of the Registration
Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting
are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the
Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably determines
in good faith that (i)&nbsp;it will not receive proxies sufficient to obtain the Parent Stockholder Approval, whether or not a quorum
would be present or (ii)&nbsp;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to
constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting, Parent may postpone or adjourn, or make one
or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting
is not postponed or adjourned by more than an aggregate of thirty (30) days in connection with any postponements or adjournments. Except
as required by applicable Law, in no event shall the record date of the Parent Stockholders&rsquo; Meeting be changed without Company&rsquo;s
prior written consent, not to be unreasonably withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
agrees that, subject to <U>Section&nbsp;7.3(c)</U>, (i)&nbsp;the Parent Board shall recommend that the holders of Parent Common Stock
vote to approve the Parent Stockholder Proposals and shall use commercially reasonable efforts to solicit such approval within the timeframe
set forth in <U>Section&nbsp;7.3(a)</U>&nbsp;above and (ii)&nbsp;the Proxy Statement shall include a statement to the effect that the
Parent Board recommends that Parent&rsquo;s stockholders vote to approve the Parent Stockholder Proposal (the recommendation of the Parent
Board being referred to as the &ldquo;<U>Parent Board Recommendation</U>&rdquo;) and (iii)&nbsp;the Parent Board Recommendation shall
not be withheld, amended, withdrawn or modified (and the Parent Board shall not publicly propose to withhold, amend, withdraw or modify
the Parent Board Recommendation) in a manner adverse to the Company, and no resolution by the Parent Board or any committee thereof to
withdraw or modify the Parent Board Recommendation in a manner adverse to the Company or to adopt, approve or recommend (or publicly
propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing
clause (iii), collectively, a &ldquo;<U>Parent Board Adverse Recommendation Change</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything to the contrary contained in <U>Section&nbsp;7.3(b)</U>, and subject to compliance with <U>Section&nbsp;6.4</U> and <U>Section&nbsp;7.3</U>,
at any time prior to the approval of the Parent Stockholder Proposal by the Parent Stockholder Approval, (i)&nbsp;if Parent receives
a bona fide written Superior Offer or (ii)&nbsp;as a result of a material development or change in circumstances that was not known to,
or reasonably foreseeable by, the Parent Board prior to the date hereof (other than any such event, development or change to the extent
related to (A)&nbsp;any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B)&nbsp;the
fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial
performance or results of operations) that affects the business, assets or operations of Parent that occurs or arises after the date
of this Agreement (a &ldquo;<U>Parent Intervening Event</U>&rdquo;), the Parent Board may make a Parent Board Adverse Recommendation
Change if, but only if in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (1)&nbsp;the
Parent Board determines in good faith, after consulting with outside legal counsel, that the failure to withhold, amend, withdraw or
modify such recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (2)&nbsp;Parent
has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period, negotiate with the Company
in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute
a Superior Offer (to the extent the Company desires to negotiate) and (3)&nbsp;if after the Company shall have delivered to Parent an
irrevocable written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall
have determined in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify
the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after
taking into account such alterations of the terms and conditions of this Agreement); provided that (x)&nbsp;the Company receives written
notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4)&nbsp;Business Days
in advance of the Parent Board Adverse Recommendation Change (the &ldquo;<U>Parent Notice Period</U>&rdquo; ), which notice shall include
a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant
proposed transaction agreements with any party making a potential Superior Offer, (y)&nbsp;during any Parent Notice Period, the Company
shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives
to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and
conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z)&nbsp;in the event
of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration or percentage of
the combined company that Parent&rsquo;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required
to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure
that at least two (2)&nbsp;Business Days remain in the Parent Notice Period following such notification during which the parties shall
comply again with the requirements of this <U>Section&nbsp;7.3(c)</U>&nbsp;and the Parent Board shall not make a Parent Board Adverse
Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions)
or (ii)&nbsp;in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period
before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related
to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Unless
this Agreement is validly terminated pursuant to <U>Section&nbsp;9.1(j)</U>, Parent&rsquo;s obligation to call, give notice of and hold
the Parent Stockholder Meeting in accordance with <U>Section&nbsp;7.3(a)</U>&nbsp;shall not be limited to or otherwise affected by the
commencement, disclosure, announcement or submission of any Superior Offer or Acquisition Proposal, or by any withdrawal or modification
of the Parent Board Recommendation or any Parent Board Adverse Recommendation Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Nothing
contained in this Agreement shall prohibit Parent or the Parent Board from complying with Rules&nbsp;14d-9 and 14e-2(a)&nbsp;promulgated
under the Exchange Act; provided however, that any disclosure made by Parent or the Parent Board pursuant to Rules&nbsp;14d-9 and 14e-2(a)&nbsp;shall
be limited to a statement that Parent is unable to take a position with respect to the bidder&rsquo;s tender offer unless the Parent
Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to
be inconsistent with its fiduciary duties under applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.4&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Efforts;
Transaction Litigation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties shall use commercially reasonable efforts to consummate the Contemplated Transactions. Without limiting the generality of the
foregoing, each party: (i)&nbsp;shall make all filings and other submissions (if any) and give all notices (if any) required to be made
and given by such party in connection with the Contemplated Transactions, (ii)&nbsp;shall use commercially reasonable efforts to obtain
each consent (if any) reasonably required to be obtained (pursuant to any applicable law or Contract, or otherwise) by such party in
connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii)&nbsp;shall use commercially
reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&nbsp;shall use
commercially reasonable efforts to satisfy the conditions precedent to the consummations of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the generality of the foregoing, each party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable
after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party
with or otherwise submitted by such party to any Governmental Entity with respect to the Contemplated Transactions, and to submit promptly
any additional information requested by any such Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
limiting the generality of the foregoing, Parent shall give the Company prompt (but not later than within two (2)&nbsp;Business Days)
written notice of any &ldquo;demand letter&rdquo; or any litigation initiated, or threatened or in writing against Parent and/or its
directors relating to this Agreement or the Contemplated Transactions (the &ldquo;<U>Transaction Litigation</U>&rdquo;) (including by
providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof.
Subject to the penultimate sentence of this <U>Section&nbsp;7.4(c)</U>, Parent shall, on behalf of the parties hereto, control and lead
all communications and strategy relating to any Transaction Litigation, subject to this <U>Section&nbsp;7.4(c)</U>. Parent will (i)&nbsp;give
the Company the opportunity to participate in the defense, settlement or prosecution of any Transaction Litigation, (ii)&nbsp;consult
with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation, (iii)&nbsp;consider in good faith
the Company&rsquo;s advice with respect to such Transaction Litigation and (iv)&nbsp;will not settle or consent or agree to settle or
compromise any Transaction Litigation without the Company&rsquo;s prior written consent (which such consent shall not be unreasonably
withheld or delayed). Without otherwise limiting the rights of current or former directors and officers of Parent with regard to the
right to counsel, following the Effective Time, current or former directors and officers of Parent with rights to indemnification as
described in <U>Section&nbsp;7.5</U> shall be entitled to retain any counsel selected by such indemnified parties to defend any Transaction
Litigation as it relates to such indemnified parties in accordance with <U>Section&nbsp;7.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.5&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Indemnification,
Exculpation and Insurance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
the Effective Time through the sixth (6th) anniversary of the date on which the Effective Time occurs, each of Parent and the Surviving
Company shall indemnify and hold harmless each Person who is now, or has been at any time prior to the date hereof, or who becomes prior
to the Effective Time, a director or officer of Parent or the Company, respectively (the &ldquo;<U>D&amp;O Indemnified Parties</U>&rdquo;),
against all demands, claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&rsquo;
fees and disbursements, incurred in connection with any claim, Action, suit, proceeding or investigation, whether civil, criminal, administrative
or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent
or of the Company, whether asserted or claimed prior to, at or after the Effective Time, in each case, to the fullest extent permitted
under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of fees, costs and expenses incurred in the defense of
any such demand, claim, Action, suit, proceeding or investigation from each of Parent and the Surviving Company, jointly and severally,
upon receipt by Parent or the Surviving Company from the D&amp;O Indemnified Party of a request therefor; <U>provided</U>, that any such
D&amp;O Indemnified Party to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to
repay such advances if it is ultimately determined that such D&amp;O Indemnified Party is not entitled to indemnification. Such undertaking,
if required, shall be unsecured and made without reference to the D&amp;O Indemnified Party&rsquo;s ability to repay such advances or,
except as may be limited by applicable Law, ultimate entitlement to indemnification. No other form of undertaking shall be required.
All rights to indemnification, exculpation and advancement of expenses or other protection in respect of any claim asserted or made,
and for which a D&amp;O Indemnified Party delivers a written notice to Parent or the Surviving Company prior to the sixth (6<SUP>th</SUP>)
anniversary of the Effective Time asserting a claim for such protections pursuant to this <U>Section&nbsp;7.5</U>, shall continue until
the final disposition of such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
provisions of the certificate of incorporation and bylaws of Parent with respect to indemnification, advancement of expenses and exculpation
of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of
Parent shall not be amended, modified or repealed for a period of six (6)&nbsp;years from the Effective Time in a manner that would adversely
affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Parent, unless such
modification is required by applicable Law. The certificate of incorporation and bylaws of the Surviving Company shall contain, and Parent
shall cause the certificate of incorporation and bylaws of the Surviving Company to so contain, provisions no less favorable with respect
to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth
in the certificate of incorporation and bylaws of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
and after the Effective Time, (i)&nbsp;the Surviving Company shall fulfill and honor in all respects the obligations of the Company to
its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&rsquo;s
organizational documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with
respect to demands, claims, Actions, suits, proceedings or investigations whether asserted or claimed prior to, at or after the Effective
Time, arising out of matters occurring at or prior to the Effective Time and (ii)&nbsp;Parent shall fulfill and honor in all respects
the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions
under Parent&rsquo;s organizational documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified
Parties, with respect to demands, claims, Actions, suits, proceedings or investigations whether asserted or claimed prior to, at or after
the Effective Time, arising out of matters occurring at or prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
and after the Effective Time, Parent shall maintain directors&rsquo; and officers&rsquo; liability insurance policies, with an effective
date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies
similarly situated to Parent. In addition, Parent shall purchase, prior to the Effective Time, a six-year prepaid &ldquo;D&amp;O tail
policy&rdquo; for the non-cancellable extension of the directors&rsquo; and officers&rsquo; liability coverage of Parent&rsquo;s existing
directors&rsquo; and officers&rsquo; insurance policies for a claims reporting or discovery period of at least six years from and after
the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions,
exclusions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&rsquo;s existing policies
as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission, neglect,
breach of duty or any matter claimed against a director or officer of Parent by reason of him or her serving in such capacity that existed
or occurred at or prior to the Effective Time (including in connection with this Agreement or the Contemplated Transactions or in connection
with Parent&rsquo;s initial public offering of shares of Parent Common Stock); provided, that, in satisfying its obligation under this
<U>Section&nbsp;7.5(d)</U>, neither Parent nor the Surviving Company shall be obligated to pay annual premiums in excess of 300% of the
annual premium most recently paid by Parent prior to the date of this Agreement for such insurance (the &ldquo;<U>Current Premium</U>&rdquo;)
and if such premiums for such insurance would at any time exceed 300% of the Current Premium, then Parent shall, and shall cause the
Surviving Company to, maintain policies of insurance that, in Parent&rsquo;s and the Surviving Company&rsquo;s good faith judgment, provide
the maximum coverage available at an annual premium equal to 300% of the Current Premium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
provisions of this <U>Section&nbsp;7.5</U> are intended to be in addition to the rights otherwise available to the current and former
officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of,
and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event Parent or the Surviving Company or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into
any other Person and shall not be the continuing or surviving company or entity of such consolidation or merger or (ii)&nbsp;transfers
all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that
the successors and assigns of Parent or the Surviving Company, as the case may be, shall succeed to the obligations set forth in this
<U>Section&nbsp;7.5</U>. Parent shall cause the Surviving Company to perform all of the obligations of the Surviving Company under this
<U>Section&nbsp;7.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.6&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Section&nbsp;16
Matters</U>. Prior to the Effective Time, each of Parent and the Company shall take all such steps as may be necessary or appropriate
to cause the acquisitions of Parent Capital Stock (including derivative securities with respect to such Parent Common Stock) resulting
from the Contemplated Transactions by each individual who will become subject to the reporting requirements of Section&nbsp;16(a)&nbsp;of
the Exchange Act with respect to Parent to be exempt under Rule&nbsp;16b promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.7&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Disclosure</U>.
The parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&rsquo;s Form&nbsp;8-K
announcing the execution and delivery of this Agreement. Without limiting any party&rsquo;s obligations under the Confidentiality Agreement,
no party shall, and no party shall permit any of its Subsidiaries or any of its Representatives to, issue any press release or make any
disclosure (to any customers or employees of such party, to the public or otherwise) regarding the Contemplated Transactions unless (a)&nbsp;the
other party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld
or delayed; or (b)&nbsp;such party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure
is requited by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such party advises
the other party of, and consults with the other party regarding, the text of such press release or disclosure; provided, however, that
each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those
attending industry conferences or financial analyst conference calls, so long as any such statements made by the Company or Parent in
compliance with this <U>Section&nbsp;7.7</U>. Notwithstanding the foregoing, a party need not consult with any other parties in connection
with such portion of any press release, public statement or filing to be issued or made pursuant to <U>Section&nbsp;7.3(d)</U>&nbsp;or
with respect to any Acquisition Proposal, Company Board Adverse Recommendation Change, Parent Board Adverse Recommendation Change, or
pursuant to <U>Section&nbsp;7.3(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.8&#8239;&#8239;&#8239;&#8239;</FONT><U>Listing</U>.
From the date hereof until the Effective Time, Parent shall use commercially reasonable efforts to maintain its existing listing on Nasdaq
until the Effective Time. At or prior to the Effective Time, (a)&nbsp;Parent and the Company shall reasonably cooperate to seek approval
of the listing of the combined corporation on Nasdaq, (b)&nbsp;in accordance with the rules&nbsp;and regulations of Nasdaq, prepare and
submit (with the prior approval of the Company) to Nasdaq a notification form for the listing of shares of Parent Common Stock to be
issued in connection with the Contemplated Transactions, and (c)&nbsp;prepare and timely submit to Nasdaq a notification form for the
Nasdaq Reverse Stock Split (if required) and submit a copy of the amendment to Parent&rsquo;s certificate of incorporation effecting
the Nasdaq Reverse Stock Split, certified by the Secretary of State of the State of Delaware to Nasdaq on the Closing Date. In accordance
with Nasdaq Marketplace Rule&nbsp;5110, the Company shall prepare and file an initial listing application for the Parent Common Stock
on Nasdaq (the &ldquo;<U>Nasdaq Listing Application</U>&rdquo;), and from the date hereof until the Effective Time, Parent shall assist
the Company in preparing and filing such Nasdaq Listing Application and to seek to cause such Nasdaq Listing Application to be conditionally
approved prior to the Effective Time. Each party will reasonably promptly inform the other party of all verbal or written communications
between Nasdaq and such party or its Representatives. Parent will cooperate with the Company as reasonably requested by the Company with
respect to the Nasdaq Listing Application and use commercially reasonable efforts to reasonably promptly furnish to the Company all information
concerning Parent that may be required or reasonably requested in connection with any action contemplated by this <U>Section&nbsp;7.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.9&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Tax
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties intend that (i)&nbsp;the Merger shall be treated as a transaction that qualifies as a &ldquo;reorganization&rdquo; within the
meaning of Section&nbsp;368(a)&nbsp;of the Code, and (ii)&nbsp;the Merger shall qualify as a non-taxable exchange of shares of Company
Common Stock for shares of Parent Common Stock within the meaning of Section&nbsp;351(a)&nbsp;of the Code. Each of Parent, Merger Sub
and the Company shall use reasonable best efforts to cause the Merger to qualify, and agree not to, and not to permit or cause any of
their Affiliates to, take any action or cause any action to be taken which to its knowledge would reasonably be expected to (A)&nbsp;prevent
or impede the Merger from qualifying, as a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code or
(B)&nbsp;prevent or impede the Merger from qualifying as a non-taxable exchange of shares of Company Common Stock for shares of Parent
Common Stock within the meaning of Section&nbsp;351(a)&nbsp;of the Code (the &ldquo;<U>U.S. Tax Treatment</U>&rdquo;). This Agreement
is intended to constitute, and the parties hereto hereby adopt this Agreement as, a &ldquo;plan of reorganization&rdquo; within the meaning
of Treasury Regulation Sections 1.368-2(g)&nbsp;and 1.368-3(a). Each of Parent, Merger Sub and the Company shall report the Merger as
a &ldquo;reorganization&rdquo; within the meaning of Section&nbsp;368(a)&nbsp;of the Code unless otherwise required pursuant to a &ldquo;determination&rdquo;
within the meaning of Section&nbsp;1313(a)&nbsp;of the Code, including attaching the statement described in Treasury Regulations Section&nbsp;1.368-3(a)&nbsp;on
or with its Tax Return for the taxable year of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
in connection with the preparation and filing of the Registration Statement or any other filing required by applicable Law or the SEC&rsquo;s
review thereof, the SEC requests or requires that a tax opinion with respect to the U.S. federal income tax consequences of the Merger
and the intended U.S. Tax Treatment be prepared and submitted (a &ldquo;<U>Tax Opinion</U>&rdquo;<U>&rdquo;</U>), (i)&nbsp;Parent and
the Company shall each use their respective reasonable best efforts to deliver to Wilmer Cutler Pickering Hale and Dorr LLP, counsel
to Parent, and to Goodwin Procter LLP, counsel to the Company, customary Tax representation letters satisfactory to each such counsel,
dated and executed as of the date such relevant filing shall have been declared effective by the SEC and such other date(s)&nbsp;as determined
to be reasonably necessary by each such counsel in connection with the preparation and filing of such Registration Statement or any other
filing required by applicable Law, (ii)&nbsp;Parent shall use its reasonable best efforts to cause Wilmer Cutler Pickering Hale and Dorr
LLP to furnish a Tax Opinion addressed to Parent, subject to customary assumptions and limitations, satisfactory to the SEC, and (iii)&nbsp;the
Company shall use its reasonable best efforts to cause Goodwin Procter LLP to furnish a Tax Opinion addressed to the Company, subject
to customary assumptions and limitations, satisfactory to the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.10&#8239;&#8239;&nbsp;</FONT><U>Directors
and Officers</U>. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the parties shall use
commercially reasonable efforts to take all necessary actions so that the Persons listed on <U>Sections 2.6(c)</U>&nbsp;and <U>2.6(d)</U>&nbsp;of
the Company Disclosure Letter are elected or appointed, as applicable, to the positions of officers and directors of Parent and the Surviving
Company, as set forth therein, to serve in such positions effective as of the Effective Time. If any Person listed on <U>Section&nbsp;2.6(c)</U>&nbsp;and
<U>2.6(d)</U>&nbsp;of the Company Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving
Company, as set forth therein, the party appointing such Person (as set forth on <U>Sections 2.6(c)</U>&nbsp;and <U>2.6(d)</U>&nbsp;of
the Company Disclosure Letter) shall designate a successor. The parties shall use reasonable best efforts to have each of the Persons
that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.11&#8239;&#8239;</FONT><U>Obligations
of Merger Sub</U>. Parent will take all action necessary to cause Merger Sub to perform its obligations under this Agreement and to consummate
the Merger on the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.12&#8239;&#8239;</FONT><U>Allocation
Certificate</U>. The Company will prepare and deliver to Parent at least five (5)&nbsp;Business Days prior to the Closing Date a spreadsheet
setting forth (as of immediately prior to the Effective Time) (a)&nbsp;each holder of the Company Common Stock, (b)&nbsp;such holder&rsquo;s
name and physical address, (c)&nbsp;the number or percentage of the Company Common Stock held as of the Closing Date for each such holder
and (d)&nbsp;the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company
Common Stock held by such holder as of immediately prior to the Effective Time (the &ldquo;<U>Allocation Certificate</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.13&#8239;&#8239;</FONT>[<U>RESERVED</U>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.14&#8239;&#8239;&nbsp;</FONT><U>Concurrent
Investment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the terms and conditions of this Agreement, the parties shall use commercially reasonable efforts to enter into Securities Purchase
Agreements with one or more investors designated by the Company to subscribe for and purchase a number of shares of Parent Common Stock
representing an aggregate commitment (inclusive of the Guarantor Investment Amount) at least equal to the Concurrent Investment Amount
and to satisfy the conditions to the Concurrent Investment as set forth in the applicable Securities Purchase Agreement; <U>provided</U>,
that the form, terms and conditions of each Securities Purchase Agreement shall be in a form reasonably acceptable to each of the Company
and Parent. The Company shall provide Parent at least five (5)&nbsp;Business Days&rsquo; written notice prior to the execution of each
Securities Purchase Agreement, which such execution shall be subject to the prior consent of Parent (such consent not to be unreasonably
withheld, conditioned or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>On
or before August&nbsp;1, 2025, Guarantor shall enter into a Securities Purchase Agreement committing to purchase not less than the Guarantor
Investment Amount, with terms (other than the Guarantor Investment Amount) and conditions of such Securities Purchase Agreement to be
substantially similar to the terms of the Securities Purchase Agreement entered into by other investors of the Concurrent Investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Prior
to the earlier of (i)&nbsp;the Closing and (ii)&nbsp;the termination of this Agreement pursuant to <U>Section&nbsp;9.1</U>, Parent agrees,
and shall cause its officers and employees, to use commercially reasonable efforts to cooperate in connection with the Concurrent Investment
as may be reasonably requested by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>At
or immediately following the Closing, in accordance with the terms and conditions of the Securities Purchase Agreement(s), Parent shall
consummate the Concurrent Investment, and issue the equity contemplated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.15&#8239;&#8239;&nbsp;</FONT><U>Parent
Equity Plans</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Prior
to the Effective Time, the Parent Board will adopt the 2025 Equity Incentive Plan, subject to the Closing and effective as of the Effective
Time, and will include provisions in the Proxy Statement for the stockholders of Parent to approve the 2025 Equity Incentive Plan. Subject
to the approval of the 2025 Equity Incentive Plan by the stockholders of Parent prior to the Effective Time, Parent shall file with the
SEC, promptly after the Effective Time and at the Company&rsquo;s expense, a registration statement on Form&nbsp;S-8 (or any successor
form), if available for use by Parent, relating to the shares of Parent Common Stock issuable with respect to the 2025 Equity Incentive
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Prior
to the Effective Time, the Parent Board will adopt the 2025 ESPP, subject to the Closing and effective as of the Effective Time, and
will include provisions in the Proxy Statement for the stockholders of Parent to approve the 2025 ESPP. Subject to the approval of the
2025 ESPP by the stockholders of Parent prior to the Effective Time, Parent shall file with the SEC, promptly after the Effective Time
and the Company&rsquo;s expense, a registration statement on Form&nbsp;S-8 (or any successor form), if available for use by Parent, relating
to the shares of Parent Common Stock issuable with respect to the 2025 ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
the avoidance of doubt, approval of the 2025 Plans by the stockholders of Parent shall not be a condition to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.16&#8239;&#8239;&nbsp;</FONT><U>Parent
SEC Documents</U>. From the date of this Agreement to the Effective Time, Parent shall timely file with the SEC all Parent SEC Documents.
As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each Parent SEC Document
filed by Parent with the SEC (a)&nbsp;shall comply in all material respects with the applicable requirements of the Exchange Act and
the Securities Act, and (b)&nbsp;shall not contain any untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made,
not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.17&#8239;&#8239;&nbsp;</FONT><U>Parent
Legacy Assets</U>. Prior to the Closing Date, but subject to this <U>Section&nbsp;7.17</U>, Parent shall be entitled, but under no obligation,
to sell, transfer, license, assign or otherwise divest the Parent Legacy Assets to one or more third parties in one or a series of transactions
prior to or substantially, concurrently with the Closing (each an &ldquo;<U>Asset Disposition</U>&rdquo; and collectively, the &ldquo;<U>Asset
Dispositions</U>&rdquo;). &#8239;&#8239;Notwithstanding the foregoing, Parent may not enter into any agreement with respect to any Asset
Disposition that would result in a continuing obligation or liability without the prior written consent of the Company (such consent
shall not be unreasonably withheld, conditioned or delayed); <I>provided</I>, that Parent shall provide the Company with a copy of any
agreement with respect to an Asset Disposition that would be reasonably likely to result in such continuing obligation or liability of
either Parent or the Company on or after the Effective Time at least five (5)&nbsp;Business Days prior to entry into such agreement.
Parent shall (i)&nbsp;permit the Company and its counsel to review and comment on the transaction documents related to any Asset Dispositions
(ii)&nbsp;consider any such comments in good faith and shall accept all reasonable additions, deletions or changes suggested by the Company
and its counsel in connection therewith; and (iii)&nbsp;not sign any agreements, contracts or other definitive documents (not including
term sheets or letters of intent) related to without first providing the Company and its counsel the opportunity to exercise their rights
under clauses (i)&nbsp;and (ii)&nbsp;above. For the avoidance of doubt, any sale, transfer, license, assignment or other divestiture
of Parent Legacy Assets on or after the Closing Date shall be governed by the terms and conditions of the CVR Agreement. Parent shall
deliver an executed copy of the CVR Agreement to the Company prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;7.18&#8239;&#8239;&nbsp;</FONT><U>Arrangements
Between Company and Company Guarantor</U>. Prior to the Closing, the Company and the Company Guarantor shall enter into the Transition
Services Agreement and the Manufacturing and Supply Agreement, the material terms of which will be substantially final on or prior to
July&nbsp;11, 2025, in each case, by and between the Guarantor and the Company, each in form and substance reasonably satisfactory to
the Company and the Guarantor (subject to Parent&rsquo;s prior written consent, which shall not be unreasonably withheld, conditioned
or delayed. At least five (5)&nbsp;Business Days prior to July&nbsp;11, 2025, the Company shall provide Parent with a reasonable opportunity
to review and comment on draft versions of the Transition Services Agreement and the Manufacturing and Supply Agreement and the Company
will consider in good faith any reasonable comments provided by Parent thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VIII</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
CLOSING CONDITIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.1&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Conditions
Precedent of each Party</U>. The obligations of each party to effect the Merger and otherwise consummate the Contemplated Transactions
to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable Law, the written waiver by
each of the parties, at or prior to the Closing, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject
to any stop order or proceeding seeking a stop order with respect to the Registration Statement and has not been withdrawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Contemplated Transactions
shall have been issued by any court of competent jurisdiction or other Governmental Entity of competent jurisdiction and remain in effect
and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;Parent
shall have obtained the Parent Stockholder Approval and (ii)&nbsp;the Company shall have obtained the Company Stockholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Lock-Up Agreements will continue to be in full force and effect as of immediately following the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments
as are necessary to consummate the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Parent
shall have obtained approval of the listing of the combined corporation on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.2&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Conditions
Precedent to Obligation of the Company</U>. The obligations of the Company to effect the Merger and otherwise consummate the transactions
to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of
each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accuracy
of Representations</U>. The representations and warranties of Parent and Merger Sub made in this Agreement (other than the Parent Fundamental
Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and
as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a)&nbsp;in each case, or in the
aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without
giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b)&nbsp;for those
representations and warranties which address matters only as of a particular date (which representations shall have been true and correct,
subject to the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes
of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made
or purported to have been made after the date of this Agreement shall be disregarded). The Parent Fundamental Representations shall have
been true and correct except in de minimis respects as of the date of this Agreement and shall be true and correct except in de minimis
respects on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&nbsp;in
respect of <U>Section&nbsp;5.2</U> for such inaccuracies which are de minimis, individually or in the aggregate or (y)&nbsp;for those
representations and warranties which address matters only as of a particular date (which representations and warranties shall have been
true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance
of Covenants</U>. Parent shall have performed or complied with in all material respects all agreements and covenants required to be performed
or complied with by it under this Agreement at or prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Parent Material Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Net
Cash</U>. The Company shall have Net Cash of at least (-$1,000,000) (negative one million dollars).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Documents</U>.
The Company shall have received the following documents, each of which shall be in full force and effect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
certificate executed by an officer of Parent certifying that the conditions set forth in <U>Section&nbsp;8.2(a)</U>, <U>(b), (c)</U>&nbsp;and
<U>(d)</U>&nbsp;have been duly satisfied; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>written
resignations in forms reasonably satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by
the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to <U>Section&nbsp;7.10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;8.3&#8239;&#8239;&nbsp;</FONT><U>Conditions
Precedent of Parent and Merger Sub</U>. The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the transactions
to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each
of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accuracy
of Representations</U>. The representations and warranties of the Company made in this Agreement (other than the Company Fundamental
Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and
as of the Closing Date with the same force and effect as if made on and as of the Closing Date except (a)&nbsp;in each case, or in the
aggregate, where the failure to be so true and correct would not reasonably be expected to have a Material Adverse Effect (without giving
effect to any references therein to any Material Adverse Effect or other materiality qualifications) or (b)&nbsp;for those representations
and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to
the qualifications as set forth in the preceding clause (a), as of such particular date) (it being understood that, for purposes of determining
the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported
to have been made after the date of this Agreement shall be disregarded). The Company Fundamental Representations shall have been true
and correct except in de minimis respects as of the date of this Agreement and shall be true and correct except in de minimis respects
on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x)&nbsp;in respect
of <U>Section&nbsp;4.2</U> for such inaccuracies which are de minimis, individually or in the aggregate, (y)&nbsp;for those representations
and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct,
subject to the qualifications as set forth in the preceding clause (x), as of such particular date), or (z)&nbsp;variances arising solely
due to the transactions contemplated under the Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance
of Covenants</U>. The Company shall have performed or complied with in all material respects all agreements and covenants required to
be performed or complied with by it under this Agreement at or prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Material Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing
Certificate</U>. Parent shall have received a certificate executed by an officer of the Company certifying (i)&nbsp;that the conditions
set forth in <U>Section&nbsp;8.3(a)</U>, <U>(b)</U>, and <U>(c)</U>&nbsp;have been duly satisfied, (ii)&nbsp;that the information set
forth in the Allocation Certificate delivered by the Company in accordance with <U>Section&nbsp;7.12</U> is true and accurate in all
respects as of the Closing Date, and (iii)&nbsp;the Contribution has been completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;IX</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
TERMINATION</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;9.1&#8239;&#8239;&nbsp;</FONT><U>Termination</U>.
This Agreement may be terminated prior to the Effective Time (whether before or after the adoption of this Agreement by the Company&rsquo;s
stockholders and whether before or after approval of the Parent Stockholder Proposal by Parent&rsquo;s stockholders, unless otherwise
specified below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
mutual consent of Parent and the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
either Parent or the Company if the Merger shall not have been consummated by December&nbsp;23, 2025 (the &ldquo;<U>End Date</U>&rdquo;);
provided, however, that the right to terminate this Agreement under this <U>Section&nbsp;9.1(b)</U>&nbsp;shall not be available to the
Company or Parent if such party&rsquo;s (or in the case of Parent, Merger Sub&rsquo;s) breach of this Agreement has been a principal
cause of the failure of the Merger to occur on or before the End Date;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
either Parent or the Company if a court of competent jurisdiction or other Governmental Entity shall have issued a final and nonappealable
order, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated
Transactions, provided, however, that the right to terminate this Agreement under this <U>Section&nbsp;9.1(c)&nbsp;</U>shall not be available
to a party if such party&rsquo;s (or in the case of Parent, Merger Sub&rsquo;s) breach of this Agreement is a principal cause of any
such Governmental Entity issuing any such order or taking any such other action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
either Parent or the Company if the Company Stockholder Approval shall not have been obtained by written consent of the Company&rsquo;s
sole stockholder in lieu of a meeting within two (2)&nbsp;Business Days of the Registration Statement becoming effective in accordance
with the provisions of the Securities Act]; provided, however, that once the Company Stockholder Approval has been obtained, neither
party may terminate this Agreement pursuant to this <U>Section&nbsp;9.1(d)</U>&nbsp;and (ii)&nbsp;the right to terminate this Agreement
under this <U>Section&nbsp;9.1(d)</U>&nbsp;shall not be available to a party if such party&rsquo;s (or in the case of Parent or Merger
Sub&rsquo;s) breach of this Agreement is a principal cause of the failure of the Company Stockholder Approval to have been obtained on
or before such second (2nd) Business Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
either Parent or the Company if (i)&nbsp;the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall
have been held and completed and Parent&rsquo;s stockholders shall have taken a final vote on the Parent Stockholder Proposal and (ii)&nbsp;the
Parent Stockholder Approval shall not have been obtained at the Parent Stockholder Meeting (or any adjournment or postponement thereof);
provided, however, that the right to terminate this Agreement under this <U>Section&nbsp;9.1(e)</U>&nbsp;shall not be available to a
party if such party&rsquo;s (or in the case of Parent, Merger Sub&rsquo;s) breach of this Agreement is a principal cause of the failure
of the Parent Stockholder Approval to have been obtained at the Parent Stockholder Meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
the Company (at any time prior to obtaining the Parent Stockholder Approval) if any Parent Triggering Event shall have occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
Parent (at any time prior to obtaining the Company Stockholder Approval) if any Company Triggering Event shall have occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>by
the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Sub
or if any representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set
forth in <U>Section&nbsp;8.2(a)</U>&nbsp;or <U>Section&nbsp;8.2(b)</U>&nbsp;would not be satisfied as of the time of such breach or as
of the time such representation or warranty shall have become inaccurate; provided that the Company is not then in material breach of
any representation, warranty, covenant or agreement under this Agreement; provided, further that if such inaccuracy in Parent&rsquo;s
or Merger Sub&rsquo;s representations and warranties or breach by Parent or Merger Sub is curable by Parent or Merger Sub, then this
Agreement shall not terminate pursuant to this <U>Section&nbsp;9.1(h)</U>&nbsp;as a result of such particular breach or inaccuracy until
the earlier of (i)&nbsp;the expiration of a 30-day period commencing upon delivery of written notice from the Company to Parent or Merger
Sub of such breach or inaccuracy and its intention to terminate pursuant to this <U>Section&nbsp;9.1(h)</U>&nbsp;and (ii)&nbsp;Parent
or Merger Sub (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice
from the Company to Parent or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this <U>Section&nbsp;9.1(h)</U>&nbsp;(it
being understood that this Agreement shall not terminate pursuant to this <U>Section&nbsp;9.1(h)</U>&nbsp;as a result of such particular
breach or inaccuracy if such breach by Parent or Merger Sub is cured prior to such termination becoming effective);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>by
the Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any
representation or warranty of Parent or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in
<U>Section&nbsp;8.3(a)</U>&nbsp;or <U>Section&nbsp;8.3(b)</U>&nbsp;would not be satisfied as of the time of such breach or as of the
time such representation or warranty shall have become inaccurate; provided that Parent is not then in material breach of any representation,
warranty, covenant or agreement under this Agreement; provided, further that if such inaccuracy in the Company&rsquo;s representations
and warranties or breach by the Company is curable by the Company, then this Agreement shall not terminate pursuant to this <U>Section&nbsp;9.1(i)</U>&nbsp;as
a result of such particular breach or inaccuracy until the earlier of (i)&nbsp;the expiration of a 30-day period commencing upon delivery
of written notice from the Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <U>Section&nbsp;9.1(i)</U>&nbsp;and
(ii)&nbsp;the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from
Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this <U>Section&nbsp;9.1(i)</U>&nbsp;(it
being understood that this Agreement shall not terminate pursuant to this <U>Section&nbsp;9.1(i)</U>&nbsp;as a result of such particular
breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>by
Parent (at any time prior to obtaining the Parent Stockholder Approval) and following compliance with all of the requirements set forth
in the proviso to this <U>Section&nbsp;9.1(j)</U>, concurrently with Parent&rsquo;s entering into a definitive agreement for a Superior
Offer (a &ldquo;<U>Permitted Alternative Agreement</U>&rdquo;) and after having paid to the Company the Company Termination Fee pursuant
to <U>Section&nbsp;9.3(c)</U>; <I><U>provided</U></I>, <I><U>however</U></I>, that Parent shall not enter into any Permitted Alternative
Agreement unless: (i)&nbsp;the Company shall have received written notice from Parent of Parent&rsquo;s intention to enter into such
Permitted Alternative Agreement at least four (4)&nbsp;Business Days in advance, with such notice describing in reasonable detail the
reasons for such intention as well as the material terms and conditions of such Permitted Alternative Agreement, including the identity
of the counterparty together with copies of the then current draft of such Permitted Alternative Agreement and any other related principal
transaction documents, (ii)&nbsp;Parent shall have complied in all material respects with its obligations under <U>Section&nbsp;6.4</U>
and <U>Section&nbsp;7.3</U>, and (iii)&nbsp;the Parent Board shall have determined in good faith, after consultation with its outside
legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with
its fiduciary obligations under applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>By
Parent, if the Company otherwise fails to secure the Concurrent Investment Amount such that as of September&nbsp;15, 2025, Parent has
not received, or at any time ceases to have, aggregate commitments equal to or in excess of the Concurrent Investment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The party desiring to terminate this Agreement
pursuant to this <U>Section&nbsp;9.1</U> (other than pursuant to <U>Section&nbsp;9.1(a)</U>) shall give a notice of such termination
to the other party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable
detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;9.2&#8239;&#8239;&nbsp;</FONT><U>Effect
of Termination</U>. In the event of the termination of this Agreement as provided in <U>Section&nbsp;9.1</U>, this Agreement shall be
of no further force or effect; provided, however, that (a)&nbsp;this <U>Section&nbsp;9.2</U>, <U>Section&nbsp;9.3</U> and <U>Article&nbsp;X</U>
(and the related definitions of the defined terms in such section) shall survive the termination of this Agreement and shall remain in
full force and effect and (b)&nbsp;the termination of this Agreement and the provisions of <U>Section&nbsp;9.3</U> shall not relieve
any party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or
other provision contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;9.3&#8239;&#8239;&nbsp;</FONT><U>Expenses;
Termination Fees</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in this <U>Section&nbsp;9.3</U> and <U>Section&nbsp;7.9</U> all fees and expenses incurred in connection with this Agreement
and the Contemplated Transactions shall be paid by the party incurring such expenses, whether or not the Merger is consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
(i)&nbsp;this Agreement is terminated by Parent or the Company pursuant to <U>Section&nbsp;9.1(e)</U>&nbsp;(<I>Termination for Failure
to Obtain Parent Stockholder Approval)</I> or by the Company pursuant to <U>Section&nbsp;9.1(h)</U>&nbsp;(<I>Termination for Parent Breach</I>)<I>,
</I>(ii)&nbsp;at any time after the date of this Agreement and prior to the Parent Stockholder Meeting an Acquisition Proposal with respect
to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn)
and (iii)&nbsp;within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to
a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay the Company, within two (2)&nbsp;Business Days
after termination (or, if applicable, upon such entry into a definitive agreement and/or consummation of a Subsequent Transaction), a
nonrefundable fee in an amount equal to $500,000 (the &ldquo;<U>Company Termination Fee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
this Agreement is terminated (i)&nbsp;by the Company or by Parent pursuant to <U>Section&nbsp;9.1(b)</U>&nbsp;(<I>Termination at End
Date</I>) (at a time when the Company has the right to terminate this Agreement pursuant to <U>Section&nbsp;9.1(f)</U>&nbsp;(<I>Termination
for Parent Triggering Event</I>)) or pursuant to <U>Section&nbsp;9.1(f)</U>&nbsp;(<I>Termination for Parent Triggering Event</I>) or
(ii)&nbsp;by Parent pursuant to <U>Section&nbsp;9.1(j)</U>&nbsp;(<I>Termination for Parent Superior Offer</I>), then Parent shall pay
to the Company the Company Termination Fee, by wire transfer of same day funds to an account designated by the Company, (x)&nbsp;in the
case of a termination by Parent referred to in the foregoing clause (i)&nbsp;or (ii), prior (and as a condition) to such termination
or (y)&nbsp;in the case of a termination by the Company described in the foregoing clause (i), within two (2)&nbsp;Business Days after
such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
(i)&nbsp;this Agreement is terminated by Parent or the Company pursuant to <U>Section&nbsp;9.1(d)</U>&nbsp;(<I>Termination for Failure
to Obtain Company Stockholder Approval</I>) or by Parent pursuant to <U>Section&nbsp;9.1(i)</U>&nbsp;(<I>Termination for Company Breach</I>)<U>,</U>
(ii)&nbsp;at any time after the date of this Agreement and prior to obtaining the Company Stockholder Approval, an Acquisition Proposal
with respect to the Company shall have been publicly announced, disclosed or otherwise communicated to the Company Board (and shall not
have been withdrawn) and (iii)&nbsp;within six (6)&nbsp;months after the date of such termination, the Company enters into a definitive
agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within
two (2)&nbsp;Business Days after termination (or, if applicable, upon the earlier of such entry into a definitive agreement and/or the
consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $750,000 (the &ldquo;<U>Parent Termination Fee</U>&rdquo;),
by wire transfer of same-day funds to an account designated by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
this Agreement is terminated by Parent or by the Company pursuant to <U>Section&nbsp;9.1(b)</U>&nbsp;(<I>Termination at End Date</I>)
(at a time when Parent has the right to terminate this Agreement pursuant to <U>Section&nbsp;9.1(g)</U>&nbsp;(<I>Termination for Company
Triggering Event</I>) or by Parent pursuant to <U>Section&nbsp;9.1(g)</U>&nbsp;(<I>Termination for Company Triggering Event</I>)) or
by Parent pursuant to <U>Section&nbsp;9.1(k)</U>&nbsp;(<I>Termination for Failure to Obtain Financing</I>), then the Company shall pay
to Parent the Parent Termination Fee, by wire transfer of same day funds to an account designated by Parent, (x)&nbsp;in the case of
a termination by the Company referred to in the foregoing clause, prior (and as a condition) to such termination or (y)&nbsp;in the case
of a termination by Parent described in the foregoing clause, within two (2)&nbsp;Business Days after such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
this Agreement is terminated by Parent or the Company pursuant to <U>Section&nbsp;9.1(d)</U>&nbsp;(<I>Termination for Failure to Obtain
Company Stockholder Approval</I>) or by Parent pursuant to <U>Section&nbsp;9.1(g)</U>&nbsp;(<I>Termination for Company Triggering Event</I>)
or <U>Section&nbsp;9.1(k)</U>&nbsp;(<I>Termination for Failure to Obtain Financing</I>), the Company shall reimburse Parent for all reasonable
out-of-pocket expenses incurred by Parent in connection with this Agreement and the transactions contemplated hereby, up to a maximum
of $500,000, by wire transfer of same-day funds to an account designated by Parent, within two (2)&nbsp;Business Days following the date
on which Parent submits to the Company true and correct copies of reasonable documentation supporting such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
either party fails to pay when due any amount payable by it under this <U>Section&nbsp;9.3</U>, then (i)&nbsp;such party shall reimburse
the other party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with
the collection of such overdue amount and the enforcement by the other party of its rights under this <U>Section&nbsp;9.3</U> and (ii)&nbsp;such
party shall pay to the other party interest on such overdue amount (for the period commencing as of the date such overdue amount was
originally required to be paid and ending on the date such overdue amount is actually paid to the other party in full) at a rate per
annum equal to the &ldquo;prime rate&rdquo; (as announced by Bank of America or any successor thereto) in effect on the date such overdue
amount was originally required to be paid plus three percent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
parties agree that, subject to <U>Section&nbsp;9.2</U>, the payment of fees and expenses set forth in this <U>Section&nbsp;9.3</U> shall
be the sole and exclusive remedy of each party following a termination of this Agreement under the circumstances described in this <U>Section&nbsp;9.3</U>,
it being understood that in no event shall either Parent or the Company be required to pay the individual fees, damages payable pursuant
to this <U>Section&nbsp;9.3</U> on more than one occasion. Subject to <U>Section&nbsp;9.2</U>, following the payment of the fees and
expenses set forth in this <U>Section&nbsp;9.3</U> by a party, (i)&nbsp;such party shall have no further liability to the other party
in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other party giving
rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii)&nbsp;no other party or their respective
Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such party or seek to obtain any recovery,
judgment or damages of any kind against such party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate,
agent or other Representative of such party) in connection with or arising out of this Agreement or the termination thereof, any breach
by such party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii)&nbsp;all other
parties and their respective Affiliates shall be precluded from any other remedy against such party and its Affiliates, at law or in
equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such party giving
rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the parties acknowledges that (x)&nbsp;the
agreements contained in this <U>Section&nbsp;9.3</U> are an integral part of the Contemplated Transactions, (y)&nbsp;without these agreements,
the parties would not enter into this Agreement and (z)&nbsp;any amount payable pursuant to this <U>Section&nbsp;9.3</U> is not a penalty,
but rather is liquidated damages in a reasonable amount that will compensate the parties in the circumstances in which such amount is
payable; provided, however, that nothing in this <U>Section&nbsp;9.3(g)</U>&nbsp;shall limit the rights of the parties under <U>Section&nbsp;10.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;X</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
GENERAL PROVISIONS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.1&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Non-survival
of Representations and Warranties</U>. None of the representations, warranties, covenants or agreements in this Agreement or in any instrument
delivered pursuant to this Agreement shall survive the Effective Time, other than this <U>Article&nbsp;X</U> and those covenants or agreements
of the parties which by their terms apply, or are to be performed in whole or in part, after the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.2&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Amendment
or Supplement</U>. This Agreement may be amended, modified or supplemented by the parties by action taken or authorized by their respective
Boards of Directors at any time, whether before or after Company Stockholder Approval or the Parent Stockholder Approval has been obtained;
<U>provided</U>, <U>however</U>, that after the Company Stockholder Approval or the Parent Stockholder Approval has been obtained, no
amendment shall be made that pursuant to applicable Law requires further approval or adoption by the stockholders of the Company or Parent,
as applicable, without such further approval or adoption. This Agreement may not be amended, modified or supplemented in any manner,
whether by course of conduct or otherwise, except by an instrument in writing specifically designated as an amendment hereto, signed
on behalf of each of the parties in interest at the time of the amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.3&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Waiver</U>.
The parties may, by action taken or authorized by their respective Boards of Directors, to the extent permitted by applicable Law, waive
compliance with any of the agreements or conditions of the other parties contained herein; <U>provided</U>, <U>however</U>, that after
the Company Stockholder Approval or the Parent Stockholder Approval has been obtained, no waiver may be made that pursuant to applicable
Law requires further approval or adoption by the stockholders of the Company or Parent, as applicable, without such further approval
or adoption. Any agreement on the part of a party to any such waiver shall be valid only if set forth in a written instrument executed
and delivered by a duly authorized officer on behalf of such party. No failure or delay of any party in exercising any right or remedy
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment
or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise thereof or
the exercise of any other right or power. No party shall be deemed to have waived any claim arising out of this Agreement, or any power,
right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set
forth in a written instrument duly executed and delivered on behalf of such party and any such waiver shall not be applicable or have
any effect except in the specific instance in which it is given. The rights and remedies of the parties hereunder are cumulative and
are not exclusive of any rights or remedies which they would otherwise have hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.4&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Fees
and Expenses</U>. Except as otherwise set forth in this Agreement, all fees and expenses incurred in connection with this Agreement,
the Merger and the other Contemplated Transactions shall be paid by the party incurring such fees or expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.5&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Notices</U>.
All notices and other communications hereunder shall be in writing and shall be deemed duly given (a)&nbsp;one (1)&nbsp;Business Day
after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon
delivery in the case of delivery by hand or (c)&nbsp;on the date delivered in the place of delivery if sent by email or facsimile (with
a written or electronic confirmation of delivery) prior to 6:00 p.m.&nbsp;New York City time, otherwise on the next succeeding Business
Day. All notices hereunder shall be delivered to the addresses set forth below, or pursuant to such other instructions as may be designated
in writing by the party to receive such notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
to Parent, Merger Sub, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Carisma Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">3675 Market Street, Suite&nbsp;401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Steven Kelly, President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">Email: [**]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><BR>
with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Wilmer Cutler Pickering Hale and Dorr LLP<BR>
7 World Trade Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">250 Greenwich Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">New York, New York 10007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>Christopher
D. Barnstable-Brown,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">Mark Nylen,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">Brian A. Johnson,&nbsp;Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">E-mail:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>cbb@wilmerhale.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">mark.nylen@wilmerhale.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">brian.johnson@wilmerhale.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
to Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">OrthoCellix,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">11 Great Valley Parkway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Malvern, Pennsylvania 19355<BR>
Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>Shankar Musunuri<BR>
E-mail:<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>[**]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Goodwin Procter LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">3025 John F Kennedy Blvd<BR>
Philadelphia, Pennsylvania 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT>Rachael
M. Bushey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">Jennifer L. Porter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">Laura U. Gulick</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><FONT STYLE="font-size: 10pt">Email:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>RBushey@goodwinlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">JPorter@goodwinlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 1.3in">LGulick@goodwinlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.6&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>Entire
Agreement</U>. This Agreement (including the Exhibits hereto), the Company Disclosure Letter, the Parent Disclosure Letter, the Securities
Purchase Agreements, the CVR Agreement and the Confidentiality Agreement constitute the entire agreement, and supersede all prior written
agreements, arrangements, communications and understandings and all prior and contemporaneous oral agreements, arrangements, communications
and understandings among the parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality
Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; provided, further, that only
the Certificate of Merger is incorporated by reference and made a part hereof for purposes of Section&nbsp;251 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.7&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>No
Third Party Beneficiaries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Nothing
in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties and their respective successors
and permitted assigns any legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement, except as provided
in <U>Section&nbsp;7.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as set forth in the Securities Purchase Agreement, the representations and warranties in this Agreement are the product of negotiations
among the parties hereto and are for the sole benefit of the parties hereto. Any inaccuracies in such representations and warranties
are subject to waiver by the parties hereto in accordance with <U>Section&nbsp;10.3</U> without notice or liability to any other Person.
In some instances, the representations and warranties in this Agreement may represent an allocation among the parties hereto of risks
associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently, except as set forth in the
Securities Purchase Agreement, Persons other than the parties hereto may not rely upon the representations and warranties in this Agreement
as characterizations of actual facts or circumstances as of the date of this Agreement or as of any other date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.8&#8239;&#8239;&#8239;&#8239;</FONT><U>Guaranty</U>.
Guarantor hereby unconditionally guarantees the complete, due and punctual performance of the Company&rsquo;s obligations set forth in
this Agreement, including all representations, warranties, covenants and other obligations. This guaranty is an irrevocable guaranty
of performance and shall continue in effect notwithstanding any extension or modification of the terms of this Agreement or any other
act or event which might otherwise operate as a legal or equitable discharge of such guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.9&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Agreement and all disputes or controversies arising out of or relating to this Agreement or the Contemplated Transactions
shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any
other jurisdiction that might be applied because of the conflicts of laws principles of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.10&#8239;&#8239;</FONT><U>Submission
to Jurisdiction</U>. Each of the parties irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement
brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery
of the State of Delaware; <U>provided</U>, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware,
then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state
court. Each of the parties hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its
property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and
the Contemplated Transactions. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the
courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award
rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute
sufficient service of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby
irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any
action or proceeding arising out of or relating to this Agreement or the Contemplated Transactions, (a)&nbsp;any claim that it is not
personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b)&nbsp;that it or its property
is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of
notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c)&nbsp;that
(i)&nbsp;the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii)&nbsp;the venue of such suit, action
or proceeding is improper or (iii)&nbsp;this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.11&#8239;&#8239;&#8239;</FONT><U>Assignment;
Successors</U>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated,
in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other parties, and any such
assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement will be binding
upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.12&#8239;&#8239;&#8239;</FONT><U>Specific
Performance</U>. The parties agree that irreparable damage would occur in the event that the parties hereto do not perform the provisions
of this Agreement in accordance with its terms or otherwise breach such provisions. Accordingly, the parties acknowledge and agree that
each party shall be entitled to seek an injunction, specific performance and other equitable relief to prevent breaches of this Agreement
and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware, <U>provided</U>, that
if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then in any federal court located in the State
of Delaware or any other Delaware state court, this being in addition to any other remedy to which such party is entitled at law or in
equity. Each of the parties hereby further waives and&nbsp;will not oppose the granting of an injunction, specific performance or other
equitable relief on the basis of (a)&nbsp;any defense in any action for specific performance that a remedy at law would be adequate and
(b)&nbsp;any requirement under any law to post any bond, surety or other security as a prerequisite to obtaining equitable relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.13&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Whenever possible, each provision or portion of any provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable Law, but if any provision or portion of any provision of this Agreement is held to be invalid, illegal or
unenforceable in any respect under any applicable Law or rule&nbsp;in any jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provision or portion of any provision in such jurisdiction, and this Agreement shall be reformed, construed
and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.14&#8239;&#8239;&#8239;</FONT><U>Waiver
of Jury Trial</U>. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.15&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same instrument and shall become
effective when one or more counterparts have been signed by each of the parties and delivered to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.16&#8239;&#8239;&#8239;&#8239;</FONT><U>Facsimile
or .pdf Signature</U>. This Agreement may be executed by facsimile or .pdf signature and a facsimile or .pdf signature shall constitute
an original for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Section&nbsp;10.17&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Presumption Against Drafting Party</U>. Each of Parent, Merger Sub and the Company acknowledges that each party to this Agreement has
been represented by counsel in connection with this Agreement and the Contemplated Transactions. Accordingly, any rule&nbsp;of law or
any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the drafting party has no application
and is expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>The remainder of this page&nbsp;is intentionally
left blank</I>.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARISMA THERAPEUTICS INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Steven Kelly</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Steven Kelly</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">AZALEA MERGER SUB,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Steven Kelly&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Steven Kelly</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page&nbsp;to Agreement and Plan
of Merger</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">OCUGEN,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Shankar Musunuri</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Shankar Musunuri</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chairman, Chief Executive Officer &amp; Co-Founder</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ORTHOCELLIX,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Shankar Musunuri</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Shankar Musunuri</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President and Secretary</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;to Agreement and Plan
of Merger</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm2518620d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONTINGENT VALUE RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS CONTINGENT VALUE RIGHTS
AGREEMENT </B>(this &ldquo;<B>Agreement</B>&rdquo;), dated as of [&#9679;], 2025, is entered into by and between <FONT STYLE="font-variant: small-caps"><B>Carisma
Therapeutics Inc.</B></FONT>, a Delaware corporation (&ldquo;<B>Parent</B>&rdquo;), and Computershare Inc. a Delaware corporation (&ldquo;<B>Computershare</B>&rdquo;),
and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company (collectively, as &ldquo;<B>Rights Agent</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>A.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></B>Parent, <FONT STYLE="font-variant: small-caps"><B>Azalea Merger Sub, Inc.</B></FONT>, a Delaware corporation and wholly owned
subsidiary of Parent (&ldquo;<B>Merger Sub</B>&rdquo;) and OrthoCellix, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;)
have entered into an Agreement and Plan of Merger, dated as of [&#9679;], 2025 (the &ldquo;<B>Merger Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>B.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></B>Pursuant to the Merger Agreement, and in accordance with the terms and conditions thereof, Parent has agreed to provide to
the Holders (as defined herein) contingent value rights as hereinafter described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>C.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></B>The parties have done all things reasonably necessary to make the contingent value rights, when issued pursuant to the Merger
Agreement and hereunder, the valid obligations of Parent and to make this Agreement a valid and binding agreement of Parent, in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the
proportionate benefit of all Holders, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 1<BR>
DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 1.1 <U>Definitions</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capitalized terms used but not otherwise defined
herein have the meanings ascribed thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Acting Holders</B>&rdquo;
means, at the time of determination, the Holders of at least 40% of the outstanding CVRs, as reflected on the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Assignee</B>&rdquo;
has the meaning set forth in <U>Section 7.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change of Control</B>&rdquo;
means (a) the acquisition in one transaction or a series of related transactions, by any Person or group (within the meaning of Section
13(d)(3) of the Securities Exchange Act of 1934) of the securities of Parent possessing more than 50% of the total combined voting power
of all outstanding securities of Parent (<I>provided</I>, <I>however</I>, that a Change of Control will not result upon such acquisition
of ownership if such acquisition occurs as a result of: (i) a public offering of Parent&rsquo;s securities or any financing transaction
or series of financing transactions, in each case for <I>bona fide</I> financing purposes or (ii) a merger or consolidation involving
Parent where the holders of the outstanding voting securities of Parent immediately prior to such merger or consolidation (taken in the
aggregate) possess beneficial ownership of 50% or more of the total combined voting power of all outstanding voting securities of Parent,
the surviving entity, the acquiring entity or a parent or holding company of the acquiring entity, immediately after such merger or consolidation);
or (b) the sale, transfer, exclusive license or other disposition (in one transaction or a series of related transactions) of all or substantially
all of the assets of Parent (on a consolidated basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
has the meaning set forth in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo;
means the common stock, $0.001 par value, of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CVR</B>&rdquo; means
a contingent contractual right of Holders to receive CVR Payments pursuant to the Merger Agreement and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CVR Payment</B>&rdquo;
means a cash payment equal to (i) the Net Proceeds received by Parent to the extent such payment relates to a Parent Legacy Transaction
entered into during the Disposition Period, if any plus (ii) the Net Proceeds received by Parent to the extent such payment relates to
any royalties, milestones or other payments received by Parent following the Closing Date under Parent&rsquo;s existing agreements as
set forth on Schedule 1.1<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>; <I>provided</I>, that Parent,
in its reasonable discretion as determined by the Board of Directors, may withhold up to 10% of any CVR Payment solely to the extent
(a) that express contractual indemnity obligations under any Disposition Agreement are in excess of any escrow fund established therein,
in each case to the extent not already deducted as Permitted Deductions and (b) of any Loss arising out of any third-party claims, demands,
actions, or other proceedings relating to or in connection with any Parent Legacy Assets during the CVR Period that have been finally
determined; <I>provided, further</I>, that any such withheld Gross Proceeds shall be distributed (net of any Permitted Deductions actually
applied against such Gross Proceeds within the (1) year period following such withholding) to the Holders no later than the date that
is sixty (60) days following the first (1<SUP>st</SUP>) anniversary of the date such Gross Proceeds would have otherwise been distributed
to the Holders in the CVR Payment from which such Gross Proceeds were otherwise deducted; <I>provided, further</I>, that such withholding
shall not be permitted if (x) the applicable indemnification period under the applicable Disposition Agreement related to such CVR Payment
has expired by its terms when the CVR Payment is received or (y) the maximum aggregate liability in respect of the applicable indemnification
obligations has been held back or setoff (including any amounts deposited in escrow) by the purchaser or acquiror under the applicable
Disposition Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CVR Payment Amount</B>&rdquo;
means with respect to each CVR Payment and each Holder, an amount equal to such CVR Payment divided by the total number of CVRs and then
multiplied by the total number of CVRs held by such Holder as reflected on the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CVR Payment Statement</B>&rdquo;
means, for a given CVR Payment, a written statement of Parent, signed on behalf of Parent, setting forth in reasonable detail and certifying
the calculation of the applicable CVR Payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;CVR Register</B>&rdquo;
has the meaning set forth in <U>Section 2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>CVR Term</B>&rdquo;
means the period beginning on the Closing and ending upon the [fifth (5<SUP>th</SUP>) anniversary of this Agreement]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disposition Agreement</B>&rdquo;
means a definitive written agreement providing for a Parent Legacy Transaction that is entered into during the Disposition Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disposition Period</B>&rdquo;
means the period beginning on the execution date of the Merger Agreement and ending on the second (2<SUP>nd</SUP>) anniversary of the
Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Gross Proceeds</B>&rdquo;
means, without duplication, the sum of all cash consideration and all cash proceeds from the sale of non-cash consideration of any kind
that is actually paid to Parent or any of its Affiliates, or is actually received by Parent or any of its Affiliates, solely as such consideration
relates to a Parent Legacy Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Holder</B>&rdquo;
means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Schedule 1.1 to be updated as of the closing date, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
Date to be agreed pending asset sale status prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Liability</B>&rdquo;
means any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute,
contingent, matured, unmatured or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Loss</B>&rdquo;
has the meaning set forth in <U>Section 3.2(g)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Proceeds</B>&rdquo;
means, for any CVR Payment, Gross Proceeds minus Permitted Deductions, all as calculated, to the extent in accordance with GAAP, in a
manner consistent with Parent&rsquo;s accounting practices and the most recently filed annual audited financial statements with the SEC,
except as otherwise set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Notice</B>&rdquo;
has the meaning set forth in <U>Section 7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Officer&rsquo;s
Certificate</B>&rdquo; means a certificate signed by the chief executive officer or the chief financial officer of Parent, in their respective
official capacities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Legacy Assets</B>&rdquo;
means all assets, technology and Intellectual Property of Parent, as they existed at any time prior to the date of this Agreement, relating
to the Company&rsquo;s research and development programs, as conducted and proposed to be conducted, including its CT-0525, CT-0508, CT-1119
and its engineered macrophage, and in vivo mRNA/lipid nanopartical CAR-M programs and its partnership with ModernaTX, Inc., including,
for purposes of clarity, the tangible and intangible assets of Parent relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent Legacy Transaction</B>&rdquo;
means the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) and/or winding
down of, and/or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction)
or other disposition of any Parent Legacy Assets, in each cased entered into during the Disposition Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Party</B>&rdquo;
means Parent or the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Deductions</B>&rdquo;
means the sum of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any applicable Tax (including any applicable value added or sales taxes) imposed on Gross Proceeds and payable by Parent (regardless
of whether the due date for such Taxes arises during or after the Disposition Period) and, without duplication, any income or other similar
Taxes payable by Parent or any of its Affiliates that would not have been incurred by Parent or any of its Affiliates but for the Gross
Proceeds; <I>provided</I> that, for purposes of calculating income Taxes incurred by Parent in respect of the Gross Proceeds, any such
income Taxes shall be computed assuming the only items of income are the Gross Proceeds attributable to the gain recognized by Parent
from the Parent Legacy Transaction and after reduction for any net operating loss carryforwards or other Tax attributes of Parent as of
the Closing Date that are available to offset such gain after taking into account any limits of the usability of such attributes, including
under Section 382 of the Code, as reasonably determined by Parent&rsquo;s tax advisers (and for the sake of clarity such income taxes
shall be calculated without taking into account any net operating losses or other tax attributes generated by Parent or its Affiliates
after the Closing Date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any reasonable and documented out-of-pocket costs and expenses incurred by Parent to preserve the Parent Legacy Assets for sale
or in respect of its performance of this Agreement following the Closing Date, including any damages, liabilities arising under any Disposition
Agreement, including any incurred in litigation or other dispute resolution therefor, and including (i) any costs related to the prosecution,
maintenance or enforcement by Parent or any of its Subsidiaries of intellectual property rights (but excluding any costs related to a
breach of this Agreement, including costs incurred in litigation or dispute resolution in respect of the same), or (ii) any costs related
to monetary liabilities of or relating to the Parent Legacy Assets that remain with the Parent following the consummation of any Parent
Legacy Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any reasonable and documented out-of-pocket costs or expenses incurred by Parent in connection with the negotiation, entry into
and closing of any Parent Legacy Transaction, including any brokerage fee, finder&rsquo;s fee, or other transaction fee, or other fee,
commission or expense owed to any broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party in relation
thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> any losses incurred by Parent arising out of any third-party claims, demands, actions, or other proceedings relating to or in
connection with any Parent Legacy Transaction, including indemnification obligations of Parent set forth in any Disposition Agreement;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any liabilities incurred during the CVR Term that would have been required to be included in the calculation of Net Cash (as defined
in the Merger Agreement) arising solely out of a Disposition Agreement to the extent not taken into account in the calculation of Net
Cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Transfer</B>&rdquo;
means a transfer of CVRs (a) upon death of a Holder by will or intestacy or by instrument to an inter vivos or testamentary trust in which
the CVRs are to be passed to beneficiaries upon the death of the trustee; (b)&#8239;pursuant to a court order; (c) by operation of law
(including by consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any
corporation, limited liability company, partnership or other entity; (d) in the case of CVRs held in book-entry or other similar nominee
form, from a nominee to a beneficial owner and, if applicable, through an intermediary, to the extent allowable by DTC; (e) if the Holder
is a partnership or limited liability company, a distribution by the transferring partnership or limited liability company to its partners
or members, as applicable or (f) as provided in <U>Section 2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rights Agent</B>&rdquo;
means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent will have become the Rights Agent
pursuant to the applicable provisions of this Agreement, and thereafter &ldquo;Rights Agent&rdquo; will mean such successor Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 2<BR>
CONTINGENT VALUE RIGHTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.1 <U>Holders
of CVRs; Appointment of Rights Agent</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The CVRs represent the rights of Holders to receive contingent CVR Payments pursuant to this Agreement. The CVRs shall be issued
and distributed by Parent in the form a dividend in connection with the Merger, and the initial Holders will be the holders of Common
Stock as of immediately prior to the Effective Time. One CVR will be issued with respect to each share of Common Stock that is outstanding
as of immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent hereby appoints the Rights Agent to act as Rights Agent for Parent in accordance with the express terms and conditions set
forth in this Agreement, and the Rights Agent hereby accepts such appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.2 <U>Non-transferable</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CVRs may not be sold,
assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, other than through
a Permitted Transfer. Any attempted sale, assignment, transfer, pledge, encumbrance or disposal that is not a Permitted Transfer shall
be void ab initio and of no effect. The CVRs will not be listed on any quotation system or traded on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.3 <U>No Certificate;
Registration; Registration of Transfer; Change of Address</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The CVRs will be issued in book-entry form only and will not be evidenced by a certificate or other instrument. Holders&rsquo;
rights and obligations in respect of CVRs derive solely from this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Subject
to the receipt by the Rights Agent of the information and instructions described in <U>Section 4.1</U>, the Rights Agent shall
create and maintain a register (the &ldquo;<B>CVR Register</B>&rdquo;) for the purpose of registering CVRs and Permitted Transfers.
The CVR Register will be created, and CVRs will be distributed, pursuant to written instructions to the Rights Agent from Parent.
The CVR Register will initially show one position for Cede &amp; Co. representing shares of Common Stock held by DTC on behalf of
the street holders of the shares of Common Stock held by such Holders as of immediately prior to the Effective Time. With respect to
any payments or issuances to be made under <U>Section 2.4</U> below, the Rights Agent will accomplish the payment to any former
street name holders of shares Common Stock by sending one lump-sum payment or issuance to DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the restrictions on transferability set forth in <U>Section 2.2</U>, every request made to transfer a CVR must be in
writing and accompanied by a written instrument of transfer in form reasonably satisfactory to the Rights Agent pursuant to its guidelines
or procedures, including a guaranty of signature by an &ldquo;eligible guarantor institution&rdquo; that is a member or participant in
the Securities Transfer Agents Medallion Program, duly executed and properly completed by the Holder thereof, the Holder&rsquo;s attorney
duly authorized in writing, the Holder&rsquo;s personal representative or the Holder&rsquo;s survivor, and setting forth in reasonable
detail the circumstances relating to the transfer. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable
determination that the transfer instrument is in proper form and the transfer otherwise complies with the other terms and conditions of
this Agreement (including the provisions of <U>Section 2.2</U>), register the transfer of the CVRs in the CVR Register. Parent and the
Rights Agent shall not be responsible for, and may require evidence of payment of a sum sufficient to cover (or evidence that such Taxes
and charges are not applicable), any stamp, documentary, registration, or other Tax or governmental charge that is imposed in connection
with any such registration of transfer. All duly transferred CVRs registered in the CVR Register will be the valid obligations of Parent
and will entitle the transferee to the same benefits and rights under this Agreement as those held immediately prior to the transfer by
the transferor. No transfer of a CVR will be valid until registered in the CVR Register and any transfer not duly registered in the CVR
Register shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>A Holder may make a written request to the Rights Agent to change such Holder&rsquo;s address of record in the CVR Register. The
written request must be duly executed by the Holder. Upon receipt of such written notice, the Rights Agent shall, subject to its reasonable
determination that the transfer instrument is in proper form, promptly record the change of address in the CVR Register. The Acting Holders
may, without duplication, make a written request to the Rights Agent for a list containing the names, addresses and number of CVRs of
the Holders that are registered in the CVR Register. Upon receipt of such written request from the Acting Holders, the Rights Agent shall
promptly deliver a copy of such list to the Acting Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent will provide written instructions to the Rights Agent for the distribution of CVRs to holders of Common Stock as of immediately
prior to the Effective Time (the &ldquo;<B>Record Time</B>&rdquo;). Subject to the terms and conditions of this Agreement and Parent&rsquo;s
prompt confirmation of the Effective Time, the Rights Agent shall effect the distribution of the CVRs, less any applicable tax withholding,
to each holder of Common Stock as of the Record Time by the mailing of a statement of holding reflecting such CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.4 <U>Payment
Procedures</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No later than forty-five (45) days following the end of each calendar quarter during which Parent receives a CVR Payment during
the CVR Term, Parent shall deliver to the Rights Agent a CVR Payment Statement. Concurrent with the delivery of each CVR Payment Statement,
on the terms and conditions of this Agreement, Parent shall pay the Rights Agent in U.S. dollars an amount equal to one-hundred percent&#8239;(100%)
of the applicable Net Proceeds (if any) for the applicable CVR Payment. Such amount of Net Proceeds will be transferred by wire transfer
of immediately available funds to an account designated in writing by the Rights Agent not less than ten (10) Business Days prior to the
date of the applicable payment. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly
(and in any event, within ten&#8239;(10) Rights Agent, an amount equal to such Holder&rsquo;s CVR Payment Amount. The Rights Agent shall,
upon any Holder&rsquo;s request in writing and as soon as practicable after receipt of a CVR Payment Statement under this <U>Section 2.4(a)</U>,
send such Holder at its registered address a copy of such statement. For the avoidance of doubt Parent shall have no further liability
in respect of the relevant CVR Payment upon delivery of such CVR Payment in accordance with this <U>Section 2.4(a)</U> and the satisfaction
of each of Parent&rsquo;s obligations set forth in this <U>Section 2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> The Rights Agent shall solicit from each Holder an IRS Form W-9 or applicable IRS Form&#8239;W-8 at such time or times as is necessary
to permit any payment under this Agreement to be made without U.S. federal backup withholding. That notwithstanding, Parent shall be entitled
to deduct and withhold and hereby authorizes the Rights Agent to deduct and withhold, any tax or similar governmental charge or levy,
that is required to be deducted or withheld under applicable law from any amounts payable pursuant to this Agreement (&ldquo;<B>Withholding
Taxes</B>&rdquo;). To the extent the amounts are so withheld by Parent or the Rights Agent, as the case may be, such withheld amounts
shall be treated for all purposes of this Agreement as having been paid to the person in respect of whom such deduction and withholding
was made. In the event Parent becomes aware that a payment under this Agreement is subject to Withholding Taxes (other than U.S. federal
backup withholding), Parent shall use commercially reasonable efforts to provide written notice to the Rights Agent and the Rights Agent
shall use commercially reasonable efforts to provide written notice of such Withholding Taxes to the applicable Holders and a reasonable
opportunity for the Holder to provide any necessary Tax forms, including an IRS Form W-9 or appropriate IRS Form W-8, as applicable, in
order to reduce such withholding amounts; <I>provided</I> that the time period for payment of a CVR Payment by the Rights Agent set forth
in <U>Section 2.4(a)</U> will be extended by a period equal to any delay caused by the Holder providing such forms. For the avoidance
of doubt, in the event that notice has been provided to an applicable Holder pursuant to this <U>Section 2.4(b)</U>, no further notice
shall be required to be given for any future payments of such Withholding Tax. Parent will use commercially reasonable efforts to provide
withholding and reporting instructions in writing (email being sufficient) to the Rights Agent from time to time as relevant, and upon
reasonable request of the Rights Agent. The Rights Agent shall have no responsibilities with respect to tax withholding, reporting or
payment except specifically instructed by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any portion of a CVR Payment that remains undistributed to the Holders six (6) months after the delivery of a CVR Payment Statement
(including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to Parent or a
person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent), and any Holder will thereafter look
only to Parent for payment of such CVR Payment (which shall be without interest).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If any CVR Payment (or portion thereof) remains unclaimed by a Holder two (2) years after the delivery of a CVR Payment Statement
(or immediately prior to such earlier date on which such CVR Payment would otherwise escheat to or become the property of any Governmental
Entity), such CVR Payment (or portion thereof) will, to the extent permitted by applicable Law, become the property of Parent and will
be transferred to Parent or a person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent), free
and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor.
Neither Parent nor the Rights Agent will be liable to any Person in respect of a CVR Payment delivered to a public official pursuant to
any applicable abandoned property, escheat or similar legal requirement under applicable Law. In addition to and not in limitation of
any other indemnity obligation herein, Parent agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty,
cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Parent, a public office or
a person nominated in writing by Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>For
U.S. federal income and other applicable Tax purposes, the parties hereto agree to treat (i) the issuance of the CVRs as a
distribution of property (and not debt or equity of Parent) by Parent to the stockholders of Parent governed by Section 301 of the
Code, and (ii) the amount of any CVR Payment as a contractual payment pursuant to the rights afforded by this Agreement to the
Holder and not as a distribution by Parent in respect of Parent stock (collectively, the &ldquo;<B>Intended Tax
Treatment</B>&rdquo;). Consistent with the Intended Tax Treatment, Parent will send, or cause to be sent, IRS Forms 1099-DIV to all
Holders notifying them of the portion of the CVR value that is a non-dividend distribution (or a dividend to the extent of
Parent&rsquo;s current or accumulated earnings and profits) for U.S. federal income Tax purposes. The parties hereto will not take
any position contrary to the Intended Tax Treatment on any Tax Return or for other Tax purposes, except as may be required by a
change in applicable Law or pursuant to a final &ldquo;determination&rdquo; within the meaning of Section 1313(a) of the Code, in
each case, after the date hereof. Parent will independently retain and pay for the services of a third-party valuation firm to
determine the fair market value of the CVRs and Parent will utilize such fair market value for purposes of all Tax reporting
(including on IRS Forms 1099-DIV) with respect to the CVRs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.5 <U>No Voting,
Dividends or Interest; No Equity or Ownership Interest</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs to
any Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The sole right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the
terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue of the CVRs, any rights or obligations
of any kind or nature whatsoever as a stockholder or member of Parent or any of its subsidiaries either at law or in equity. The rights
of any Holder and the obligations of Parent and its Affiliates and their respective officers, directors and controlling Persons are contract
rights limited to those expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>By voting in favor of the adoption of the Merger Agreement, the approval of the principal terms of the Merger, and the consummation
of the Merger and receiving the benefits thereof, including the receipt of CVRs in connection therewith and any consideration payable
in connection with the CVRs, each Holder hereby acknowledges and agrees that the CVRs and the possibility of any payment hereunder with
respect thereto are highly speculative and subject to numerous factors outside of Parent&rsquo;s control, and there is no assurance that
Holders will receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is highly possible
that no Parent Legacy Transaction will occur prior to the expiration of the Disposition Period and that there will not be any Gross Proceeds
that may be the subject of a CVR Payment Amount. It is further acknowledged and agreed that neither Parent nor its Affiliates owe, by
virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend
solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged
and agreed that this <U>Section 2.5(d)</U> is an essential and material term of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 2.6 <U>Ability
to Abandon CVR</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Holder may at any time,
at such Holder&rsquo;s option, abandon all of such Holder&rsquo;s remaining rights represented by CVRs by transferring such CVR to Parent
or a Person nominated in writing by Parent (with written notice thereof from Parent to the Rights Agent) without consideration in compensation
therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Parent of such transfer and cancellation.
Nothing in this Agreement is intended to prohibit Parent or its Affiliates from offering to acquire or acquiring CVRs, in private transactions
or otherwise, for consideration in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 3<BR>
THE RIGHTS AGENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.1 <U>Certain
Duties and Responsibilities</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the
extent such liability arises as a result of the willful misconduct, intentional breach, bad faith, fraud or gross negligence of the Rights
Agent (in each case as determined by a final non-appealable judgment of court of competent jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>The
Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect
to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or
responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Parent. The Rights
Agent may (but shall not be required to) enforce all rights of action under this Agreement and any related claim, action, suit,
audit, investigation or proceeding instituted by the Rights Agent may be brought in its name as the Rights Agent and any recovery in
connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may appear on
the CVR Register.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.2 <U>Certain
Rights of Rights Agent</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no
implied covenants or obligations will be read into this Agreement against the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent may rely and will be protected by Parent in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it
to be genuine and to have been signed or presented by or on behalf of Parent or, with respect to <U>Section 2.3(d)</U>, the Acting Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking, suffering or omitting any
action hereunder, the Rights Agent may rely upon an Officer&rsquo;s Certificate, which certificate shall be full authorization and protection
to the Rights Agent, and the Rights Agent shall, in the absence of bad faith, fraud, gross negligence or willful misconduct (each as determined
by a final non-appealable judgment of a court of competent jurisdiction) on its part, not incur any liability and shall be held harmless
by Parent for or in respect of any action taken, suffered or omitted to be taken by it under the provisions of this Agreement in reliance
upon such Officer&rsquo;s Certificate; provided, that, Parent shall not be authorized to deliver an Officer&rsquo;s Certificate inconsistent
with the provisions set forth in this Agreement without the prior written consent of the Acting Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence
of bad faith, fraud, gross negligence or willful misconduct (in each case, as determined by a final, non-appealable judgment of a court
of competent jurisdiction) on the part of the Rights Agent, be full and complete authorization and protection in respect of any action
taken, suffered or not taken by the Rights Agent in reliance thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any permissive rights of the Rights Agent hereunder will not be construed as a duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss, liability, damage,
judgment, fine, penalty, claim, demand, settlement, cost or expense (including the reasonable and documented fees and expenses of legal
counsel) (each, a &ldquo;<B>Loss</B>&rdquo;) which may be paid, incurred or suffered by or to which it may become subject, arising from
or out of, directly or indirectly, any claims or liability resulting from any action taken, suffered or omitted by the Rights Agent in
connection the execution, acceptance, administration, exercise and performance of its duties under this Agreement, including the costs
and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder,
except to the extent such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted
from the Rights Agent&rsquo;s willful misconduct, bad faith, fraud or gross negligence; provided that this <U>Section 3.2(g)</U> shall
not apply with respect to income, receipt, franchise or similar Taxes levied against the Rights Agent by a Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>Parent
agrees (i) to pay the fees of the Rights Agent in connection with the Rights Agent&rsquo;s performance of its obligations hereunder
as set forth in a fee schedule agreed upon in writing by the Rights Agent and Parent on or prior to the date of this Agreement (the
 &ldquo;<B>Fee Schedule</B>&rdquo;), and (ii) to reimburse the Rights Agent for all reasonable and documented out-of-pocket expenses
and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this
Agreement and the exercise and performance of its duties hereunder, including all stamp and transfer Taxes (and excluding for the
avoidance of doubt, any income, receipt, franchise or similar Taxes levied against the Rights Agent by a Governmental Entity) and
governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial
liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment
of such funds or adequate indemnification against such risk or liability is not reasonably assured to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall have no responsibility to Parent, any holders of CVRs, any holders of shares of Common Stock or any other
Person for interest or earnings on any moneys held by the Rights Agent pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the Merger
Agreement or any other agreement between or among any of Parent, the Company or Holders, even though reference thereto may be made in
this Agreement, or to comply with any notice, instruction, direction, request or other communication, paper or document other than as
expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either
itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect
or misconduct of any such attorney or agents or for any loss to Parent or the Company resulting from any such act, default, neglect or
misconduct, absent willful misconduct, bad faith, fraud or gross negligence (each as determined by a final non-appealable judgment of
a court of competent jurisdiction) in the selection and continued employment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this Agreement
(except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed
to have been made by Parent only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall act hereunder solely as agent for Parent and shall not assume any obligations or relationship of agency
or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the
receipt of any written demand from any Holders with respect to any action or default by Parent, including, without limiting the generality
of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand
upon Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (a) any guaranty of signature
by an &ldquo;eligible guarantor institution&rdquo; that is a member or participant in the Securities Transfer Agents Medallion Program
or other comparable &ldquo;signature guarantee program&rdquo; or insurance program in addition to, or in substitution for, the foregoing;
or (b) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered,
changed, amended or repealed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent shall not be liable or responsible for any failure of Parent to comply with any of its obligations relating to
any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations
under applicable regulation or law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The obligations of Parent and the rights of the Rights Agent under this <U>Section 3.2</U>, <U>Section 3.1</U>. and <U>Section
2.4</U> shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of
the Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but has
not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection
therewith, in each case, unless and until it has received such notice in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.3 <U>Resignation
and Removal; Appointment of Successor</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent may resign at any time by written notice to Parent. Any such resignation notice shall specify the date on which
such resignation will take effect (which shall be at least thirty (30) days following the date that such resignation notice is delivered),
and such resignation will be effective on the earlier of (x) the date so specified and (y) the appointment of a successor Rights Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date on
which such removal will take effect. Such notice will be given at least thirty&#8239;(30) days prior to the date so specified (or, if earlier,
the appointment of the successor Rights Agent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the Rights Agent resigns, is removed or becomes incapable of acting, Parent will promptly appoint a qualified successor Rights
Agent. Notwithstanding the foregoing, if Parent fails to make such appointment within a period of thirty (30) days after giving notice
of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent,
then the any Holder may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent
so appointed will, upon its acceptance of such appointment in accordance with this <U>Section 3.3(c)</U> and <U>Section 3.4</U>, become
the Rights Agent for all purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a successor Rights
Agent in accordance with <U>Section 7.2</U>. Each notice will include the name and address of the successor Rights Agent. If Parent fails
to send such notice within ten (10) Business Days after acceptance of appointment by a successor Rights Agent, the successor Rights Agent
will cause the notice to be mailed at the expense of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding anything to the contrary in this <U>Section 3.3</U>, unless consented to in writing by the Acting Holders, Parent
will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust
department of a commercial bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Rights Agent will reasonably cooperate with Parent and any successor Rights Agent in connection with the transition of the
duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including
the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any additional expenditure
or assume any additional liability in connection with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 3.4 <U>Acceptance
of Appointment by Successor</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every successor Rights Agent
appointed hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Parent and to the resigning or removed
Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any
further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <I>provided</I>
that upon the request of Parent or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument
transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent, except such rights
which survive its resignation or removal under the terms hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 4<BR>
COVENANTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.1 <U>List of
Holders</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parent will furnish or cause
to be furnished to the Rights Agent, in such form as Parent receives from Parent&rsquo;s transfer agent (or other agent performing similar
services for Parent), the names and addresses of the Holders within fifteen (15) Business Days following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.2 <U>No Obligations
of Public Company</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>[Notwithstanding anything herein to the contrary, (a) Parent and its Affiliates shall have the power and right to control all aspects
of their businesses and operations (and all of their assets and products) with respect to any Parent Legacy Assets), and subject to Parent&rsquo;s
compliance with the terms of this Agreement, Parent and its Affiliates may exercise or refrain from exercising such power and right as
it may deem appropriate and in the best overall interests of Parent and its Affiliates and its and their stockholders, rather than the
interest of the Holders, (b) none of Parent or any of its Affiliates (or any directors, officer, employee, or other representative of
the foregoing) owes any fiduciary duty or similar duty or any other implied duties (including the implied covenant of good faith and fair
dealing) to any Holder in respect of the CVRs or the Parent Legacy Assets and (c) following the Disposition Period, Parent shall be permitted
to take any action in respect of the Parent Legacy Assets in order to satisfy any wind-down and termination Liabilities of the Parent
Legacy Assets. For clarity and without limitation of the foregoing, following the Disposition Period without a Parent Legacy Transaction,
Parent may take any action in respect of the Parent Legacy Assets in its sole and absolute discretion. Notwithstanding anything else herein,
none of Parent or any of its Affiliates may amend, modify, restate, amend and restate, terminate, rescind, sell, dispose of, waive any
third-party&rsquo;s obligations under or otherwise modify or transfer any of the agreements listed on <U>Schedule 1.1</U>.]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.3 <U>Books
and Records</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until the end of the CVR Term,
Parent shall, and shall cause its Affiliates to, keep true, complete and accurate records in sufficient detail to support the applicable
CVR Payments, if any, payable hereunder in accordance with the terms specified in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 4.4 <U>Audits</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until the Termination
Date and for a period of one (1) year thereafter, Parent shall keep complete and accurate records in sufficient detail to support
the accuracy of the payments due hereunder. The Acting Holders shall have the right to cause an independent accounting firm
reasonably acceptable to Parent to audit such records for the sole purpose of confirming CVR Payments received by Parent or its
Affiliates. Parent may require such accounting firm to execute a reasonable confidentiality agreement with Parent prior to
commencing the audit. The accounting firm shall disclose to Rights Agent or the Acting Holders, as applicable, only whether the
reports are correct or not and the specific details concerning any discrepancies. No other information shall be shared, and in no
event shall Parent be required to provide any Tax returns or any other Tax information it deems confidential to the Acting Holders
or any other party. Such audits may be conducted during normal business hours upon reasonable prior written notice to Parent, but no
more than frequently than once per year. No accounting period of Parent shall be subject to audit more than one time by the Acting
Holders, as applicable. Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be made
by Parent to reflect the results of such audit, which adjustments shall be paid promptly following receipt of an invoice therefor.
Whenever such an adjustment is made, Parent shall promptly prepare a certificate setting forth such adjustment, and a brief,
reasonably detailed statement of the facts, computation and methodology accounting for such adjustment to the extent not already
reflected in the audit report and promptly file with the Rights Agent a copy of such report and promptly deliver to the Rights Agent
a revised CVR Payment Statement for the relevant CVR Payment. The Rights Agent shall be fully protected in relying on any such
report and on any adjustment or statement therein contained and shall have no duty or liability with respect to, and shall not be
deemed to have knowledge of any such adjustment or any such event unless and until it shall have received such report. The Acting
Holders, as applicable, shall bear the full cost and expense of such audit unless such audit discloses an underpayment by Parent of
the CVR Payment due under this Agreement, in which case Parent shall bear the full cost and expense of such audit. The Rights Agent
shall be entitled to rely on any audit report delivered by the independent accounting firm pursuant to this <U>Section 4.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
Discussion of duties/obligations of Parent to be discussed pending outcome of legacy asset transaction structures and timing.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 5<BR>
AMENDMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">Section 5.1 <U>Amendments
Without Consent of Holders or Rights Agent</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 27pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent, at any time and from time to time, may (without the consent of any Person, including the Holders, other than the Rights
Agent, with such consent not to be unreasonably withheld, conditioned or delayed) enter into one or more amendments to this Agreement
for any of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 27pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the
covenants and obligations of the Rights Agent herein in accordance with the provisions hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>subject to <U>Section 6.1</U>, to evidence the succession of another person to Parent and the assumption of any such successor
of the covenants of Parent outlined herein in a transaction contemplated by <U>Section 6.1</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with any
other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement;
<I>provided</I> that, in each case, such provisions do not adversely affect the interests of the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as may be necessary or appropriate to ensure that the CVRs are not subject to registration under the Securities Act or the Exchange
Act and the rules and regulations promulgated thereunder, or any applicable state securities or &ldquo;blue sky&rdquo; laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as may be necessary or appropriate to ensure that Parent is not required to produce a prospectus or an admission document in order
to comply with applicable Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as Parent may reasonably determine to facilitate the administration or performance of obligations under this Agreement and does
not adversely affect the Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>to cancel the CVRs (i) in the event that any Holder has abandoned its rights in accordance with <U>Section 2.6</U>, or (ii) following
a transfer of such CVRs to Parent or its Affiliates in accordance with <U>Section 2.2</U> or <U>Section 2.3</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>as may be necessary or appropriate to ensure that Parent complies with applicable Law; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Promptly after the execution by Parent of any amendment pursuant to this <U>Section 5.1</U>, Parent will (or will cause the Rights
Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <U>Section 7.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.2 <U>Amendments
with Consent of Holders</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In addition to any amendments to this Agreement that may be made by Parent without the consent of any Holder pursuant to <U>Section
5.1</U>, with the consent of the Acting Holders (whether evidenced in a writing or taken at a meeting of the Holders), Parent and the
Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions
of this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> Promptly after the execution by Parent and the Rights Agent of any amendment pursuant to the provisions of this <U>Section 5.2</U>,
Parent will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with
<U>Section 7.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.3 <U>Effect
of Amendments</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the execution of any
amendment under this <U>Article 5</U>, this Agreement will be modified in accordance therewith, such amendment will form a part of this
Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of Parent
which states that the proposed supplement or amendment is in compliance with the terms of this <U>Article 5</U>, the Rights Agent shall
execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights Agent shall not be required
to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations
or immunities under this Agreement. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 6<BR>
CONSOLIDATION, MERGER, SALE OR CONVEYANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 6.1 <U>Change
of Control</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the Termination Date,
Parent shall not consummate a Change of Control without the consent of the Acting Holders (such consent not to be unreasonably withheld,
conditioned or delayed), unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Person that is the relevant transferee, assignee, acquiror, delegate or other successor (including by operation of law) in
such Change of Control (the &ldquo;<B>Surviving Person</B>&rdquo;) shall assume or succeed to the obligations on all CVRs (when and as
due hereunder); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parent has delivered to the Rights Agent an Officer&rsquo;s Certificate stating that such Change of Control complies with this
<U>Article 6</U> and that all conditions precedent herein provided for relating to such Change of Control have been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.2 <U>Successor
Substituted</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation of any
Change of Control in accordance with <U>Section 6.1</U>, the Surviving Person shall succeed to, and be substituted for, and may exercise
every right and power of, and shall assume all of the obligations of Parent under this Agreement with the same effect as if the Surviving
Person had been named as Parent herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 7<BR>
MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.1 <U>Notices
to Rights Agent and to Parent</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, requests and
other communications (each, a &ldquo;<B>Notice</B>&rdquo;) to any party hereunder shall be in writing and shall be deemed to have been
duly delivered and received hereunder when sent (a) fees prepaid, via a reputable international overnight courier service in the case
of delivery in person, by FedEx or other internationally recognized overnight courier service or (b) on the date sent in the place of
delivery if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on
the next succeeding Business Day, in each case to the intended recipient as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">if to the Rights Agent, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: [&#9679;]<BR>
Email: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">if to Parent, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Car<FONT STYLE="font-size: 10pt">isma Therapeutics Inc. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3675 Market Street, Suite 401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: Steven Kelly, President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">with a copy, which shall not constitute notice,
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Wilmer Cutler Pickering Hale and Dorr LLP<BR>
7 World Trade Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">250 Greenwich Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, New York 10007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Attention:</TD><TD STYLE="text-align: justify">Christopher D. Barnstable-Brown, Esq.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">Mark Nylen, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">Brian A. Johnson, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">E-mail:</TD><TD STYLE="text-align: justify">cbb@wilmerhale.com</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">mark.nylen@wilmerhale.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">brian.johnson@wilmerhale.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or to such other address as such party may hereafter specify for the
purpose by notice to the other parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.2 <U>Notice
to Holders</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Notices required to be
given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to
each Holder at such Holder&rsquo;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the
earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice
to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder
will affect the sufficiency of such Notice with respect to other Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.3 <U>Entire
Agreement</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As between Parent and the
Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter of this Agreement,
notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written and
oral, among or between any of the parties with respect to the subject matter of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.4 <U>Merger
or Consolidation or Change of Name of Rights Agent</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Person into which the
Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or
consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer
or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under
this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that
such Person would be eligible for appointment as a successor Rights Agent under the provisions of <U>Section 3.3</U>. The purchase of
all or substantially all of the Rights Agent&rsquo;s assets employed in the performance of transfer agent activities shall be deemed a
merger or consolidation for purposes of this <U>Section 7.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.5 <U>Successors
and Assigns</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement will be binding
upon, and will be enforceable by and inure solely to the benefit of, the Holders, Parent and the Rights Agent and their respective successors
and assigns. Except for assignments pursuant to <U>Section 7.4</U>, the Rights Agent may not assign this Agreement without Parent&rsquo;s
prior written consent. Subject to <U>Section 5.1(a)(ii</U>) and Article 6 hereof, Parent may assign, in its sole discretion and without
the consent of any other party, any or all of its rights, interests and obligations hereunder to one or more of its Affiliates or to any
Person with whom Parent is merged or consolidated, or any entity resulting from any merger or consolidation to which Parent shall be a
party (each, an &ldquo;<B>Assignee</B>&rdquo;); <I>provided</I>, that in connection with any assignment to an Assignee, Parent shall agree
to remain liable for the performance by Parent of its obligations hereunder (to the extent Parent exists following such assignment). Parent
or an Assignee may not otherwise assign this Agreement without the prior consent of the Acting Holders (such consent not to be unreasonably
withheld, conditioned or delayed). Any attempted assignment of this Agreement in violation of this <U>Section 7.5</U> will be void <I>ab
initio</I> and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.6 <U>Benefits
of Agreement; Action by Acting Holders</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Agreement,
express or implied, will give to any Person (other than Parent, the Rights Agent, the Holders and their respective permitted successors
and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision
herein contained, all such covenants and provisions being for the sole benefit of Parent, the Rights Agent, the Holders and their permitted
successors and assigns. The Holders will have no rights hereunder except as are expressly set forth herein. Except for the rights of the
Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision
of this Agreement, to institute any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder
or other group of Holders will be entitled to exercise such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.7 <U>Governing
Law</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and the CVRs
will be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any provision of law
or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.8 <U>Jurisdiction</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In any action or proceeding
between any of the parties hereto arising out of or relating to this Agreement or any of the transactions contemplated hereby, each of
the parties hereto: (a)&#8239;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court
of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the
State of Delaware or the United States District Court for the District of Delaware, and appellate courts thereof; (b) agrees that all
claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <U>Section
7.8</U>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d) waives any objection that such
courts are an inconvenient forum or do not have jurisdiction over any Party; and (e) agrees that service of process upon such Party in
any such action or proceeding shall be effective if notice is given in accordance with <U>Section 7.1</U> or <U>Section 7.2</U> of this
Agreement; provided that nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted
by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.9 <U>WAIVER
OF JURY TRIAL</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>EACH OF THE PARTIES
HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III) EACH
PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <FONT STYLE="font-size: 10pt"><U>SECTION 7.9</U>. </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.10 <U>Severability
Clause</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that any provision
of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any reason determined to be
invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons
or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or
otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination,
the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the fullest extent possible; <I>provided</I>, <I>however</I>, that if an excluded provision shall affect the rights, immunities, liabilities,
duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written Notice to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.11 <U>Counterparts;
Effectiveness</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be signed
in any number of counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto
were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic
communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when
each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a
counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation
hereunder (whether by virtue of any oral or written agreement or any other communication).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.12 <U>Termination</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement will automatically
terminate and be of no further force or effect and, except the rights, protections and immunities of the Rights Agent under <U>Article
3</U>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation
therefor, upon the earliest to occur of (a) the expiration of the CVR Term, (b) the expiration of all payment obligations under the Disposition
Agreements or any of the agreements listed on <U>Schedule 1.1</U> or (c) the delivery of a written notice of termination duly executed
by Parent and the Acting Holders (such date, the &ldquo;<B>Termination Date</B>&rdquo;). The termination of this Agreement will not affect
or limit the right of Holders to receive the CVR Payments under <U>Section 2.4</U> to the extent earned prior to the termination of this
Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement until such CVR Payments,
if any, have been made, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.13 <U>Funds</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All funds received by Computershare
under this Agreement that are to be distributed or applied by Computershare in the performance of services hereunder (the &ldquo;<B>Funds</B>&rdquo;)
shall be held by Computershare, as agent for Parent, and deposited in one or more bank accounts to be maintained by Computershare in
its name as agent for Parent. Until paid pursuant to the terms of this Agreement, Computershare may hold or invest the Funds through
such accounts in: (a) funds backed by obligations of, or guaranteed by, the United States of America; (b) debt or commercial paper obligations
rated A-1 or P-1 or better by S&amp;P Global Inc. (&ldquo;<B>S&amp;P</B>&rdquo;) or Moody's Investors Service, Inc. (&ldquo;<B>Moody&rsquo;s</B>&rdquo;),
respectively; (c) Government and Treasury backed AAA-rated Fixed NAV money market funds that comply with Rule 2a-7 of the Investment
Company Act of 1940, as amended; or (d) short term certificates of deposit, bank repurchase agreements, and bank accounts with commercial
banks with Tier 1 capital exceeding $1 billion, or with an investment grade rating by S&amp;P (LT Local Issuer Credit Rating), Moody&rsquo;s
(Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). Computershare shall
have no responsibility or liability for any diminution of the Funds that may result from any deposit or investment made by Computershare
in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party.
Computershare may from time to time receive interest, dividends or other earnings in connection with such deposits or investments. Computershare
shall not be obligated to pay such interest, dividends or earnings to Parent, any holder or any other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.14 <U>Further
Assurance by Parent</U>.</B> Parent agrees that it will perform, execute, acknowledge and deliver or cause to be performed, executed,
acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required or requested by the
Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.15 <U>Confidentiality</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Rights Agent and Parent
agree that all books, records, information and data pertaining to the business of the other party, including inter alia, personal, non-public
CVR holder information, which are exchanged or received pursuant to the negotiation or the carrying out of this Agreement including the
Fee Schedule shall remain confidential, and shall not be voluntarily disclosed to any other person other than representatives of the Rights
Agent or Parent, except as may be required by Law, including, without limitation, pursuant to subpoenas from state or federal government
authorities (e.g., in divorce and criminal actions).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.16 <U>Force
Majeure</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding anything to the contrary contained
herein, the Rights Agent will not be liable for any delays or failures in performance resulting from acts beyond its reasonable control
including, without limitation, acts of God, epidemic, pandemic, terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions
or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information storage or retrieval
systems, labor difficulties, war, or civil unrest.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.17 <U>Construction</U>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the masculine
gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter
gender will include the masculine and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>As used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, will not be deemed
to be terms of limitation, but rather will be deemed to be followed by the words &ldquo;without limitation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement
and will not be referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Unless stated otherwise, &ldquo;Article&rdquo; and &ldquo;Section&rdquo; followed by a number or letter mean and refer to the specified
Article or Section of this Agreement. The term &ldquo;Agreement&rdquo; and any reference in this Agreement to this Agreement or any other
agreement or document includes, and is a reference to, this Agreement or such other agreement or document as it may have been, or may
from time to time be, amended, restated, replaced, supplemented or novated and includes all schedules to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m. on
the last day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. on the next Business Day if the last day
of the period is not a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless
otherwise specified. The parties hereto and Parent have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties
and Parent and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All references herein to &ldquo;$&rdquo; are to United States Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of page intentionally left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, each of the parties
has caused this Agreement to be executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">CARISMA THERAPEUTICS INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="width: 45%">&#8239;</TD></TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top">&#8239;</TD></TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top">&#8239;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Contingent Value Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, each of the parties
has caused this Agreement to be executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">COMPUTERSHARE TRUST <BR>
COMPANY, N.A. and <BR>
COMPUTERSHARE INC.,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="font-size: 10pt">&#8239;</TD></TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>On behalf of both entities</I></FONT></TD>
    </TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&#8239;</TD>
    </TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    </TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    </TR>
  <TR>
    <TD>&#8239;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Contingent
Value Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule 1.1</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Collaboration and License Agreement, dated as of January 7, 2022, by and between Carisma Therapeutics
Inc. and ModernaTX, Inc.</TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>tm2518620d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPORT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Support
Agreement</B></FONT> (this &ldquo;<B><I>Agreement</I></B>&rdquo;), is made as of [&#9679;], 2025, by and among <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>OrthoCellix,&nbsp;Inc.</B></FONT>,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Ocugen
Inc.</B></FONT>, a Delaware corporation (the &ldquo;<B><I>Guarantor</I></B>&rdquo;), <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Carisma
Therapeutics,&nbsp;Inc.</B></FONT>, a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), and the Person set forth on <U>Schedule&nbsp;A</U>
hereto (the &ldquo;<B><I>Stockholder</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, as of the
date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;),
of Parent set forth opposite the Stockholder&rsquo;s name on <U>Schedule&nbsp;A</U> (all Common Stock owned by the Stockholder, or hereafter
issued to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder prior to the termination of this Agreement,
as well as shares set forth on <U>Schedule&nbsp;A</U>, being referred to herein as the &ldquo;<B><I>Subject Shares</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, concurrently
herewith, the Company, the Guarantor, Parent and Azalea Merger Sub,&nbsp;Inc., a Delaware corporation and wholly owned subsidiary of Parent
(&ldquo;<B><I>Merger Sub</I></B>&rdquo;), have entered into an Agreement and Plan of Merger, dated as of the date hereof (as such agreement
may be amended, restated, amended and restated or otherwise modified from time to time, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;),
which provides, among other things, for the merger of Merger Sub with and into the Company, with the Company continuing as the surviving
company (the &ldquo;<B><I>Merger</I></B>&rdquo;), upon the terms and subject to the conditions set forth in the Merger Agreement (capitalized
terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, as a condition
to its willingness to enter into the Merger Agreement, the Company has required that the Stockholder, and as an inducement and in consideration
therefor, the Stockholder (in the Stockholder&rsquo;s capacity as a holder of the Subject Shares) has agreed to, enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally
bound, do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;I<BR>
VOTING AGREEMENT; GRANT OF PROXY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Stockholder hereby covenants
and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Voting
of Subject Shares</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the date hereof and prior to the Expiration Time (as defined below), at every meeting of the holders of Common Stock (the &ldquo;<B><I>Parent
Stockholders</I></B>&rdquo;), however called, and at every adjournment or postponement thereof (or pursuant to a written consent if the
Parent Stockholders act by written consent in lieu of a meeting), the Stockholder shall, or shall cause the holder of record on any applicable
record date to, be present (in person or by proxy) and to vote or cause to be voted the Subject Shares: (i)&nbsp;in favor of adopting
the Merger Agreement and approving the Merger and the other Contemplated Transactions, (ii)&nbsp;against approval of any proposal made
in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and (iii)&nbsp;against any Acquisition
Proposal or any agreement, transaction or other matter that is intended to, or would reasonably be expected to impede, interfere with,
delay, postpone or materially and adversely affect the consummation of the Merger and the transactions contemplated in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as permitted under clauses (A)&nbsp;through (J)&nbsp;of <U>Section&nbsp;1.2</U> below, the Stockholder shall retain at all times the
right to vote the Subject Shares in the Stockholder&rsquo;s sole discretion and without any other limitation on those matters other than
those set forth in this <U>Section&nbsp;1.1</U> that are at any time or from time to time presented for consideration to the Parent Stockholders.
In the event of a stock split, stock dividend or distribution, or any change in the Common Stock by reason of any split-up, reverse stock
split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &ldquo;Subject Shares&rdquo;
shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which
or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Inconsistent Arrangements</U></B>. Except as provided hereunder or under the Merger Agreement, prior to the Expiration Time, the Stockholder
shall not, directly or indirectly,&nbsp;(a)&nbsp;create any Lien other than restrictions imposed by Law or pursuant to this Agreement
on any Subject Shares; (b)&nbsp;transfer, sell, assign, gift or otherwise dispose of (collectively, &ldquo;<B><I>Transfer</I></B>&rdquo;),
or enter into any contract with respect to any Transfer of, the Subject Shares or any interest therein; (c)&nbsp;grant or permit the grant
of any proxy, power of attorney or other authorization in or with respect to the Subject Shares; (d)&nbsp;deposit or permit the deposit
of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares; or (e)&nbsp;take
any action that, to the knowledge of the Stockholder, would make any representation or warranty of the Stockholder herein untrue or incorrect
in any material respect or have the effect of preventing the Stockholder from performing the Stockholder&rsquo;s obligations hereunder.
Any action taken in violation of the foregoing sentence shall be null and void <I>ab initio</I>. Notwithstanding the foregoing, the Stockholder
may (A)&nbsp;Transfer Subject Shares as a <I>bona fide </I>charitable contribution, gift or donation; (B)&nbsp;Transfer the Subject Shares
to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder; (C)&nbsp;Transfer the Subject
Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the
immediate family of the Stockholder; (D)&nbsp;Transfer the Subject Shares to stockholders, direct or indirect affiliates (within the meaning
set forth in Rule&nbsp;405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder,
as applicable, or to the estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership,
limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder; (E)&nbsp;make
Transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement;
(F)&nbsp;make Transfers not involving a change in beneficial ownership; (G)&nbsp;if the Stockholder is a trust, Transfer the Subject Shares
to any beneficiary of the Stockholder or the estate of any such beneficiary; (H)&nbsp;exercise an option or warrant to purchase Common
Stock or settle a restricted stock unit or other equity award (including a net or cashless exercise of such option or warrant); (I)&nbsp;Transfer
Common Stock to Parent to cover tax withholding obligations of the Stockholder in connection with the vesting, settlement or exercise
of any options, warrants, restricted stock units or other equity awards, as applicable; (J)&nbsp;Transfer Common Stock with the prior
written consent of Parent; <I><U>provided</U></I> that, with respect to clauses (A)&nbsp;through (J)&nbsp;above, the transferee agrees
in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or the transferee provides Parent with
a copy of such agreement promptly upon consummation of any such Transfer; <I><U>provided further</U>,</I> that in each case, the underlying
shares of Common Stock shall continue to be subject to the restrictions on Transfer set forth in this Agreement notwithstanding that such
transferee has not executed a counterpart hereof or joinder hereto; or (K)&nbsp;Transfer Common Stock to another holder of capital stock
of Parent that has signed a support agreement in the same form as this Agreement. The Stockholder agrees that any shares of capital stock
or other equity voting securities of Parent that such Stockholder acquires or with respect to which such Stockholder otherwise acquires
sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Time (as defined below),
including, without limitation, by gift, succession, in the event of a stock split or as a dividend or distribution of any Shares (&ldquo;<B><I>New
Shares</I></B>&rdquo;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Subject
Shares. For purposes of this Agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage or adoption, not
more remote than first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Documentation
and Information</U></B>. The Stockholder shall permit and hereby authorizes the Company and Parent to publish and disclose in all documents
and schedules filed with the SEC, and any press release or other disclosure document that the Company or Parent reasonably determines
to be necessary in connection with the Merger and any of the Contemplated Transactions, the Stockholder&rsquo;s identity and ownership
of the Subject Shares and the nature of the Stockholder&rsquo;s commitments and obligations under this Agreement. The Company is an intended
third-party beneficiary of this <U>Section&nbsp;1.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Irrevocable
Proxy</U>. </B>The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted
with respect to the Subject Shares. In the event and to the extent that the Stockholder fails to vote the Subject Shares in accordance
with <U>Section&nbsp;1.1</U> at any applicable meeting of the Parent Stockholders or pursuant to any applicable written consent of the
stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent and any of its designees
with full power of substitution and resubstitution, as attorney-in-fact and proxy for and on behalf of the Stockholder, for and in the
name, place and stead of the Stockholder, to: (a)&nbsp;attend any and all meetings of the Parent Stockholders, (b)&nbsp;vote, express
consent or dissent or issue instructions to the record holder to vote the Subject Shares in accordance with the provisions of <U>Section&nbsp;1.1</U>
at any and all meetings of the Parent Stockholders or in connection with any action sought to be taken by written consent of the Parent
Stockholders without a meeting and (c)&nbsp;grant or withhold, or issue instructions to the record holder to grant or withhold, consistent
with the provisions of <U>Section&nbsp;1.1</U>, all written consents with respect to the Subject Shares at any and all meetings of the
Parent Stockholders or in connection with any action sought to be taken by written consent of the Parent Stockholders without a meeting.
Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. The foregoing
proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be affected by the death,
incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of this Agreement and shall not be terminated
by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to <U>Section&nbsp;3.2</U>.
The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to
file this proxy and any substitution or revocation with the Secretary of Parent. The Stockholder hereby affirms that the proxy set forth
in this <U>Section&nbsp;1.4</U> is given in connection with and granted in consideration of and as an inducement to Parent, Merger Sub
and the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <U>Section&nbsp;1.1</U>.
The proxy set forth in this <U>Section&nbsp;1.4</U> is executed and intended to be irrevocable, subject, however, to its automatic termination
upon the termination of this Agreement pursuant to <U>Section&nbsp;3.2</U>. With respect to any Subject Shares that are owned beneficially
by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by the Stockholder that are held
in the name of a bank, broker or nominee), the Stockholder shall take all action necessary to cause the record holder of such Subject
Shares to grant the irrevocable proxy and take all other actions provided for in this <U>Section&nbsp;1.4</U> with respect to such Subject
Shares. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate
upon the termination of this Agreement in accordance with the terms set forth in <U>Section&nbsp;3.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Ownership Interest</U></B>. Nothing contained in this Agreement will be deemed to vest in Parent any direct or indirect ownership or incidents
of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares
will remain and belong to the Stockholder, and Parent will have no authority to manage, direct, superintend, restrict, regulate, govern
or administer any of the policies or operations of Parent or exercise any power or authority to direct the Stockholder in the voting of
any of the Subject Shares, except as otherwise expressly provided herein with respect to the Subject Shares and except as otherwise expressly
provided in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Exercise of Appraisal Rights; Waivers</U></B>. In connection with the Contemplated Transactions, the Stockholder hereby irrevocably and
unconditionally (a)&nbsp;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&rsquo;
rights and any similar rights (including any notice requirements related thereto) to the extent permitted under applicable Law, relating
to the Merger that Stockholder may have by virtue of, or with respect to any Subject Shares (including all rights under Section&nbsp;262
of the Delaware General Corporation Law, a copy of which is attached hereto as Appendix I) and (b)&nbsp;agrees that the Stockholder will
not, under any circumstances in connection with the Contemplated Transactions, exercise any dissenters&rsquo; or appraisal rights in respect
of any Subject Shares, and (c)&nbsp;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute, participate
in or voluntarily aid any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Entity,
which (i)&nbsp;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii)&nbsp;alleges that
the execution and delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by the board of directors of
Parent (the &ldquo;<B><I>Parent Board</I></B>&rdquo;), breaches any fiduciary duty of the Parent Board or any member thereof; <I><U>provided</U></I>
that the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder
that relates solely to the Stockholder&rsquo;s capacity as a director, officer or securityholder of Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Solicitation of Transactions</U></B>. The Stockholder hereby agrees that, prior to the Expiration Time (as defined below), the Stockholder
shall not, directly or indirectly, including through any of its officers, directors or agents: (a)&nbsp;solicit, initiate or knowingly
encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry
or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (b)&nbsp;furnish any non-public
information regarding Parent to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (c)&nbsp;engage
in discussions (other than to inform any Person of the existence of the provisions in this <U>Section&nbsp;1.7</U>) or negotiations with
any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (d)&nbsp;approve, endorse or recommend any Acquisition Proposal;
(e)&nbsp;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction
(other than an Acceptable Confidentiality Agreement (as defined in the Merger Agreement) permitted under the Merger Agreement); or (f)&nbsp;publicly
propose to do any of the foregoing<I>. </I>The Stockholder hereby represents and warrants that the Stockholder has read Section&nbsp;6.4
(No Solicitation) of the Merger Agreement and agrees not to engage in any actions prohibited thereby. Notwithstanding the foregoing, the
Stockholder will not be responsible for the breaches by its officers, directors or agents that have otherwise entered into a separate
support agreement with Parent (in a form reasonably acceptable to the Company), unless the Stockholder knowingly and intentionally caused
such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;II<BR>
REPRESENTATIONS AND WARRANTIES OF THE Stockholder</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Stockholder represents
and warrants to Parent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Organization;
Authorization; Binding Agreement</U></B>. The Stockholder, if not a natural person, is duly incorporated or organized, as applicable,
validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has full legal
capacity and power, right and authority to (a)&nbsp;execute and deliver this Agreement and to perform the Stockholder&rsquo;s obligations
hereunder and to consummate the transactions contemplated hereby and (b)&nbsp;vote all of the Subject Shares in the manner set forth in
this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental
Entity). This Agreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid and binding
obligation of the Stockholder enforceable against the Stockholder in accordance with its terms (except to the extent that enforceability
may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&rsquo;
rights generally or by general principles of equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Ownership
of Subject Shares; Total Shares</U></B>. The Stockholder is the record or beneficial owner of the Subject Shares and has good and marketable
title to the Subject Shares free and clear of any Liens (including any restriction on the right to vote or otherwise transfer the Subject
Shares), except (a)&nbsp;as provided hereunder, (b)&nbsp;pursuant to any applicable restrictions on transfer under the Securities Act
and (c)&nbsp;as provided in the certificate of incorporation or bylaws of Parent. The Subject Shares listed on <U>Schedule&nbsp;A</U>
opposite the Stockholder&rsquo;s name constitute all of the Common Stock owned by the Stockholder as of the date hereof. Except pursuant
to Parent&rsquo;s certificate of incorporation and bylaws, no Person has any contractual or other right or obligation to purchase or otherwise
acquire any of the Subject Shares. For purposes of this Agreement &ldquo;<B><I>Beneficial Ownership</I></B>&rdquo; shall be interpreted
as defined in Rule&nbsp;13d-3 under the Exchange Act; <I><U>provided</U></I> that for purposes of determining Beneficial Ownership, a
Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person pursuant to any Contract or upon
the exercise of conversion rights, exchange rights, warrants or options, or otherwise (irrespective of whether the right to acquire such
securities is exercisable immediately or only after the passage of time, including the passage of time in excess of 60&nbsp;days, the
satisfaction of any conditions, the occurrence of any event or any combination of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Voting
Power</U></B>. The Stockholder has full voting power, with respect to the Subject Shares, and full power of disposition, full power to
issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement,
in each case, with respect to all of the Subject Shares. None of the Subject Shares are subject to any proxy, voting trust or other agreement
or arrangement with respect to the voting of the Subject Shares, except as provided hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Reliance</U></B>.
The Stockholder has had the opportunity to review the Merger Agreement, including the provisions relating to the payment and allocation
of the consideration to be paid to the Parent Stockholders, and this Agreement with counsel of the Stockholder&rsquo;s own choosing. The
Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the transactions contemplated
by the Merger Agreement. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations
made by Parent, the Company, Guarantor or any of their respective agents or representatives. The Stockholder understands that such Stockholder
(and not Parent, the Company, Guarantor or the Surviving Company) shall be responsible for such Stockholder&rsquo;s tax liability that
may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. The Stockholder understands and acknowledges
that the Company, Guarantor, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&rsquo;s execution,
delivery and performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Absence
of Litigation</U></B>. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending
against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&rsquo;s properties or
assets (including the Subject Shares) that could reasonably be expected to prevent, delay or impair the ability of the Stockholder to
perform the Stockholder&rsquo;s obligations hereunder or to consummate the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Non-Contravention</U></B>.
The execution and delivery of this Agreement by the Stockholder and the performance of the transactions contemplated by this Agreement
by the Stockholder does not and will not violate, conflict with, or result in a breach of: (a)&nbsp;the organizational documents of such
Stockholder, (b)&nbsp;any applicable Law or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental
Entity to which the Stockholder is subject, or (c)&nbsp;any Contract to which the Stockholder is a party or is bound or to which the Subject
Shares are subject, such that it could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the
Stockholder&rsquo;s obligations hereunder or to consummate the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;III<BR>
MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Notices</U></B>.
All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be
given, (a)&nbsp;if to Parent, in accordance with the provisions of the Merger Agreement and (b)&nbsp;if to the Stockholder, to the Stockholder&rsquo;s
address or electronic mail address set forth on a signature page&nbsp;hereto, or to such other address or electronic mail address as the
Stockholder may hereafter specify in writing to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Termination</U></B>.
This Agreement shall terminate automatically, without any notice or other action by any Person, upon the earlier of (a)&nbsp;the termination
of the Merger Agreement in accordance with its terms and (b)&nbsp;the Effective Time (the &ldquo;<B><I>Expiration Time</I></B>&rdquo;).
Upon termination of this Agreement, neither party shall have any further obligations or liabilities under this Agreement; <I><U>provided</U>,
<U>however</U>, </I>that (i)&nbsp;nothing set forth in this <U>Section&nbsp;3.2</U> shall relieve either party from liability for any
breach of this Agreement prior to termination hereof, and (ii)&nbsp;the provisions of this <U>Article&nbsp;III</U> shall survive any termination
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Confidentiality</U></B>.
Except to the extent required by applicable Law, the Stockholder shall hold any&nbsp;non-public&nbsp;information regarding this Agreement,
the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until Parent has
publicly disclosed its entry into the Merger Agreement and this Agreement;&nbsp;<I><U>provided</U></I>,&nbsp;<I><U>however</U></I>, that
the Stockholder may disclose such information (a)&nbsp;to its attorneys, accountants, consultants, trustees, beneficiaries and other representatives
(<I><U>provided</U></I>&nbsp;such representatives are subject to confidentiality obligations at least as restrictive as those contained
herein), and (b)&nbsp;to any Affiliate, partner, member, stockholder, parent or subsidiary of the Stockholder,&nbsp;<I><U>provided</U></I>&nbsp;in
each case that the Stockholder informs the Person receiving the information that such information is confidential and such Person agrees
in writing to abide by the terms of this&nbsp;<U>Section&nbsp;3.3</U>. Neither the Stockholder nor any of its Affiliates (other than Parent,
whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement
with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the
prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party
shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Amendments
and Waivers</U></B>. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed,
in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be
effective. No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof
nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Binding
Effect; Benefit; Assignment</U></B>. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and assigns. Except as set forth in <U>Section&nbsp;1.3</U> and <U>Section&nbsp;3.3</U>, no provision
of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any Person other than
the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights
or obligations under this Agreement without the consent of the other party hereto, except that Parent may transfer or assign its rights
and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; <I><U>provided</U></I>
that such transfer or assignment shall not relieve Parent of any of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Governing
Law; Jurisdiction</U></B>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the
parties hereto arising out of or relating to this Agreement, each party hereto: (a)&nbsp;irrevocably and unconditionally consents and
submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not
have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the
foregoing courts has jurisdiction, the Superior Court of the State of Delaware (the &ldquo;<B><I>Delaware Courts</I></B>&rdquo;); (b)&nbsp;agrees
that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&nbsp;of
this <U>Section&nbsp;3.6</U>; (c)&nbsp;waives any objection to laying venue in any such action or proceeding in such courts; (d)&nbsp;waives
any objection that such courts are an inconvenient forum or do not have jurisdiction over any party hereto; (e)&nbsp;agrees that service
of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section&nbsp;3.1</U>
of this Agreement; and (f)&nbsp;irrevocably and unconditionally waives the right to trial by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Counterparts</U></B>.
This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one
and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic
transmission in .PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Entire
Agreement</U></B>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written
and oral, among or between any of the parties with respect to the subject matter hereof and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Severability</U></B>.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or
provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination will have the
power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision
that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and
this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the
prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term
or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term
or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Specific
Performance</U></B>. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of
any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude
the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms
and provisions hereof in any Delaware Court, this being in addition to any other remedy to which they are entitled at law or in equity,
and each of the parties hereto waives any bond, surety or other security that might be required of any other party with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Construction</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter
gender shall include masculine and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
parties hereto agree that any rule&nbsp;of construction to the effect that ambiguities are to be resolved against the drafting party shall
not be applied in the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise indicated, all references in this Agreement to &ldquo;Sections,&rdquo; &ldquo;Articles,&rdquo; and &ldquo;Schedules&rdquo;
are intended to refer to Sections or Articles of this Agreement and Schedules to this Agreement, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Further
Assurances</U></B>. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents
and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be
done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Capacity
as Stockholder</U></B>. The Stockholder is entering into this Agreement solely in the Stockholder&rsquo;s capacity as a holder of Common
Stock, and not in the Stockholder&rsquo;s capacity as a director, officer or employee of Parent or in the Stockholder&rsquo;s capacity
as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to the contrary, nothing herein shall
in any way restrict a director or officer of Parent in the exercise of his or her fiduciary duties as a director or officer of Parent
or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation
on the part of any director or officer of Parent or any trustee or fiduciary of any employee benefit plan or trust from taking any action
in his or her capacity as such director, officer, trustee or fiduciary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Agreement Until Executed</U></B>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement
shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and
until (a)&nbsp;the Parent Board has approved, for purposes of any applicable anti-takeover laws and regulations, and any applicable provision
of Parent&rsquo;s organizational documents, the Merger, (b)&nbsp;the Merger Agreement is executed by all parties thereto, and (c)&nbsp;this
Agreement is executed by all parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(SIGNATURE PAGE FOLLOWS)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="text-transform: uppercase">Carisma
    Therapeutics,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-transform: uppercase; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase; font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="text-transform: uppercase">OrthoCellix,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-transform: uppercase; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">Ocugen Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">STOCKHOLDER</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Print Name of Stockholder)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Signature)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Name and Title of Signatory, if Signing on Behalf of an Entity)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Address for Notices:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Email:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Name
    of Stockholder</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><P STYLE="border-bottom: Black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No.&nbsp;Shares &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&bull;]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&bull;]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Appendix I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&sect; 262. Appraisal
rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&nbsp;Any stockholder of a corporation of this State who holds shares
of stock on the date of the making of a demand pursuant to subsection (d)&nbsp;of this section with respect to such shares, who continuously
holds such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, who has
otherwise complied with subsection (d)&nbsp;of this section and who has neither voted in favor of the merger, consolidation, conversion,
transfer, domestication or continuance nor consented thereto in writing pursuant to &sect; 228 of this title shall be entitled to an appraisal
by the Court of Chancery of the fair value of the stockholder&rsquo;s shares of stock under the circumstances described in subsections
(b)&nbsp;and (c)&nbsp;of this section. As used in this section, the word &ldquo;stockholder&rdquo; means a holder of record of stock in
a corporation; the words &ldquo;stock&rdquo; and &ldquo;share&rdquo; mean and include what is ordinarily meant by those words; the words
 &ldquo;depository receipt&rdquo; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares,
or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &ldquo;beneficial owner&rdquo;
mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and
the word &ldquo;person&rdquo; means any individual, corporation, partnership, unincorporated association or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&nbsp;Appraisal rights shall be available for the shares of any
class or series of stock of a constituent, converting, transferring, domesticating or continuing corporation in a merger, consolidation,
conversion, transfer, domestication or continuance to be effected pursuant to &sect; 251 (other than a merger effected pursuant to &sect;
251(g)&nbsp;of this title), &sect; 252, &sect; 254, &sect; 255, &sect; 256, &sect; 257, &sect; 258, &sect; 263, &sect; 264, &sect; 266
or &sect; 390 of this title (other than, in each case and solely with respect to a converted or domesticated corporation, a merger, consolidation,
conversion, transfer, domestication or continuance authorized pursuant to and in accordance with the provisions of &sect; 265 or &sect;
388 of this title):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;Provided, however, that no appraisal rights under this section
shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record
date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine
the stockholders entitled to consent pursuant to &sect; 228 of this title, to act upon the agreement of merger or consolidation or the
resolution providing for the conversion, transfer, domestication or continuance (or, in the case of a merger pursuant to &sect; 251(h)&nbsp;of
this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&nbsp;listed on a national securities
exchange or (ii)&nbsp;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for
any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders
of the surviving corporation as provided in &sect; 251(f)&nbsp;of this title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&nbsp;Notwithstanding paragraph (b)(1)&nbsp;of this section, appraisal
rights under this section shall be available for the shares of any class or series of stock of a constituent, converting, transferring,
domesticating or continuing corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or
by the terms of a resolution providing for conversion, transfer, domestication or continuance, pursuant to &sect; 251, &sect; 252, &sect;
254, &sect; 255, &sect; 256, &sect; 257, &sect; 258, &sect; 263, &sect; 264, &sect; 266 or &sect; 390 of this title to accept for such
stock anything except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a. Shares of stock of the corporation surviving or resulting from such
merger or consolidation, or of the converted entity or the entity resulting from a transfer, domestication or continuance if such entity
is a corporation as a result of the conversion, transfer, domestication or continuance, or depository receipts in respect thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b. Shares of stock of any other corporation, or depository receipts
in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of
the merger, consolidation, conversion, transfer, domestication or continuance will be either listed on a national securities exchange
or held of record by more than 2,000 holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c. Cash in lieu of fractional shares or fractional depository receipts
described in the foregoing paragraphs (b)(2)a. and b. of this section; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">d. Any combination of the shares of stock, depository receipts and
cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this
section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&nbsp;In the event all of the stock of a subsidiary Delaware corporation
party to a merger effected under &sect; 253 or &sect; 267 of this title is not owned by the parent immediately prior to the merger, appraisal
rights shall be available for the shares of the subsidiary Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4)&nbsp;[Repealed.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(c)&nbsp;Any corporation may provide in its certificate of incorporation
that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment
to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all
or substantially all of the assets of the corporation or a conversion effected pursuant to &sect; 266 of this title or a transfer, domestication
or continuance effected pursuant to &sect; 390 of this title. If the certificate of incorporation contains such a provision, the provisions
of this section, including those set forth in subsections (d), (e), and (g)&nbsp;of this section, shall apply as nearly as is practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;Appraisal rights shall be perfected as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;If a proposed merger, consolidation, conversion, transfer,
domestication or continuance for which appraisal rights are provided under this section is to be submitted for approval at a meeting of
stockholders, the corporation, not less than 20 days prior to the meeting, shall notify each of its stockholders who was such on the record
date for notice of such meeting (or such members who received notice in accordance with &sect; 255(c)&nbsp;of this title) with respect
to shares for which appraisal rights are available pursuant to subsection (b)&nbsp;or (c)&nbsp;of this section that appraisal rights are
available for any or all of the shares of the constituent corporations or the converting, transferring, domesticating or continuing corporation,
and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation
is a nonstock corporation, a copy of &sect; 114 of this title) or information directing the stockholders to a publicly available electronic
resource at which this section (and, &sect; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder
electing to demand the appraisal of such stockholder&rsquo;s shares shall deliver to the corporation, before the taking of the vote on
the merger, consolidation, conversion, transfer, domestication or continuance, a written demand for appraisal of such stockholder&rsquo;s
shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing
system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation
of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&rsquo;s shares.
A proxy or vote against the merger, consolidation, conversion, transfer, domestication or continuance shall not constitute such a demand.
A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10 days after the effective
date of such merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or converted entity shall
notify each stockholder of each constituent or converting, transferring, domesticating or continuing corporation who has complied with
this subsection and has not voted in favor of or consented to the merger, consolidation, conversion, transfer, domestication or continuance,
and any beneficial owner who has demanded appraisal under paragraph (d)(3)&nbsp;of this section, of the date that the merger, consolidation
or conversion has become effective; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&nbsp;If the merger, consolidation, conversion, transfer, domestication
or continuance was approved pursuant to &sect; 228, &sect; 251(h), &sect; 253, or &sect; 267 of this title, then either a constituent,
converting, transferring, domesticating or continuing corporation before the effective date of the merger, consolidation, conversion,
transfer, domestication or continuance, or the surviving, resulting or converted entity within 10 days after such effective date, shall
notify each stockholder of any class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation
who is entitled to appraisal rights of the approval of the merger, consolidation, conversion, transfer, domestication or continuance and
that appraisal rights are available for any or all shares of such class or series of stock of such constituent, converting, transferring,
domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent
corporations or the converting, transferring, domesticating or continuing corporation is a nonstock corporation, a copy of &sect; 114
of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &sect;
114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective
date of the merger, consolidation, conversion, transfer, domestication or continuance, shall, also notify such stockholders of the effective
date of the merger, consolidation, conversion, transfer, domestication or continuance. Any stockholder entitled to appraisal rights may,
within 20 days after the date of giving such notice or, in the case of a merger approved pursuant to &sect; 251(h)&nbsp;of this title,
within the later of the consummation of the offer contemplated by &sect; 251(h)&nbsp;of this title and 20 days after the date of giving
such notice, demand in writing from the surviving, resulting or converted entity the appraisal of such holder&rsquo;s shares; provided
that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly
designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the
stockholder and that the stockholder intends thereby to demand the appraisal of such holder&rsquo;s shares. If such notice did not notify
stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, either (i)&nbsp;each
such constituent corporation or the converting, transferring, domesticating or continuing corporation shall send a second notice before
the effective date of the merger, consolidation, conversion, transfer, domestication or continuance notifying each of the holders of any
class or series of stock of such constituent, converting, transferring, domesticating or continuing corporation that are entitled to appraisal
rights of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance or (ii)&nbsp;the surviving,
resulting or converted entity shall send such a second notice to all such holders on or within 10 days after such effective date; provided,
however, that if such second notice is sent more than 20 days following the sending of the first notice or, in the case of a merger approved
pursuant to &sect; 251(h)&nbsp;of this title, later than the later of the consummation of the offer contemplated by &sect; 251(h)&nbsp;of
this title and 20 days following the sending of the first notice, such second notice need only be sent to each stockholder who is entitled
to appraisal rights and who has demanded appraisal of such holder&rsquo;s shares in accordance with this subsection and any beneficial
owner who has demanded appraisal under paragraph (d)(3)&nbsp;of this section. An affidavit of the secretary or assistant secretary or
of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the
absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive
either notice, each constituent corporation or the converting, transferring, domesticating or continuing corporation may fix, in advance,
a record date that shall be not more than 10 days prior to the date the notice is given, provided, that if the notice is given on or after
the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the record date shall be such effective
date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on
the day next preceding the day on which the notice is given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&nbsp;Notwithstanding subsection (a)&nbsp;of this section (but subject
to this paragraph (d)(3)), a beneficial owner may, in such person&rsquo;s name, demand in writing an appraisal of such beneficial owner&rsquo;s
shares in accordance with either paragraph (d)(1)&nbsp;or (2)&nbsp;of this section, as applicable; provided that (i)&nbsp;such beneficial
owner continuously owns such shares through the effective date of the merger, consolidation, conversion, transfer, domestication or continuance
and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&nbsp;of this section and
(ii)&nbsp;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made,
is accompanied by documentary evidence of such beneficial owner&rsquo;s beneficial ownership of stock and a statement that such documentary
evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive
notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection
(f)&nbsp;of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(e)&nbsp;Within 120 days after the effective date of the merger, consolidation,
conversion, transfer, domestication or continuance, the surviving, resulting or converted entity, or any person who has complied with
subsections (a)&nbsp;and (d)&nbsp;of this section and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding
by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding
the foregoing, at any time within 60 days after the effective date of the merger, consolidation, conversion, transfer, domestication or
continuance, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named
party shall have the right to withdraw such person&rsquo;s demand for appraisal and to accept the terms offered upon the merger, consolidation,
conversion, transfer, domestication or continuance. Within 120 days after the effective date of the merger, consolidation, conversion,
transfer, domestication or continuance, any person who has complied with the requirements of subsections (a)&nbsp;and (d)&nbsp;of this
section, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly
designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity
a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation, conversion, transfer, domestication
or continuance (or, in the case of a merger approved pursuant to &sect; 251(h)&nbsp;of this title, the aggregate number of shares (other
than any excluded stock (as defined in &sect; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted
for purchase or exchange in, the offer referred to in &sect; 251(h)(2)&nbsp;of this title)), and, in either case, with respect to which
demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided
that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&nbsp;of this section, the record holder of such shares shall
not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to
the person within 10 days after such person&rsquo;s request for such a statement is received by the surviving, resulting or converted
entity or within 10 days after expiration of the period for delivery of demands for appraisal under subsection (d)&nbsp;of this section,
whichever is later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(f)&nbsp;Upon the filing of any such petition by any person other than
the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20 days after
such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names
and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have
not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be
accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place
fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons
shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court,
and the costs thereof shall be borne by the surviving, resulting or converted entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(g)&nbsp;At the hearing on such petition, the Court shall determine
the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who
have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the
Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction,
the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation, conversion, transfer, domestication
or continuance the shares of the class or series of stock of the constituent, converting, transferring, domesticating or continuing corporation
as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to
all holders of such shares who are otherwise entitled to appraisal rights unless (1)&nbsp;the total number of shares entitled to appraisal
exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&nbsp;the value of the consideration provided in
the merger, consolidation, conversion, transfer, domestication or continuance for such total number of shares exceeds $1 million, or (3)&nbsp;the
merger was approved pursuant to &sect; 253 or &sect; 267 of this title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(h)&nbsp;After the Court determines the persons entitled to an appraisal,
the appraisal proceeding shall be conducted in accordance with the rules&nbsp;of the Court of Chancery, including any rules&nbsp;specifically
governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element
of value arising from the accomplishment or expectation of the merger, consolidation, conversion, transfer, domestication or continuance,
together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court
shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except
as provided in this subsection, interest from the effective date of the merger, consolidation, conversion, transfer, domestication or
continuance through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve
discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation
or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting
or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as
provided herein only upon the sum of (1)&nbsp;the difference, if any, between the amount so paid and the fair value of the shares as determined
by the Court, and (2)&nbsp;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted
entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the
appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by
the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this section may participate fully in all proceedings
until it is finally determined that such person is not entitled to appraisal rights under this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i)&nbsp;The Court shall direct the payment of the fair value of the
shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall
be so made to each such person upon such terms and conditions as the Court may order. The Court&rsquo;s decree may be enforced as other
decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or
of any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(j)&nbsp;The costs of the proceeding may be determined by the Court
and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list
filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this section who participated in the proceeding
and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable
attorney&rsquo;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an
appraisal not dismissed pursuant to subsection (k)&nbsp;of this section or subject to such an award pursuant to a reservation of jurisdiction
under subsection (k)&nbsp;of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(k)&nbsp;Subject to the remainder of this subsection, from and after
the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, no person who has demanded appraisal
rights with respect to some or all of such person&rsquo;s shares as provided in subsection (d)&nbsp;of this section shall be entitled
to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other
distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation, conversion,
transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with this section shall deliver
to the surviving, resulting or converted entity a written withdrawal of such person&rsquo;s demand for an appraisal in respect of some
or all of such person&rsquo;s shares in accordance with subsection (e)&nbsp;of this section, either within 60 days after such effective
date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of the shares subject to
the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall not be dismissed as
to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including
without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&nbsp;of this section; provided,
however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding
as a named party to withdraw such person&rsquo;s demand for appraisal and to accept the terms offered upon the merger, consolidation,
conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation, conversion, transfer,
domestication or continuance, as set forth in subsection (e)&nbsp;of this section. If a petition for an appraisal is not filed within
the time provided in subsection (e)&nbsp;of this section, the right to appraisal with respect to all shares shall cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<I>l</I>)&nbsp;The shares or other equity interests of the surviving,
resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but
for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or
other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no
longer entitled to appraisal pursuant to this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>tm2518620d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUPPORT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Support
Agreement</B></FONT> (this &ldquo;<B><I>Agreement</I></B>&rdquo;), is made as of [&#9679;], 2025, by and among <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Orthocellix,&nbsp;Inc.</B></FONT><FONT STYLE="text-transform: uppercase">,</FONT>
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), <FONT STYLE="font-variant: small-caps"><B>Ocugen, inc.</B></FONT>,
a Delaware corporation (the &ldquo;<B><I>Guarantor</I></B>&rdquo;), <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Carisma
Therapeutics Inc.</B></FONT>, a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), and the Person set forth on <U>Schedule&nbsp;A</U>
hereto (the &ldquo;<B><I>Stockholder</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, as of the
date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.00001 per share (&ldquo;<B><I>Common
Stock</I></B>&rdquo;), of the Company set forth opposite the Stockholder&rsquo;s name on <U>Schedule&nbsp;A</U> (all Company Common Stock
owned by the Stockholder, or hereafter issued to or otherwise acquired, whether beneficially or of record, or owned by the Stockholder
prior to the termination of this Agreement, as well as shares set forth on <U>Schedule&nbsp;A</U>, being referred to herein as the &ldquo;<B><I>Subject
Shares</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, concurrently
herewith, the Company, the Guarantor, Parent and <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Azalea Merger Sub,&nbsp;Inc.</B></FONT>,
a Delaware corporation and wholly owned subsidiary of Parent (&ldquo;<B><I>Merger Sub</I></B>&rdquo;), have entered into an Agreement
and Plan of Merger, dated as of the date hereof (as such agreement may be amended, restated, amended and restated or otherwise modified
from time to time, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;), which provides, among other things, for the merger of Merger Sub
with and into the Company, with the Company continuing as the surviving company (the &ldquo;<B><I>Merger</I></B>&rdquo;), upon the terms
and subject to the conditions set forth in the Merger Agreement (capitalized terms used but not otherwise defined herein shall have the
respective meanings ascribed to such terms in the Merger Agreement); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, as a condition
to its willingness to enter into the Merger Agreement, Parent has required that the Stockholder, and as an inducement and in consideration
therefor, the Stockholder (in the Stockholder&rsquo;s capacity as a holder of the Subject Shares) has agreed to, enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in
consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally
bound, do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;I<BR>
VOTING AGREEMENT; GRANT OF PROXY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Stockholder hereby covenants
and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Voting
of Subject Shares</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the date hereof and prior to the Expiration Time (as defined below), at every meeting of the holders of Company Common Stock
(the &ldquo;<B><I>Company Stockholders</I></B>&rdquo;), however called, and at every adjournment or postponement thereof (or pursuant
to a written consent if the Company Stockholders act by written consent in lieu of a meeting), the Stockholder shall, or shall cause the
holder of record on any applicable record date to, be present (in person or by proxy) and to vote or cause to be voted the Subject Shares:
(i)&nbsp;in favor of adopting the Merger Agreement and approving the Merger and the other Contemplated Transactions, (ii)&nbsp;against
approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and (iii)&nbsp;against
any Acquisition Proposal or any agreement, transaction or other matter that is intended to, or would reasonably be expected to impede,
interfere with, delay, postpone or materially and adversely affect the consummation of the Merger and the transactions contemplated in
the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
furtherance of subsection (a), promptly following the declaration of effectiveness of the Registration Statement, but in any case within
twenty-four (24) hours thereafter, take any action reasonably necessary to cause the Subject Shares held by such Stockholder to be voted
in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as permitted under clauses (A)&nbsp;through (J)&nbsp;of <U>Section&nbsp;1.2</U> below, the Stockholder shall retain at all times the right
to vote the Subject Shares in the Stockholder&rsquo;s sole discretion and without any other limitation on those matters other than those
set forth in this <U>Section&nbsp;1.1</U> that are at any time or from time to time presented for consideration to the Company Stockholders.
In the event of a stock split, stock dividend or distribution, or any change in the Common Stock by reason of any split-up, reverse stock
split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &ldquo;Subject Shares&rdquo;
shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which
or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Inconsistent Arrangements</U></B>. Except as provided hereunder or under the Merger Agreement, prior to the Expiration Time, the Stockholder
shall not, directly or indirectly,&nbsp;(a)&nbsp;create any Lien other than restrictions imposed by Law or pursuant to this Agreement
on any Subject Shares; (b)&nbsp;transfer, sell, assign, gift or otherwise dispose of (collectively, &ldquo;<B><I>Transfer</I></B>&rdquo;),
or enter into any contract with respect to any Transfer of, the Subject Shares or any interest therein; (c)&nbsp;grant or permit the grant
of any proxy, power of attorney or other authorization in or with respect to the Subject Shares; (d)&nbsp;deposit or permit the deposit
of the Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to the Subject Shares; or (e)&nbsp;take
any action that, to the knowledge of the Stockholder, would make any representation or warranty of the Stockholder herein untrue or incorrect
in any material respect or have the effect of preventing the Stockholder from performing the Stockholder&rsquo;s obligations hereunder.
Any action taken in violation of the foregoing sentence shall be null and void <I>ab initio</I>. Notwithstanding the foregoing, the Stockholder
may (A)&nbsp;Transfer Subject Shares as a <I>bona fide </I>charitable contribution, gift or donation; (B)&nbsp;Transfer the Subject Shares
to any trust for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder; (C)&nbsp;Transfer the Subject
Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the
immediate family of the Stockholder; (D)&nbsp;Transfer the Subject Shares to stockholders, direct or indirect affiliates (within the meaning
set forth in Rule&nbsp;405 under the Securities Act), current or former partners (general or limited), members or managers of the Stockholder,
as applicable, or to the estates of any such stockholders, affiliates, partners, members or managers, or to another corporation, partnership,
limited liability company or other business entity that controls, is controlled by or is under common control with the Stockholder; (E)&nbsp;make
Transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement;
(F)&nbsp;make Transfers not involving a change in beneficial ownership; (G)&nbsp;if the Stockholder is a trust, Transfer the Subject Shares
to any beneficiary of the Stockholder or the estate of any such beneficiary; (H)&nbsp;exercise an option or warrant to purchase Company
Common Stock or settle a restricted stock unit or other equity award (including a net or cashless exercise of such option or warrant);
(I)&nbsp;Transfer Company Common Stock to the Company to cover tax withholding obligations of the Stockholder in connection with the vesting,
settlement or exercise of any options, warrants, restricted stock units or other equity awards, as applicable; (J)&nbsp;Transfer Company
Common Stock with the prior written consent of Parent; <I><U>provided</U></I> that, with respect to clauses (A)&nbsp;through (J)&nbsp;above,
the transferee agrees in writing to be bound by the terms and conditions of this Agreement and either the Stockholder or the transferee
provides Parent with a copy of such agreement promptly upon consummation of any such Transfer; <I><U>provided further</U>,</I> that in
each case, the underlying shares of Company Common Stock shall continue to be subject to the restrictions on Transfer set forth in this
Agreement notwithstanding that such transferee has not executed a counterpart hereof or joinder hereto; or (K)&nbsp;Transfer Company Common
Stock to another holder of capital stock of the Company that has signed a support agreement in the same form as this Agreement. The Stockholder
agrees that any shares of capital stock or other equity voting securities of the Company that such Stockholder acquires or with respect
to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and
prior to the Expiration Time (as defined below), including, without limitation, by gift, succession, in the event of a stock split or
as a dividend or distribution of any Shares (&ldquo;<B><I>New Shares</I></B>&rdquo;), shall be subject to the terms and conditions of
this Agreement to the same extent as if they constituted the Subject Shares. For purposes of this Agreement, &ldquo;immediate family&rdquo;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Documentation
and Information</U></B>. The Stockholder shall permit and hereby authorizes the Company and Parent to publish and disclose in all documents
and schedules filed with the SEC, and any press release or other disclosure document that the Company or Parent reasonably determines
to be necessary in connection with the Merger and any of the Contemplated Transactions, the Stockholder&rsquo;s identity and ownership
of the Subject Shares and the nature of the Stockholder&rsquo;s commitments and obligations under this Agreement. The Company is an intended
third-party beneficiary of this <U>Section&nbsp;1.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Irrevocable
Proxy</U>. </B>The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted
with respect to the Subject Shares. In the event and to the extent that the Stockholder fails to vote the Subject Shares in accordance
with <U>Section&nbsp;1.1</U> at any applicable meeting of the Company Stockholders or pursuant to any applicable written consent of the
stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent and any of its designees
with full power of substitution and resubstitution, as attorney-in-fact and proxy for and on behalf of the Stockholder, for and in the
name, place and stead of the Stockholder, to: (a)&nbsp;attend any and all meetings of the Company Stockholders, (b)&nbsp;vote, express
consent or dissent or issue instructions to the record holder to vote the Subject Shares in accordance with the provisions of <U>Section&nbsp;1.1</U>
at any and all meetings of the Company Stockholders or in connection with any action sought to be taken by written consent of the Company
Stockholders without a meeting and (c)&nbsp;grant or withhold, or issue instructions to the record holder to grant or withhold, consistent
with the provisions of <U>Section&nbsp;1.1</U>, all written consents with respect to the Subject Shares at any and all meetings of the
Company Stockholders or in connection with any action sought to be taken by written consent of the Company Stockholders without a meeting.
Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. The foregoing
proxy shall be deemed to be a proxy coupled with an interest, is irrevocable (and as such shall survive and not be affected by the death,
incapacity, mental illness or insanity of the Stockholder, as applicable) until the termination of this Agreement and shall not be terminated
by operation of law or upon the occurrence of any other event other than the termination of this Agreement pursuant to <U>Section&nbsp;3.2</U>.
The Stockholder authorizes such attorney and proxy to substitute any other Person to act hereunder, to revoke any substitution and to
file this proxy and any substitution or revocation with the Secretary of the Company. The Stockholder hereby affirms that the proxy set
forth in this <U>Section&nbsp;1.4</U> is given in connection with and granted in consideration of and as an inducement to Parent, Merger
Sub and the Company to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under
<U>Section&nbsp;1.1</U>. The proxy set forth in this <U>Section&nbsp;1.4</U> is executed and intended to be irrevocable, subject, however,
to its automatic termination upon the termination of this Agreement pursuant to <U>Section&nbsp;3.2</U>. With respect to any Subject Shares
that are owned beneficially by the Stockholder but are not held of record by the Stockholder (other than shares beneficially owned by
the Stockholder that are held in the name of a bank, broker or nominee), the Stockholder shall take all action necessary to cause the
record holder of such Subject Shares to grant the irrevocable proxy and take all other actions provided for in this <U>Section&nbsp;1.4</U>
with respect to such Subject Shares. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall
automatically terminate upon the termination of this Agreement in accordance with the terms set forth in <U>Section&nbsp;3.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Ownership Interest</U></B>. Nothing contained in this Agreement will be deemed to vest in Parent any direct or indirect ownership or incidents
of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to the Subject Shares
will remain and belong to the Stockholder, and Parent will have no authority to manage, direct, superintend, restrict, regulate, govern
or administer any of the policies or operations of the Company or exercise any power or authority to direct the Stockholder in the voting
of any of the Subject Shares, except as otherwise expressly provided herein with respect to the Subject Shares and except as otherwise
expressly provided in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Exercise of Appraisal Rights; Waivers</U></B>. In connection with the Contemplated Transactions, the Stockholder hereby irrevocably and
unconditionally (a)&nbsp;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&rsquo;
rights and any similar rights (including any notice requirements related thereto) to the extent permitted under applicable Law, relating
to the Merger that Stockholder may have by virtue of, or with respect to any Subject Shares (including all rights under Section&nbsp;262
of the Delaware General Corporation Law, a copy of which is attached hereto as Appendix I) and (b)&nbsp;agrees that the Stockholder will
not, under any circumstances in connection with the Contemplated Transactions, exercise any dissenters&rsquo; or appraisal rights in respect
of any Subject Shares, and (c)&nbsp;agrees that the Stockholder will not bring, commence, institute, maintain, prosecute, participate
in or voluntarily aid any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Entity,
which (i)&nbsp;challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii)&nbsp;alleges that
the execution and delivery of this Agreement by the Stockholder, or the approval of the Merger Agreement by the board of directors of
the Company (the &ldquo;<B><I>Company Board</I></B>&rdquo;), breaches any fiduciary duty of the Company Board or any member thereof; <I><U>provided</U></I>
that the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder
that relates solely to the Stockholder&rsquo;s capacity as a director, officer or securityholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Solicitation of Transactions</U></B>. The Stockholder hereby agrees that, prior to the Expiration Time (as defined below), the Stockholder
shall not, directly or indirectly, including through any of its officers, directors or agents: (a)&nbsp;solicit, initiate or knowingly
encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry
or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (b)&nbsp;furnish any non-public
information regarding the Company to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry; (c)&nbsp;engage
in discussions (other than to inform any Person of the existence of the provisions in this <U>Section&nbsp;1.7</U>) or negotiations with
any Person with respect to any Acquisition Proposal or Acquisition Inquiry; (d)&nbsp;approve, endorse or recommend any Acquisition Proposal;
(e)&nbsp;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction
(other than an Acceptable Confidentiality Agreement (as defined in the Merger Agreement) permitted under the Merger Agreement); or (f)&nbsp;publicly
propose to do any of the foregoing<I>. </I>The Stockholder hereby represents and warrants that the Stockholder has read Section&nbsp;6.4
(No Solicitation) of the Merger Agreement and agrees not to engage in any actions prohibited thereby. Notwithstanding the foregoing, the
Stockholder will not be responsible for the breaches by its officers, directors or agents that have otherwise entered into a separate
support agreement with the Company (in a form reasonably acceptable to Parent), unless the Stockholder knowingly and intentionally caused
such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;II<BR>
REPRESENTATIONS AND WARRANTIES OF THE Stockholder</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Stockholder represents
and warrants to Parent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Organization;
Authorization; Binding Agreement</U></B>. The Stockholder, if not a natural person, is duly incorporated or organized, as applicable,
validly existing and in good standing under the laws of its jurisdiction of incorporation or organization. The Stockholder has full legal
capacity and power, right and authority to (a)&nbsp;execute and deliver this Agreement and to perform the Stockholder&rsquo;s obligations
hereunder and to consummate the transactions contemplated hereby and (b)&nbsp;vote all of the Subject Shares in the manner set forth in
this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental
Entity). This Agreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid and binding
obligation of the Stockholder enforceable against the Stockholder in accordance with its terms (except to the extent that enforceability
may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the enforcement of creditors&rsquo;
rights generally or by general principles of equity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Ownership
of Subject Shares; Total Shares</U></B>. The Stockholder is the record or beneficial owner of the Subject Shares and has good and marketable
title to the Subject Shares free and clear of any Liens (including any restriction on the right to vote or otherwise transfer the Subject
Shares), except (a)&nbsp;as provided hereunder, (b)&nbsp;pursuant to any applicable restrictions on transfer under the Securities Act
and (c)&nbsp;as provided in the certificate of incorporation or bylaws of the Company. The Subject Shares listed on <U>Schedule&nbsp;A</U>
opposite the Stockholder&rsquo;s name constitute all of the Company Common Stock owned by the Stockholder as of the date hereof. Except
pursuant to the Company&rsquo;s certificate of incorporation and bylaws, no Person has any contractual or other right or obligation to
purchase or otherwise acquire any of the Subject Shares. For purposes of this Agreement &ldquo;<B><I>Beneficial Ownership</I></B>&rdquo;
shall be interpreted as defined in Rule&nbsp;13d-3 under the Exchange Act; <I><U>provided</U></I> that for purposes of determining Beneficial
Ownership, a Person shall be deemed to be the Beneficial Owner of any securities that may be acquired by such Person pursuant to any Contract
or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise (irrespective of whether the right to acquire
such securities is exercisable immediately or only after the passage of time, including the passage of time in excess of 60&nbsp;days,
the satisfaction of any conditions, the occurrence of any event or any combination of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Voting
Power</U></B>. The Stockholder has full voting power, with respect to the Subject Shares, and full power of disposition, full power to
issue instructions with respect to the matters set forth herein and full power to agree to all of the matters set forth in this Agreement,
in each case, with respect to all of the Subject Shares. None of the Subject Shares are subject to any proxy, voting trust or other agreement
or arrangement with respect to the voting of the Subject Shares, except as provided hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Reliance</U></B>.
The Stockholder has had the opportunity to review the Merger Agreement, including the provisions relating to the payment and allocation
of the consideration to be paid to the Company Stockholders, and this Agreement with counsel of the Stockholder&rsquo;s own choosing.
The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the transactions contemplated
by the Merger Agreement. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations
made by Parent, the Company, Guarantor or any of their respective agents or representatives. The Stockholder understands that such Stockholder
(and not Parent, the Company, Guarantor or the Surviving Company) shall be responsible for such Stockholder&rsquo;s tax liability that
may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. The Stockholder understands and acknowledges
that the Company, Guarantor, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&rsquo;s execution,
delivery and performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Absence
of Litigation</U></B>. With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending
against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&rsquo;s properties or
assets (including the Subject Shares) that could reasonably be expected to prevent, delay or impair the ability of the Stockholder to
perform the Stockholder&rsquo;s obligations hereunder or to consummate the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Non-Contravention</U></B>.
The execution and delivery of this Agreement by the Stockholder and the performance of the transactions contemplated by this Agreement
by the Stockholder does not and will not violate, conflict with, or result in a breach of: (a)&nbsp;the organizational documents of such
Stockholder, (b)&nbsp;any applicable Law or any injunction, judgment, order, decree, ruling, charge, or other restriction of any Governmental
Entity to which the Stockholder is subject, or (c)&nbsp;any Contract to which the Stockholder is a party or is bound or to which the Subject
Shares are subject, such that it could reasonably be expected to prevent, delay or impair the ability of the Stockholder to perform the
Stockholder&rsquo;s obligations hereunder or to consummate the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;III<BR>
MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Notices</U></B>.
All notices, requests and other communications to either party hereunder shall be in writing (including electronic mail) and shall be
given, (a)&nbsp;if to Parent, in accordance with the provisions of the Merger Agreement and (b)&nbsp;if to the Stockholder, to the Stockholder&rsquo;s
address or electronic mail address set forth on a signature page&nbsp;hereto, or to such other address or electronic mail address as the
Stockholder may hereafter specify in writing to Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Termination</U></B>.
This Agreement shall terminate automatically, without any notice or other action by any Person, upon the earlier of (a)&nbsp;the termination
of the Merger Agreement in accordance with its terms and (b)&nbsp;the Effective Time (the &ldquo;<B><I>Expiration Time</I></B>&rdquo;).
Upon termination of this Agreement, neither party shall have any further obligations or liabilities under this Agreement; <I><U>provided</U>,
<U>however</U>, </I>that (i)&nbsp;nothing set forth in this <U>Section&nbsp;3.2</U> shall relieve either party from liability for any
breach of this Agreement prior to termination hereof, and (ii)&nbsp;the provisions of this <U>Article&nbsp;III</U> shall survive any termination
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Confidentiality</U></B>.
Except to the extent required by applicable Law, the Stockholder shall hold any&nbsp;non-public&nbsp;information regarding this Agreement,
the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until Parent has
publicly disclosed its entry into the Merger Agreement and this Agreement;&nbsp;<I><U>provided</U></I>,&nbsp;<I><U>however</U></I>, that
the Stockholder may disclose such information (a)&nbsp;to its attorneys, accountants, consultants, trustees, beneficiaries and other representatives
(<I><U>provided</U></I>&nbsp;such representatives are subject to confidentiality obligations at least as restrictive as those contained
herein), and (b)&nbsp;to any Affiliate, partner, member, stockholder, parent or subsidiary of the Stockholder,&nbsp;<I><U>provided</U></I>&nbsp;in
each case that the Stockholder informs the Person receiving the information that such information is confidential and such Person agrees
in writing to abide by the terms of this&nbsp;<U>Section&nbsp;3.3</U>. Neither the Stockholder nor any of its Affiliates (other than the
Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other
public announcement with respect to this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or
thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance
such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Amendments
and Waivers</U></B>. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing and is signed,
in the case of an amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom the waiver is to be
effective. No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof
nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Binding
Effect; Benefit; Assignment</U></B>. The provisions of this Agreement shall be binding upon and shall inure to the benefit of the parties
hereto and their respective successors and assigns. Except as set forth in <U>Section&nbsp;1.3</U> and <U>Section&nbsp;3.3</U>, no provision
of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any Person other than
the parties hereto and their respective successors and assigns. Neither party may assign, delegate or otherwise transfer any of its rights
or obligations under this Agreement without the consent of the other party hereto, except that Parent may transfer or assign its rights
and obligations under this Agreement, in whole or from time to time in part, to one or more of its Affiliates at any time; <I><U>provided</U></I>
that such transfer or assignment shall not relieve Parent of any of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Governing
Law; Jurisdiction</U></B>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the
parties hereto arising out of or relating to this Agreement, each party hereto: (a)&nbsp;irrevocably and unconditionally consents and
submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not
have subject matter jurisdiction, the United States District Court for the District of Delaware or, to the extent that neither of the
foregoing courts has jurisdiction, the Superior Court of the State of Delaware (the &ldquo;<B><I>Delaware Courts</I></B>&rdquo;); (b)&nbsp;agrees
that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a)&nbsp;of
this <U>Section&nbsp;3.6</U>; (c)&nbsp;waives any objection to laying venue in any such action or proceeding in such courts; (d)&nbsp;waives
any objection that such courts are an inconvenient forum or do not have jurisdiction over any party hereto; (e)&nbsp;agrees that service
of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section&nbsp;3.1</U>
of this Agreement; and (f)&nbsp;irrevocably and unconditionally waives the right to trial by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Counterparts</U></B>.
This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one
and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic
transmission in .PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Entire
Agreement</U></B>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written
and oral, among or between any of the parties with respect to the subject matter hereof and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Severability</U></B>.
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or
provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination will have the
power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision
that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and
this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the
prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term
or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term
or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Specific
Performance</U></B>. Any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of
any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude
the exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms
and provisions hereof in any Delaware Court, this being in addition to any other remedy to which they are entitled at law or in equity,
and each of the parties hereto waives any bond, surety or other security that might be required of any other party with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Construction</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the masculine
gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter
gender shall include masculine and feminine genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
parties hereto agree that any rule&nbsp;of construction to the effect that ambiguities are to be resolved against the drafting party shall
not be applied in the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As
used in this Agreement, the words &ldquo;include&rdquo; and &ldquo;including,&rdquo; and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words &ldquo;without limitation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise indicated, all references in this Agreement to &ldquo;Sections,&rdquo; &ldquo;Articles,&rdquo; and &ldquo;Schedules&rdquo;
are intended to refer to Sections or Articles of this Agreement and Schedules to this Agreement, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;&#8239;&#8239;(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement
and shall not be referred to in connection with the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Further
Assurances</U></B>. Each of the parties hereto will execute and deliver, or cause to be executed and delivered, all further documents
and instruments and use their respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be
done, all things necessary under applicable Law to perform their respective obligations as expressly set forth under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>Capacity
as Stockholder</U></B>. The Stockholder is entering into this Agreement solely in the Stockholder&rsquo;s capacity as a holder of Company
Common Stock, and not in the Stockholder&rsquo;s capacity as a director, officer or employee of the Company or in the Stockholder&rsquo;s
capacity as a trustee or fiduciary of any employee benefit plan or trust. Notwithstanding anything herein to the contrary, nothing herein
shall in any way restrict a director or officer of the Company in the exercise of his or her fiduciary duties as a director or officer
of the Company or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to
create any obligation on the part of any director or officer of the Company or any trustee or fiduciary of any employee benefit plan or
trust from taking any action in his or her capacity as such director, officer, trustee or fiduciary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><U>No
Agreement Until Executed</U></B>. Irrespective of negotiations among the parties or the exchanging of drafts of this Agreement, this Agreement
shall not constitute or be deemed to evidence a contract, agreement, arrangement or understanding between the parties hereto unless and
until (a)&nbsp;the Company Board has approved, for purposes of any applicable anti-takeover laws and regulations, and any applicable provision
of the Company&rsquo;s organizational documents, the Merger, (b)&nbsp;the Merger Agreement is executed by all parties thereto, and (c)&nbsp;this
Agreement is executed by all parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(SIGNATURE PAGE FOLLOWS)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-transform: uppercase; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase; font: small-caps bold 10pt Times New Roman, Times, Serif">Carisma Therapeutics Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-transform: uppercase; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase; font: small-caps bold 10pt Times New Roman, Times, Serif">Orthocellix,&nbsp;Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-transform: uppercase; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase; font: small-caps bold 10pt Times New Roman, Times, Serif">Ocugen,&nbsp;Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be duly executed as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">STOCKHOLDER</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Print Name of Stockholder)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Signature)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">(Name and Title of Signatory, if Signing on Behalf of an Entity)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Address for Notices:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Email:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Support Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Name
    of Stockholder</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid"><U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No.&nbsp;Shares&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</U></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&bull;]</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&bull;]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Appendix I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&sect; 262. Appraisal
rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(a)&nbsp;Any stockholder
of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&nbsp;of this
section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, conversion,
transfer, domestication or continuance, who has otherwise complied with subsection (d)&nbsp;of this section and who has neither voted
in favor of the merger, consolidation, conversion, transfer, domestication or continuance nor consented thereto in writing pursuant to
 &sect; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&rsquo;s shares
of stock under the circumstances described in subsections (b)&nbsp;and (c)&nbsp;of this section. As used in this section, the word &ldquo;stockholder&rdquo;
means a holder of record of stock in a corporation; the words &ldquo;stock&rdquo; and &ldquo;share&rdquo; mean and include what is ordinarily
meant by those words; the words &ldquo;depository receipt&rdquo; mean a receipt or other instrument issued by a depository representing
an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository;
the words &ldquo;beneficial owner&rdquo; mean a person who is the beneficial owner of shares of stock held either in voting trust or by
a nominee on behalf of such person; and the word &ldquo;person&rdquo; means any individual, corporation, partnership, unincorporated association
or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(b)&nbsp;Appraisal rights
shall be available for the shares of any class or series of stock of a constituent, converting, transferring, domesticating or continuing
corporation in a merger, consolidation, conversion, transfer, domestication or continuance to be effected pursuant to &sect; 251 (other
than a merger effected pursuant to &sect; 251(g)&nbsp;of this title), &sect; 252, &sect; 254, &sect; 255, &sect; 256, &sect; 257, &sect;
258, &sect; 263, &sect; 264, &sect; 266 or &sect; 390 of this title (other than, in each case and solely with respect to a converted or
domesticated corporation, a merger, consolidation, conversion, transfer, domestication or continuance authorized pursuant to and in accordance
with the provisions of &sect; 265 or &sect; 388 of this title):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(1)&nbsp;Provided,
however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or
depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting
of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &sect; 228 of this title, to
act upon the agreement of merger or consolidation or the resolution providing for the conversion, transfer, domestication or continuance
(or, in the case of a merger pursuant to &sect; 251(h)&nbsp;of this title, as of immediately prior to the execution of the agreement of
merger), were either: (i)&nbsp;listed on a national securities exchange or (ii)&nbsp;held of record by more than 2,000 holders; and further
provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the
merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &sect; 251(f)&nbsp;of
this title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(2)&nbsp;Notwithstanding
paragraph (b)(1)&nbsp;of this section, appraisal rights under this section shall be available for the shares of any class or series of
stock of a constituent, converting, transferring, domesticating or continuing corporation if the holders thereof are required by the terms
of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, transfer, domestication or continuance,
pursuant to &sect; 251, &sect; 252, &sect; 254, &sect; 255, &sect; 256, &sect; 257, &sect; 258, &sect; 263, &sect; 264, &sect; 266 or
 &sect; 390 of this title to accept for such stock anything except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">a. Shares of
stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity or the entity resulting
from a transfer, domestication or continuance if such entity is a corporation as a result of the conversion, transfer, domestication or
continuance, or depository receipts in respect thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">b. Shares of
stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof)
or depository receipts at the effective date of the merger, consolidation, conversion, transfer, domestication or continuance will be
either listed on a national securities exchange or held of record by more than 2,000 holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">c. Cash in lieu
of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white">d. Any combination
of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing
paragraphs (b)(2)a., b. and c. of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(3)&nbsp;In
the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &sect; 253 or &sect; 267 of this title
is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware
corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(4)&nbsp;[Repealed.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(c)&nbsp;Any corporation
may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class
or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation
is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant
to &sect; 266 of this title or a transfer, domestication or continuance effected pursuant to &sect; 390 of this title. If the certificate
of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&nbsp;of
this section, shall apply as nearly as is practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(d)&nbsp;Appraisal rights
shall be perfected as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(1)&nbsp;If
a proposed merger, consolidation, conversion, transfer, domestication or continuance for which appraisal rights are provided under this
section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20 days prior to the meeting, shall
notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance
with &sect; 255(c)&nbsp;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&nbsp;or
(c)&nbsp;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting,
transferring, domesticating or continuing corporation, and shall include in such notice either a copy of this section (and, if 1 of the
constituent corporations or the converting corporation is a nonstock corporation, a copy of &sect; 114 of this title) or information directing
the stockholders to a publicly available electronic resource at which this section (and, &sect; 114 of this title, if applicable) may
be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&rsquo;s shares shall deliver
to the corporation, before the taking of the vote on the merger, consolidation, conversion, transfer, domestication or continuance, a
written demand for appraisal of such stockholder&rsquo;s shares; provided that a demand may be delivered to the corporation by electronic
transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand
will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby
to demand the appraisal of such stockholder&rsquo;s shares. A proxy or vote against the merger, consolidation, conversion, transfer, domestication
or continuance shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand
as herein provided. Within 10 days after the effective date of such merger, consolidation, conversion, transfer, domestication or continuance,
the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting, transferring, domesticating
or continuing corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation,
conversion, transfer, domestication or continuance, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&nbsp;of
this section, of the date that the merger, consolidation or conversion has become effective; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(2)&nbsp;If
the merger, consolidation, conversion, transfer, domestication or continuance was approved pursuant to &sect; 228, &sect; 251(h), &sect;
253, or &sect; 267 of this title, then either a constituent, converting, transferring, domesticating or continuing corporation before
the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, or the surviving, resulting or converted
entity within 10 days after such effective date, shall notify each stockholder of any class or series of stock of such constituent, converting,
transferring, domesticating or continuing corporation who is entitled to appraisal rights of the approval of the merger, consolidation,
conversion, transfer, domestication or continuance and that appraisal rights are available for any or all shares of such class or series
of stock of such constituent, converting, transferring, domesticating or continuing corporation, and shall include in such notice either
a copy of this section (and, if 1 of the constituent corporations or the converting, transferring, domesticating or continuing corporation
is a nonstock corporation, a copy of &sect; 114 of this title) or information directing the stockholders to a publicly available electronic
resource at which this section (and &sect; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice
may, and, if given on or after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, shall,
also notify such stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication or continuance.
Any stockholder entitled to appraisal rights may, within 20 days after the date of giving such notice or, in the case of a merger approved
pursuant to &sect; 251(h)&nbsp;of this title, within the later of the consummation of the offer contemplated by &sect; 251(h)&nbsp;of
this title and 20 days after the date of giving such notice, demand in writing from the surviving, resulting or converted entity the appraisal
of such holder&rsquo;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information
processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs
such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&rsquo;s
shares. If such notice did not notify stockholders of the effective date of the merger, consolidation, conversion, transfer, domestication
or continuance, either (i)&nbsp;each such constituent corporation or the converting, transferring, domesticating or continuing corporation
shall send a second notice before the effective date of the merger, consolidation, conversion, transfer, domestication or continuance
notifying each of the holders of any class or series of stock of such constituent, converting, transferring, domesticating or continuing
corporation that are entitled to appraisal rights of the effective date of the merger, consolidation, conversion, transfer, domestication
or continuance or (ii)&nbsp;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within
10 days after such effective date; provided, however, that if such second notice is sent more than 20 days following the sending of the
first notice or, in the case of a merger approved pursuant to &sect; 251(h)&nbsp;of this title, later than the later of the consummation
of the offer contemplated by &sect; 251(h)&nbsp;of this title and 20 days following the sending of the first notice, such second notice
need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&rsquo;s shares
in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&nbsp;of this section. An
affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either
notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes
of determining the stockholders entitled to receive either notice, each constituent corporation or the converting, transferring, domesticating
or continuing corporation may fix, in advance, a record date that shall be not more than 10 days prior to the date the notice is given,
provided, that if the notice is given on or after the effective date of the merger, consolidation, conversion, transfer, domestication
or continuance, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective
date, the record date shall be the close of business on the day next preceding the day on which the notice is given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">(3)&nbsp;Notwithstanding
subsection (a)&nbsp;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&rsquo;s name, demand
in writing an appraisal of such beneficial owner&rsquo;s shares in accordance with either paragraph (d)(1)&nbsp;or (2)&nbsp;of this section,
as applicable; provided that (i)&nbsp;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation,
conversion, transfer, domestication or continuance and otherwise satisfies the requirements applicable to a stockholder under the first
sentence of subsection (a)&nbsp;of this section and (ii)&nbsp;the demand made by such beneficial owner reasonably identifies the holder
of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&rsquo;s beneficial
ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an
address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and
to be set forth on the verified list required by subsection (f)&nbsp;of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(e)&nbsp;Within 120 days
after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, the surviving, resulting or
converted entity, or any person who has complied with subsections (a)&nbsp;and (d)&nbsp;of this section and who is otherwise entitled
to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the
value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60 days after the effective date of the
merger, consolidation, conversion, transfer, domestication or continuance, any person entitled to appraisal rights who has not commenced
an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&rsquo;s demand for appraisal
and to accept the terms offered upon the merger, consolidation, conversion, transfer, domestication or continuance. Within 120 days after
the effective date of the merger, consolidation, conversion, transfer, domestication or continuance, any person who has complied with
the requirements of subsections (a)&nbsp;and (d)&nbsp;of this section, upon request given in writing (or by electronic transmission directed
to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive
from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger,
consolidation, conversion, transfer, domestication or continuance (or, in the case of a merger approved pursuant to &sect; 251(h)&nbsp;of
this title, the aggregate number of shares (other than any excluded stock (as defined in &sect; 251(h)(6)d. of this title)) that were
the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &sect; 251(h)(2)&nbsp;of
this title)), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders
or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&nbsp;of
this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such
aggregate number). Such statement shall be given to the person within 10 days after such person&rsquo;s request for such a statement is
received by the surviving, resulting or converted entity or within 10 days after expiration of the period for delivery of demands for
appraisal under subsection (d)&nbsp;of this section, whichever is later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(f)&nbsp;Upon the filing
of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon
such entity, which shall within 20 days after such service file in the office of the Register in Chancery in which the petition was filed
a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements
as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted
entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give
notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted
entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall
be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(g)&nbsp;At the hearing
on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal
rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates
to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and
if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the
merger, consolidation, conversion, transfer, domestication or continuance the shares of the class or series of stock of the constituent,
converting, transferring, domesticating or continuing corporation as to which appraisal rights are available were listed on a national
securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal
rights unless (1)&nbsp;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible
for appraisal, (2)&nbsp;the value of the consideration provided in the merger, consolidation, conversion, transfer, domestication or continuance
for such total number of shares exceeds $1 million, or (3)&nbsp;the merger was approved pursuant to &sect; 253 or &sect; 267 of this title.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(h)&nbsp;After the Court
determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules&nbsp;of the
Court of Chancery, including any rules&nbsp;specifically governing appraisal proceedings. Through such proceeding the Court shall determine
the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation,
conversion, transfer, domestication or continuance, together with interest, if any, to be paid upon the amount determined to be the fair
value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines
otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation,
conversion, transfer, domestication or continuance through the date of payment of the judgment shall be compounded quarterly and shall
accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between
the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of
judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash,
in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&nbsp;the difference, if any, between the amount
so paid and the fair value of the shares as determined by the Court, and (2)&nbsp;interest theretofore accrued, unless paid at that time.
Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding,
the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal.
Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this
section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under
this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(i)&nbsp;The Court shall
direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to
the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The
Court&rsquo;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted
entity be an entity of this State or of any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(j)&nbsp;The costs of
the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application
of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&nbsp;of this
section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such
expenses, including, without limitation, reasonable attorney&rsquo;s fees and the fees and expenses of experts, to be charged pro rata
against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&nbsp;of this section or subject
to such an award pursuant to a reservation of jurisdiction under subsection (k)&nbsp;of this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(k)&nbsp;Subject to the
remainder of this subsection, from and after the effective date of the merger, consolidation, conversion, transfer, domestication or continuance,
no person who has demanded appraisal rights with respect to some or all of such person&rsquo;s shares as provided in subsection (d)&nbsp;of
this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares
(except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger,
consolidation, conversion, transfer, domestication or continuance). If a person who has made a demand for an appraisal in accordance with
this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&rsquo;s demand for an appraisal
in respect of some or all of such person&rsquo;s shares in accordance with subsection (e)&nbsp;of this section, either within 60 days
after such effective date or thereafter with the written approval of the corporation, then the right of such person to an appraisal of
the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, an appraisal proceeding in the Court of Chancery shall
not be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court
deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&nbsp;of
this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding
or joined that proceeding as a named party to withdraw such person&rsquo;s demand for appraisal and to accept the terms offered upon the
merger, consolidation, conversion, transfer, domestication or continuance within 60 days after the effective date of the merger, consolidation,
conversion, transfer, domestication or continuance, as set forth in subsection (e)&nbsp;of this section. If a petition for an appraisal
is not filed within the time provided in subsection (e)&nbsp;of this section, the right to appraisal with respect to all shares shall
cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(l)&nbsp;The shares or
other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section
would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but
not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person
that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: lightgrey"></FONT></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: lightgrey"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>tm2518620d1_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[&#9679;</B>]<B>, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned (the &ldquo;<B><I>Stockholder</I></B>&rdquo;)
understands that: (i)&nbsp;<FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Carisma therapeutics Inc.</B></FONT><FONT STYLE="text-transform: uppercase">,</FONT>
a Delaware corporation (&ldquo;<B><I>Parent</I></B>&rdquo;), has entered into an Agreement and Plan of Merger, dated as of [&#9679;],
2025 (as such agreement may be amended, restated, amended and restated or otherwise modified from time to time, the &ldquo;<B><I>Merger
Agreement</I></B>&rdquo;), with <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Orthocellix,&nbsp;Inc.</B></FONT>,
a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Ocugen,&nbsp;Inc.</B></FONT>,
a Delaware corporation (the &ldquo;<B><I>Guarantor</I></B>&rdquo;), and <FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>Azalea
Merger Sub,&nbsp;Inc.</B></FONT><FONT STYLE="text-transform: uppercase">,</FONT> a Delaware corporation and wholly owned subsidiary of
Parent (&ldquo;<B><I>Merger Sub</I></B>&rdquo;), pursuant to which, at the effective time (the &ldquo;<B><I>Effective Time</I></B>&rdquo;),
Merger Sub will be merged with and into the Company (the &ldquo;<B><I>Merger</I></B>&rdquo;) and the separate corporate existence of
Merger Sub will cease and the Company will continue as the surviving corporation; and (ii)&nbsp;in connection with the Merger, the stockholders
of the Company will receive shares of common stock, par value $0.001 per share, of Parent (&ldquo;<B><I>Parent Common Stock</I></B>&rdquo;).
Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a condition and inducement
to the willingness of each of the parties to enter into the Merger Agreement and to consummate the Contemplated Transactions, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Stockholder hereby agrees that
the Stockholder will not, subject to the exceptions set forth in this letter agreement, during the period commencing upon the date hereof
and ending on the date that is 180 days after the Effective Time (the &ldquo;<B><I>Restricted Period</I></B>&rdquo;), (a)&nbsp;offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock received
by the Stockholder in connection with the Contemplated Transactions or any securities of Parent received by the Stockholder in connection
with the Contemplated Transactions that are convertible into or exercisable or exchangeable for Parent Common Stock, including without
limitation, Parent Common Stock or such other securities which may be deemed to be beneficially owned by the Stockholder in accordance
with the rules&nbsp;and regulations of the U.S. Securities and Exchange Commission and securities of Parent which may be issued upon exercise
of a stock option or warrant or settlement of a restricted stock unit or other equity award (collectively, &ldquo;<B><I>Shares</I></B>&rdquo;),
(b)&nbsp;enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of the Shares, regardless of whether any such transaction described in clause (a)&nbsp;or (b)&nbsp;above is to be settled
by delivery of Parent Common Stock or such other securities, in cash or otherwise, or (c)&nbsp;make any demand for or exercise any right
with respect to the registration of any Shares, in each case other than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)&nbsp;transfers of Shares
as <I>bona fide </I>charitable contributions, gifts or donations as such term is described in Section&nbsp;501(c)(3)&nbsp;of the Internal
Revenue Code of 1986, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)&nbsp;if the Stockholder
is a natural person, transfers or dispositions of Shares to (A)&nbsp;any person related to the Stockholder by blood or adoption who is
an immediate family member of the Stockholder, or by marriage or domestic partnership, or to a trust formed for the benefit of the Stockholder
or any of the Stockholder&rsquo;s immediate family, (B)&nbsp;to the Stockholder&rsquo;s estate, following the death of the Stockholder,
by will, intestacy or other operation of Law, (C)&nbsp;by operation of law, such as pursuant to a qualified domestic order or in connection
with a divorce settlement, or (D)&nbsp;to any corporation, partnership or other entity, in each case, all of the beneficial ownership
interests of which are held by the Stockholder or an immediate family member of the Stockholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)&nbsp;if the Stockholder
is a corporation, partnership or other entity, (A)&nbsp;to another corporation, partnership, or other entity that is a direct or indirect
affiliate (as defined under Rule&nbsp;12b-2 of the Exchange Act) of the Stockholder, including investment funds or other entities under
common control or management with the Stockholder (including, for the avoidance of doubt, where the Stockholder is a partnership, to its
general partner or a successor partnership or fund, or any other funds managed by such partnership), (B)&nbsp;as a distribution or dividend
to equity holders, current or former partners, members, stockholders or managers (or to the estates of any of the foregoing), as applicable,
of the Stockholder (including upon the liquidation and dissolution of the Stockholder pursuant to a plan of liquidation approved by the
Stockholder&rsquo;s equity holders), (C)&nbsp;transfers or dispositions not involving a change in beneficial ownership or (D)&nbsp;with
prior written consent of Parent (as constituted following the Closing);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iv)&nbsp;transfers or dispositions
of Shares by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the
immediate family of the Stockholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(v)&nbsp;transfers of Shares
to stockholders, direct or indirect affiliates (within the meaning set forth in Rule&nbsp;405 under the Securities Act), current or former
partners (general or limited), members or managers of the Stockholder, as applicable, or to the estates of any such stockholders, affiliates,
partners, members or managers, or to another corporation, partnership, limited liability company or other business entity that controls,
is controlled by or is under common control with the Stockholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(vi)&nbsp;transfers that
occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(vii)&nbsp;transfers or dispositions
not involving a change in beneficial ownership;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(viii)&nbsp;if the Stockholder
is a trust, transfers or dispositions to any beneficiary of the Stockholder or the estate of any such beneficiary; <I><U>provided</U></I>
that, in the case of any transfer or distribution of this clause (viii)&nbsp;such transfer is not for value and each donee, heir, beneficiary
or other transferee or distributee shall sign and deliver to Parent a lock up agreement in the form of this letter agreement with respect
to the shares of Parent Common Stock or such other securities that have been transferred or distributed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ix)&nbsp;transfers pursuant
to a bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of the Parent&rsquo;s
capital stock involving a change of control of the Parent, <I><U>provided</U></I> that in the event that such tender offer, merger, consolidation
or other such transaction is not completed, the Shares shall remain subject to the restrictions contained in this letter agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(x)&nbsp;any sales in open
market transactions (including, without limitation, the establishment of a 10b5-1 Plan (as defined below) and any sales pursuant to such
10b5-1 Plan) during the Restricted Period to generate such amount of net proceeds to the Stockholder from such sales (after deducting
commissions) in an aggregate amount up to the total amount of taxes or estimated taxes (as applicable) that become due as a result of
the vesting and/or settlement of restricted stock units held by the Stockholder that are scheduled to vest and/or settle immediately prior
to or during the Restricted Period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(xi)&nbsp;transfers pursuant
to an order of a court or regulatory agency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(xii)&nbsp;transfers, distributions,
sales or other transactions with the prior written consent of Parent (as constituted following the Closing); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(xiii)&nbsp;transfers, distributions,
sales or other transactions of Parent Common Stock, if any, issued in connection with the Concurrent Investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or (d)&nbsp;publicly disclose the intention to
do any of the foregoing described in clauses (a), (b)&nbsp;and (c)&nbsp;above; <I><U>provided</U></I>, that in each case of clauses (i)-(viii),
(1)&nbsp;other than with respect to clause (v), no filing by any party (including any donor, donee, transferor or transferee, distributor
or distributee) under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with
such transfer or distribution (other than filings made in respect of involuntary transfers or dispositions or a filing on a Form&nbsp;5
made after the expiration of the Restricted Period), (2)&nbsp;other than with respect to clause (v), any such transfer or distribution
shall not involve a disposition for value, and (3)&nbsp;the transferee or donee agrees in writing to be bound by the terms and conditions
of this letter agreement and either the Stockholder or the transferee or donee provides Parent with a copy of such agreement promptly
upon consummation of any such transfer; <I><U>provided further</U></I>, that in the case of clause (x), filings under Section&nbsp;16(a)&nbsp;of
the Exchange Act shall only be permissible if such filing clearly indicates in the footnotes thereto that the filing relates to securities
being sold to generate net proceeds up to the total amount of taxes or estimated taxes (as applicable) that become due as a result of
the vesting and/or settlement of Parent equity awards. For purposes of this letter agreement, &ldquo;immediate family&rdquo; shall mean
any relationship by blood, marriage or adoption, not more remote than first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding the restrictions
imposed by this letter agreement, the Stockholder may (a)&nbsp;exercise an option or warrant to purchase Shares or settle a restricted
stock unit or other equity award (including a net or cashless exercise of such option or warrant <I><U>provided</U></I> the Shares are
transferred to Parent and not sold on the open market) and <I><U>provided further</U></I>, that the underlying Shares shall continue to
be subject to the restrictions on transfer set forth in this letter agreement, (b)&nbsp;transfer Shares to Parent to cover tax withholding
obligations of the Stockholder in connection with the vesting, settlement or exercise of such options, warrants, restricted stock units
or other equity awards, as applicable, (c)&nbsp;establish a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act (&ldquo;<B><I>10b5-1
Plan</I></B>&rdquo;) for the transfer of Shares, <I><U>provided</U></I> that such plan does not provide for any transfers of Shares during
the Restricted Period (except as provided in clause (ix)&nbsp;above) and, <I><U>provided further,</U></I> that, no filing under the Exchange
Act or other public announcement shall be made voluntarily in connection with the establishment of such a plan (except if the Stockholder
is a director or officer of Parent, for disclosure required under Item 408 to Regulation S-K), (d)&nbsp;transfer Shares to Parent pursuant
to arrangements under which Parent has the option to repurchase such Shares, or (e)&nbsp;transfer or dispose of Shares acquired on the
open market following the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any attempted transfer in
violation of this letter agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual
or constructive knowledge of the transfer restrictions set forth in this letter agreement, and will not be recorded on the stock transfer
books of Parent. In order to ensure compliance with the restrictions referred to herein, the Stockholder agrees that Parent may issue
appropriate &ldquo;stop transfer&rdquo; certificates or instructions. Parent may cause the legend set forth below, or a legend substantially
equivalent thereto, to be placed upon any certificate(s)&nbsp;or other documents or instruments evidencing ownership of the Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE SUBJECT TO AND MAY&nbsp;ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE
OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Stockholder hereby represents
and warrants that the Stockholder has full power and authority to enter into this letter agreement. All authority conferred or agreed
to be conferred and any obligations of the Stockholder under this letter agreement will be binding upon the successors, assigns, heirs
or personal representatives of the Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event that during
the Restricted Period any holder of Parent&rsquo;s securities that is subject to a substantially similar agreement entered into by such
holder, other than the Stockholder, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for
value other than as permitted by this or a substantially similar agreement entered into by such holder, the same percentage of shares
of Parent Common Stock held by the Stockholder shall be immediately and fully released on the same terms from any remaining restrictions
set forth herein (the &ldquo;<B><I>Pro-Rata Release</I></B>&rdquo;); <I><U>provided</U></I>, <I><U>however</U></I>, that such Pro-Rata
Release shall not be applied unless and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise
transfer or dispose of all or a portion of such equity holders&rsquo; shares of Parent Common Stock in an aggregate amount in excess of
1% of the number of shares of Parent Common Stock originally subject to a substantially similar agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the release of any Shares
from this letter agreement, Parent will cooperate with the Stockholder to facilitate the timely preparation and delivery of certificates
or the establishment of book entry positions at the Parent&rsquo;s transfer agent representing the Shares without the restrictive legend
above and the withdrawal of any stop transfer instructions at the Parent&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Stockholder understands
that each of Parent and the Company is relying upon this letter agreement in proceeding toward consummation of the Merger. The Stockholder
further understands that this letter agreement is irrevocable and is binding upon the Stockholder&rsquo;s heirs, legal representatives,
successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This letter agreement and
any claim, controversy or dispute arising under or related to this letter agreement shall be governed by and construed in accordance with
the laws of the State of Delaware, without regard to the conflict of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Stockholder understands
that if the Merger Agreement is terminated in accordance with its terms, or the board of directors of Parent makes a Parent Board Adverse
Recommendation Change, the Stockholder will be released from all obligations under this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This letter agreement may
be executed by electronic (i.e., PDF) transmission, which is deemed an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Print Name of Stockholder:</P></TD>
  <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>Signature (for individuals):</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>Signature (for entities):</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[<FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to Lock-up Agreement</FONT>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>tm2518620d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Carisma Therapeutics and OrthoCellix Enter into
Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary
of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused
on orthopedic diseases</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>OrthoCellix is developing the Phase 3-ready NeoCart&reg; as an autologous
cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PHILADELPHIA, PA and MALVERN, PA. June 23, 2025 (Globe Newswire) --
Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq:
OCGN) (Ocugen), a clinical-stage company developing regenerative cell therapies for orthopedic diseases, today jointly announced that
they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus
on the development of OrthoCellix&rsquo;s NeoCart&reg; technology for the treatment of knee articular cartilage defects and plans to initiate
a U.S. Food and Drug Administration (FDA)-endorsed Phase 3 clinical trial for NeoCart&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We believe merging OrthoCellix with Carisma will allow us to
create a publicly-traded company focused on the development of NeoCart&reg; and provide value for both Ocugen and Carisma stockholders
while unlocking true market potential of NeoCart&reg;,&rdquo; said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder
of Ocugen. &ldquo;We believe NeoCart&reg; has tremendous potential to deliver a truly transformative approach to cartilage repair, and
we&rsquo;ve established OrthoCellix with dedicated resources to bring this revolutionary technology to the patients who desperately need
it.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Carisma evaluated a range of strategic alternatives, and we
believe this proposed transaction represents an opportunity to deliver significant value to our stockholders,&rdquo; said Steven Kelly,
President and Chief Executive Officer, of Carisma. &ldquo;OrthoCellix is strongly positioned with its NeoCart&reg; platform, a dedication
to developing regenerative cell therapies, and a well-credentialed management team to lead the combined company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About OrthoCellix&rsquo;s NeoCart</U></B><U>&reg; <B>Portfolio</B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OrthoCellix is developing NeoCart&reg; as an autologous cartilage implant
technology utilizing patient cells to repair articular cartilage defects of the knee. The novel platform merges a fortified 3D scaffold
and patented bioprocessing technology to grow chondrocytes&mdash;the cells responsible for maintaining cartilage health&mdash;to produce
adolescent-like cartilage at the time of implant. NeoCart&reg; has the potential to accelerate healing and reduce pain by creating a similar,
functional joint surface to help patients return to normal activities and prevent complications associated with articular cartilage damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OrthoCellix anticipates launching its Phase 3 clinical trial by the
end of 2025. Previously, NeoCart&reg; received Regenerative Medicine Advanced Therapy (RMAT) designation and concurrence from the FDA
on a single, confirmatory Phase 3 clinical trial to enable submission of a Biologics License Application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About the Proposed Transactions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the merger agreement, OrthoCellix will merge
with and into a wholly-owned subsidiary of Carisma, with OrthoCellix continuing as a wholly-owned subsidiary of Carisma and the
surviving company of the Merger. Carisma will issue to the pre-merger OrthoCellix stockholder shares of Carisma common stock as
merger consideration in exchange for the cancellation of shares of capital stock of OrthoCellix. Carisma also expects to enter into
subscription agreements for a private financing with Ocugen and other select investors, which is expected to close concurrently with
the completion of the merger, to enable the combined company to complete the Phase 3 trial of NeoCart&reg; without any additional
cost or investment from Ocugen. In connection with the closing of the proposed transactions, Carisma stockholders will be issued
contingent value rights representing the right to receive certain payments from proceeds received by the combined company, if any,
related to Carisma&rsquo;s pre-transaction legacy assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the merger agreement, upon the closing of the proposed
transactions and after giving effect to the contemplated $25.0 million concurrent financing, OrthoCellix&rsquo;s stockholder and the other
participants in the concurrent financing are expected to own approximately 90% of the combined company, and existing Carisma stockholders
are expected to own approximately 10% of the combined company, each on a fully diluted basis. The percentage of the combined company that
each company&rsquo;s former stockholders will own after completion of the merger is subject to adjustment based on Carisma&rsquo;s net
cash at the closing and the proceeds from the concurrent financing, among other adjustments, in each case as described in the merger agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon the closing of the proposed transactions, &ldquo;Carisma Therapeutics
Inc.&rdquo; is expected to be renamed &ldquo;OrthoCellix, Inc.&rdquo; and trade on the Nasdaq Capital Market under the ticker symbol &lsquo;OCLX.&rsquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transaction has been unanimously approved by the board of directors
of both companies and is expected to close in the second half of 2025, subject to customary closing conditions, including approvals by
the stockholders of each company and the effectiveness of a registration statement to be filed with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) to register the shares of Carisma common stock to be issued in connection with the merger. In connection with
the companies&rsquo; entry into the merger agreement, directors and officers of Carisma and OrthoCellix&rsquo;s stockholder have executed
support agreements, pursuant to which they have agreed to vote all of their shares of capital stock in favor of the merger or the issuance
of Carisma equity in the merger, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Advisors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wilmer Cutler Pickering Hale and Dorr LLP is serving as legal counsel
to Carisma and Lucid Capital Markets, LLC is providing a fairness opinion to Carisma&rsquo;s board of directors. Chardan is serving as
M&amp;A advisor and co-placement agent to OrthoCellix and Ocugen. Lake Street Capital Markets, LLC is co-placement agent to OrthoCellix,
as a subsidiary of Ocugen, Goodwin Procter LLP is serving as legal counsel to Ocugen and OrthoCellix, and Paul Hastings LLP is serving
as legal counsel to the placement agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About OrthoCellix</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OrthoCellix is a regenerative cell therapy company dedicated to
developing a first-in-class technology platform focused on cartilage defects and other orthopedic diseases to address considerable
unmet medical needs. The lead program within OrthoCellix is NeoCart&reg; with revolutionary 3D cell therapy technology designed to
repair and restore articular cartilage defects in the knee. The Company has a pipeline of additional treatments based on its
proprietary scaffold bioreactor and adhesive. OrthoCellix will utilize the Good Manufacturing Practice facility established by
Ocugen to support OrthoCellix&rsquo;s initial development of NeoCart&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Carisma Therapeutics</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma Therapeutics is a biotechnology company pioneering macrophage
engineering to develop groundbreaking therapies for fibrosis and cancer. With a strong commitment to patient-centric innovation, Carisma
aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA.
For more information, please visit www.Carismatx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Cautionary Note on Forward- Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this communication, other than purely
historical information, may constitute &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws,
including for purposes of the &ldquo;safe harbor&rdquo; provisions under the Private Securities Litigation Reform Act of 1995,
concerning Carisma, OrthoCellix, the proposed financing and the proposed merger between Carisma and OrthoCellix (collectively, the
 &ldquo;Proposed Transactions&rdquo;) and other matters. These forward-looking statements include, but are not limited to, express or
implied statements relating to Carisma&rsquo;s and OrthoCellix&rsquo;s management teams&rsquo; expectations, hopes, beliefs,
intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and
completion of the proposed merger by and between Carisma and OrthoCellix; the Proposed Transactions and the expected effects,
perceived benefits or opportunities of the Proposed Transactions; the combined company&rsquo;s listing on Nasdaq after the closing
of the Proposed Transactions; expectations regarding the structure, timing and completion of a concurrent financing, including
investment amounts from investors, timing of closing of the Proposed Transactions, expected proceeds, expectations regarding the use
of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors
of the combined company; each company&rsquo;s and the combined company&rsquo;s expected cash position at the closing and cash runway
of the combined company following the proposed merger and any private financing; the future operations of the combined company,
including research and development activities; the nature, strategy and focus of the combined company; the development and
commercial potential and potential benefits of any product candidates of the combined company, including expectations around market
exclusivity and intellectual property protection; anticipated clinical drug development activities and related timelines, including
the expected timing for announcement of data and other clinical results; expectations regarding or plans for discovery, preclinical
studies, clinical trials and research and development programs, in particular with respect to NeoCart&reg;, and any developments or
results in connection therewith, including the target product profile of NeoCart&reg;; the anticipated timing of the commencement of
and results from those studies and trials; the sufficiency of post-transaction resources to support the advancement of
OrthoCellix&rsquo;s pipeline through certain milestones and the time period over which OrthoCellix&rsquo;s post-transaction capital
resources will be sufficient to fund its anticipated operations; the cash balance of the combined entity at closing; expectations
related to the anticipated timing of the closing of the Proposed Transactions (the &ldquo;Closing&rdquo;); the expectations
regarding the ownership structure of the combined company; the expected trading of the combined company&rsquo;s stock on Nasdaq
under the ticker symbol &ldquo;OCLX&rdquo; after the Closing; and other statements that are not historical fact. All statements
other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements
that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking statements. The words &ldquo;opportunity,&rdquo; &ldquo;potential,&rdquo; &ldquo;milestones,&rdquo;
 &ldquo;pipeline,&rdquo; &ldquo;can,&rdquo; &ldquo;goal,&rdquo; &ldquo;strategy,&rdquo; &ldquo;target,&rdquo;
 &ldquo;anticipate,&rdquo; &ldquo;achieve,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;possible,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and similar expressions
(including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these
words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current
expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future
developments and their potential effects. There can be no assurance that future developments affecting Carisma, OrthoCellix, or the
Proposed Transactions will be those that have been anticipated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements involve a number of risks and
uncertainties, some of which are beyond Carisma&rsquo;s or OrthoCellix&rsquo;s control, or other assumptions that may cause actual
results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks
and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed
Transactions are not satisfied, including the failure to timely obtain approval of the proposed reverse stock split from
Carisma&rsquo;s stockholders and the proposed merger from both Carisma&rsquo;s and OrthoCellix&rsquo;s stockholders, if at all; the
risk that the proposed concurrent financing is not completed in a timely manner, if at all; uncertainties as to the timing of the
consummation of the Proposed Transactions and the ability of each of Carisma and OrthoCellix to consummate the Proposed
Transactions; risks related to Carisma&rsquo;s continued listing on Nasdaq until closing of the Proposed Transactions and the
combined company&rsquo;s ability to remain listed following the Closing; risks related to Carisma&rsquo;s and OrthoCellix&rsquo;s
ability to correctly estimate their respective operating expenses and their respective expenses associated with the Proposed
Transactions, as applicable, pending the Closing, as well as uncertainties regarding the impact any delay in the Closing would have
on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce
the combined company&rsquo;s cash resources; risks related to the failure or delay in obtaining required approvals from any
governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or
other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or
pendency of the merger on Carisma&rsquo;s or OrthoCellix&rsquo;s business relationships, operating results and business generally;
costs related to the merger; the risk that as a result of adjustments to the exchange ratio, OrthoCellix stockholders and Carisma
stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of
Carisma&rsquo;s common stock relative to the value suggested by the exchange ratio; the uncertainties associated with
OrthoCellix&rsquo;s NeoCart&reg; portfolio, as well as risks associated with the clinical development and regulatory approval of
product candidates, including potential delays in the completion of clinical trials; risks related to the inability of the combined
company to obtain sufficient additional capital to continue to advance these product candidates; uncertainties in obtaining
successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to
realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and
difficulties involved in successfully bringing product candidates to market; the outcome of any legal proceedings that may be
instituted against Carisma, OrthoCellix or any of their respective directors or officers related to the Proposed Transactions; the
ability of Carisma and OrthoCellix to obtain, maintain, and protect their respective intellectual property rights; competitive
responses to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or expenses resulting from
the Proposed Transactions; potential adverse reactions or changes to business relationships, operating results, and business
generally, resulting from the announcement or completion of the Proposed Transactions; changes in regulatory requirements and
government incentives; risks associated with the possible failure to realize, or that it may take longer to realize than expected,
certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results,
legislative, regulatory, political and economic developments, and those uncertainties and factors; and the risk of involvement in
litigation, including securities class action litigation, that could divert the attention of the management of Carisma or the
combined company, harm the combined company&rsquo;s business and may not be sufficient for insurance coverage to cover all costs and
damages, among others. Actual results and the timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully
described in periodic filings with the SEC, including the factors described in the section titled &ldquo;Risk Factors&rdquo; in
Carisma&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2024, which was originally filed with the SEC on March
31, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K/A, which was filed with the SEC on April 29, 2025,
subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Carisma makes and will make with the SEC in
connection with the Proposed Transactions, including the Form S-4 and Proxy Statement described below under &ldquo;Additional
Information and Where to Find It&rdquo;, as well as discussions of potential risks, uncertainties, and other important factors
included in other filings by Carisma from time to time, any risk factors related to Carisma or OrthoCellix made available to you in
connection with the Proposed Transactions, as well as risk factors associated with companies, such as OrthoCellix, that operate in
the biopharma industry. Should one or more of these risks or uncertainties materialize, or should any of Carisma&rsquo;s or
OrthoCellix&rsquo;s assumptions prove incorrect, actual results may vary in material respects from those projected in these
forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the
forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak
only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither
Carisma nor OrthoCellix undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize
all of the conditions, risks and other attributes of an investment in Carisma or OrthoCellix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>No Offer or Solicitation </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This communication and the information contained herein is not
intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect
of the Proposed Transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to
purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance
or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by
means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance
with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain
facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would
constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including
without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a
national securities exchange, of any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR
DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Important Additional Information about the Proposed Transactions
Will be Filed with the SEC</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This communication relates to the proposed merger involving Carisma
and OrthoCellix and may be deemed to be solicitation material in respect of the proposed merger. In connection with the Proposed Transactions,
Carisma intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the &ldquo;Form S-4&rdquo;) that
will contain a proxy statement (the &ldquo;Proxy Statement&rdquo;) and prospectus. This communication is not a substitute for the Form
S-4, the Proxy Statement or for any other document that Carisma may file with the SEC and/or send to Carisma&rsquo;s stockholders in connection
with the proposed merger. CARISMA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY
STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS,
CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CARISMA, ORTHOCELLIX,
THE PROPOSED TRANSACTIONS AND RELATED MATTERS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors and stockholders will be able to obtain free copies of the
Form S-4, the Proxy Statement and other documents filed by Carisma with the SEC (when they become available) through the website maintained
by the SEC at <I>www.sec.gov</I>. Copies of the documents filed by Carisma with the SEC will also be available free of charge on Carisma&rsquo;s
website at <I>www.carismatx.com</I>, or by contacting Carisma&rsquo;s Investor Relations at investors@Carismatx.com. In addition, investors
and stockholders should note that Carisma communicates with investors and the public using its website at https://ir.Carismatx.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Participants in the Solicitation </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carisma, OrthoCellix, and their respective directors and certain
of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from
Carisma&rsquo;s stockholders in connection with the Proposed Transactions under the rules of the SEC. Information about
Carisma&rsquo;s directors and executive officers, including a description of their interests in Carisma, is included in
Carisma&rsquo;s most recent Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March
31, 2025, as amended by Amendment No. 1 to the Annual Report on Form 10-K, which was filed with the SEC on April 29, 2025.
Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the
directors and executive officers of OrthoCellix, and a description of their direct and indirect interests, by security holdings or
otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when
they become available. These documents can be obtained free of charge from the sources indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>carm-20250622.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayI+bOdzZR+6YkxtmB3bbm6vygmpmX8kyKH0dU2weYJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:CARM="http://carismatx.com/20250622" elementFormDefault="qualified" targetNamespace="http://carismatx.com/20250622">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://carismatx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="carm-20250622_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="carm-20250622_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>carm-20250622_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>carm-20250622_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://carismatx.com/role/Cover" xlink:href="carm-20250622.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://carismatx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 22, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 22,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Carisma Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-6422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CARM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2518620d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>carm-20250622.xsd</File>
    <File>carm-20250622_lab.xml</File>
    <File>carm-20250622_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2518620d1_8k.htm">tm2518620d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2518620d1_8k.htm": {
   "nsprefix": "CARM",
   "nsuri": "http://carismatx.com/20250622",
   "dts": {
    "schema": {
     "local": [
      "carm-20250622.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "carm-20250622_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "carm-20250622_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2518620d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://carismatx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2518620d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2518620d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-25-061397-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-061397-xbrl.zip
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ME+L"P&I+=WVC,(A.MSEJ??D;?>UIR+_<18_2% %>2+#+7 _]-I/F\%_7!(%
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ML 56#__7GK' A?]/7OG.Q9>)X\?L%B-M:R-U SB%10>&BAR_%[CL^BU;?&D
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M5A4%;MBD?",_6RB<T-H)(%7*EUF.<@'_0YU\.<'$LJ.QIJB7$C*J)D[D2K@
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M+E">ZD[-X@DW^EIRP+,%\-3AE0+NZ0X!3N@]WFR4HE\QG>/;$JIED0IXG]B
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M"9A*CYTD<<93OF;L9\67O<HZ4&WE#:0TVX=(5S3[RPHER47,&XXA9\I2:Q!
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M)&4G)G]6Q:%(QT/-'J6)LN%DLA"R5<$(>/P/;"[L[:A>M_0N WE?2&Y;ZGO
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M)7HN,"VDT-5>X],BRJ8X6M&C;>D>[9.0+MXHSWV6V^+MZ6 (4?N<J\"4EQ@
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M'^*.>B<(#<[FVR]/SX<2]C58X_#-:0?6W_ND@'1V.H!=#OOMDT&[@R\-:!$
M((#<$0!D"*)D\+@$0\_L0ZCCJ_*7"0\NCUQ;$^RE/@[G6HGU"E26N3HD><DH
M@N9[-DAK';2^@'O*Q.4PRI^,[(5*Y(@ABCY *J*>:;%$H8G]W#N\NKK: $UI
MXR*\Q&[20&3&!E9=$[_F J])'6G+X2#!U!6*D)?E6LDU9JL9\R>2ZPW8&ZY)
M*J;$+XUR S6*ZE7>EY%Q'%"5>_^_CC[FAF5497G5!YWU%60FS\OX+%,]*?51
MB'UQ;9_?;H^^.VVKTR29Q\\V-[UHPUC:YN.B$5">SJ@:UIOK;10?M?.CO)*E
M- ,VNW&24C_U-HSDHBXOSA?M-OAMDV8!3ZF:-"^!<-Y5@0H$ILC>F'=^JTB3
M5J898=M&#GYIF&-CTJ*6G _M9+E#E.10 (FI9FF--C,XRKMT8LWAB^X.(VR7
MW_0LC/F55*C64P37^J&PLYT/.]\UUFS]0*SYYOE+(LT;NEFC=[HU\ZEY< I;
M<X8Y-"Q#0*&Q:FAHGJ2TF.R;SM_*MP.GF$\Y(O"Q1-1;?%#(4:->4Z)=L.S8
MGW>@&6)*0Q_KUL*ZQ'K@Y%IR+M7R6F9V*#%KB?H[KE)@,8 I0576ELQ<1T",
M^84EH_#R,;?J>_I/Y.-A(Q^/KPMLH:UJUA;VX1J^[M^IX>N#]79]I?(+!UI,
M-NMO&/\-35Y_:4SB=%C24G@*RG<=%PR#!>%5Y,RU*7^3+]RO6HGZ!XOH(,5Y
M*87X86<[H;I4.=FM<+CY6W;<):^5PG%I V2^K(Q&]N^;1HXR;:&2%O@_M)/2
MW0%ZX5LOUEK&[LO>7PJ)$L96MFC'GD9L\F(MF;5VFGN[K8;;_,*N6_7FQC29
MW2=X6AO-_ZL XI1C0CD)E0RV!"U*.U[_:L P[RLX\RG$*_R+-<I <D5&DM9M
MNB7U^!'OG<53B*4K !0X.'<&6NT8_1!X([*NS^HW);>_.SYSM)L6M%^YUYQ?
MG9-]FS^XA\3F58\%#)%[/Q>\T^2V2%J.2TLP](>0\2%VG1D<F!.9W?7[@:J3
MU!7/$F5708;*P[P!259Y[^>R0@!XZP'0K/4S>.$OMW$3TZIN,OHQ#+M'B5ZF
M>/\2\AG.9NL!D'+K,2#EO6_<0,KE]V;]3#GX(%BS_0!8L_T8L.;>-VY@3?'6
MN/]=0G)___ZU$KQ X9?'K(?8^!]T5\P9M2[O\PQ_GE7)V[D5[Y]Y+%SI'IG.
M]C*GV$_$BGO;4H>*1='I*JVNA$4.C^\=82-B3.JRUS$8Y+K"L2]B(+V FM)^
M>MD_5@[\)__XX6[CT;W/D_R_RU"SU#OQ@(O)[NR4B5#J[KNLR6$X\Q)J*:^E
M@M,%-[N-YKKS9'WGB1)TV@U?@_I;WI)5YJ3A%9S\$F:M<HD*U.F"*NV22BJ2
MS3)4M-(QN12F+5M;<SJG1,"_4A8G6@[)@;Q3T\7+%ZX874>HRMNT]?&.'?SU
M<1A,>"-/:F7"'%[,HP.A#Y,*5KL]JK>T.+1QKX[,3E.+-N <A]D571L/2Y;E
M7MA[CJ 9PRV)H^W]$T>[]SC:?8=!'\SM+^%R;TDWE3,->J]/VL/S?G?P,V9[
MX'VI[)^S7%5.ODHE5Y)2?LT7/M37F#,6JZ>^Z-#I\KI8?MVOS(2&17 E$[G8
MB$T=?V+I5ZF*!Y#-IU@(0L,Y*9C,6$OY4"UR_V[UXD;E(J]?YW7K>PTRR>QC
MS/UMGW7/A[W.0"88=PH!8RYDGO/_+-=N!3QV&KFXVXKO;:W^FE3(Q9O;3W\K
ML3_N O5[A/3+Q3-#D=.VLUR&K1UNQIOV(,&"9_LM(.GB=@=QG^@"E@/\C1:C
M73 6;S[:6Y[G?2[<!-\=T/DV*/PW[A.M?%)"2='M3#TV 68ND]-.>7):"0"$
MRO@8\ZOV#^Q37MKXS#YV0!'_1=3$QU'V70;A 8/]GS@S .ZU>WU@]X[HCR^-
MO9=?0+E@ >\!@?NAU]@?UZ^^?FB\O?K:?C_M;KX_75SO'$_G1R]9ZVO_<_*Y
M__FO7K3W*OW#G<X6B]'O;\;^Z+5_V?WSXZL__XRV_^Q]?-MO[(6-Q9N7CM\^
M'\>G#>=I_]7;Z(\W_>!K=SN^/)]-/[T\OGSY-?CXX7)R^7WO*MQ[>?'Y[>>O
M\T_OW[/TTCU]>SWX]L[__#T>_]4>^L?SJP  <[R[.PW^;/G]\-+MGCBO+E\&
M?_E?+YI/OSN-B^W=CONGX^_O-_MO_GP]ZLV'W3\7WTY^O]CI#E]^39_NOO]T
MW3Q_.?C3._WC]]Z\^WUK%%U\_+J]W_+V_EA<C4;GI^/7OT>;_9=75^%@_OD%
MA\CF*'07^.\TF?F'_Q]02P,$%     @ -#W76AOR&FE-80  DS@" !8   !T
M;3(U,3@V,C!D,5]E>#$P+3$N:'1M[7UI<]M6FNYW5O$_X&9F^DI5L&)Y23JQ
MQW5I278T8\LN24XFU34?0.)00AL$V%@DLW_]?=>S *"LI+U(IJ9K8ILD@(.S
MO.OS/N_37TY?OWHV'CW]Y6"RCW^>'IZ^.GCV]'O^$S[X7K]Y_F;_=_@3__?T
M;71R^ONK@__\;EX6S<_1[OUE$YUF"U-'1^8R.BX721'S!W%T8JIL_B1:)-59
M5OP<X4_O/XD:\Z&YE^39&7PT,T5CJN^>_>7?_OK@X4]/GG[_]MEG>$J5G9TW
MWSU[^OS9P8?S;)HU<,.=W:??/W_VF1[X95Y+GP+OM??FZ/3PZ.7!T6GTZ^35
MNX/H^/#E+Z<GT>3E\<'!:_CXUK_LW]NZR>8K^3 K4H,WO;_S."MH!DY_.3R)
MUDS#>&3G(<*)V&K.LSKZ2Y[^HRV?P+63L\J8!=P0O_Q+11]OQU&:-":-DCHJ
MY]'?_O)O/_WPXT]/_C>.'MQ_\#B.X ;TWO"+K&C*:+J*DB*-IJ:Y-*:(GKZ
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MQ4 '*C\*C'<7??-#V+&%:MALO?!*6($)JVN2"LL+8#RIN3!YN=2 ZUF5++A
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MI>7;B=X4[+WHO:7!R""?"7>TLT]DUDQ;Q>T1XL*4_*%1W$"I?)<$U/.E395
M"4\)=8)B<\"J( >2<O'!QYC,<Z=AJ*>3$KH-]G:JT>OTR&L'S8/PB3K2&8+_
MI=(X<=+^)NZV+Z@.'Z Z/"J+>VJXHQ6VL1K/"G6D)Q16,G L4V36XYX&J4.5
M4BG7,C?I&?[%%#,B5F+,E<3Z!%K*%3#>=9KA9"C6/);";'9OX._H",4V#T)D
M<N3G(45J/^JP$TT0  :?+9;X.:-@><!\,!P0EL>KPZTT5<R#0=XI$=]$73CP
M+%9WXQ%,S$6);:"FK)=*.GS$-A 9$N>>BK3L^5.D0ZN%50HG"&SUAEWS>@6?
M+\AAKY+4_<)C43?25F##C^Q#/K*15V,"XIFK]3FF\23R_X6KHLOWQ.MM,$E3
M%+0WXK#?6;E_TLKM&&IAV(D,38+Z46]4[Q0:,CUG;)V&]4@V5N4"CCMJ<TKR
M>#S21HA%V$$NA&C0 .$R-.PD'BW@P$WF7[X5YEXD^^RDG?X=5M-6(9''M&PT
MVA<86A(IS@J"8UF@)V\CH66UK3([0;M'7$$8]^\J^F96&=R<>$-".1%0TQ*7
M])KP#O.Y;5NHI.!QN2L%_TX;.W$WWI[BJW>H#WG C&)/'X\NE:[B_KGT',$X
M\">5*2N8'IGET&+&(R,M!=8-05Q#.&#U>7E)?3ALM@=?><^D,#W)8@GRO]QQ
MKC%EBM"-JWM^G/)"[I_N!6R$TL"D@=/;=-NY?.16'L5D_4<=T]]"#Y0YN2WI
M-I$0X=3.F"]HBD2LJ=)K!\'A1[C/X =Y>3FPVV@VT2M9+)'HF?>*\#T*S@5W
M-X;+90J(2<>;!YF#8 +PW2V+%IA [6)Y#XLO],[>\/$I,.6?62A^(0%X/=#*
MHSO0RA<$K=QA *]M9(GRBZSN0U$NDEJ+!,ECYF36>F[0!ZS;L,_8BM+_<"<6
M4'AK]:P2$NP+3-P2+& \0AVAU)@LE)(B4YLM5" :N+9WRPHV_[RR@AJ4<CU/
MD(%_-:AJ?/V$^;BS%JS$/"L,9^0(2).V55#:@"RWEB1E3M7LQ&W";>54)\-=
MN 17?ENR>9DUE#S4I(UEH9/D'PI&+AO.E@E%C%C[>*WFK%]*;U!'KTT*>I#*
MB[C .([2-E])1;U7!VVJG/./N6E<^;VDX1MM(>X^<TP5<-2KPB#+/=XX:9OS
MLJ(B&'3B><4&+UP2!QMV,U'UFW")?S7T:VX1IG#P*ZA_B6T?N7\I$9U5X-=C
MX!4U81??W-B P3M,\JLQIZ4KNJ,*8H)89XO%V*=+ST78"<(1_R>.T=-_L+]9
M,W(7>"DD)"[A.P>8L#0=K)"-1^DAP9&A("$;*4$9@(<[$-B\EV7LG]7MV)F6
MX8CF"O )>/,M55[00!LI,/OSIRX8&C.(;<!386'_&'<2?)#UT?"AUE*84^)U
M ?\_9Y8B6@9L[0Q&,")S]2)'N'_*I3\T26"<G!E&@5"$QR9>MZ62K $C,;88
M9X(25%XLP8/58?D5-HO$1U.8"=DEZ/[V'&NQ89#@D%;@MN]#U0E5N$TZ@<FB
M,^9'SB2W<Q5A89 9N:+-.<\)_9@P';D)%MO8:C>L,]"&V+S;Q/]5QORP0SI&
MP]&Y8"#(.@O7[JGIBJ6:?E#"JQ^5P9Y+@J0,OQ*GX3\R$Z0Y"C>#M.HTIX,7
M:AA)XWR1A/DVSD>_C4#:B6HO%"(+K 5T1H(:'4-:'^4'!P4]!\VI.XX2LJ>,
MV9IAN7>*PJ[[-+5E0@T<J-J;J8IB_,=BV3"A+;XT*5<;.M5)63<54=B0&BNS
M5FMJG/_ 0C&!-@;0*6.=9(7J,W1"$2G%PQ+FK$ZC!W7=;?Y;JV$_POYZ]0+I
M>&W5;_CFZP,Z=H+1PKP@\W=6+ET=+;VFS$)XSXT31K<1)JV=?U%E"5#O#X2\
MQ"0. (:ZC^&"'MHA6@-VP&VV-JC4#1H>\TG'K_R8X4[4\0/7V)P],P##B$'I
MMFYZO&Z>5:Y0L#^V=>=&<FN#LZ.&:1PA6T.7% +KM+W62S&%= G'P;.Y9C)I
M&&YB5'@OP.'0DK2PD8DV*98&,K9Q%H[L)I[<+YBX>X2>AFTW]=9ZTS<B W>7
M>KNF9#L*NKRA0[ZZ-\=SN_7H\6!C-\.)<>%\RN&?217]HTTJO(E4C7"O-<M*
M1K"T6LQ^V_Z)?FJQ_%1A$MLR(Y(.JDN'A&IX,]N\: =[W%,)BS)S,O:?;K2R
M Q^\%H2(U I<3R9V1@M.;7^88(*\VSG9 1<TSQ/,$_0;8Y6%N7<.KE=%'-D5
M8DQED;9V[]__CVV"=79PQ4$GT"UN%NK206OZ(8'D1[ 0/UYJ<;R>@>)D>LXI
ME6]4[C,:2="-W3*/8$?)6BHYM-(F-1P^"V))@[DV=.-(RC,Z!)0JO/IV]+RM
M,5I71_NX#7W=!_:PU^?#!USKNW;-//Q=\#(HTODUT=JV4$9S5C(W*%(/K+?5
MK46-O3L9]$C]-2]H7V@#1E.XE=P.[K*^15K'8>DW:&.3?,!]&(^HV 7'T;F)
MFK7>,I K74=UR6U.A:66R\*%R\;.W9JSYL<+PJ042D*,$6.35PSW^<W8&G%M
MK)6NWD?'8J[=D7ZA^QJ==V7&2,MVVH0GD&#Z1:FM&EUE!E68==@6;%,)_]VD
MCLE)BU[7ND&8W[H)L#% &ZOF7H@BA6SHQBZ4']CI-+9?]XR;:(5\[<+QQW<Y
MN(TN'+\-F)2N(;9&JM.NFV42DO":;*(".3P^0>&XB'Z[]Q,QX3A%J%_)8WZ[
M]]=((^A-Q@QT#<T$"'\$2!HL*$JJ%3E2W+HV\D )P[%A#YN@T2"R=N8&2QQS
M:NW:+GU'#9570@H?/U1(?<>20D071["9\X8[\@KJ2YILXS\4"ZTYJV'<]L#5
MG!UH..2O18Q#H7\L\S,7J]BUE.J4.]L^V%+C24%RH5=RBY$GEU(4Z76T5:Z_
M]649T99SYW_S^PQ3#B3TZD^#"DG2EO(<#(K5I1M=P)W4G3#E>N8:4 R]3DW<
MZ6@M-_;HUQH&#'%(#XTCCQ^PGTX -4V&(%:/:V,N2F/9KDZ>JKX\+Q?\_-22
MZ_E+2?-QF=2T"W>B0^D'AW:8OB87[L%$7#(E( 8*K][7V-W:14F\J1<ZPBT/
MR^QO^/&HO^.W.YN[Y?S? BS]3'J,64(>,T>%7S.16!AEXM#QL"LT4">@B_.O
M/4T-H/X,]$L=+1(*#<L@=%TNE_"<ECK8SX/TL/]HYN83*43I. Q=A[GY08E7
ME> 9H#?@???73IUM3,EV4NQ<*05;R?0:>.O.'J:^9,\09:?MI5Z%F4S?3AQR
M<ZQ%1_;HL,6H?A@=Y%31$?)$ZRD0PYO)X7C.DK;N)?Q=ETIZ19K( 3.:+%&R
MHY5G7PY.(S(:]X!MUFT+E,7+ZRY]7Y!UWI [RL:^A<[/\"1)1[QRQV$ETYRW
M!,5P.+GA[6G3UC27?^P$<#K7[@?,C1K<O<R0X@5Z/5=J"]G4</0\X9K)WEZ/
M?Z1=A-_BGT26R;X(9\W1"<%^@7:8ZKYI -.O^5UG-J@O9//RRO#1+7[K1E*]
M%R[!X]<-+MU&\#*"5N-,ZH3X58&;YH[<"@Q8+[>*AATNLI!(!)++8P@D2(!7
M^RD;6D5]G7V(MG[81DY"L.4\7F3?@UX3/.B29W U/_R^+;"[IT%TAYF]9S!L
MP1@!EQ <Z.*^[4#*_'0G%;L6H4<="1N<K0XBJQB(52EQ-!V;KC)F7)6/:1XZ
M\]NQ!2Z(I*21-J[R/R_+]QA\S%?>\#KJI1>)V.(HJQ6=:H$3<P:(B^V-.XJW
M$>9P..^VLR+@DYY.V6+;WH$DCC U#-2.NBRCK0?;T<I0D/D/'D0\8D.X'MIR
M<,<\P] ^!5R%@J>_&YD6RD'<3 WG-VF$F<SCSEAZ_67PS5]Z;M=X=$!L--OQ
MP'8?FA4\2%UVF*4M=I@&*<-7R66\;B >S@UO206!?B0\%!K1%Y$9\PH9=9@Q
M$Q;!=DXFBCBE5*K$+B":-Q[5LC(76=G6"%(1+YJ?VI0LB(JRVSNY(D2B*6HI
M7E21HBYJ(V2^.^/1D<G(<I.A%P,^I!7$&']E5G)O>*%[U\D)6<E-G$'+=@J+
M%]EN3YZ!R143WNHF4WBU$CG&=5UCNP<])S\W9P19)2O3<P##?4)^)&@;+CEI
M2IFVAHE]87=IKIN'H05F1*"'&\I&<:4-FW4!J15JS1D'IMOC8C8*:9PGU4*R
M(+T)#6VV3C-(6#ELY4*\IG7C,YKV[H0>/7&\\:D,$$<#O T^_1&=2'MH[(F(
M.PMER&R\YAG9.!5UB\ O6C3W M<S".MI@X5"!'ZWEX>&?V(I.*K(\6 1Q$>
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METKCJ3^XPRS> H-T#5V([7Z&:N^BE,BU4^UL9&D?&G&9[97<Y5ZU9C<W.\
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MP0=I"(%Q;00,LV!<C\8*#"@1F3X';:_Y4BAQ08)NFK3;^L=MV\KKB7K]>-H
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MU9XOB(F2"Q_5,B;*OC16/PD[8W*%#_]")JB3LI4,##WM-/D WS5MQ1P:SGW
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MO'GW;1=)=KS5']E;/2)Z&.ZKU2\-4C#3QGJP$W9,<8IB;;] L4BM!$!*I;9
M XP9:A%_#_+?,_AYA@,S7U**Q/SCL;W9 )37'\IIDG[W<I3T:.X[6A.CO)#"
ML>%U\T /@9QA).^=&U,S<4R6QM%%EA"O%/*Z("2)DF*V-Q1RZA2DX[")(G;X
M%=9MQ=QAM0&%.VS$%4U#*9H$;^F%20\^.*<JN'N^(HZMLR+[)WK>:Q^%+MAT
M6UL-<P-628904!;D+E/#NC',^1<P (/-V+C$4]*A2(P$MS3(.5.5L'S*Y&5-
M#;W/MNM]\L//]^]'RYW%3K2%^^SWLGH?[2&M2@-;;3OVJ#*E_7I4P(Y2VP(7
MTV<7#ZLU_'QD@18US$JV) 8U[#]O&B'RF9J\O/R6HA&=IZ!E,\0GWY2?_*4_
M\_OQ?_G>?_O+O_WTPX\_/?G?SW+WSSGR"1X5/!,_1^XE2'$>X*'R/[T-KW;5
MIM.*\=N]U?:2JA_Z\"E8LGJ1(-50E2Q-"YJIC@Z+V4[TJ0EU_3$]_.''Q]'K
MI'IOD$P+G!N8Y9,V QG^Z/[N9WGBV_,L3T"$+\^S)([>3J+=GW;O/_K<)^2D
M(4#*?QM0:_!4;$>4JBFU=YZ9>73 J5?0W1+(N16GQK_W9SOVPT=%=#;2NBGQ
M7I@M8!==;#3L!GVK3^]O6;X JV>O;7(LX,]F[PT1/_Z2"/?X?EE5T:M7;UD&
M_QC]5E9@?)]6B#G;(P_CLXSKP>/[T4LXN,4EK@"?X<_R(#6LXLB:6+OW[]__
M\8N<D]/)<W ,T1U\.]G?/SQZ^9_?W?^._GWR=K*G__Z3SV>O_7[/9[]O.<;@
M19%D[/18'W&!P=U9DJM]!G=8PS"$@]_7R^1V-@9RNO^L_^UN5H3WRLV\\:59
M][K!Y^Z=5UD-PT*[?G\G>IY4<"+1A[CWO"HO828.ZG_LT)TPVGUZC*/!2?[4
M:SE4WX *)SI:Y<8.XU-NH=W>0V6^GU=94D23G>B_RO."7*!/__"[_;MN_Q[<
M(_UTK<T[FT[_WR4)7- H9@<\^:^T4^&G[W<*W*F]\7SR73/T_"ENV9V_\W[]
M7$/X''2/7D]2Z10F3>43X?SD" M&[2VAN1!,KQ22/!XI)GFZ\LB2*5)O^9DQ
M8X9W:,I/=Y)O4BCP@0L%4B1PTXL6,.PGD=&@*!T9<L\R-/)EB[A><ARAXR^W
M!#?F(D*2,#4?L)=1G:]LZG2[&^Q;$/URC"RM=7-OEB=P']B>#4;F;<0.R=PI
M=B182$WX\C]M=M@_#C:$)"&SL $VFM/(B.,1F>$_:^J>;3BAA;\Q295G04LH
M_L3^$-]O5F5320I3\DI).@7*S!/KVEYP1Z @PLG3Z$?[X&*<&:3LC Z9_);B
M9I<XLW)NN?V1#Z^NY4[3%5T-[VDR9:/'!DXYE6F6]&4XN$*;5!E&)/(C^=NH
M+NTR>:'<;-9BJRE^.!8"8?K/59/;I@BS56<J>HPP+'@VM!3A6DF[1W=)NTU(
MVEU3?3':'_R6RG@8\LW57C6(TN82<0!7%7/U /TNGL+(.4,SZG45T;M2RD7,
MHJ[LDO(5HA=B9JN!7HE$NA&@U1FIA^B\@@TP1YWEGB]MU*1K(Z:83(JE 5@G
M0%D:KPL9\\^C )5'P+S"D3NW^1].XE4)MH):E%Q\IB_H,6;^*^]Y$T7W%SR6
MU(;IM:G.4!W"[&)5+$K81"OS')3G*&'V[AM Q'L#SJ\EG>4J2XY[]HLQ7>^%
M(:I.+4?%^2=0,^U@OE=FOY[9-4%KIK2LH=S[A-H%<+7,BN^$30$)+NVMI#_$
M7I^@*T9H\]I<!K2RW&"*S7*94SUPV)[4 GEI4PE2%QO]<-]2S1G7KD_.$"?I
ME4-SS29\_LIRL&T(2QEJJ=C%;BE6W:NXJK!_B5C#;#@NN=$B]2]M*Y9XR+CF
MQ*S^MB.1V"&-'0H3,9L"0Y89Y/H:+&F!;9=A;G_.;"66+_8J=EC'!A>61'K@
MNH=,3\/-*\"1GITG-2?B"?%6:24C=D/"^AX'@_.?Y!P6[K@I76!M,Y@.MU.G
M43CR>EYP%5 7*9&,1W;71N&FQ8FPQ64#=9X_?I$F&#==A#\.T*G29W)"X/G-
MC0Z<#M=!3C.R,\8C;,@5NK4&.X7-#*%KIBMI1X:^)S:4PZY;+%:FIC#SK"$(
M:< Q?E4]LVO>+-8)IA?KSI)QO4.]@PR.9BGEE?096TO#' 1Z" 8*!%%]$'$:
MW60(N(K"K]M/.VQ-)N4YV/MLB$[X\<[N5K*]E64XA&UZ3XM3%Z;HV*>.XZ'$
M0;]>UZ+7;SS,Z)P.&X/7C2WF#RJ55XXQ+/88 [K,UPYLU6%&Z+?W94U"<&:5
MU*R<0=4Z2D2GNGM:&L>'YGFSNE)31VL4=;=S&\A)#I4J?JWP &P3J97Q(6Q/
MH@X#;2PU-[2JA:R@TN9Z6XW?.YK8^IM@*&2_4QBG0M!60;VK1&MU%4' O$05
MHX-KL15V'9-+S(<,E]#1X7.)LAWF]HXM V;.21VPW?@NMG?U$6#UF<E:_&L5
M:\PN<V67@)T(K4?T1Q;+QJ3^S/?<$URMBZS,+>BMKP.I,MF*L8LR2W'ADRFV
M@L>G$_EPPMUVBU(@ZANN,W^@MLPLRIFWQ#$WTZHS1T6X_ANK3(_*-57J,1:^
M4[B<J!2Y7BCFO8A170T2B #=\OIP6"A7'T?H18<'%><2JU2;AOO3#:E0K[2.
M'F]U-@ME+"$DPQ>S!@RG)<V!Z&&P2$FKS/(D6PQ7?,"W_#D%N(7>GNA-U0(?
MC[JM_^)(2EC.H[ M@V>U3XTV96RTC:TS-O[P?-E)(F]#9BD*[(S3;G)$NQ(*
M\Z83T(8MDH39J5V&Q&4LI'C%MUTH7,1WTI84H6O9N3@>$KEN7'929*WPA!K0
M2',R#N!7UA*#@WN154W+)+/^:GDK-$!5!)LULV@E4HDSRUQ;E>KF)IB%N63Z
M>=Y!O::-O3MS:@:;_8$7E+9);C,0UCL^J\IVZ;<\<G:IZRNH=4W2F)%F<\,E
M^8\HR5\R*AT-^U?)Y<;*Z=,^?;(2\$JN"].?-%?$D<$;DT+*5=LCAV%>&$XS
M7MH #75:Q7_L@S5S">(@MF;4&5?M20V<9MUL&P:NPZ8MCVSTC@MMW9W#;LY_
M;ZNL3C-:]WJ;35F.G3@^)^%L=;:2&SO>*+B%5H?89&KO^3?Q9'WUK-[CNZS>
M75;/2M^_HO3]+^]8;:SL%<##D,DP'EV1L^((L>TE@W*4K1:_5K]O@7IW\AHG
MU6'G).;;BKF$23LFAP_^&6O-9-JRJC(7Y8QX5S@U9QU8B@R+XUM+;F^ZR)1'
M$FW"6=[6:)W[0I9^">8NFV*DB\JV8KHW3"S-A/MKG?B/._W(Q8!NL9-R:;@A
M!1F'G2R?/P8M*@>#.*,$5ZML9F"0#NH<_/T[<)UA!D^866P?VQC [>1JM6[M
MQX$Z)!M[N30Y+@*/MF;NLQ+V%Y;(40BEMOP-XQ%Y&S7W'&<CTG(*#IF@-B9T
M;I**RPD]PBZ[%/EJJ.P>GH7J$DL,^^&$\0C.-)'91UNS[>@R@=O4O-EH@B5"
ME2?4&)U7-G/MT8>'FQ7>PM5PYW3=G945 [-7-&T)M9'B1D_P-"JV@]EO%Q1/
M*=T&"'8=6CCL=V+ C-A5HBT3SKNM6ISS4,&%Q9@PCY2N(\*8J]]L@(XLFRM"
MT2*;/L;CO3O04^!'[330H]U[$B:3\&GDG+LV\^)\#I2D(NFJ!4I=)MQ&D,D1
M$*0)4V+L;,BO0$06)G GP;T"(_LF&D=?4/']A(OUV^3PUX/C\>C-B^B_WAW_
M'IT>'TY>;:P&?/K\V<%D[Y<(9N/TEX/H+5;Q'YR,1[\<'!^<OHGPC^>_1X?'
MQP>_OMF;/'_U>T3S=Q)-CGZ'_]^/)J]>1<>'+W\YC>#G-)<17$ S>WA$OWIU
M\!(^?'O\9N_@ ,'ST>3X\ 3_?//N%)_[YC@Z/G@U.3W8IUO\<@B/G[P\/CC
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MFQ1NK>T_O=K8H#B$T+V4KJG/LZ6E=+^B)G?CCO;9+3C:3D=1"E*.=*U<)W"
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MR%Z![:WPZKA7])GC:7)F(M)A8+ ,)@FO<-1#[_N0)T18/$P<(1M('5^(/+8
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M\PN6138\,3A#<3UP'(]Z SI!-X$IA-:74D,?PG'[5_14*Y@B+@L8BMLXC)Q
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M0@R<:6L&T'P@$_';@D-BW:R$H9I/Y-6;VA@4#X0;Q_M^Q!NQ2SBFF9=(.O2
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M":!#$7TM.D?-PY*RIE3@B^.Q2@^K512+&I;"A/RL5]M S/:)LX 1+36K_)9
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M6@^"_RGWF+$;R/3OA40,=YT YLY^$!7"EA?+NGIB@\O@ K,;;CI1.*@3B>W
M:SWDY?V(KHL)PR55]>=3MFHU5UH9]R38*O;LH;:)IR16Z)YVDH@'ZROS+X.<
MO*$RL?WJ2]IK>?#"BW=$5GM9,'0I^;K4D<H&,&,^$LK2D6J,_;+4OC]98F/&
M&38ISP0)^=GSDM?+FT&8.&H!FH-)'7XL&D2-U4"_J"TBDS=^NOU0U6Q/EBP1
MR^+YW!5)O4E7]P&F]GE%Q7O5.0XN2937:*D%U[I#PN+2&9GV?-$WV.\J;O)M
M>06E/FC;D=C6=2.61K?,C4'M+HCAL1XY<(E*6\W(#B"OC?7*\[,:H0Y\@KT0
M;G+D3P?.JFH^1GI0,6:J(UX)+HE3\95:"H.B$"L;#XIA6;$KQ00W[RS#6@(]
M>Y^+$XAG5";2L'Z+=2ELQ34J&E+,N3\)U6D ?NP70:5N,4OLC8L=:5W" 285
MB\70^WEI6Y?8F#7WH+\&BDVQB[@K]VN3KLB7FCG!)N.^1"'"/PZHY6D_Y6A5
M@3XGQ20C@ZU?IX]F!17 9([8:7M(U&(DRZ8I5=,-(P^DB8P&/7!?UMIO8;NR
M+I^4LJ=G1^0[A</:10X86,P=7.U,5#VD(HM&2VIY-T3:,(X1R6"%'>PNFVR7
M2]"V>@.KOK)'T>=LT;N &5"P@W2U!78!5LAH^+>GT_ "N172)3T(AI.29IZ"
MX)!%Q,PTM08U/)&<.$<["U2N:+[!1-;IAA"ST)>F2?V6Y/ M3H4 0@J8JR+J
ME-/7X[SNYI>4&''=JH.Y>Y<$33/%'K1$WBPHX##8<O7F\K3U?#I/[WTZM]"G
M<XF$VJ3CGSW))*- ?]^/_MO++O4ET[ <\JPI+Y.P:CD9H .ILE6C>2%LWDGR
MA%;_B@6PR:EA@?R*GN#8?$Z1L#R47]\O=A;FVVD40"T5R;D;AU?F) S8F9CF
M'),J75@-V$P=P5"QDH?\EQ6H,'XS9(^>PLK/>_$&G:)U4;=FG:WE3Q7MJ.)+
M4SN;!]2\&H52D!-,B:"F:(TSZJC*UBQZ=8J'X:,-G?WW8Y/$HB)6RW6Z--H"
M=(CDS $L'&4=S(&/^K>"DC./N;7NZTR@-)Z.EG>P'Z^>!IV_(N)Z+*[S-4VP
MID#4_CR.J?QJ6;F-&%Y\'\BW7]&3O8YW^]WR<B*>J*,DEJ_R2[K9TM&#5&>O
MU*G!NEL<92.MEE)WTI1FWO-5<+]01U5H-8Q@\T_Q4GNU;;@6(A,[':? EF#A
MX+28CJ3JQ_CL$2>U=.+WH>?AI9ZL&]_*<#FWA#*9*(>J@%=F>.)PN.V"S*V2
M*XLG74*G#K.$PGB7:]_UEO?+X]6F.LLD*) F7M>L#G(Q>;7@5B_3'I(U#:4J
M #JJ_,KYW0/JGX,T/^FIO_N,+<[6Y ]R?(V?!-10SWHP3V&S;G*4RI5DX"9K
MD[UR#5?K<=>E0!TVM1YI'C'T)/<[MM;"[VV9RFY&&L;(PU%EA2"IDE_B_]C+
M9P2%V?5*H,:8G#/C@IYM+AE!'9@3XZ7_>W6.J$26FV9@C.P2DH?9-"+GX,]9
M,J6,>!-ZU:5YK18>@U'W/KQ^$S%:[#< Q2H]F0!T:*[Z1NC5^H+>%1+^:8,D
MC"& %9#*8"&3@(S]6@\D7^E)KP02P_OHK#+8T)G(@J2G_4DMK$@C[+%C$%CE
M0$X**XOE6%$MW$7)%;WZBI6EAZ$DIXYZ(6"5W(6[4_?_R=[/&Z2+8^)0[&?W
MPY7$SRWR;13>Y9!-U&*X&@@FN19^G0\5F4!0XBSB#P(Y[2QR+JM!QZLE6PGM
M",M[*'5P17[2JBVC6(F/B4KIJL&.C5S.9D:JDW5W@0!HAW^ZE3&R[+[QEP@6
M!7%?XNH:X<L<>:HZY[1<+ WILL'FI :T-]=UQ1V,5+T?.9D5AQ('5TM-%DZ/
M5!<ASXHK2;+"H]IF(B44-=B$[1_-LJ2"*P*_='>.5'8$NT!N<3!5-HW.00_B
M/H*G55)S P/*"^-V>,,C2;NAH<-1BG35:8*R,]HB"#8;WD5^ZUHZA9&KSGD]
MI0B;4L0HA0\LDVRQ,6AV9&)8@C9:E"ELBDD[[2 '3*Q.9S/:?M<*$:.HM;D@
M\V8J+DW5G<?/OK/KZZ]8CV-X:?AS\0SH[^D(B(1 %4((KFO-+<N:LLAXNMJW
M V0(MLJF<#T;#>!7 KA\WN%$[HJ$>/3P>D6$R :YHU0\03,S0M>?*JB*LVOZ
MM>OWP? \.H,97!=3JM,K9MHNL-,)&DRVDQA3N2(8MNF(A(# 4_[@[,B.I:Z2
MU!/G0DI=,TX373V/%FJWFL(@('!A]"4V;43=9OT2#MV)B:MFE,.BU88U)I$J
MTV2!2.0Y)3U0F0-U4&I3 6'[O>*P0\Z1<R-]MB3381!H$Z>%Y<$2?5'QTPX^
MD\J:R(Z(I_(P4JD27YEZ84&Z6F<#%U0V1VO_NAP7EI3Z5^UW4+"U//LKDY)O
M<J'MY+FWE-H*K%=Z.H!HA2*80[@FYE=,C" 42<HFAD9E!:3FY[)<:+(GKP\C
MA+H%['DB+EJQ1PT>KC(IL>T/-MMFE404"RDF[B.;?FQ%0'9ZJ7PMF5]T@UG<
M>AZ+'^\]%G?/8_'HNK(O;$"I+11B!=3-)?QUMNH1;E2X5H1O-V (OB%38K0.
M5(R5A HC$2<<2?;)!N76S]@6!Q;:8G'$HJ5&$!INP&$FQ/[REJU]=#X@'(IQ
M1,D^?;=(ZBDF-V*"BO&B7OSG9X8J/$G36].BR<\_KO?#'XP.85\S.(8J!?SY
MR$S"(3JOK.\@R4TV0G(G0SXSIQY1+(<M%,8>.GN_K:6@4 $^L)AD\Y:C.9)*
MFS0!=6)ISS0H-II6R:RQ,89\O-3:A\+4T$7H%;'S7TOB7>J:C:1DW,'SGV[D
M_ ] 46OKH2:2;/ Q*"">-KE[6F4.+U[P#29%^U^>)94V0V@T!21H2.V7?@/=
M54./";I(V"N('6NKA/6PP8IQLS+/P>BV8<+!C#7TQHVX)Q.\>P22;H1 .)Z,
MB@<Z<P1CVK":8AJ+S0FVG]'F6UU@LM3#$+]:;6E$/I=LGSH>("RM-5G+=S"1
MR@119_1R_(<.3^TS9,@1Z\6..A0$X"+(\MONDQLB$[,Y.3(I\_3!+)D2"I"0
MLV%EFUH\2@PNL*YD+C=AR8FJ':Y@&0(5] ^9;;[@.1JT$DQNN$/<OYB0<2;
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M8,Q)=PW?$2\CMO9UY<)M$6ZV*.;1B[\=V\J!'VSE0 3RI=>OE5A_YVRNF[K
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MA 2TTDWAO;TA_$96HI$&?2#O*CS@<XI/7"W2@$L+@ 'C5<$9"  ((FSUWE.
M[64%K[!<D65(JX#>F#1E>._"L./&^P6A?Z1^4>[G+,LY"WUI8#P)R\95]PM0
M,3/@7ZO!$%B[_:I4$J/=!\CWHHXT91W19JA090C<RP9(1'&&IU]$ &L* :(3
M+VC+G>=*:-T6)*/@'-[X=&SGD5#^@&6J5/2^H9![E.ZIYIVP>DW-OTCTX/MP
M"K@I:96<#^H'@Q%FPEPDWY4,6LGZG1' ;*M37-\-<G%"7W9[/\]/?-EE[,OR
M0"Q?<C]M>E3,.X<#8<4NE@&>4H9QORO0^DU#]9Y15<X<.>S&SG(;*J=R9;<'
M6N).9H/\:B1Q7#8ZF<_A=N-1%RW&/]-FL]8Q'/QTS=$5*\N>?)X3Z[)U<9TE
M\NP41(WF$SF@4TV7)5!K1IP@K,1QNKOS=#=U"9'LUMWEPZ5R*7PT9%E$5$H'
MI01^@9N)[A"ZTUG1E/P=7WOD*S-&?Z:GM F536V%'\<>;%D9!&B8*'J3ZZK_
M,C]US]I($]SHN%=*BO0K)%SD4G6'31&K(PC,QL9;3\[05@=>F:JO6I+**S0+
MGUC7IIY1Z(##S&;<Q4&#[$_4%(=*=:X9#>=!)TX/]R?CXD_P6B+19WR.7G"F
M;U_HTOPQ9AUPCT']SL[MBM?.N[#*#)A_-26+9.6?HU!_1_(H%]1R"H$B3WBH
MG.FZ2C+H^;:FP. L@!-F5:"(P)2RDIFAN$\O&.4<(C=6O-<H/(HN:Z1;]%[@
M2@C]O_WPU$_W\-2MAJ?4X/M-M3=1Z2563>ZH*/<8YNV4(E<%4(J=K6WIU 9^
M*0H%&]J-5*:Q;(0 "E*,/#>_5S<"?C44B2*^;7T!+,8J,25&%%A%\:.98\D&
M*AEJ;90@I]2N&N,J<2!DH]0D-[2E)9E2$6G4OFL)C69(0-)E8<:\<:KNGYDA
MEY0DVF:5,F0.BP )"$\M7&F>&I5]P=A]T\D]B&]084#B,,$V)!;UD=*CFC!J
MEVN/@-=\130B'AX,-B0$?C3OH+>?>]')R/%0W%9=1L0TW,S(U%1M=-XOY4<V
M($E<8"\P$?9=:#[SJ4DJ+?37I?5*)L$5*R6C%K,=DRS7K5\;I1'SR0E% E!!
M-5"$AHA)HE,<Y8C337QPO#D<_E+Z#J6:JHC@O*@4QH6$Y"7AB5HU-=@Z)E;V
ML=5-W;^+P*8+<U5"N(60D:8H'S0A:10A:<0>PJ&)8D'5Q]XU[YJ-@^7(26WE
MA(454 %3 +\<81JM\-=Y[_96A[\4E[(8J3TOMH6M*,W4XJ63UY+EN<@:&27X
MTL*P3.S;6X.<5O)<-18&"<[3O[##^=0&=0UA(%)]D<U9%4@SH/^:JVLNEEJ"
MEH%?#F!E\S_8OS0C2YI?[(87YNJIJ,0H_4(;7LSZ-9J9'IBN 0(K(I,T<N0Z
MH\5YY6OE_9+!N&[IHX%KLVKO82((7+DP+=](06+%J:P':(*23FG<U@-%8@&H
M+^_;W"/A6%C%S8#R_^@_;7!.VSA?WLH# QMBGMG(=ATS=DZP'OJIEIN%<;3:
MYG57L;)FUMANR++_XU&TR/(\DS)?UD2E"RX8R*7I)ZOKV]Q">:&HSH$%)9FZ
MK3BH [8\UK5!>-(@U&ME,$9EM5/!N(;J5E<MT+AG>0Y@\'[Q#F2;WB.(K1 +
MSQ$2G,,95J31#O)>E$'L2F7^Z*8[*A@EFJC7?,*26=[6J+J)V6%RPV5BX&]^
M $1Q'813LSX)S.=T(4F78,D#:06F_'4F.S;EW)#%0UNN'19BD4&Q.-Z62>9!
MX<FB; N/(-0]%^X&B)8B"**B;77?>YQ3RVU3,BZB<[0/K52GJF#?SO#68=Q6
MB7Z2WPHI8*'G(H6"@/5BA!H!R(Y:'3M%QC ORS2:)BWZKU%192"0ZUF2F/#+
M '?"\6+7@L*>V*;=+8&#7U^Q3"ZTD"E^_$>;SD.\"JD(^Q+!,O[1)J# 4O49
MF_,#VTN>X2;Z 5C_F=SS-P:Y<PYF"EJ:&"L%^TG'0!C;3GC/:D)+89F[*-I@
M 2 \@6[1"J&]00,%M27\;]I6>I$$AYJ8YASMMRMN83<A5G7\2S9F+SKP7&=^
M7E[1, YFMU#L:H\QC'L\O=EX-A%5L$HN;%#I2E<9U8^B/8878X6[V-GK!,A;
MB@M.CI1+AOJP=9"E6;&K*+C5WM>Z7> 2 T4AS<C!12XAO>O^F<BDZI+OON[S
M*+,CT%[Y0=BQ1THEJ5Y@%]1PPR Z"UY6&JM2PR^5* <\-+CTN!R)*U%;]LI@
M:8CU^$>"CL5LFBTI%K 85=%]?4^#D4+6$^NOB?HKA,KU)("_>$-ZX82SC L6
M#CB0+Y.SG.[D/'HU@S7X [#TZL .5^SC:LC6:"&<D; *N0!N.V=M3@DNC!:Y
MB[6]!20&QGW6</1E097*?+%B8UQD?5(M\!*UN%M"Z?;CT3_?X]&;P:-OGWJN
M86\.,%&SLY)*PETAV./9&N.(VMUJ[>^J05LA%.C=4V;U>T#9%TY1 3%A4,(0
M*FY3,+SK[I!R#LK@2#:P3CD2(:E#9LP8JH<E>:$?P)R-I@\:C":8<LTZ<4;S
M#^KQ0)_.H^01I9UC W[=#9I0Y)&?SF?;)$I.!:E6^,$M-!W_\&B345<58LZ8
MLBF<ELO[NH*@MLDG/_2&9(GIG'=J#% $XH0-H38:Q."W\AM0&L@YLY:T1$S]
M,UP%5Y:6B/IXTC+M:Z"\*:!]MQ1Z@!9A43.QPML+6W(.[AC>XWCH5G"%.<SG
MQWA/V0GVF,APGAT=V_SS/%MDC1@O-GX6]1C@YE5A+NP-FQE!7(GCZ!]VJO R
M_'?5U&I2LNU T:9H7B1!>2C+K<@J]$SJ0 GRU2E4"P1Y,^,=0_\<.0,"C#AL
M1/%1U+'.DZK380O/'FPC2TM_@&%3IYD$FO;=YB,OO(5W6U=R[/:) !JS@&-+
M->6O8RYS:P-T&G[%5*"B[ :X]1V2-A6UURL6716N(.-0-(>S>'RH8)TNK;W8
M,DI_H.)HW6 5LE(D7HWM!(U!\Z0[]6ND).]26R_"'0";8])*Z8TB#.MAF&/@
M.;+UO0?A)1J\W\WPEE@=3LOG_KYHK&;UJ@RIZX]DW"771=(]:M(EDB#6TW<2
MC:9<!B<D 3*2G'(5=ZBM$J>1J,DH&:V8HM(C/@E;0###Y00YL#:?*,U8 )9$
MI0T&% ]ESTGNHN(/%JO5I7>K[70K54N!6(K9#5?4M6T[&(-CT=+4U.TQG]L4
M))3IA5&S2/*BJ$<"D$=U/U=B$!47*V00>*$)._-;I*:"!_XN>% (RQ?]7A0B
MJ]>JYN/KO7W%!SFZ)[&Y<DA78J\45Y;-^.J1$+PJ#QBMTI-I?PP3TE!"N^ W
ME-^EY;>][4R(L$)R&(A/_L+X<4)U)8 \LGT+;D6H^":C_%=7K*:<M9$JZ*.\
MQ+)DB3;I\S8^3%:L>6U\E0F7'1.GHYS+$4X !/6:M+J"6SZ?N'TZV/.C%_GS
M[XY>>&:6ZWPBK9?1(+JPIKS7\&+=TA?631XZ[=D[[VG)W6C1T*@IVSSE\ ^_
MK;V^"M0,#KD.J,//XEM/4-L,$+286XY(<[UQ,<^4FHL,.K4EW "M[C5W[K(8
M,<&N<0T,;#HLA'G22+T&NA7;6WE9S$>K5?E6R.W#-K\.3/KXX7[TGDJEU<^B
MMPG8DC<&-?UZ(;7?O7S_^J\O\!^_GOSE[8O_#U!+ P04    "  T/==:G]0J
M+=!*  !PE $ %@   '1M,C4Q.#8R,&0Q7V5X,3 M,RYH=&WM?6EO&U>6]G<!
M^@\UF9E  LJ*E]A)+(\!V983S;AMPU(F;Z/1'XJL2ZJ<8A6[%LF:7_^>]2ZU
MD)0MN66UTD!;)&NYR[EG?<XYSWX[^<N;Y]M;SWX[/'@%_T;XW[.3HY,WA\^?
M_<#_PJ\_R,_/7KQ[]=?H^.2O;P[_Z[M9631/HP?WETUTDBU,';TUY]&'<I$4
M,7\11\>FRF;?P8UPZWN]KS&?FGM)GLV+IU&5S4^;_6B15/,,/M[_[OFS%\\/
M/YUFDZR!1^\]>O;#"QC(^\XCO.N_+R;U<K]_R::C\UX.E][?C_SA34W1F(H&
M=?S[^_?O/IQ$![]^.#S\R^';D^&1?>9KKWD>']NZR687\F56I 8?>G_O<59\
M]_SD-*NC9Z_?O3WQWWGO+*FR!"^K%TF>WYLFRUKN;ZJDJ&=EM7@:M<NEJ:9)
M;7B-X&-9-=M;!_/*F 6\A!<)G_T\VFGP1=_GZ3_:<A^N?G;TW+ONZ#E>^WU%
MO^[&$5RZ2%(3)754SJ*_??_OOSSYZ9?]O\?1P_L/'\?1Y")*BC1*%F4QOYK!
MOZN:TW)J\CS[%/-F'!73/6\"P5M6/"N6Z[>WDNB5R9/SI#+1M*Q@:9(F*PM<
M"!.NP\MRL4R*B_XJ;#0S'OZTG1N@B2P<='R)4?S:)C"AIJP^<QSK5O@EW )7
M;V^=G)HJ69JVR:9UU%GE.!H;;S#6]_#S$-D@4>#$WINJAIMJTT0PE.8T@@_/
M?G]^/#TU:9L;WN"#9S_\#ML$HS%-.; @QTTY_?.TS%/36Y*]6W'T89I__';X
MX?#@&.<6RV&#==C>2I/&1+@RY2RF%?46 P\G?B6?^):H:!<3_E2?PN[0HZ;E
M8H';@/?&T3*IHK,D;TWT'_?W[L-_#R*@#[Z\L[\OZ<;M+7IK?YOEE7)N_&T&
M#E1G,/3.D+^O:KRUCHID8<:)(=H!8K:/Y4'P8[:WRO/"I,AX.H^&T52T4LFL
MH;6I6[@." J^+N':ZCRK@8]-_]%FE4GCZ/S4X+?1Q!1FEDTS>.,%73N+*@,4
MG](#Q]ZVO;6L,O@=GH^_P!L76<$GA!8%ML9R5=K0<V!I^*]LR@8G KBKR8"M
M5F9FJHKG@O/+"GQ._Y2TDX]F"ES_F-[0W:RK(^R;=%*F93%M*^1!^05SD/.L
M.8U]JN0/EJG&$?,L8E%7PD\/_B_)31+]Q51S("?8AF&Y-2X"<"3G0%9(?T1N
M=3NILS1+J@LD)AEO>##=V_JG\C0Y,Q&I3/"L#"8-;W#4",. ][W/$Z)4?DX<
M(9])'>.)/+X#AQ'HM9V>1HD^ _;O J@3Y+Z!_8&3 @37X!-B_8HFI=^&1W!1
MIMDL,^GVUJPJ%U$#A$''"/Z-^V0M$UVAHIR?9C"V956>92F2&"LC]#X\B,4<
MOIOA485'+_AI=N*X@-M;2#,T8%JL@';H)Y_' <4U6='BP9136+?567:&7TSE
MFKX(X[?UQ]XN8?^5@=2\-34?9&4M\,(T0SKQF4;&=W47)]H!@LT:.$G_A_P"
MGQFU-3*PMHF*LO%V(06FA[0F' 78$O GHAR2.[!U2QA$=H9KEA2XBC#?:95-
MF!$1/? +1L:RNX]+>BNY#FQ\XO9E>PO6(VN Q6>@M1;SPM0U+A&=0$=2W?6Q
MC.@4'E<9%DMP9=+T)1OIV#4>8QA9.^6]9H+%<0"S,,Q+8"RXH3/D<UUM84<V
M:D@< ]DDTZRYX*F%"H4(EHCERBZ-ES@!$D(<3M,7>[=&-WO[[@]X&A+ ZW<?
M#ID$,ECJ8.5UM6#IS;PD]B ZL'>4*K.$3_!XN@4&![( Q5*& YV69Z: #S5O
MMRZC?^PG)B_/Z>>9LM3MK7E9,KM%G2Z9Y"8DB5@&,379DHFF;F>H\)AB2O*%
M^2<*)20=M.BF?Q;E>6[2.3)TO!LT1AQCQ"HZSKX!+H^3A%T'.9";.:I/VUN3
MLBW@GK2TS\)I(%7-0+Z5Y_73;X4HK,]A0W,3%0%8I*FJ<$?/7GR <?WONY.C
MM[\Z=\5^].N' WC@N]?1^P_O_M]??</V&UF9-5Z,D.D(&5C:9A%'5%$3L_MF
M"&+EM!_L/=C[_M]_?OCHE_TK_0>UA]^?_V\)*L<<3)]9AQFCF8 4](VSV@>X
MA.'$=Y+=ZUC/UZ!Q"@F2E=A5=?&7P+ [_+3,A,'C)$D75M6)N#$Z.YK(G!E0
MUA?&X$:I*. C0"KUL"D[ZH'RCU#/D@,%OSS'%X+4SG/2N7$^.H@D_5BV54$J
M LP#[/ &E$Q6&1K5Z/&'MJK;!.T!-!"B\RIK@*F3[,!+L]"T]P<$ J)!D[AW
M2Q'EF6EQOHFNQ6Y?#R%5DXQK5CJG":BHK'4ZQ8--\(BL(YC3<IEG4Y)M\@-M
M&HHBD#XB4TG!6;+#"1X. P2;X-/%+@OB,CHKX9:RTO>1X,+OT@$MYREL3K;+
M1P&>.DO.V#.0I.62MGA0^Z9]6)(E$EZBJ@ ;)2_A))G%,B?3Z 2E"2PHZP,[
MF;XUF2=94:.U1@],<GI]09."/87/Y)>%P8FO!4D4%Z2L6"M<+&$#Z%MG$O=&
M+&81[F"[6 2*C%J&.'885G]<,)8#]*;(N]_KN,J*]\PINHV;HS4%8?@-GT"@
MW*P6E4)T2KCHO&QSM" 3V$[8>#(WS2=4I-@ R6!^J0&C&F^L9D#7,L\43&PP
MW)3N\5GP*N!,Y."A+4KAH-0&/\UF9&FM7 *[>]XT:K(#[29FK'CWUO<&\^7O
MG+[Q;_?N1:\SDZ=/P229FWVX_A\M:(<&'AO=NR?QJ&>OCOXW#/S<:\HE7/)P
M:4-']R9ETY2@&#W![R9P4$UEOWN1@V(9/8"7UV6>I3" ?B!IV?@3??8#O'/@
M]1,@BS_O3=#,@3$N:<S^D)X,C B'>=E7>@OS ZX,+\9-W,W/E+(J;"?7(FR/
MX%3,V@I/>P+41"[I=E(;9@0@X6-D9HME R>1S0-EFZF9YHFSJPP=4S"@R+26
MP_G!S+.ZD8N.T<_$S 9='1F+#=3,B2O0^3R'GR_NS4 X1CL/?P0[%OZJ6222
M,@!\*OG3,._B(7K<IP#[J:[1(P>\QTJLCM0 +2(G9S%Y1WR9YTD;Y%A.H.!#
M6*B((]!G]Z-"9C4W:ECIOL',YPO)=7HMY'KX:6J6*-AJU"(6J-ND$9BSJ&CE
MN.-UM',@4K YK<IV?AKM_+=\ ;N%7GRF;?[JP=Y#BF60FCBB!@&)-0E2*^PK
M?&IH#<E>QX@\J6:DM@S0V@IO#O!7.$-9/86G6P<S'(.R;8B\60#G&<Q1SA@^
MJT3?+ GEVGI/$_EA>ZOC>\18=6^^#VB^)-'1G9#PV\C!"]3>\_:JXF;8G1&Z
M4T)';*!_[FUO'?'D0>-%)0;U38IM137HB< #^$.:H4>X(/=SBKPB ]Y 'A%1
M4:8PO[G1E?1U<SS$?/I5[:(GWVN7Z.LF]8%? @O#KP2]5%VOXG8!%6PB,2'Z
M.4_J.IN!&JO?9(47!8A!NY'Q>*$[5L_R[$]QC:/'52V&D![$.H#Q$%U-D(D"
MPR!=B2)($<4!4%>9YFUJF$?)>[SX%-[,/P5KR$XI?Q7%345AOVD+ID!&1 EO
M(8<26*L5;:NXEPH*KN'320RX=TLH@>=.>Z4+01^<=XI<6&>D;8G[V7' ;YS7
M62_"PVOQ(@3.A+<E'A\Z;'6#Q^< 79!S]C5:AT+$W! I0B(K'"I@?@C[PG\,
M.[976= ]1J@46Y1P9YK!+C<<B(7%D4\24$.? /T!? W-/Z2I-QD8H!ZWPI!3
ME8E4!!NAK#E\^R8YCSRC-^IYJX%>66D(C]5^A,H1\WSR^Z&> +9#CE& &K8T
MCN;9K DC7'!,\,5(Z3M34&Q8>8%YA,;^B3RP9^#3V?'\ZAIWJM#PIHB4^)0C
M^5&?%%F40"@KA-^1J00+Q!I"5L#DIC*Y.;JA:85(]-%#Z#OR.HG=^8GLJG.V
MT$%2E%5A+IQ%E[0@*RKA?V295KW1]@<'@TAE$*DA2[8S#/F6!C(H!\E_<5:R
M75[! 8LZRZ<_)K[=FSBRWVB4<,N.45( 19$M8-$44>;%>J?UGML(BA_+8<-V
MH:IF&!*@)>.8P,7 W1JM:X$66L.'!&1(17%_47K5V+7S05B$Q/5$D\8G+RL2
MGJIQ^R\A00T;@#[N@=^MFE%.@*=Q),/Q!A#.!]ZZP#2)%,ZR,A^)DY *@/:!
ME5Q%B[(((QIEED9P4I()/ /=#'A4]J*W98,[5C>)!"'\YPTP&!0Q5G6S9Z5#
M1Q3Y@G=-0../9L#P(GP92"(0;1I5\50(/?5IR2(>R/A%]PU],F)G&RI%1*<:
MEF9&YS,]@:4T0T0@-V4+$.\9,L)9LLCR(7J!0;U<,2C%BI S+R.G''-2C-OC
MP4![)RVGK9X99" 4TD<!C :1IZE1#"@@YS-@]J<FJV*'L:E8"X@61D%*Y/?;
M;"JOUJ\OA:8]53$>6MID-LMR?!LH]&P="C: XMP=5?>#!>7\>/^Q)_6.G=)S
M,&W E!4<2L1JSP(NPZA9@=KTSASF7[%KC+1ND\(-O 8U.ZB*9"ZNXB[#((/$
M.4!)>94EY[VHK8IJU38[>S?5V YG\,WZV*1@$@@T4[WS-%O"<&0&,)-D @]O
M+BSNP4J"25MG9*LCAVDNV"2@\U/F-8%*Y4/.TKDD+)O86JR&RP4.@!'2PJ'0
MPH(XL5($AY2B<@J;0<]=>M'9'%0 7_XGT3]:T,H0B@)$#OI;DTV!?G/A:.2\
MLM[4HA"W!6-%4"\N*^19IFER$B*@>N^\]D85N4$A\B(KSLJ<_,*)9W<X\!E!
M?VB)87:_JNNY?_@S9%/$/>)H$T83'+U17B*GVB<D[T88T6\R(O/)5%,"TJ'C
MN2.R<%5AA6%ZM;7<MK<"NPJ]_K1D, O5U1#Q1#^V1>8TJ0@A$8A(@(>C!YK,
M%EZ_PC3LR*]/<Z(R'92:%KV1[>+N''7YQU!4IFMXHKNGQ&!+DWRBS<>%HR"/
M)_T&%G: :O"2,R0S$%+$981RV.9Q4Z"CM P1 G4\O%SU\'K5#%*Q7&/?>2JZ
ML^]LD!TI*_'=&(_%H^VCK 1S0JT#MAR.GHLJU-6HUGM0D@DL<\Q^=%6U$3K
MH6)83AR*@QP0TD"!F0Q$0HW!0TOU<)AT@<G$6!@\!^[%"/!D1)GB=.3D3\OE
MA24TIU%:3R9!NKK1!'NJ=/6[RQ>)HY2 GW8=*;!@$K@/79FLV1"7S"](<[(
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M5F@86GCASI4]MYT(@U=,CH#'H.9*EQC/H^(*I#QXE-Y[Y-'<H1:T XI;62Z
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MG=Y1XU<?^X'T140HJK2S_.=%!6[9+MSQA)LY]KM]N;F>P\UL.\^E>(CM7;_
MJWBI%[*[\9\23+SI'H1_78_7HSN/US?H\;+TR@7SI!8#O_) $YENB/]I,W?3
M9017A]EOS-NOG*/^C./V]R4WLZ;3U9X$RBQ99/G%TW6/[0E.3%D#HX1G$GI5
M>)>EV?V5"*2'W=E0'7[_2%TA[8XPC_M[/SWV^,?O5RNOWI9[3,G'IUBH^$M3
M"FD'WC\?U4+^"81YG<3XM^\G;9[O_WTEU<E4B'0&9K)NIO([#OW*UL$RRVM=
MB4'-Y^;)D>^N4BQLI&'\>*=A?/,:QL%RB57F/T5'UZ]<7).T <*95V5;I*B)
ME-53+*O:&)K@]S7U0'SXY.%>!#.MDJQ.\NTM;C;W+4W6!D)'9VNSN[&*LM?0
MF[*M,;>\ B,G":HT<7>I\].2RJE0H=U*BICC_5H5(Y4>5%RQ\D])@T^BU"RH
M-FY;U6W"P53L&"XEHVQ[)7G;]E;M%Y/R&FE020M^-[7$ICSXK&C+%NOTR-#<
M-? TF/_\U"NVB-G\P2@E51S3[I&;)%PUCVIH550?7UK$S/"J%.OP-[9I=J7O
M3ZA6/2U/4. -FR10-4::R(HI1_H#+I,^1_N#G94-]FS/BFB6G)75YD./-ALY
M-227UFPFU>1WOPVNMW' TO2H//S9T@=5(QXMOYSH>=(:@Z,MW&9)5F%A?M?M
MK1XHQ\.[2^3*Y*=UF4S0J+L&NJNG53:1]D9V^6NOT9F?X-_9#& $=104=Y0?
M7&E'K:\7C%(J["U,4H0%B"J#-:S=J<%:._YQV^\78*0+!PKZT1+H]_@F;E4L
MI5[/I:T$5<Q.*M!O>#@-;P"VDJ>W#+PP-<NRSC#<@<,UV;()WZ+?NF+1K@P8
M=YGG8@A1\" LI85$@8T9J1XW\&.L!@8K\, VW=2#39TZM?B7*WS)=9\<R^GP
MJEB;3O'2UCH /7W$G^R8]KEP>#!U+KPSQ79CY7EA=U(GON2^K'@Z,VXVU+V!
M!M?AC*<@]K47,\P6SC(U[= "1!.LC!5AOX@"2_(4\$P-*G'5>'JIJ_#K$QW_
MYH^2:WIC6<FS+&VQ9'&P0 AW@6'6I]DRAC.#_>GX5\*RU.64ZYMPCU<:,1WD
MFUP=Z-*R3P^^E?&VGZSE7LE9DN54B$2[.KI-Q?6=YK!8$;4IJ;) "C))<@$7
M*LG"S!BWW#'CBCYY#)G[20E#IB/BBV!B$E?'ZZ7:'PE#$XIDY>N/'T0[)5<;
MQ/;#]O7K[MJ9=_@H"8'=V%WRT/O[1^_OQ][?3[R_?]*_M[<>/O[9_?#DD?>W
M]Z G3W"Z\NG1+_<[\FG']52FQL!4(I]:L5.!2V8P79TCT4VD%O)8<E!7%WM'
M^,?K*K<I:8%-5V!NAHO-3-[KJ;"]99E;V$O*+LEC?TE^[HCLW:<W]VCS_R.
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M>=;M14R[?(,5HR_@G@]EKIV*HM3N *@T69ZB_629;,=JBJ^;LX*F=I7:5D
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M-CWF9TF\*-6;AB*-SF'8@\UP1+$/VF*YL68KG+P90XEIY!Z=16.0G1%!%[Y
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MY(<7[U[]]3G^\=O)7]X\__]02P,$%     @ -#W76C8AX,/8%P  4FP  !8
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MC2N8(4FR(:HBTRK99'H,;UD8:0)Z(F;=24WS6C[YK2K1I6-LH7ZI= D*"WH
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MF[ATL_L?=G(1>MU_!28(QUXICJ,C@N294/N;8C5YJN(C'^T#PO3V2L$DV]
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M 8[HY[<T3X2'[-KA+PU\"NY'HKAX*%$IR(752SAM2H1]C.T6 D<-%*%7-%,
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MAC>.ARH4H#:,V$G0,>:C\,8/J4\V\[,\BQ/#L+H68&!J5C@C6#01"3:<G#I
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M9WUK8D^714J8,\&?N+_QX\>C]:)]_\'HO%.(OKWU7JF:@@/<%T+YD4*+.J7
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M5"@#4IK8CR5?4).:O");E11P/+RC^;64!I\^4*!_]S/.T'ZU2004B8!7FT1
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M']:5$YXE]J;)QJY<:H/M.+5GE8P B',0LK'"1I<>CU?O=02)Y3]R(!+Q^VN
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M/<*8+V*=EL=U[.YYW:GA9'PU[HPH=DHM[37P@Q?&$==B.CPHL"'\/(NQ2&)
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MOS7K3?+(>I/A?8NPUPY*#-6PQVIXIUC,.U3./?JT&IRF<R#S;F'SED.-W]4
M#P=>?,4]*S(#]O%5WFZG2";+/"\@3$AY-')<$4L'G5K0<CM<%,*RQ3.A[E@P
M)&9NP3EQ@ (=?4*1"]*O5$\/ LM:, LR'I) ]+<U+F4E@/ 4L&#<6[GMA )?
M!"E E@(/Z"D>'H\JPZG2HL^#]B#A\^L AYES5.%F\:LR?H,^M1#QA*@AI"I&
M $3> !08J#\\SVB,&"I]T%6^'I[%;"N&&U%98Y%#J=FO.(?+TCE"^]U23W!
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MPZ\*-@95F7DR8!T=Y@C]/W#S^XR&0,K,R86C'E/8WH191,X7NQIP&*NT&,A
MA[BU>@0RQ\$!J@\BFM,P.;A6,30<VPD6EH,&XW7R_3=QQOEL074+&,T;+48J
M&K-P_NAO LC2L'\=V^>HN?OV%MY^MTCQVTA@91H3V.^=5#WM>74Y,;^/X%'3
MBLI O9F2JJQ$0X8SK"6B\3RGRH*F);R,Y.#T.R-)_LK1L=: <E5_W;CFQ>\H
M4U[:K@[QYZ#]O*([<_7;6_<O_T@OGW?:!"16ZOE%8DWL9G*-^W>L@S3\ WT-
M0AABA@Q]&JSB)C=4'DHN2VSC6CK!-WI[/XD(N&W:Z\F+X']NL+XK*YCSI._3
MI$IP(1F&3*]IYUB_6]ZG>6:T3]!KD7^9O!LZW&&8<GMBD(W9>SPB,-1!9L'9
M6[!V ZJT*PH9"\PT=UM68S*D4?00D;G8W*FRMU,CFDZ0X#N%C@N;'W%K6!RW
M)HI4BI&I*'Y L'UNQ.A(_,N=G@X=S21JHB9Y F^7@G>&U81J[()\:GX9)#KW
M90Q;&'ZT8_H\B*AAR&NQ >CE7-!PI1W+ L;?$&9]S</H ,!U4'F.6\QE"O,-
MO\&72&WY*RZA]5""0:NZU,UB6VPH\LZ8U)!Z:&YWNN=Z]'D0\"%4PZOJ@&2J
M8!"4<;WDCC,3EGDQGNA_:QY)&&82IX&8_1(D(Y ?]'(Y=*NLJ:LCIF>]B-)9
M]-TRNE[V:Z.N<K<X]LAEU'/@,EO:'1BJB0D>NC/7"AUK2TMUUGPMM"IU?KDW
MJJL.J3626R\,C3J/SYIU'B_@# Z&@8_Q*W(=";H&^ZQL@U@ 1NR+*Z6$QFC&
MR9VU&F&L<'(GV1;VSN_H0"]KA4YA@I RG23Q** 41,+)17<&EJ02 T[F$%!Z
M'*82WM6Y-OU7QZI!XA1R;>A#@Y='BHX:?5AAJX2*.M/O+2H<S7A^5X_#JU;8
MD&JQ!(/(9#FIH]*[87?"#E*;S&C-8D'%2\90BL'X')'CF"-%F!?MR!=]G*RJ
M(]C:AI)<.!\W@9Z21#/+:FY$_2JYT/L&F#"FRF V(S6[B06Z!M2I^JJCN+P#
M@B?3E8P<2%U>OAED*<32LH*_*2P('KP5%,:2E4'#](VEREQ3A=^G] Q).TMW
MGO6A9?/R:ZRW6FIX"%)75TMLPEG-1LX9LEM/4BMJ6*84KH!G,LBQ6L% /&'R
MD9U,"OK86TS7V=0U8I83X%.SW*PN^+EDK1J4 ^O1NBJT]*R:3CW*A.MG2THO
MLY6JL42GK,=J0RW%IDBW3B&GY ^EYMT&H+,7%^D\D_GA]I8-GS[KYVC)F0<+
MOGM,J!,.2=BG*JCO6=4'FC[5NH/M+9L$'1U.,YEN75M0H:XS:Z!C6ETFE?7;
MX,I=6KH?(NN=Q8/ \AG,I!=AY+C?U*)K&00":]*!LB$F@H1MX@X9^;+O=5>"
MD2CJ?CM41 ([/.,^=HY*NFW/9B-4@@:2A.4 I8PB+,5/RYTZ%$^E3AT9+VW\
M/'M<F;DQEYW(R$-]F#GS2:FF(<DGV> .N4B=^1'^>XQR!Y3)Q^@8QE;-8VG"
M;>J67<!*K-PR!D[T]&G)J&F[O\A[4WZH.("+C#=VW),MV.91@W-651]LJJJM
MJNJ#355UR\V/Q27NW\5^PGZ6R8)9  "FM67Z28QG'L[-((?+']X$1<Y'SJ4^
M.HK3HDR,"$#P*''H9$DZ5AY,SE%]R%"[Z]!Z6IUY,VO5';O>U@:PX+,1L6(B
M>UQPT9]IY;#DG-6%7M76?ZLBP!"R_);E(QBS1CR491CC 5/[8HGB8T1LBUF&
M6WM5=P/;IE'46&?;U%E*Z-^3Y8;SNRBY*+RULGX^ST-.)2&15$M?RB&[HEE+
MAVXUC@'Y_'5X%-.-OSWO+#,CZ>ZS_'A4NSW/IS2?"*1.*MRWMTY,*&(7,[$_
M_O[%*(3Z=(M%"'O(K$,*"[FH3 LK+C%=IYD"?;'/R^9L^W=5HV&'AB<VGL:X
MSZ(1&,GP]".>&,7:5XMFNHE(/"K5N>* R]7L8ZQ:9W H=0:2=KRG6[4CE>4_
M$#>H8/3HT':G/H3@Z+D97K2[TZVA(5HEZ+#I;E&G&##^3&E!-OZ/QB"0:EZ:
M#$1K'8@@T]56JX,.05O5?>"()=(=V^&R\9&/5^[0@V*#ED8%'0'71X?^1)Q^
M"MGB/>"5=SGJ0W]?<7T-IV9]J4^1)YBE=#P+V@<3_O"^82A_C>.AT\J#E=*A
M]&A0J(9TJN5I&]P D 76^J!.(X4)A&)=!1F(E3@FQJYQI*1J!\^*8(RA8 SY
M#ZYAC^%;ZI2IO(LW"I(T0RB(44[#'L&=R<?]1!>1RY%Q5TE;? TBBMA+^N(6
MC+0TIG2#/4P&+B3OW=?1(YW,A6<A=+1)PIITJY.]39S9>D4@WL]8U'@&C<ZV
M['H[@S@,]2!4NSGH(Q#!J4_U..9/5JIUKA4M65A'06TX=KV!NV6G"0I%0) K
M*:;O_>'_S]Z[-;>-9-G"[XK0?\##Q(04 7MTL5UVU1<G0F6[:CQ=%[?MGCXO
MYP$D00EE$E #I%2<7__EVI?,G;B0E$OTT"$]S'29(H%$(G/GOJR]%GNY&6O0
M\.OG:L<EU\/SP/I1U2I0R1T/? LJ(\EQG2A.CWSCVTS!!)EZ'C)1(I5N"%K3
M+@+6QRV1$\408%PTQO=&_8,152(09090QG@R2L4L+C,L.[;6]"?_T*FVG$DG
M81K59;% $LH9!/]E+$4?REXIH"8-X(74:%"F9ENYKP"/<RE?BM -\L]%Q@TR
MU]C+;'N0BY15.,5^<"8VIW8Z+L74)#$5Y!F%H2=64B+0,[_*A;941!P^\D31
MTNR%6\0("V=..U_QO23=]D+\@1>SI-2XE@843(CE6N'9I>T1F18S2N 2,).>
M7SD +?OMP*GG%1&H_)9/N(&'&AS<JZ_0]%.1>E;NSGFTO%@3,F:7WGUZS+^A
M[+U;&*SPY"P9$9F.JPD!="Z7:GII[:3.:YA<ZMKX8UF.I1'6!<+@ _9+:Y9?
M4DK/IC9EQU'T:-I5?LEN8WA\R$FV6C &7E3HDG-AR#8ORG=[9DTG8]W3\0GU
MW;MV:SJW_Z^W:^ZO4[EEKO/\,==I<IWGC[G./0]L=IKK1"SI'0UU+])P)D<5
MJ. 66Y">Z6I,Y0Q)U"/W(E0"R]AP+AP>A .)_(/E"":N88I7WP@8?$1[?L$+
M<RZZC PMD^Y8**A%UKD&Q#H^@Q?BQCZ3+TC@=1-.%;2J"@'X](EM7]7ZLG4_
MLAE] !8W%*7(7?'NQ*B:K/H8_7K:,F.?U2:P1BN-:[JY)5^&ZTMQW4LI6AHT
M;1C9"?*^+*R4CEL.'-<$BOY0G)(;$QS9PP.[TO#;CV]?^U;,.D?SI-;V(U_E
M]-SKMKM+GCZ'2(\-U3^&]-E; 3PG%]SE>?KJ_%EJN]R.:"#FW=I?Q(URF3_L
M^S-R2>!NO6N:WGMV@730>G(Z%STC:"NW&R?'N$4^)#)3$V;DO#,C9CX^FK:&
MSI3@J]$4QQS%9C#2)ENK_8B0[. \J!3D(;<>@02R^;S2=@,*;*P;;%>0!GQQ
MDZ L:+^\WN0S- G0+*!7F04LJ,^9A5IE3F5[0 )>FY5NS!L*04[#6&VUN=1:
M *N+SZS1;6)0=!,9W";U[]I;6TZR*P](@&E3SK8:@8Z3(U,TH?9Q?C#6)7(C
M;_+[9OW87S?RWC/$G?SPCA7<?PHD(K0^:1,_)H1WA5@77M&XL8P2G+0%NJW>
M^%ZWW;L&0+>_VSNY@"Z)VU;^S2;AQ7:UU]XAQ"CFO=]^FKSMX1=<=_T.A'K=
MY9$\.E8E(*)A3(U^N)\I?=JHT1T)7_<3(\U!#D\C0&?%LWFI\ &JX%%5?99)
M82;8]FS^8 [-\)HV7AL$%GPHP7H"^"N-M.0X90T5-VMPHGO!#M(NH@ZV2<'J
M!D<^QM?#./Q-PG?JTM1$TO$/;?(K&C'P!+.5BHBD@U/':]*0"FG6-1T@%*(7
M0O(28(OLP/<:U8N4&R C.LG\>"DK.?&DN^9+,A7A:>F,<3Y_:=(>!BZ-29!*
M?E%:7$$OF&^;E4FPOA*N[TS<(I1FB:YFE6?UDQS.QP361C-Y$(KP98K-N19#
M^_2P[.Q.XU-3>!-,+D<WM.N<9?W74OA1QN-ZR6X--D5-6!A!+2K,)IO1;FZN
M\GS1%63=QA:F+<G-3@>VDGFMXD;.N TDY)=EU,Y&CDCA@7*<GES=MB"&WY"$
MLC3PT7^S1^8SUN*6!7>4#!=[?W4^%5TK(MN-9Z3;@2G,N0.V27<N]S,8&C-.
M( >(=>IU1?0ZG-DE[/&R;C%N&ZM*=O<:U-O7R)^3[G2! 2^N++>(28ZO?7G)
MEU*;MV+N/=[>6Z9 GSVF0$T*]-EC"G2OXZ<>A,V.=4>0%?U'&<S?+\&X!9FK
MS:> %'M:O>=W/@@"90>?!&SUPP$0+H.> 4872'O<1,*+H>-!CX4QB^G1Z:E'
M1-4Y(@X/.*&&$R7*S*TQ_O=H^X]*:*>@H":=@*B6AA.7NNH\1"3 0WC,4E'G
MTG( DBB+ \@SG3> 4V$*KU"JR/.BH03-=5UX[(9'I% $B)IE=+!L/%>^P6/E
M:VSIE[O=TA<C$D]D(1(1I7D=&#O?WO@D22^]3&_5^R6^OU&1(!6GY;^6I91P
M3U\Y1_+LY.SY]R&G':A^UZ;S>Y+VZ]!>:S+'D=]T142"RK?L_E345@-EMAK:
MO>MWK CV1-\@5]Q?NHUUWY83V@;QY(_Z6C=WY6*W"Q$C"\Y7$<UHPBW;/CZ-
MODOVUGZ9>"*W++<C15IM)@E>GQW]@:OU<<*ZW8V\QUH.WUHVS[1V<.M$B@H@
M3$ QR;DWON#:!"V!O$12B7OY.;WGJQ968*Q)CO3<Q;8F"4(/UA8\R(I :EK;
MTW9O ?>,E3.O!?%N$Y/8,I#"JR;*9,/'>H?+9C+,'C1TFPXUE99BNXQ(51_;
M42"TD3L//T\+M'0]8[C6?(3:10HD(X'D/:^Y>3QEH/1=*0'4;N9TT[,R'4$C
M*073/HOKX@^9'B;AW5OD??Q."_3^YTLA6BA*TI.AODS8ZIBQZPZ#O,^X<?\M
MP#WGF63KRWJ)?6PY#R9IZ^7+OJU$9X!^F_3\,.6W&%<4BR[MZ!/F6PTMJQA&
MZ&4%8W4U)JA!<_RP7O9..Y4\*Z.GWX)">]&T;0GC3^7$%H:O(0*@W@:<5N'A
M0;W!R4ZV*U&C'1[,!'=M]"S,>V-X.3Z-3'^ >AL$.$&TL0SHFX"0=^ V=&;U
M_ABE'<6PKF.*0F&",.M+"-/*R?^PED.^RPU-O:!BQ',KUYDE+GR@:,B7&97I
M",3[Q;] I2\P*;?!164Y91HY%V@L:V&EDQ/9D S$M ,_N(_V]WUNF19^_I@6
M-FGAYX]IX3VW*=-=VA1Q 1F][TOHV/F?LC^M",;<A7@5N)8M-TCMDR"-D7%J
MJFE6:_$_P YLM2X3%Q)1 E7N*@N%.SSX!6(A9'Y(.7IB#SB?6.3#ZH$G%%_M
M-J'XBW/Q.,<MC(2?* U%Y'S"I 0*(@I<N4E/0,C\%Z:F\[U+18DEL (C;*'Z
MH>I0!G(ECR<N#<CR8JR#,!JL""\$D^)&Y:S0,4FCL$I9JIGGP,[:9O]97*'A
M,"]-&1T+,9(P\E\>ZF\)RC>"5!&H]YQH'5QDA.0H,Q-65)M MJ]:Y1U@1Q$D
MB"0%9[O@LS&B8J1KEY@<GC3JX*=ZOG2\LY278G]]T<:]![ *84JS.;:TI& 7
MX(ZH&[HW]B\G*__M].2$./ )E3-J7ZS)\\^^!>G&O,*R*I^X4(%PH\A>S(I\
M&E61_/.TE/7$[=3:0HLAWE*BAAXH:8HRK5#4/^5!S]P6Y9,7/8!TY1GFQ<PS
M^,7K!Y-"2Z8B!10:XE7!;974.KNB5JU91@FE,42\<AA  RNO(K[$#>#R!V[V
M3D_NV]*]-BW>%.7\(CHP79),.LYH WEP_R"LCRZ%/S%-5[O!SE0@*$SS(+74
M[!$V,'S:N7=0T,H(#-2E(-'L$(4+>.++,EGIOK]2@8OD[.3LS)W"H86<EYMV
M@"(GL"RUVQMK]9) 9'0DHR[(*]T%'E73$'^Z?_*.4 TTMK[LN5,3C^K#N;@2
MM1%@,#,PI4\)YSW*9]7M<?=-P:RQ#E7T=K@UMO&1-=C$LYK>)#DR0L?-P/69
M3$,$8W>G79[5_(,@2C( 9<=A +%OU,Q)"Y5H]!4;+\^.!M&02L.OM%.W$6,G
MME+',-PB_IX?+SXL\3;<''3M((QPH"O$2O.$2H)QG+=T4JMZG4RJ&O,UBJFY
M0%<M)I,E5+]0/-6S04B)3(3(B,;1+LBT0Z? FQU@U@$ZA1:; AW@5&N[+&YD
M&]#>835.3T;@SH!J+&X/SD7W$/DMMV]Q#:S%IW!X8.D6:*@MPH=- S1<^N^E
M];OT-3K_ITWC.CQH$SU$XQ*^!B_I<*=R[$,_L^Y)%#N<6?^99[/%U>'!:WA.
M'T(?WZ_<T7['0O_IZ5:5_L>*[+V]PD^63 P6K"4!M=$!57P/C*N&&#@N..QH
M .XL,X;Y^+"CX5[.!15NBQD3XN)PU_A#@XWCU&.)<)TEY!O=,JB)=)9:!*B-
M"UQ\6@^N:O+B^=,UGH=Z450T],?RN.V"X<"ZHC6.<R2G#K<V.GH=94%,(4%^
M U/7N#-3&NM\:CMUIQ/96$_2"ODFZBQPQVQUZ[[R/5W_)VG/^ZFJW+GSIEY>
M\K/]>S:_!E%5,\^=G:9>/T.U\-.;UQ?V0/Z!&V18WY/W,9;T#2P\_?396?*/
MIQ^?OGZ:_'L#L 2P-*<)8;K_]?38LG-PTTE1DN;L+]F(66-7R;LY40/2R[\(
M[!W4T?CR9?<.R=F+\TP&I@_IS/>$IE1[?B\@(7UT^KSUTV=A:#\$#B7X)Q.2
M*B"!4.ZH/#H[;?WXY4G[U]H">>$<E"=_*\:?1\BN?F3.##-R]*7R-4[/STZR
M)]^-7+@JUQB[=^Q\/HE'$=BY28:30K0<G8>7"V31KW]R?A8F-ROF,OCS]N#/
MOSM[E0 U:(8?MVC'5_FE[^[:M2O/D.DSN">N/P\.^-7SLM3IK@L0-\T.#V0M
MT9'P4YTM)V':3E]V+O'L.[D J=G1&^9J[=#\N*__FJ.]Q5W^Z!/H?9+_^]_O
MWKWS[;.5].0IVY*;-?^;8N)_\^[_QK](6C\@9\ISH-#^=3XTBR#8CEZR6!CR
M#ZW.6FZ^/SS0I02_[<\G>"9^0N[P]]?G'GO=3L'<D64P,"EP9#5,_#3+7-C!
MFGX3TI'BMB^6BN8<0H24(1]\XNR%,S7.)ZTN2=EWDLQI;F:X"W:_6JHT^2P+
M'T&1&V9 =%W6V5QXL"C: +#U<YY?<]L9KS/*IT&"78OKZL"%EF<W.WIO#@"H
MT9]I<"C(P51<%;7T#_L#A&VHNXZ7)@*)XPUUY1*? 1T.C7J)50-2K<JD@EDZ
MT;U)^D:@-S@\L-9>'K0AV6@F(6BR:8[_O:Z+FPQL!$KJI:$<X8V!,P;AM7=A
M3;^UPE6X"Y_LI[DG9H\-Z>'!+%A2>I'995DUL.SV*-'G3K<^ELR98+?J+RW5
M61?+"JOXNO23$0Z:J@R;E626#B^#T.-PH(73ZY!^^2/9 X\5%8V_ML>]QW[]
MEC7!%X\U05,3?/%8$]SSJ.3K,8.+#).J*<76(8AJ *UW2<>WE>ASSA=D!XA"
MSGPLN2])T2.<<('E3$4QF!W"HL7";WU.I)@S]D4TE/JR^_MKE+XU)-G%S!V'
M<284N:AI^&>S'$F 0"$5D>\(B2AY(VD@:$%@B),91REU*6>S%>4X R'?)%MD
MBJH7KQ2IWAH);6FIAN.0)LZMFA%D,6ND^17%P"F7V6A,BT4_!XT&W(@PX1(1
M&I9[:SAY%E)<Y#(BV*,?(-Y++HQ_#[\NBO.B,"^DUGN6:)1+]UZ%;[,1]Y0?
M#WXC=E3D*_(^X>NS%P,GAH1J^%I\9K?/:QL\TG4)XMV^,J)Q4/8I'(RO.,KQ
M*Q0ZLWI\A<PK_&$J-+B=SB*?Y"P3])!<9'QH\@< (KIS$?^+75S3CYTW0O^%
M.?X/ZS=W162.+.=D7!2(J7=":!^2O('"M56<)A_XEJ8C2OJ+A$'\3?'4;:'@
M]BHOS9(3I\^MAOX5<'@@2^ 6+AP(,M( WK)4&<-\$1YXJ3W"81/Z4"C*ZWL
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M2825LPR^#<'=PU01V6.V:LU9*H>4OT5K;'"JW#FG'_H=T;C5#,=1>L%!B40
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M]]$BC_A<-/T8,D"2;:/,Z."N,<E;A79.=:?%&VH@$DE]')(2@M0</L9,M3R
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MB*VD3WO.4/J_5>,4(!Y1NBN:8_-<>^Q$;EF9.'^L3)C*Q/EC96+/ YF=@M?
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M7%Y]74&I4C,CN7]%7:+J\%Q,I\Y+R18==]W64CT$]!B,=:4YMJ[X.I!W(=#
MR A8,L9'$G(>*?W.'7/)LY-GN-V'_'(I6>V/3_XF7\#%/W)E%QF1"[0,9XUS
MW%IRQ. <HP;A/TP&3FXN<\,/Y-X7*[:Y2WT#&-%=+OKSH47_VL5V&3A-WXL^
M)"_UC^N!!FT8%!)KVU1 @O=3U!IUPJ'RPF-NF8G'?Y,SX1QR2B7P:_1!Z+X+
M?6Z>>?=*<VAL]3@9SF!^Z5>D#!Q#TLE0(K&529^H@(G=32Z+Z8)& @\"LQ.+
M.2U+YQR"WH9D?A'O1I6Z"HE$2%.)'-7*D/?>>80\,=J43/\(]S>2GO1E. =N
MX5 P4LV!,1N;;"<!^X@=>19/8!IH=#$^*=[H&*7^Q.-$M<GX[WBW/\E-7S-$
M)'DOC'R\@=V73E]]]QVQ,1,[.S+W ,'[VT'00>NC!%LK)(),90#Z"6MP4=J$
MG__P '-%I+I^]N95*4E<40SPQ)>LQ)V;.S,1/?J_W;O/TS"O=3XB>)2;7S=C
M"$RG,W;69,;3Y',Q_CR"'^H+7YW7H@&.BYI0E'C0YN?9D/DA7+<HC[@(4D.Z
MNQD@.CJ=4V3H/3R+EA;H;93&D%B03>%_O9BG2$>X?U9H@A%P%UI9W)4XO3&C
M@G[M3R^4Z"1?PR<KA2I-&[7[EF]T,7%'6= 6^V O0R@C;N3FW/KA@9L;[%<\
MV06XR*+OZS%NQI)D<GVEML???R=Y1ZQ%W:A,+9SHE,LV_L?3CT^3-SF\1EV\
M^/A3314ZM_%;*#D&Y+=#<"$=!^IT9'8QT@+!!_W7TBVP:<&.0HW\S/*Z$M+:
MP"!/[X@).'CVM#DX93$+=HD8:8L$;T8%BY293F^H'UM?AE8-=>XBSI=4Z+XU
M1>O%/:,?4<F&9UW-AC,_Q8P<+ZPQ-DV1M94K+%:QM+<%2+:6(M\ 5"#TQ.X=
M:">\+P7COVQSO@<Y%GGC25#E!FYNO7B/_1[#*#U#0>4/#EU[31L3R6_[0J<V
M)@[]9&4P2/B>J34MWH&A$WU8!W(=. FNR7JO9M)096[!MGM<U./E'.XN,?P&
MUW,8JWI)*BPVIQ_@A4M2[9-Q]=5TPPK'W5LSL,?F?,ODS-EC<L8D9\X>DS/?
MF$OQ?,BE^)$TZ1H1?G'O5T7J.N)T:5?2KJM79QJ$MPC\GV\GML+G_3076^P#
M"<_I+<EE$O_H],807&<V8SWIOBJ"5!T*TO4$E_5$[1_/A:'O9N6^0/'=F1'?
MK]O)1KGAJR9IT6AB_4YZ?0D+L.#X=V>7S6[0(<O(I$':II!-1V]IR&?LL6W^
M"OOBQ;JDY>_T C^8J%I9[_Y)TX] *<IU*2RL[OG)K?])7/9S][IP(==XEO.@
M_AM73.,,CCLE-$D@K'O(<\FQ7A(458MGJ2F=^7=NMFB\0/H*;NX=?,ZMDJ"(
M9'-8+1#?^ FI-,[/MW);,ELT57Z#?4NNDW,3" 4(%-_1:,F$]%#(F;FMX9L&
M+IWG4_LF4-KP[H"XK-S?CZ,'I8PC/2D6\D<PWTV*K)9 ]B\][[JGZE;^*;S_
MPQ/A$RHP'V>-&Y447S5(;TNX#>_+#W$*!Q^+[U5#OF[):1Z ,NAOGL[=O9TC
MN1+".3=3+/(@9$5N5%?)U-E 'J>W6D$);_C79MY:?2.LK1/- 0EVR22L?VXL
MC?;3PB)R#DF]:0)PUU4U;TQUU-F-C$U?$N\SH@;#&Q)DZR:DRW&(#+N=BK3.
MJW*P?V?#@B'R#CW_2":K=Z?OL?F-C2X[H9MX;>D7E)3'7'WO#BNW0L$_Z7[X
M8^?Q?_3^XH_Q===>YH-[O ]OWW]X^_'M;Y\N/KW[_;>/R<5O;Y)_7GSX</';
MIW=O/R:__Y2\O_C@_DQ_^/7MAY_??D@^_N-'[Y[^N,=:W'<X[.3<\3E=MWA]
M(8'6',%M>?-^?/LZ>5.YH)#I5A9$R[R@L#-/CL[E"C\JAN%-!FYRBY'I5_9,
M?&F#^$-]<)E=7]-]?27$Q::Y[^\WO %<_VC# MJ'J#U#5\:QE'9!RTS#F6"]
MOCENZ02K<^$6#;V&H: RSJ[9DHCY^5 TGY.?F,^RC?;XJ:K=>"9/?JDJTM<A
M:!+7GEK?_#NX@ HV<DSN]G<D=>2#-V:H%R.<B[]2IWJ"FZ>AX#DQ9UOOXR7]
M3Q?WKW".@&L'A&]K/AL9(S?CDX)\8YP9E.$G=4 ^W.AQ9_*X1*R+D^F8;+)/
MVK>D0P5^6./HK!C/V^1>50^\M?DX,M9F9<R8B2D<IL[%5?73^#!I)6#D2YT2
M8I1\.RH6H@1$WI1*O[;&(&EI:_O1WL1(Y/&2E"C[GD>=F*&A /[#0<L$^V@2
MWU.T^^Q=>PEG.<(8OG^T4:/J-[)=-XH'Z]R,M_*D "):-S+.0K@HV,?'J6?"
MD@?$^C0^E=^\=M]V7(!&(K/F^_VUQKL.0IX_/5T'.@X1R>_U959*AM5MWH]2
MR:8)?E_=\NK>8W?B6Z-V9ZWNP15.L!$MI6'/3)9$'$ OR8BM<E)AQ7_&#D.6
MG_BRB8@ML'9[O27%*(1SZ?" $ZML4OY8.JL]*?PVQZ8,++-@S$G>KMV<1W^:
MNAZ+/# (,3>U08M"Q.KB@RMDZ=U>KF[=&Z>D>6+5[#">MH1>10)G*[4AEMK*
M1;9!D4VXK"@SOPI$NC1YOA)")Y=MU)A4L:Z>$:_RDZG4]-'L1?K ?)SIC 9A
M+'8-C!X9'EFS]I&@5NO).; DXRIC#ZUP/'P,S!.">3V7%FW[>):A:\O-1^I&
MFQ--<FYD7DB$IJE,I<A.#S>I1G.Q([(+:0K+=-4-BN#\5-7*J]?T2,5W#_*!
M*YGC'-1:E&AQ!Q;IO#O_A= L:50)297?A?Y;.-*PTA?BVTZ#%+DGK&;RF$W5
MDU%N-.V0#L1 /3!;5U/J-2EG!0.?J=C>$Y&GTB+4#?5;&[N=!4D5I@X#=7M5
M$:\1/#0E@#;#9#QVLPT.6X0L&1F>?S%.]P?2DE=:2,YUN0^NG(FYX2,LE6BB
M;Q/P _@W4Y4 .Z]?).)H"17W;*GER'M8)8JY)_T-?E6^7\V3F/,-E*Y-*G6:
M[2+_*N+.,%+FWCBM>=EJ=%,U4UR07^D__<)"X7;DGA>Y?#(!+M0IB+UD#)^?
M03--P),Q6Q9+>E#%NRSP*BG(B2KV/#W45"%NI#Y :@<CUVM/$R=1J"A?U<)\
M'3!!9L*JB#Z+[3O/81HHUVG]+1=482+03N.NXJWS;<9K=2R8M[RNW5'6S'4!
MD_UW=W6>> 98  $*Y<L_5\)3XS9,35$JK1\\XW5!-*  P)1,",K]M70N^M&T
MA6]__^]W;YZ<OF*6EF,=PJT+S/*2NI);.=#4X_5- 1[?FB,0<:.>9;<IC@!*
M,I?1^<U(* KJ1+P;#5R0W!;E-'00A%+^6!N=<;>>?D=*+' \UX@&.TCM?0I!
M5[S[EESXYXN+]WZ%$MFLBPY"SDPT0^8FZ^@N]\R\5"*% ,BDK)8E?Y/F@V4G
MQJN^4P0F[[G5-Y4\M#X@6TGD/2OE&"(K3I\?FU@S6_C6+][OE Y7^C*/KV@5
M7'Y(.G:.A=C:@1Q;MD9,V^FQ6<_D!IT?<S4 MIHQ8K3/8OOE1G%W R8*!6"R
M ZEH3>$^,1[+\87AK3UI1 LP$QPK+2"W@2DV+JXSV:A_P:[M<3RS)7+@_!$Y
M8) #YX_(@3V/J7<J9/->4L*(+IP5O2FJ93-;;:@4=46^QM5U89#X"+<HMB+;
M]LZ&PO2[$?>G@<$[BHL!6I8/>DQ;%#/'TF86H+L^.\[7H1]FI&83DID<I$*C
ME(IFD4@I^A'CJFYW@+%WSE?KT-^T <@QD#R>.:C"V*ES-]"9JTG5Y2:;P5XS
M; ].RD3+"7MLIG>?OSM;N_XM:0 Z"-CM1OZN&G]^3-G=/S^9(2.2&(<;S$Q@
M"X^M:-BS/W]^DIZ<T/]Q2ZZ-KYT)FJ/KAGZ/[?E\^+OOJ?924Y#DOO[T\""T
MHU-%#O\(6:4R^:]EF6NW-X&UG[?K&+\RX0\YQF_<)FTS<8F;^.PT_>[ER_3D
MU8NA)Y#EEAP1UPE'(8)5EI\<)[?<D ?%/T[G+1<A820BA *WPC<UA:D:@3!D
M*T9@,55*F9%\,5GT(_KAX0%X("15(Y .][N:JQC+.<M MQJC+*:+>P0;#1*&
M$%0T).\HZ_-1%BL'JHST]0@N[(ST]8*9+-!V:-G-_B>OJ^3HY'C#HJ"Y(+HL
M.+HRIQ&+&"J2FE?#55ZDS\Z>I>??O3@\V.+2K<8MW]R.C%!X0?K[WZ\%"!QH
MPS8]ARZ-]MUZKOY!^OAUB5-2(+E 69!.GVSLCH]):"3HG#>D$DZ'IV_*Q#]X
MDQP>&-(&]P3;/L"7SY:@N(1H[<;3OE4];Z:UN]?M%D^@9E9$?SMD-G)'*4=(
M[OQN R3=R2)2LJEBG@)K-Z=:D78S-QY5Y80@^B/W7::#==^U'3Z67T6(_A=*
MP.+I%(XX5W4#[X Z0$2T#MUF'&^J])X1DL$CI3:#-'3YX[!13>.OG>L8$A6'
MA25G[^89BJA_;59#C!UTU!--7C"YX:#MYO2GM\Z'!S#/[>16>PG20UW[?-9-
M'FH_;O2+6:Z])'?=>X!]Y,T8C5FHT>#YT["QDO8QHIVTTH1@[^93JV$#M Y1
M74GN54HQ7U^X>(F+E=<3:FS];/BM&G%">[EMUD-[F?*B'%RDY&DG@\^VU0J\
MTP0,7=-9W7@"5 R11X*VG'S,3/;^;-)N^"OT&,^U\,$_T.]8HI>E6R%-:L;"
M-&'28:]$8[ZN1<//R+'?=C/Z$B<_M8D1_%0\8=!RQ@O5WSX-2HW ++BE>ZT]
MW)6>88(:0(N+<S^HTV4^+Q;2WOW:JVWY880G$S4LWH9;K+^JS3SE#>Z:QP>1
M*TL34WKQ+RRJM+N84ID_D@S5M11EZ.^X]-FZ[7POFQ56U6;M>?ND"4$L<)9C
MCDH[KX\Y<_M62SPQ(9@F$-:_ECI775*@90&PB2F"='EX:&?\Y.'%$D68YU+B
M%S";<8,5!JT*'>H$BZ1;&@. H=^1]MVLU0UF>3 LDX&\GD6];.QR;PGNM/@-
M/-IG\RN+&3"\FR\_1*XF]*CW]7YAR%RBX)'&/8/\"N;7^M]6,I9%5 K)6$B)
M( N,45R99" HD38)_>&Z9>R<MR\RR=&<['%0OF7>^=ECWMGDG9\]YIWW/#&T
MT[SSQL20R:3:Y-!I*]4SYHB3?H:";XTTR#)/_NWDZ<G)*;PO_G(:K&ATB0SI
MAZUR+.$'(OTH%-]><Y!-V![;J6]-,Y;6R/H<@SWL(Y%7@X;17D2"K%D&[KLD
MS+@WG?5??4:#\_FME-7^+X =9M[/MWBMB/_-P2Z-KMVLP+GM11U&;0/#(FF&
MGL+4S!D.7V?RMS68*HN<H3"P ^9LEV""#F(+U>E;32-?SB>%X=25$?C48U.[
M^%->;\, U&03_K2RX&231=UOA&E(TGX;&--F]R!33$D/S#1($?[OPDQI'%O"
M3"]PGIK<UE"$'D0BMDWI2-V8)MWL<B)NH?.9$5<8^LIO?*HZD+5P[Y;"+&R,
M7PHW?YT&XK9_8N0R9#A5"'=L@J>O4-Q.'=.F\B.L E?63#C'^!9I,L_G(\D-
MZ3W(Z5F4G4__J J$Y3><=S9_&!RW_PZ-6B(Q_UDW_6Q3&>U,Q[2R$%3N0674
M'-&E8*LN#'^XJ&WB,FXC^>I$2#4(RPME#3R8"7:')8)(L9N9QS R[$"Z[JS"
MB3C6"J_E24N32X;FY;DB+IUMOLH$S!:FR= NZ+R U$]N4'B0KDU8^;B86YZ?
M&F^6V?^X[8 $S6=!=UH@V'1>E9?9I5@PX\ML2?<L/$8-7X93/*4QEP(+H^:\
MNY(>/&C_YMEV_LV%'IF/<(*OV0&DODU0= ^^C7=HDLB?$0GMD%$TY.SL1YET
MIWI?%D_$CMH@%'_+#=MF7$-($KCA\PV55M5L-H4[3PX>X24:'=9KA-03;93I
M;]:,?OI.!M2ASNICN.<Y64]Q;]"\\4OL5<@8_+8OJ'5GFVGY^NUCH*QM186$
MLAY80@)3EF(CCJ'ACBX1IY&!F&4(4:6<$\+]%XI19)2(]F-!S$D47GE[.CE)
MOG8-*M'CFD5H8MN@!V@I;/N6AAL'HBSF9O@M:R;9OY)B[HZW@J'+G*9C/Q,(
M/=XUJCPE^)\8,1C'7-BF#$W +S[D[%3RS3]>N].7F((\AU!K-?=]'Z(@D J/
MX#M0+Q2B3AZLD*7I&I-'TYW@+^)7W;H[M0$S<#:=+?ZCLE+ *,:["!1D'2R$
M+G0>?(7^7?K1E"B4WJU#:1AK@,</UK\K24>'+$\UR]LZ#6%]P@1$%_!\EK2O
MQ+IR)-'7-=[=-6EB%]SAP001O>4R3(/%L9===6BFL!E(W0D!*0?8##XM!!1B
MW;7UW=-$IDN04/)NE09P?<=U#_X&!PI!;@CWA?@B;EFB4HN_$SN6HI%.U#P(
MMT8K2\V [B'PUD);TXVIFMV@^P)"?UXMPP5N-AE@HWP6MXO:G6SK!P(S\HRK
MNI'DAB2Y#@]\OQ2C4K7W!P05I7/.9WQ:<8RQS^356Q9OGC\6;TSQYOEC\6;/
MW?#=%V_$Z)$64TIR3LD\S\F.D.T'1$0L/V'OP'=*63>X5YXPW9A/ O )2078
MK)W%FG,W0C:IKA?$<>:V";.<!_]DDK.6&65>O/+3FM"XIAQ:39D"(@EDFUYZ
M(,2(<R#=ZK3V15F4G,VM\L'JL[?<%TB ,G^; :&G+PH,ND&!)*GBJ*"-Z;.=
M''')I'=HZF<LKYD$VF,<[.";1;UD[TO=HPAQV_^.UOE+[M4X#_/2TU?"84X)
M%W$/;XS2V@&0:T;'6!62\(4K F9'!CS0H4VXP!C0:AIB6R0[<=.)?^C6V_#[
MB'">\.\U%%GK<Z:;'<XX\NSQ%O6;#'IQC@6IJKFYBS:G9:D8K<*VU&[+1)HM
MC^'Z?1^8+'12A<9GRTV)N,#LRG3]2V[%6_2B6^YJ&E@K)')29Y0X?H8VID3U
MZ\<,Q_I_>A[W'I=02XFKNX9:T^!7$2SFP(ZN<^\I?[,IOF^KAKTF5(-)HUU:
MNG..I?.FG4"1]64;P1O6IM.N+Q[WF6M3-=$6#NH4[TOW_G6)P?9)M2Z+]%2I
M7"D#;4^9GBDBU>.=30W0'Z'#9<O9,>P:P_:!ZW,A)?--@41VF$-_OL6V$;Y?
M-[E3%^FZ>."U2";0:HR(_/=_+K^=]'J?A'+1)0IW[S#JV-B T=A>0+F3D*)T
MQ_HTBU91UVLKW[%^%I.#B,"+5 Z/ \*D4-GG]4/T=L0W_S8JA:N2K)2NHK4N
M<AR>:XCR2,[>^$YB0B @B*9;IDS$,LWPU2.ZDW!C@+B2]44(%Y!=<V5Q013K
MN(2;A&.N:?0(2'OYZ'@HJ5>.9M*[,69@-I/,' E)&[A#-G9_-'1<9#=-VLTS
MF8J0M;LM8^L69ERQY/48FASF<BC7TZD&P/6UL /+2[?J2<SR9,'P QGWH0FA
M8CCNW@"ODTW89Z-(19]20"J^L#PQP/N<F>PY<K(/%X#OXDFK& Q-H$G5&J%L
M$[:EW:YRJ]#BENZZ9GS343XD]FO"V]+G;3W$0YL^^M#MMNAM$.VC5?3-7G[T
MGM9X@[#A&GQ.C-:4'"592&Y3"$%GR\VVVC9!^R9 3;B!K4E\6R&:#OIMWXA[
M )-(D468=8@_::F4RO2&O5:@>RP)Z%I*T;T+D?.J.YJJ7-OTE$^*R@X&>*3T
M-^;M3Q2,1.VB.^"KH[*<.WXV 8GV]\3?,IO\XC&;;++)+QZSR7ON=>XTFPQ'
MWQ]]F0_Z:&V3_;+5O^"0V'XFP\ &ZD:8]D1=(7&!]*3LH4]+"AL@LVI+NZNJ
MUT(/1(M?Y.F:HBCZNF-#OP8/T3HSOLC;K>J.Y&#LK1X>* F :<R.A.#LI./?
MX+97OH<Z1^98X3/1:7IZ[IGRW15/GWMIS:HK@9M28"+'V/J(_:XY]B/C-,"K
MIOFR+H(^ @^ ^%W]"-IM!Z8ZVZ?J&TL$IYW'3&)B>7,U(8N#<A&@.S/;5\<<
MHY4BF 0F,$(K3/-YI:W)K/]H?"3SZC2?$;N+OH="WNN;?):1[)Y[## & NSC
MOD8LE)@=/RN28WSS\^M?+/D%Z;S*Q/KO!E0[/*<F^!M6'=(X3T0.85^8%U0D
M<O2_H)^8^L%YR]%8U'5H!^+LCLI$XNO@S(H1UJ)[V_6,;O(O<HTV0ZSWUS/:
M?5[IQ79Y)6>9#@\^\'[^P1WIRO,;U"(>LTH[HYASN\LM9SV:I\NZ9.5D,9UT
M:D#, 4D*[(&L07Y\#=T<BLDX5%EL&^\T39JQNR0,":O;FFJEP/$\2UJ;VFB+
MX863MQF4^$V.,"R65=%;05W\,B>3KIJ^8&^Y*D:%#,X/6V_G0?,^R!2M,7?Q
M6/["XPN#R,AH%:1'^)#I0L>L_DP$[#1,67%D*6<%>($:L-(X>S?UO'N$6+N&
M.9H(D%*_OX5J#8W1@RLG2H!'D\A7$=;57O$<=E_8'8AT>&7L33C![GX\'QYT
MSF?Z9E:/LC)OGOS^YRQ?J5SXV<G)61NJU_UFS!LF4#L*P-F_,<443W3($7JZ
MZ9QTQ]]\.;L,BT&23=+2Z*LH _.HTC6L5$Y;SV\BVG!$]2,BM!FSV!JZ7O91
MLB3^3FN;T9>,'DYM(*[T;W('*N[CX(*GW\;RHY1R?C/)4?+T10*[[%/X/J\5
MPTOXC,9).R^:&015RLN'9>IW#PP*U/GFM;78MNN<W7 FPVI9/^:O/E9V^ G1
M7T5&SAJW8_6P^A8T8!Z^\5$AW]=US@3)I!ODWD&9U]ID3D D-16CJOJL_C^
MG"9+&K=4]EXYQGX>'H!S6W&?GL5=DV[+,G.S@V<+DT:&X1KI]H4\]$_.YLM)
M<_+D[]YDO7U]S&9-]/'LP_ 1.EG6OI;AKEA4Q ]W [CHQ&-10W0%)W9,,RW#
MY/>D;R8*(<CTDG20]FBMM\$V]8DY6I:$&8MLL9I88AFG$WA]8*"'<QRU\V@%
M *WQ E FLY7BS-Q8W2AZ!ZLQ-U)I-!5A71N&%%_Q\>/@LW$A]1UYDO@4C2XK
MBA(41IF^4O)W@DBD;Q&3ET>')1^[1Y+HWG)-N1DIX3K,=&$O:UH;JSRKG^3<
M\(MFN&P"(Z-&-Q-\'I6JD)3A_VX);J1A'K$(YGBYQZDX+!TT-&T(?=7V6([>
M]>'!T.DF(:9[\4^3CX/.F&^WU(0T<QNCWL)GN@9H82U>HZ)!H1_:#4'0S^KT
MU]['X/0(-KO/[),25X_I,[GV*#IF"GZLVJA<$/0 S(S\DMURLPU9) 8G=4Q2
M:&KAPYZ9*LB#F+LS/0C<]J_WH1=T%$/4PZB.>1R]J8J9"W5Y@:W;XLZ&SX@(
M'^ 7-^4N:&9JH?W'(6V9Z/_N,=%O$OW?/2;Z]]P[W"D6SB8"<F<@]6R'*5 +
MU5C91>K7KB3JI<ZY"0EL'A&]YE3MV8=P7IR>9T].GQ_EIF9Y^GQB/S(2;C:J
M.W9'2$L&=>CNL*N3O'$SS<=>7K)J*FLDA;"<?%S!%(N%;L5!L3)LBT2$3WK2
M6)GX!ODXE=[)D*.20<<;Z.'*<.-P4>[.<796BA3HLI].W5DG9!_A"^$LTR^,
MQ-"S(T>G(+K5"=D@/'\9Q",U>S/)QP)V0>:SGI@S8!()IF;M7# #U^VC\?$W
MOBKR:?_0Y6_=4;?.QQS\4!I^AJY!;HMO,[D<'FRS'E!/;TM/A7,^/L93]3SE
M*"ZC+_2$, F+H!)^@M\^7/PH$/@;O(4X-/#\#;[C4MUAYJ-PS^)B*WXY&4G<
M]LX&^;-^!H1 H6\*_+?S<N+1-[2 W:U\TY^I!M'X_-B8DE0%J^05@6%G?QV
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MB'GI2:A[,$%O^L:'V;W6[4%9E:NO9%4(N^_[#C9#]TS[K((^.LBZ_7]3.X1
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M17^!NCJ"\,+KWW_\<"%FO9_/FA,[7E:G-Z]#*_,O/T@2/T=5<[[(SQ>14]5
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MTTGM1KUG?&TSHKXV(**GSI!AXP_G>OYW\:^BG38K>GR48P1?8_LCD+/MVC1
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MINA3?^43#']<]._B)XD/6NAFAU/Q5&XLG#-OWV0_B)"2KR+DLGEDS^2 EV-
M'),]I:H9/YZ=O9<2RH97R[[HS;"^\P6O1LDMW#)W]5Q2:OJZ(6<V2NAN**:
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M?-2_1#6C$!NC9:@WU)2E B@TH[$-D^T#60QW;%IM%6^TU(K9C_%RJRFS8EL
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MC"I$Y.#,"@HFL9']+2#I(CEMP>9B:;+V/FQ\ XABJFZRZCKZK1MJ[ $:&$#
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M8R%J;VS=:T-V*E;2C486%A#9<AX\'395ZP48]:HEPF2T"E36XK+"!HMPCEH
M"6B2?593UG%G- D!K[#>37T#8?+32E*[1X3N&/>@-TUV\I1_*SQ*V0] ;JC[
MD%P$*!OSUF*S0"^4WF:P@4)C;/8/G3ZY7>FZ@]DN=8'O%97/V9I1+H>PC';3
MX)H6[U#'B,R_0'CI1=PNOOW39XF'USP;OP67FCHJ-84/E_%A!3TJX+<2]<D@
MG('R>&^_9.)N,UTL1QW-!E^A[#9\V4[629CCZN4X+WE3GY=N1A? Z=BL.K^X
M()7L2<O#:Y\^RO[)^4]$BLO9<%&"I+@0;P;X2N>5%+[N/ $7%[D4R/0%3CWW
M(I37I<CVAKYU7 UU>[J+C_H<9%.H_45,.7XZYQUON(V*V#P-G(@X'/9*F#A"
M;UN?B)] /A@]M^8AO?;+US\'EI@7JQ8\C00X<H\S5_>M3OANQH3/-K4XNC35
M_-PNKLB86A=XCP9HC]!"".]1W4_\0P/( @+/$R8)JQO>4(B/I58+0#.=/$G8
M+CYCS57/(8Z %[F!)GQYR]LXR:?D[/1A-$V+9QH_IU"\)6ZQ<=A.+$UJ=##A
M^)'IO^(]VU*,O%QJX'BKP$L2$X2&DY:_1\[S\C@7FHQ/9;GHO;;Q.<@J2U;=
M!(/P'>S*87"456*Y[0,3O"2 <*!JC)(BF+XB#ERFX2?P%9?-'EN4+7/A3P^Y
M<),+?WK(A>_YJ;9330/*XMJSPQ*R3Z!WGSHP$)1*(9$G*>-V/88P&N\\#_->
MPA4^7 _D(BREC;\@$X9UV-D(:AB?@4OE]#'HMUY-Q/JUB+5D\SH4D2C.0PK>
M$DXXS[RA_QK#OH#,%D=^=*0./]X>F]7=EW=>W*Z\L]1#B7B(RQ9Q#'\C'"26
M>[(?QA'BWM-.0+@MRKL' >_AN\77@C4#XV$^=H(?JV;&L\DU,:; 2LC#)-.#
M* _7=@;D33EPBKZ3=?:LZI#Q*$)8RC*=S\L+&A;.CA@&3[N>JXX< D;6,)0A
M <DTCSV(S(2,Q[EY@8@3 A-'U\W\FKTRG_<M"# 4YO532+:J8UV "612FU8!
M31IG(I%G&+TI1X4\2'"3Y"6"^(]H*0EUH*+'F*]@B''\!44M4XP_X%D3C4T!
M,P_%,%4:]'&&X(N0X6]-F;@P)NRW!T**>FIR;9H5ZT&+,4N\]K,[:5S<P%2"
M'G\7OMMKI-F +87 IJTJ0P@]1@<:53;<[!0@@LDA=$B2:-K_8F;<L];MAGE)
M;_:/=^\P\>T>-?&G=Y38AJ2E9N1RHN(@M#;DD\4)AMPJA$.48 6)#<F]X.Y+
MQ/+=REU51QN;]X.$3(^75S#(G&/Q?P>Q&/R T(MQ? _# ;W/^$*2?!8KIRLF
M'+IPX=!)S$L'=HXL'ON@3:M9_O1"6B<>X>:R1&M$2X:G*YRM>#[&I@G34YB:
MHF51E=-'QT> \.:5:Q#=NG0%5,5SM 6F^X4!B#%+<23,RTD9FV7!31-?ZV5$
MRIRJF+TT .%H%3('.BXQ>4/S1G;I03:>2\3<22$IU6+^H+V(;V_C1?R?#V\_
MOOWPC[<__-_[T2VXPW'[[C!N7S1N+V\S;F)1WWY\_YX\U+.-,<-6S9#]LB2W
M'2*5B 7>(A\"TF03_-<WMKGC6EW,N@%?AK2GB.N%V-=$/5E^IR>@>E[6<45H
MA0!Y%70:7I?*8S= =Q0%;XS2%%TN?3\8O.P$?N$%V]XPK.@7N3BY^%:NS33S
MN;=;%.O6/:@S]-.5L&VQUTG%=2$3-^^(QZ3REH+/J.'<P/V3R3S[&OV $(V\
MF:2<S+NZC6-WTR<-8O,I.67VMMB*.ZG<0>]K<N Z7*W(<0\' &> LJGV(GHW
M"IH]H-I<'1? !)H90T&*H'O87'2/3<F6><5GA[RBR2L^.^05[]=Q]NI+CK/G
MCY^<_+<4W><%86VS=[.@!R>(+DR1QU?1G9]_\N3Q>!D=+\)IG!^<K;(GW_$1
M'7U,_R@ S6D"^D^V"Y$@P.85Y#6A8'R:D8J@[S+#@S0VSJ;S2'MK"6EI3EQX
M:K''N>E_<J>0J</1&; >?M/,F6,+Y#)_SRU^%B: \Z@,$@-\#DAI(KM/Z8X,
M2..8!BJ*'3BA^3\KMZ9F:SYV@]4!T_PI5H2"]I6B+YUJ/RM+0DYB%\.]4\ P
M(IDXM61'RKY2?#$N>,8*F[9-*TE4% PGXUB.CTH4%?%0%IQJKN#WW*HMUE8S
M"Y<(?U;;3/@-;?[$;B3[HN3FH%XIP_@ "DB/2G T/82CE6&:O6@(C%YGP4B]
M7NJ3&I6QQ71 IL=H\]!J0M6>TST^MD-#20?DN$WD;Q#)FQOZ/V>KA?-5(:GE
MOOA](MGTO9YFWX=7'KW0!_>"9S_\\.[7=[_\?/93=O;CA[=O__;VYU\_ZM'X
M_1[3I^[Z*/KNT9/;'$4?R@M0 .)ZP$<A5'@-%://ZTQ_<3_BU7O3_G'68><F
MP4R*+@A<3^# XLPUPD[RZ,C[K]5\3>/WY&6>/7W\] 4$:56(WA/K7BY ( KM
M%W)^:BCQ\>T;Z %?X#PKDT8 %S=6W""6N^QOU$?(!S]8N%1U [[]-Y2C #C=
M!64X-3..*5YJ0^8# !T GP?N!#-!KHHY*?LK4T[(+!3)E>H3/IP2U5DZ##;@
MP6!1X)@8+,!=ZV8Q0^9^^*LS4W3/C]\\CX/LX(]A:%T%\.CPQ00!0S!:@/-.
M"3,,<2+=(_J&PFJ".\+I@]R9SGD2 D/_<-8 I <U'Z03"<;#YQL^>@6O,\_+
MX06\>$D%^ET,%R9*6^= 7%?M<E6FJF.A$DA Q!QJC,EM6$.)[L.4NRWFN<.>
MYG-YH1)\JMZD!FRZH=[?H]"E2C2.GT/=W+!4Z6YE#]J]8WHBXJ(2.EH>$MVN
MYF6G.7,H7EZLYERL /NRFE\4)HQPR]@V!VUS<RJQ6?J!+ANP7+EL/[D^=0],
MC:EC:(+JD*.#A;%.EYT(0AK[H(OYJ<P^;#XN7+I--YOU;%3ZZ1_U'-U^I5G<
M764+P.KO0KN\MGQ04I]+/2HC'04Z83^(]LY_<B9U+[UA8 MO\:;4OC.?R\VY
M*JCAPDH)E>TZGI53P!_G9-ARJ\/G*9S<8H][SW596HVV#;LP+"Z-[>]'V5L#
M-A J/'I/XVF+>3<F.V8;TTXX0.D85 KT2I0MEN'<9)3SF5C1JG5^YLR= Q"-
M=KVB4X\+H&(0=A":N8TW+VY\-P29<49I#^RZ'A55):S??9J.U&08-'6G1P(=
M;H;N8' Q/2@O;Z>@9PE/!070P^N/K8(3F3GN_H,BN7'"<M-(PKP.M,PAZ'6_
M([].5]Q2&").H7'%;0%_ M'I4J"-P6]7B'4)M#4@#]_9@S\20/8GTM\??7R4
ML2VQ-F0.ED->Z8<?W_PD"7HCD\MU9$Z_H(5:U<MV55IG"P@J]-$ \8!FF FJ
M\7,A4!<_8E,EYWPY'I2*>GP]QYNGN#$X"T\U1^4,_BIZ<'-D@Q:T1=5.5E>4
M;I >)G7QW"$./&9P!<H:7%4=]$T"A[:S>^9 &E\RUG[A*5&1J8&1J-T+.O,X
MZV4I>H8.;9@TR6#1R2T6:GH>-U"_TTQA0B6<JFQ\IOHT.G<X/1'5&:/-M$6G
M#@ 55]I8(S.9C\&0>@),T7)+S(>)UG=F*W(&U^79>=&14YP"=&)737SF>@X
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MF!@2YA.3:DB4Z=U&^,@7[^UXN(B45C8J#(-QFXZH9!T?)0<""R(F92<7_YE
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M"LMF$^CCL9^/$@6YZ:^#H6A-<L1-&/%$=]RJ4@ X%[%P!@_(17%J!YPR^P"
M-BA0LHU.+&I/.LB:I_*U>:0>G):3.4Z:=AIJ?M&M-$WIL*: N^Q))QZ-E:_&
M<3DOK9?MT5L"@;)O,)3U'=YK^.TM-MOQT<;=E@\U5XM4\L;89ZN5<WSDE@**
M07#6J,C,^@=(-]1];?-D0/7LETK1=:NK1=1#5TB#<K18>.XT<*TLC*0?YFWU
MNHDEON5[!8N?7X[P>U_U=GOL?>T^K?7D\2;4&0/[R73_PJ!_@CC\'7/?%B7<
M.GNQ<AM62(JI$ 3DA&Q@)-4R37$*QSO+AF&WD\M1,*BW' *)LAK@A)CNL)X
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M6^$YP[YZWK/)]N<1\!%\#(DX*VHM^ A"DQ!T15T>T-91U"N( U?*D_AQM8!
M-\*!:M"H !\*W5@>(Q+5 <;P.5M;L6/'1_^UFJ\90:40*A'1(?V<<WI-JS3N
M7S,:@%SD.@A:R%P&%%Y:/RQJ3 Z[ N6:_BXG)BR*&$*37JWB_V[GOEI^?N2W
MO86_EAI'^U))?"2[NL;Q,0<ZAFMI=VW:NN,2."8[>^SYU95]U>**)Y63[^K<
MQ:Y<@.U1AT^59GTJ9TG,4GM\8(8FBHZF<6O$WR"'R*WY/V=N-)T7YK:.^^+W
MSO@LJXDPO_[CW;MW?_G3]WJ0?!]>>O1*']P;OOGIEX_O?OXQ>_/+SS^\^_7=
M+S]_U"/I^__<WU'=]1'P\M&3T:1XO[]A*K'+>U"%G7(@+$G)Y=HW>T6R6:5G
MA@5_&R,\VE9,*P:=PYH_Z0.4TJ3,DN?SG_<E6RF6M3W8LAI1"E5[DAT8#R85
M/L@TB=&\*= A/E^'$AB<Q\E3^L9Z&,J0\'<\%LQ[Y7_>^X5Y;Z 9OT(%<H#%
M)>"F068B7UL=P.+%NIKIE'=PB%H2$CS6G%?+^6=<(PTHW2%U0%E^PG5K/Y(J
M_ V\#MSYLNCXOB4A0MVY=W.H\-_=>OH9/"]GD9H6*@EN8MP\5$0T"/.%O/=
M*%.SC!R8E*(NL0'RMU6MQ*(4[=,<,]VF9"_4I"D4>=0.Q@Q+W)F)/BB@-E<M
M6FHH_)1HY7YSZ[6;5M&C_(C9 EA(SN5]JPJ5 U\CXO\KE$,06GFML+=E5/&L
M4=65/<Q+EGWDD\#=XZKX]$7OGCD?"Z2;'M;RWFG].R)""U97<PY%.RJJ:2'2
M%[R!]IS*XWUP?>C2]Z\F?T]=[F'-[DZAZ'@8]OA5.N'&QWQ^*0W>+B!= =8&
MU)(-\"C1C!W"V2,FH/V=O2U3?2\/J3Z3ZGMY2/7MN079O;B\(-5(HST[4S6:
M'MGCBF$U4X-)V5Y&)A>@B!)K*1RFPWXFB/!"UI@P>K25\[2*Q3UB=ME_X78!
MP8ZX#C&$[E;25/L_1SO,USP=G8"M\C5N@_QB*O4!C&$P?6/=L]OG;Y9WG;))
MIV'"A/IX]B5,V1S2+SM-OT M:3)9M<5DC>7L#P$!<>=77<A,3&5J=P9 -:,*
M\-'P!T,+AEB]'D]7KXN<O_S753TM*,:%K%!PR]/>\87 1*HCM,!S**A)!4NF
MT)L]$C*C+Q-=CN)H/,E2Q$UZ9'9 &Y7RPZL9O3\'Y /7*3\C7D2!H&&MJFDS
MD:I1VA H!I4M[>!94<U7K40%0(P:OP:AAB#6']8\(?%HF8:_215.5%LI9B!]
MP&;ESHX+I.!4:]-PS43E? 77R7_9<%U-<DCY#Y(;S#([D=FWXM(SKRN\86%2
M3H-IO.#Z!%FIYVN>#M+PK28K8!? 97)"WXDOO&GUY4A98$UC^ 9)"I4%&G\T
M;XAE@54@J&/53C,/=^H"=\C9P#<0 ],MH6X%Z+ <^QD6*W<PHP8U@%R8CUM"
MOX*WNEY]?/ ('K-:R.9!4.34RR;R:_+D]BE?8>UC 1(?JK5+#4<0]\8F#+;?
MG].J(X5L("!!H]2W&K$!,[,&^G0IH\';KP+N\PP&ZPJEQ._&A*0NKO)TW0;#
M\(4&AJ31T4S0[>/R]\EGM31>*L]],4;FOGCT% X 4@%:81&<5Y#96< 6K:\&
M=YHZTS!=87U>;9=A/()MO/X#MW%TX6A7.Q\HWM:QP_-%N_KS^*[>?\_YWA0
M *M./*0D7HK25M=E76A+2H UQ9EGXE)"^Y)"O(3$@XT8B/3T*3I:,7P?+S5
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M+[*C7-9:: 18]>M;@EN!12!8'!6(ZG9<.LF 3B:FPQ#'1>WK$+ZLFW,G/;O
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M@/'U:G>7]=9[ZS_G5T%\':3>YW$VCL=IQ*\5L=@\N84+S0580PM75W^D0?5
M2_R8)+W;B##>NNA312-J(;Z.[9>[I(AZ'[Q_ /UCA'9O<--C$BVX)-S[,4_G
MQ&.V;LZ"[E40#M;7/F^AQ_4JG#<3JU/[?H'SB!#HX6C+.TW2^5O3=0,?!>,T
M\+YL>1_' S#Z_PA4T%Z<B=(@U\^87OY^R;=]$-P^H-7P"]/,CQG\B$EG48,_
MQNC?FUFB?VU@6:G=TK,RA7K#[3G9_GX5=;!T4< -7/B; P8!Q42OHQ"88NK;
M.7LUWYYCP[L(\UI 6HQ3X(29U>PPDQ%^/:O N]G'(!AUP0RH'MH\88EP1M;
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M;R=U)DL1!DK57"65$2#7N)S/N5+_^^+S/S6-S]Y=?QR-^^?#,?SL]\1UGUS
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MYRP(U&>##"U*WTFH< T+V)TK!<UKB.)4 ,)ZOKY%V[(2W-B"??U'1IVJLL9
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MY6K!I[RL)3&^YZP4=Y C-6*\U4O"%NCDE9YO]H@M9ZQD7F=&!3.-(3H+<UK
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ML,-]&"Y#HZL;R9S;@,E%.=%H\0@MW*UQ*CAXS\[,S+9Y\05)UL0[G!47=G@
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M#JR=X)^[Q[_3?/)Q>C%^]U]02P$"% ,4    "  T/==:F$*B9RP#  #E"P
M$0              @ $     8V%R;2TR,#(U,#8R,BYX<V102P$"% ,4
M"  T/==:2&LYG/T*  !_A@  %0              @ %; P  8V%R;2TR,#(U
M,#8R,E]L86(N>&UL4$L! A0#%     @ -#W76I62V\I5!P  UE<  !4
M         ( !BPX  &-A<FTM,C R-3 V,C)?<')E+GAM;%!+ 0(4 Q0    (
M #0]UUHH$K?IY3@  !$5 0 2              "  1,6  !T;3(U,3@V,C!D
M,5\X:RYH=&U02P$"% ,4    "  T/==:&_(::4UA  "3. ( %@
M    @ $H3P  =&TR-3$X-C(P9#%?97@Q,"TQ+FAT;5!+ 0(4 Q0    ( #0]
MUUH'?^H]CTD  #N. 0 6              "  :FP  !T;3(U,3@V,C!D,5]E
M>#$P+3(N:'1M4$L! A0#%     @ -#W76I_4*BW02@  <)0! !8
M     ( !;/H  '1M,C4Q.#8R,&0Q7V5X,3 M,RYH=&U02P$"% ,4    "  T
M/==:-B'@P]@7  !2;   %@              @ %P10$ =&TR-3$X-C(P9#%?
M97@Q,"TT+FAT;5!+ 0(4 Q0    ( #0]UUH/KE&G*I<! )[5"@ 5
M      "  7Q= 0!T;3(U,3@V,C!D,5]E>#(M,2YH=&U02P$"% ,4    "  T
M/==:C!,2FP@B   M?P  %@              @ '9] ( =&TR-3$X-C(P9#%?
@97@Y.2TQ+FAT;5!+!08     "@ * )P"   5%P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2518620d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="carm-20250622.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2025-06-22</startDate>
            <endDate>2025-06-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-22" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-22" id="Fact000004">0001485003</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-22" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-22" id="Fact000011">2025-06-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-22" id="Fact000012">Carisma Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-22" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-06-22" id="Fact000014">001-36296</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-22" id="Fact000015">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-22" id="Fact000016">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-06-22" id="Fact000017">Suite&#160;401</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-22" id="Fact000018">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-22" id="Fact000019">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-22" id="Fact000020">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-22" id="Fact000021">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-22" id="Fact000022">491-6422</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-22" id="Fact000023">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-22" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-22" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-22" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-06-22" id="Fact000027">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-06-22" id="Fact000028">CARM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-06-22" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-22" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
